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Outline 
The present thesis has been divided into five different chapters. 
The Chapter 1 and Chapter 2 consist of the scientific background and motivation of the work 
performed in this thesis regarding the discovery of cancer biomarkers based on alterations of 
glycosylation. 
The Chapter 1 is a general introduction to the fields of gastric cancer, glycobiology and 
biomarkers in cancer. 
The Chapter 2 summarizes the main objectives of the thesis. 
The Chapter 3 reports the main results obtained during the work project. It consists of three 
main studies related to altered glycosylation observed in gastric cancer, and were subdivided in 
three parts: 
The first study, Chapter 3.1, focuses on the identification of glycoproteins expressing 
truncated O-glycans in serum of patients as source for biomarker discovery. "Glycoproteomic 
analysis of serum from patients with gastric precancerous lesions. Published in J. Proteome 
Res., 2013, 12 (3), pp 1454–1466." 
The second study, Chapter 3.2, focuses on the biological role of SLeX in gastric cancer cell 
behavior using a cell line model overexpressing ST3Gal IV. "Expression of ST3GAL4 leads to 
SLeX expression and induces c-Met activation and an invasive phenotype in gastric carcinoma 
cells. Published in PLoS One, 2013, 8 (6):e66737." 
The third study, Chapter 3.3, focuses on the identification of the SLeX expressing 
glycoproteins using a gastric cancer cell line model overexpressing ST3Gal IV, and validation 
in gastric carcinoma tissues as putative new biomarker in gastric cancer. "CEACAM5 
carcinoembryonic antigen carries SLeX in gastric carcinoma cells - implications for diagnosis 
improvement. Manuscript in preparation." 
The Chapter 4 consists on a general discussion of the main findings and future perspectives, 
finishing with final conclusions.  
The Chapter 5 includes other scientific contributions.   
  
Abstract 
All the cells that constitute epithelial surfaces are decorated by a large diversity of 
glycoconjugates that have been involved in numerous cellular processes, including cancer cell 
transformation. During malignant cancer cell transformation, cells express on their surfaces 
different glycan structures when compared with their normal counterpart. The expression of 
these altered glycans occurs mainly in glycoproteins and glycolipids and are characterized by 
the expression of abnormal truncated glycans (e.g. Tn, STn and T antigens) and increased 
sialylation in complex glycan structures (e.g. SLea and SLeX antigens). The study of these glycan 
alterations common in cancer as well as the identification of proteins carriers of the altered 
glycans will contribute to the understanding of the carcinogenesis process and help in the 
finding of new cancer biomarkers.  
The main objectives of this work were: to identify new serological biomarkers in gastric 
carcinogenesis, by the evaluation of T and STn expression in gastric carcinoma precursor 
lesions (gastritis and intestinal metaplasia) and in gastric carcinoma; to characterize the 
biological behavior of gastric carcinoma cells expressing SLeX, to evaluate the molecular 
modulation of SLeX expressing cells by tyrosine kinase receptors activation; and to identify 
protein carriers of SLeX.  
STn and T antigens were shown to be expressed in biopsies of individuals with gastritis, 
intestinal metaplasia and tissues from gastric carcinoma patients. The proteomic study of 
serum from individuals with gastritis, intestinal metaplasia and gastric carcinoma revealed the 
presence of these truncated glycans and lead us to identify some proteins such as acute phase 
proteins (mainly complement proteins), vitronectin and plasminogen. The detailed mass 
spectrometry analysis of glycan structures in serum plasminogen from intestinal metaplasia 
individuals allowed the validation of the STn structure. The overexpression of ST3Gal IV in 
gastric carcinoma cell line MKN45, induced the expression of type 2 sialylated Lewis structure, 
SLeX, in cellular and secreted proteins. The SLeX expression lead to a more aggressive in vitro 
phenotype of gastric cells, characterized by an increased cellular invasion with increased 
adhesion capacity to extracellular matrix proteins such as collagen IV and vitronectin. Using the 
chicken chorioallantoic membrane (CAM) as in vivo model for the evaluation of cancer cell 
invasion capacity we demonstrated that cells expressing SLeX show increased capacity to 
infiltrate and invade CAM. From the evaluation of tyrosine kinase receptors activation we 
observed increased activation of c-Met in SLeX expressing cells, a receptor already described as 
playing a role in cellular invasion and metastization process. As follow consequence of c-Met 
activation we observed increased phosphorylation of Src, FAK and activation of RAC1, RhoA and 
Cdc42 GTPases contributing for the modulation of cellular biological behavior. The identification 
of SLeX protein carriers, by a proteomic approach, lead us to identify the carcinoembryonic 
antigen (CEA). This result was further confirmed in cells by proximity ligation assay (PLA) and 
validated by immunoprecipitation. The expression of CEA and SLeX and the presence of 
CEA/SLeX was evaluated by immunohistochemistry and PLA in gastric carcinoma tissues, and 
revealed that 80.6% of the cases show CEA/SLeX. This result was associated with the presence 
of venous invasion of the carcinomas.  
Overall, our results give new insights for the application of both plasminogen STn and CEA 
SLeX glycosylation pattern as serum biomarkers of gastric pathologies, and open new avenues 
for future targeted evaluation of these specific glycobiomarkers in additional immunoassay-
based approaches. Moreover, we showed that SLeX expression on the surface of malignant cells 
plays an important role in tumor invasion and metastasis.    
  
  
Resumo 
Todas as células que constituem as superfícies epiteliais são decoradas por diversos 
glicoconjugados que estão envolvidos em inúmeros processos celulares, inclusive na 
progressão para cancro. Aquando da transformação maligna, estas células passam a 
expressar, à sua superfície, diferentes estruturas de glicanos. A expressão desses glicanos 
alterados acontece maioritariamente em glicoproteínas e glicolípidos e é caracterizada pela 
expressão de formas truncadas anormais (antigénios Tn, STn e T), assim como aumento da 
sialilação de glicanos complexos (antigénio SLea, SLeX). O estudo destas alterações comuns em 
cancro, assim como a identificação de proteínas portadoras destes glicanos alterados pode 
contribuir significativamente para a compreensão do processo de carcinogénese e da 
progressão tumoral assim como ajudar na descoberta de novos biomarcadores de cancro.  
Este estudo teve como objetivos: identificar novos biomarcadores serológicos envolvidos na 
carcinogénese gástrica através do estudo da expressão de glicanos truncados como STn e T em 
lesões precursoras de carcinoma gástrico (gastrite e metaplasia intestinal) e em carcinoma 
gástrico; caracterizar o comportamento biológico de células de carcinoma gástrico que 
expressam SLeX, avaliar a modelação molecular por ativação de recetores de tirosina cinase em 
células que expressam SLeX; e identificar proteínas portadoras de SLeX. 
A expressão de estruturas STn e T foi observada em tecidos de biopsias de indivíduos com 
gastrite e metaplasia intestinal, assim como em casos de carcinoma gástrico. A análise 
proteómica do soro de indivíduos com carcinoma gástrico e lesões precursoras de carcinoma 
gástrico (gastrite e metaplasia intestinal) revelou a presença dessas mesmas estruturas, e levou 
à identificação de proteínas de resposta de fase aguda (maioritariamente proteínas do sistema 
de complemento), de vitronectina e plasminogénio. O estudo detalhado, por espectrometria de 
massa, da estrutura de glicanos do plasminogénio sérico levou à validação da presença da 
estrutura STn em indivíduos com metaplasia intestinal. A sobre-expressão, in vitro, da 
sialiltransferase ST3Gal IV numa linha celular de carcinoma gástrico, MKN45, induziu a 
expressão de estruturas Lewis sialiladas do tipo 2, SLeX, em proteínas celulares e secretadas. A 
expressão de SLeX levou a um comportamento mais agressivo das células in vitro, caracterizado 
pelo aumento da invasão celular assim como maior capacidade de adesão celular a proteínas 
de matriz como colagénio IV e vitronectina. A aplicação, como modelo in vivo, da membrana 
corioalantóica (CAM) de embrião de galinha para a avaliação da capacidade invasiva de células 
que expressam SLeX evidenciou uma maior capacidade destas células em penetrar e invadir a 
membrana corioalantóica. Da avaliação da ativação de recetores de tirosina cinase, 
observamos aumento de ativação de c-Met em células que expressam SLeX, um recetor já 
descrito como estado envolvido no processo de invasão e metastização celular. Como efeito 
subsequente à ativação do c-Met, um aumento de fosforilação de Src, FAK e ativação de RAC1, 
RhoA e Cdc42 GTPases foi observado como participando na modulação do comportamento 
biológico celular. O estudo proteómico de identificação das proteínas transportadoras de SLeX 
identificou o antigénio carcinoembrionico (CEA), e este resultado foi posteriormente confirmado 
por PLA em células e validado por imunoprecipitação. A presença da co-expressão de CEA e 
SLeX foi também avaliada por imunohistoquímica e PLA em tecidos de carcinoma gástrico, e 
revelou que 80.6% dos carcinomas gástricos apresentam co-expressão de CEA com SLeX. A co-
expressão de CEA com SLeX apresentou associação com invasão venosa dos carcinomas.  
Os resultados obtidos poderão contribuir significativamente para a aplicação de alterações 
de glicosilação de proteínas, como plasminogénio com STn e CEA com SLeX, como possíveis 
novos biomarcadores de patologias gástricas, e abrem novas portas para o desenvolvimento de 
novos testes sorológicos que avaliem estas alterações. Adicionalmente, este trabalho permitiu 
demonstrar que a expressão de SLeX em células tumorais está associada com a invasão 
tumoral e com o processo de metastização. 
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GENERAL VIEW OF CANCER INCIDENCE AND MORTALITY 
Cancer is a leading cause of death worldwide (Twombly 2005) and a tremendous effort has 
been made to improve health by developing new approaches for early diagnosis, treatment and 
prevention.  
In 2008, it was estimated an overall incidence of more than 12 million new cancer cases 
resulting in approximately 8 million cancer deaths (Ferlay et al., 2010). Lung cancer remains the 
most frequent cancer worldwide, presenting both higher incidence and mortality rates. The 
ranking, in terms of incidence, is followed by breast cancer, the second most common cancer 
overall, colorectal cancer, stomach cancer, prostate cancer and liver cancer. Regarding mortality, 
gastric cancer is the second cause of cancer death worldwide followed by liver cancer, colorectal 
cancer and breast cancer.  
GASTRIC CANCER - GENERAL ASPECTS 
Epidemiological Perspective 
The International Agency for Research on Cancer (IARC), a part of the World Health 
Organization (WHO), often estimates the cancer incidence and mortality in broad areas of the 
world and more recently it provides a more detail estimate comprising the country level through 
the GLOBOCAN series. 
According to the last estimate, gastric cancer is one of the main cause of cancer death 
worldwide, especially in developing countries (Ferlay et al., 2010). About one million new cases 
were estimated to have occurred (989,000 cases, 7.8% of the total), making it currently the fourth 
most common cancer malignancy in the world. This estimative differs significantly from the first in 
1975, when stomach cancer was globally the most common neoplasm (Parkin et al., 1984; La 
Vecchia et al., 2010). Incidence of gastric cancer in developing countries represents more than 
70% of total cases, and half of the world total cases occurs in Eastern Asia, mainly in China 
(Ferlay et al., 2010). In addition, gastric cancer is the second leading cause of cancer death in 
both sexes worldwide and the highest mortality rates are estimated in Eastern Asia with Central 
and Eastern Europe, and Central and South America also present high mortality rates. 
Nonetheless, the lowest mortality rate is observed in Northern America. 
Besides these GLOBOCAN perspectives, there is also estimates of cancer burden in Europe. 
Overall, it was estimated about 3 million new cancer cases diagnosed and 1.7 million cancer 
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deaths in Europe in 2006 (Ferlay et al., 2007). This study estimated that overall, the most 
frequent cancer types were breast cancer, followed by colorectal cancers, lung cancer, prostate 
cancer and gastric cancer. In terms of mortality, lung cancer was the most common cause of 
death from cancer, followed by colorectal cancer, breast cancer, gastric cancer and prostate 
cancer. Higher incidence and mortality rates are still recorded in Eastern European countries. 
This European estimative differs from the GLOBOCAN worldwide estimative and fortunately, 
gastric cancer incidence and mortality are declining throughout Europe, in both men and women 
(Boyle et al., 2005; Ferlay et al., 2007).  
The incidence of gastric cancer varies from country to country, probably as a result of genetic, 
epigenetic, and environmental factors. Gastric cancer has been associated with many factors 
known to contribute to the development and progression of the disease (Crew et al., 2006). Some 
of the factors thought to be involved in the development of gastric cancer are sex, where gastric 
cancer occurs twice as often in men; age, where gastric cancer is more common in people over 
the age of 55 (Yamaoka et al., 2009); race, in the United States of America some studies point 
for differences in incidence among the different populations (Schlansky et al., 2011) and dietary 
factors in particular a high salt intake along with the use of nitrate for food preservation (Ramon et 
al., 1993; Tsugane 2005; Peleteiro et al., 2011). Other related risk factors are fruit and 
vegetables intake (Riboli et al., 2003; Soerjomataram et al., 2010), smoke habit (La Torre et al., 
2009), alcohol consumption (Duell et al., 2011) and high body mass index (Hampel et al., 2005; 
Kubo et al., 2006). In addition to these environmental factors, Helicobacter pylori, a gram-
negative bacterium that is thought to be present in the stomach of half the global population, has 
also been implicated in gastric carcinogenesis (Peek et al., 2002; Lochhead et al., 2007; 
Lochhead et al., 2008).  
In this regard, the decline in incidence and mortality rates observed in gastric cancer 
throughout Europe is generally attributed to better food preservation, enhanced nutrition and 
improved control of Helicobacter pylori infection.  
Gastric Carcinogenesis 
Based on epidemiologic evidence, the IARC classified in 1994 H. pylori as a class I carcinogen 
(IARC 1994). Since then, continuous increasing data supports the role of H. pylori in gastric 
carcinogenesis that was firstly established with a very elegant study with the Mongolian gerbil 
animal model demonstrating gastric cancer induction by H. pylori infection (Watanabe et al., 
1998).  
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H. pylori colonization is generally acquired during childhood (Malaty et al., 2002; Rowland et 
al., 2006) but if not treated the infection persists lifelong (Vincent 1995; Blaser et al., 2004; 
Lehours et al., 2007). The transmission infection mode is reported to be human to human 
(Graham et al., 1991; Neale et al., 1995), most probably by gastric-oral transmissions associated 
with gastroenteritis and vomiting and oral-oral or fecal-oral transmission (Leung et al., 1999; 
Parsonnet et al., 1999; De Schryver et al., 2006; Perry et al., 2006; Solnick et al., 2006). 
As referred above, H. pylori infection is considered a major risk factor that together with other 
environmental factors triggers a cascade of gastric lesions that cause alterations in the gastric 
mucosa resulting in atrophy of the mucosal barrier which may increase the risk of carcinogenesis 
in the underlying epithelial layer leading ultimately to gastric cancer (Uemura et al., 2001; Correa 
et al., 2007). In 1992, Pelayo Correa first described the gastric carcinogenesis pathway 
characterized by a multiple step process started by H. pylori infection (Correa 1992) (Figure 1). 
Figure 1: Gastric carcinogenesis pathway proposed by Pelayo Correa in 1992, characterized by a multi-step process 
started by H. pylori infection leading to gastric tissue inflammation that can evolve to atrophy, metaplasia, dysplasia 
and ultimately gastric cancer. 
This multistep model propose that H. pylori infection, in association with other environmental 
factors, triggers a cascade of events that starts with a chronic inflammation or a chronic 
gastritis that can evolve to atrophic gastritis with focal loss of glands. As consequence of this 
atrophy, several changes can occur and the local gastric cells can be replaced by intestinal type 
cells conferring a tissue intestinal phenotype named intestinal metaplasia. The next step in the 
cascade is characterized by atypical changes in nuclear morphology and irregular tissue 
architecture and is called dysplasia (reviewed in Correa et al., 2007). High-grade dysplasia 
commonly progress to gastric cancer of the more common intestinal subtype, the final step of 
the cascade (de Vries et al., 2007).  
Regarding this well established model, gastric mucosal atrophy is a major risk factor to 
develop gastric cancer. In addition, different patterns of atrophic gastritis are associated with 
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different risk of developing gastric cancer. A recent system of gastritis classification, the OLGA 
(Operative Link for Gastritis Assessment)-staging system, consider both the topography (antral 
and corpus mucosa) and the extent of gastric mucosa atrophy (score) to determine gastritis-
associated gastric cancer risk (Rugge et al., 2008). Taking in consideration this classification, 
several studies consistently associated increased risk of developing gastric cancer with OLGA 
stages III/IV (Rugge et al., 2007; Rugge et al., 2010; Rugge et al., 2011; Marcos-Pinto et al., 
2013). More recently, a modification in the OLGA system of classification, OLGIM (Operative Link 
on Intestinal Metaplasia Assessment), was proposed to consider the assessment of intestinal 
metaplasia instead of atrophy and this new classification has been shown to be more accurate in 
determine gastric cancer risk (Capelle et al., 2010). These classifications show to be important for 
the application of follow-up strategies for patient-specific clinico-pathological future evaluations 
(Dinis-Ribeiro et al., 2012; Marcos-Pinto et al., 2012). 
All H. pylori strains have the capacity of promoting gastric inflammation, however most of the 
infected individuals show few or no symptoms and a very small percentage of H. pylori infected 
individuals will develop gastric carcinoma (Dooley et al., 1989; Suerbaum et al., 2002; Amieva et 
al., 2008). Considering this reality, the outcome of H. pylori infection for each individual is difficult 
to predict since it depends on different aspects such as host genetic susceptibility, strain virulence 
characteristics and environmental factors. 
Host Genetic Susceptibility 
It is recognized the importance of host genetics in gastric cancer development and the 
association with H. pylori infection. The prevalence of a number of genetic polymorphisms in 
some inflammation-related genes have been demonstrated to be associated with risk of 
developing gastric lesions, mainly in H. pylori infected individuals. 
It has been shown that human genetic pro-inflammatory polymorphisms within the genes 
interleukin (IL)-1B and IL-1RN are associated with risk for gastric cancer development (El-Omar et 
al., 2000; Machado et al., 2001; Figueiredo et al., 2002). IL-1B gene encodes for a pro-
inflammatory cytokine IL-1β that plays an important role in initiating and amplifying the 
inflammatory response upon H. pylori infection (Noach et al., 1994). On the other hand, IL-1RN 
gene encodes for an interleukin 1 receptor antagonist IL-1ra, an anti-inflammatory cytokine, that 
competitively binds IL-1β receptors modulating the potentially damage effects of IL-1β (Arend et 
al., 1998). The expression of IL-1B-511*T, IL-1B-31*C and IL-1RN*2 alleles have been associated 
CHAPTER 1 | General Introduction 
 
 31 
with increased IL-1β production (Pociot et al., 1992; Danis et al., 1995; Santtila et al., 1998; 
Hwang et al., 2002) and have been found to confer an increased risk for the development of 
gastric cancer (Machado et al., 2001) chronic atrophic gastritis (Furuta et al., 2002) and 
intestinal metaplasia (Figueiredo et al., 2002; Zambon et al., 2002).  
Furthermore, polymorphism in the tumor necrosis factor α (TNF-α) gene and interferon 
gamma receptor 1 (IFNGR1) has also been associated with increased gastric cancer risk (El-Omar 
2001; Machado et al., 2003; Canedo et al., 2008). The pro-inflammatory TNF-α cytokine, 
encoded by TNF-α gene, has been shown to be increased in gastric mucosa of patients infected 
by H. pylori (Noach et al., 1994; Arend et al., 1998), and the expression of TNF-α-308*A allele 
has been associated with increased risk for chronic atrophic gastritis and gastric cancer 
development (Machado et al., 2003). IFNGR1 is a cytokine receptor for IFNϒ, a cytokine that has 
been described to play a pivotal role in promoting H. pylori induced mucosal inflammation when 
upregulated (Smythies et al., 2000). The presence of IFNGR1-56*T polymorphism has been 
reported as a relevant host susceptibility factor for gastric cancer development (Canedo et al., 
2008). 
In addition, other findings claimed that MUC1 polymorphism present different susceptibility for 
the development of gastric lesions  (Silva et al., 2001) and gastric carcinoma (Carvalho et al., 
1997). It was also reported that H. pylori adhesion to gastric cells depends on the size of the 
MUC1 variable number tandem repeats (VNTR) domain (Costa et al., 2008). 
Helicobacter pylori  Virulence Factors 
Although the final clinical outcome is dependent also on host and environmental factors, it was 
also observed that not every H. pylori strain resulted in similar damage for the host, leading to the 
distinction between high and low pathogenic strains. Thus, it was possible to identify bacterial 
features that confer increased risk to develop gastric disease (van Doorn et al., 1998; Figueiredo 
et al., 2005). 
The presence of cytotoxin-associated gene pathogenicity island (cagPAI) was associated with 
more severe disease outcomes and was considered to be involved in the development of atrophic 
gastritis, peptic ulcer disease and gastric carcinoma (Blaser et al., 1995; Kuipers et al., 1995; 
Figueiredo et al., 2002; Nomura et al., 2002), a feature that has been well established in animal 
models (Ogura et al., 2000; Wiedemann et al., 2009). Bacterial strains that are cagPAI positive 
(cagPAI+, more virulent strains), are characterized by containing genes that encode a type IV 
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secretion system, which functions as a needle that permits the insertion of bacterial products into 
the host cells (Censini et al., 1996; Tanaka et al., 2003) as well as the gene encoding the CagA 
protein, one of the proteins delivered to epithelial cells through this system (Backert et al., 2000). 
Once inserted in epithelial cells, CagA protein associates with proteins from the tight junction 
complexes, leading to loss of epithelial integrity (Amieva et al., 2003) and its phosphorylation on 
tyrosine residues by Src family kinases promotes the interaction with several cell signal-
transduction pathways resulting in cytoskeleton rearrangement, motility, proliferation and 
apoptosis (Segal et al., 1999; Asahi et al., 2000; Odenbreit et al., 2000; Stein et al., 2000).  The 
presence of an intact type IV secretion system as well as CagA protein phosphorylation is also 
associated with the production of interleukin (IL)-8 in gastric cells (Brandt et al., 2005; Figueiredo 
et al., 2005; Lai et al., 2011).  
Several other virulent factors have been characterized and described such as the vacuolating 
cytotoxin gene (vacA) that encodes a toxin that induce epithelial cell damage by cell vacuolization, 
membrane channel formation, disruption of endosomal/lysosomal function, apoptosis, and 
immunomodulation (Cover et al., 1992; Cover 1996; reviewed in Cover et al., 2005). 
Additional, H. pylori virulence factors can comprise genes that encodes for blood group 
antigen binding adhesin (BabA) (Ilver et al., 1998) and sialic acid-binding adhesin (SabA) 
(Mahdavi et al., 2002). The expression of these adhesin proteins in the surface of H. pylori strains 
are involved with the capacity of the bacteria to colonize gastric mucosa by adhering to epithelial 
cells through host antigens receptors. H. pylori adhesion to the gastric epithelial cells constitutes 
a crucial step for gastric mucosa colonization and establishment of a successful infection, 
because it provides protection from clearance mechanisms such as liquid flow, peristaltic 
movements or renewal of the mucous layer. The host antigens receptors involved in bacteria 
colonization are glycan structures present on proteins or glycolipids in the surface of the host 
gastric epithelial cells namely H-type 1 and Lewis b (Leb) for Bab A adhesin (Boren et al., 1993; 
Ilver et al., 1998) and Sialyl Lewis X (SLeX) and Sialyl Lewis A (SLea) for SabA adhesin (Johansson 
et al., 2005; Walz et al., 2005; Aspholm et al., 2006). H. pylori has the capacity of modulate the 
expression of these two adhesins to achieve a long-term colonization, according to the host 
antigen receptors expression. For this reason, H. pylori take advantage of expressing SabA 
adhesin in inflamed gastric tissues that is characterized by increased expression of sialylated 
structures (Ota et al., 1998; Mahdavi et al., 2002). Infection with H. pylori that expresses BabA is 
associated with increased epithelial proliferation and inflammation, increased risk for duodenal 
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ulcer, gastric atrophy, intestinal metaplasia, and gastric adenocarcinoma (Gerhard et al., 1999; 
Prinz et al., 2001; Yu et al., 2002).  
Gastric Cancer Classification 
Most of gastric cancers are adenocarcinomas that occur in the lining of the stomach and 
account for nearly 90% of the total cases. About 2-7% of the gastric malignancies are lymphoma 
of mucosa-associated lymphoid tissue (MALT) (Wotherspoon 1998), and the remainder 
percentage includes very rare cases of gastric stromal tumors (sarcomas) developed from the 
muscle or connective tissue of the stomach wall (Duffaud et al., 2003), and carcinoid tumors 
(Zhang et al., 2011).  
Different stages of gastric adenocarcinoma are characterized by the capacity of invasion 
deeply into the stomach wall extending to nearby organs such as lymph nodes, abdominal cavity, 
liver, pancreas, esophagus or intestine (Washington 2010). Furthermore, gastric carcinoma cells 
released by the primary tumor into lymphatic and/or blood circulation can spread into distant 
target organs (lungs, brain, ovaries, bones) forming secondary tumors (a process also called 
metastization) (Kemp et al., 2010; Ahn et al., 2011; Yamanishi et al., 2011). 
Several classification systems have been proposed to aid in the description of gastric cancer 
based on microscopic pattern (Ming, Carneiro, and Goseki). The two most commonly used are 
the World Health and Organization (WHO) Lauren systems. According to WHO, gastric carcinomas 
are classified in adenocarcinoma, papillary carcinoma, tubular carcinoma, mucinous carcinoma 
and signet ring-cell carcinoma. However Lauren's classification is the predominant histological 
classification worldwide that divides gastric carcinoma in two major subtypes - intestinal type and 
diffuse type carcinomas (Lauren 1965) although considering an third subtype designated  
unclassified or mixed type carcinoma. Nevertheless, intestinal type and diffuse type carcinomas 
don't differ only by histological appearance, but also by epidemiology, pathogenesis, and genetic 
profiles differences (Shah et al., 2011). Morphologically, these two types of gastric carcinoma 
differ in the intercellular adhesion molecules that are well preserved in intestinal-type tumors and 
defective in diffuse carcinomas. In intestinal-type carcinoma, cells are still attached in tubular or 
glandular formations (similar to adenocarcinomas arising in the intestinal tract - hence their 
designation as intestinal-type); in contrast to the lack of adhesion molecules in diffuse carcinomas 
allows individual tumor cells to grow and invade neighboring tissues without the formation of 
tubules or glands. Moreover, the molecular basis of these two carcinoma types is also different. In 
the diffuse-type carcinoma the main carcinogenic event is the loss of function of E-cadherin, a key 
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cell surface protein for intercellular adhesion and maintenance of the organization of epithelial 
tissues. Impairment of E-cadherin function occurs through biallelic inactivation of its related gene 
CDH1 via germline or somatic mutation, allelic imbalance events (loss of heterozygosity), 
epigenetic silencing of gene transcription through aberrant methylation of the CDH1 promoter 
(Oliveira et al., 2006; Carneiro et al., 2008; Yamamoto et al., 2011; Corso et al., 2012), or by 
modulation of E-cadherin N-glycosylation (Pinho et al., 2011). In the intestinal-type carcinoma the 
main carcinogenic event is H. pylori infection followed by a cascade of events where several 
molecular changes occur leading to transformation of gastric cells into intestinal type cells (as 
mentioned above).  
Although H. pylori associated preneoplastic lesions are a feature of intestinal-type gastric 
cancer, some evidences claimed that there is an association between H. pylori infection and 
diffuse-type gastric cancer (Handa et al., 1996; Uemura et al., 2001). The association of H. pylori 
infection and diffuse-type gastric cancer is observed during the progression of atrophic gastritis in 
individuals presenting active gastritis (Sipponen et al., 1992; Solcia et al., 1996). Conversely, in 
hereditary diffuse gastric cancer this association is not observed (Carneiro et al., 2004). 
Besides  gastric carcinoma, H. pylori infection in gastric mucosa is also associated with the 
development of mucosa-associated lymphoid tissue (MALT), increasing the risk of gastric MALT 
lymphoma (Parsonnet et al., 1994; Sagaert et al., 2010). This involvement is support by the fact 
that most of the patients with low-grade MALT-lymphoma are infected with H. pylori, and that, in 
most of these cases, eradication of H. pylori infection results in tumor regression (Thiede et al., 
1997; Zullo et al., 2010; Kuo et al., 2012). 
Briefly, there are several factors that contribute for gastric disease development. As mentioned 
above, also glycan antigen receptors expressed in the surface of gastric epithelial cells contribute 
for the development of gastric diseases. 
GLYCANS: WIDESPREAD MOLECULES THAT DECORATE CELL 
SURFACES 
It is amazing to observe that all living cells present a vast collection of glycan structures that 
decorate cell surfaces (Varki et al., 2009a; Varki 2011). Glycan expression on intracellular and 
cell surfaces proteins and lipids are implicated in numerous biological functions (Varki 1993). 
Oligosaccharide moieties are involved in cell-cell and cell-matrix interactions and recognition, intra- 
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and intercellular protein trafficking, pathogen infection, immuno responses and recognition of self, 
modulation of  protein function and signaling, as well as altering the dynamics of glycoprotein 
endocytosis and regulation of proper maturation and folding of newly synthesized proteins (Varki 
1993; Moremen et al., 2012) 
Glycosylation 
Glycosylation is characterized by the enzymatic covalent attachment of a carbohydrate to a 
polypeptide, lipid, polynucleotide, carbohydrate, or other organic compound catalyzed by 
glycosyltransferases using specific sugar nucleotide donor substrates; in opposition to the non-
enzymatic chemical reaction of glycation. 
The synthesis of a glycan structure is a very complex and organized process that involves a 
huge number of genes including those that code for glycosyltransferases, glycosidases and 
chemical chaperons, as well as the enzymes responsible for nucleotide sugars synthesis and 
transport (Rini et al., 2009). Furthermore, the availability and localization of the nucleotide sugar 
donors can compromise glycosyltransferases activity in the synthesis of a glycan structure. 
The human genome contains about 250 to 500 genes that are involved in the glycan 
assembly, like those that code for proteins involved in the synthesis and degradation of glycans or 
transport of sugar donors, accounting for approximately 2% of the total human genome 
(Schachter et al., 2009). Generally the enzymatic attachment of glycans occurs in non-
carbohydrate molecules forming the glycoconjugates. Glycoconjugates comprise a different class 
of molecules such as glycosphingolipids, glycosaminoglycans present as free polysaccharides or 
as part of proteoglycans, glycoproteins and glycosylphosphatidylinositol-linked proteins (Figure 
2). 
 Glycan structures can be attached to a lipid structure forming glycolipids. Almost all 
glycolipids in vertebrates are glycosphingolipids (GSLs) that belongs to the sphingolipid family 
(Schnaar et al., 2009). GSLs are characterized by the linkage of a glycan structure to an 
sphingolipid core structure called ceramide. The biosynthesis of GSLs occurs by a stepwise 
addition of sugars first to ceramide, typically in a β-linked galactose (galactosylceramide-GalCer) 
or glucose (glucosylceramide-GlcCer), and then to the arising glycan. GlcCer synthesis starts in  
the cytoplasmic face of the endoplasmic reticulum (ER) and early Golgi apparatus and is further 
elongated by a series of glycosyltransferases in the Golgi lumen. Conversely, GalCer synthesis 
occur on the ER lumen and then go through the Golgi, where it may be sulfated to form sulfatide. 
The elongation process leads to a variety of different combinations that subclassify GSLs as 
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neutral (no charged sugars or ionic groups), sialylated (having one or more sialic acid residues) 
generally known as gangliosides, or sulfated. GSLs are found embedding in the cell membranes, 
due to hydrophobic properties of the lipid tail, contributing for the maintenance of cell membranes 
integrity and clustered in lipid rafts contributing for cell signaling processes (Schnaar et al., 2009). 
 
 
Figure 2: Common classes of animal glycan structures. The major classes of animal glycans are shown, with 
an emphasis on typical vertebrate sugar chains. Most glycans on membrane and secreted proteins are found in 
N-linkage to Asn or in O-linkage to Ser/Thr. O-linked glycans are classified by their initiating monosaccharide. Addition 
of GalNAc initiates mucin-type O-linked glycans and extension with Gal, GlcNAc or GalNAc produces eight different 
core structures. Man linked initiates another class of O-linked glycan (O-Man glycans), as well as Fuc residues (O-Fuc 
glycans). O-linked GlcNAc is found on the extracellular domains of some proteins and on numerous cytosolic and 
nuclear proteins. Furthermore, O-linked glycan structures can be found attached to other amino acids, including Glc 
residue to Ser and Tyr residues of glycogenin, and Gal on hydroxylysine of collagen domains. Also 
glycosaminoglycans (GAGs) are O-linked glycans initiated by a conserved tetrasaccharide 
(GlcA-β1,3-Gal-β1,3-Gal-β1,4 Xyl-β) and classified by the composition of their disaccharide repeat that are usually 
found attached to proteins forming proteoglycans. A GAG-like polymer that forms hyaluronic acid is the only glycan 
that is not linked to a protein or lipid. In addition to proteins, sphingolipids can be modified by glycosylation, which 
are ceramide-linked glycans.The monosaccharide abbreviations are Man, Mannose; Gal, Galactose; GalNAc, N-
acetylgalactosamine; Fuc, Fucose; Glc, Glucose; GlcNAc, N-acetylglucosamine; GlcN, Glucosamine; Xyl, Xylose; GlcA, 
Glucuronic acid; and IdoA, Iduronic acid. Adapted from (Moremen et al., 2012). 
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Glycosaminoglycans (GAGs) are larger linear polysaccharides, formed by repeated 
disaccharide building blocks composed of an amino sugar (N-acetylglucosamine-GlcNAc, 
glucosamine-GlcN  that is variously N-substituted, or N-acetylgalactosamine-GalNac) and either an 
uronic acid (glucuronic acid-GlcA or iduronic acid-IdoA) or galactose (Gal). GAGs can be found as 
free polysaccharides, such as hyaluronic acid, or as part of proteoglycans. Proteoglycans are 
characterized by one or more GAGs covalently attached to a protein core. GAGs are attached to 
proteins by a conserved tetrasaccharide (GlcA-β1,3-Gal-β1,3-Gal-β1,4 Xyl-β) to Ser residues in an 
O-linkage that will be further elongated with disaccharide repeats giving rise to two different 
classes: chondroitin sulfate and heparan sulfate (Esko et al., 2009). Besides proteoglycans, GAGs 
can also be found as a free polysaccharide such as hyaluronic acid. Hyaluronic acid is the only 
glycosaminoglycan synthesized in the plasma membrane, with the growing polymer being 
secreted into the extracellular environment. The synthesis of hyaluronic acid is catalyzed by 
hyaluronan synthases (HAS) and consists of repeating disaccharides composed of GlcNAc and 
GlcA. Hyaluronic acid is the only glycan that is not linked to a protein or lipid (Hascall et al., 
2009). Proteoglycans and glycosaminoglycans can be found on the cell surface, inside the cell, 
and in the extracellular matrix (ECM) and account for many functions like promoting cell adhesion 
to ECM; binding of cytokines, chemokines and growth factors; acting as receptors for proteases 
and as coreceptors for various and tyrosine kinase growth factors receptors (Esko et al., 2009).  
As mentioned above, proteins can also be glycosylated giving rise to glycoproteins. 
Glycoproteins show a huge heterogeneity in its glycan structure that can be usually attributed to a 
non template driven biosynthetic process in endoplasmic reticulum and Golgi compartment, and 
a lack of any proofreading machinery. In addition, the composition of the final glycan structure 
relies on the polypeptide backbone as well as a number of variable factors such as the expression 
levels of glycosidases and glycosyltransferases and the availability of substrates, which fluctuate 
during cell growth, differentiation and development (Schwientek et al., 2002; Varki et al., 2009b; 
Du et al., 2010; Fernandez-Valdivia et al., 2011). There are several types of glycan linkage on 
proteins that present different glycan biosynthesis and composition wich will be discussed with 
detail in the next section. 
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GLYCOSYLATION THE MOST DIVERSE POST-TRANSLATIONAL 
MODIFICATION OF PROTEINS  
Newly formed proteins synthesized in the ER, can be further decorated with one or more 
biochemical moieties, a process so called post-translational modification (PTM), giving rise to a 
huge protein heterogeneity. Several types of modifications can occur in proteins and the 
understanding of the extent and pattern of these PTMs gives insight into the function and 
dynamics of the proteome.  
PTM can be classified in two main categories: the first include the covalent addition of 
chemical groups by enzymatic catalysis, the second comprises the cleavage of peptide backbones 
by the action of proteases or autocatalysis. Many modifications resulting in the addition of 
chemical group to an amino acid residue can be found in proteins, and the major types of protein 
covalent modifications are phosphorylation, acetylation, glycosylation, methylation, and 
ubiquitylation. These covalent addition are classified according to the type of amino acid side 
residue involved, the class of the enzyme implicated in the process and the degree of reversibility 
(Walsh et al., 2005). Among these major types of PTMs, glycosylation is the most diverse and 
complex modification that occurs in proteins, with at least one half of the known proteins 
estimated to be glycosylated (Apweiler et al., 1999). This type of modifications strongly influences 
many of the protein functional aspects, including cellular localization, turnover and protein quality 
control (Fukuda et al., 1989; Parodi 1999; Arnold et al., 2007). Protein glycosylation can be 
classified into several types according to the glycan linkage site: N-linked glycosylation, O-linked 
glycosylation, C-linked glycosylation (C-mannosylation), Phospho-linked glycosylation or 
phosphoglycosylation and glycophosphatidylinositol (GPI)-anchored glycosylation or 
glypiation (Spiro 2002; Moremen et al., 2012) (Figure 2). 
Proteins at the cell surface can be integrated in the cell membrane by a GPI-anchored 
moiety, called GPI-anchored proteins firstly described in 1985 (Ferguson et al., 1985). 
Proteins are attached to GPI via their carboxyl termini through a phosphodiester linkage of 
phosphoethanolamine to a trimannosyl-non acetylated glucosamine (Man3-GlcN) core (Man(α1–
2)Man(α1–6)Man(α1–4)GlcN), and can be found in the outer leaflet of the lipid bilayer facing the 
extracellular environment. The reducing end of GlcN is linked to phosphatidylinositol (PI) which is 
then anchored by another phosphodiester linkage to the cell membrane through its hydrophobic 
region and the distal, nonreducing mannose residue is attached to the protein via an 
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ethanolamine phosphate (EtNP) bridge between the C-6 hydroxyl group of mannose and the α-
carboxyl group of the carboxy-terminal amino acid. The Man3-GlcN core oligosaccharide core can 
suffer various modifications during all the process of secretion from the cell (Ferguson et al., 
2009). GPI-anchored proteins have been described as having a critical role in a variety of receptor 
mediated signal transduction pathways, adhesion, and antigenicity (Maeda et al., 2011). 
Another type of protein glycosylation is the phosphoglycosylation, the most abundant 
protein glycosylation in parasites. This type of glycosylation is characterized by the enzymatic 
addition of sugar residues to serine (Ser) residues in the polypeptide chain, through a 
phosphodiester linkage. The presence of phosphoglycans in proteins, more specifically GlcNAcα-
1-P, was firstly described in 1980 by Gustafson and Milner in endopeptidase Proteinase I isolated 
from Dictyostelium discoideum (Gustafson et al., 1980), but it was only in 1995 that this linkage 
was demonstrated to be in Ser residues, catalyzed by UDP-GlcNAc:Ser protein N-
acetylglucosamine-1-phosphotransferase (Ser:GlcNAc phosphotransferase) and the process called 
phosphoglycosylation (Freeze et al., 1995). Since that, other sugar residues were found to be 
linked to Ser residues by a phosphodiester linkage such as Mannose (Man) residues (Ilg et al., 
1994) or Xylose (Xyl) (Haynes et al., 1996). A specific role for phosphoglycoproteins is not yet 
elucidated, however some studies associate phosphoglycoproteins with the immunogenicity of the 
parasites (Cooper et al., 1993; Ilg et al., 1993).  
Moreover, mannose (Man) carbon-carbon (C-C) linkages to the C2 position of tryptophan (Trp) 
residues were also described and named C-mannosylation (Hofsteenge et al., 1994; de Beer et 
al., 1995; Loffler et al., 1996). This type of protein glycosylation can be found in cells from a 
variety of mammals (Krieg et al., 1997), and involves a protein O-mannosyltransferase (POMT) 
that uses dolichyl-phosphate-mannose as a precursor (Doucey et al., 1998), know to occur in a 
consensus sequence -W-x-x-W/F- (x could be any amino acid) in which the first Trp residue 
becomes mannosylated. Sequences presenting alternative phenylalanine (Phe) to Trp residue 
show a reduced efficiency of 3.5-fold in C-mannosylation (Krieg et al., 1998).  
In addition to the above described types of glycosylation, there are two main types of protein 
glycosylation in eukaryotes, the N- and the O-linked glycans. N- glycosylation is described by 
the addition of a sugar precursor to a nitrogen group of an asparagine (Asn) amino acid. In 
contrast, O-glycosylation is characterized by the addition of monosaccharides to a hydroxyl 
group of Ser, threonine (Thr) and tyrosine (Tyr) residues; and, to a lesser extent, to hydroxyproline 
and hydroxylysine (Spiro 2002). The different classes of O-glycans are known to be dependent on 
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the first added sugar (Brockhausen et al., 2009), including α- or β-linked O-Gal (Seyer et al., 
1977), β-linked O-GlcNAc (Hart 1997), α-linked O-Man (Endo 1999), α-linked O-Fuc (Harris et al., 
1993; Hofsteenge et al., 2001), α- or β-linked O-Glc (Harris et al., 1993), β-linked O-Xyl (GAGs) 
(Kresse et al., 1994; Lin 2004) and the most abundant form of O-linked glycosylation in higher 
eukaryotes α-linked O-GalNAc also known as mucin type O-glycans (Van den Steen et al., 1998). 
The structural complexity of the chains initiated by O-linked GalNAc is very high, exceeding that of 
other O-linked and N-linked chains. In addition, there is the O-GlcNac glycosylation that is the only 
type of protein glycosylation, mainly found on intracellular nucleocytosolic proteins. This type of 
glycosylation is characterized by a reversible process comprising a single GlcNAc residue added to 
Ser and/or Thr, and is important in the modulation of the biological activity of intracellular 
proteins (Holt et al., 1986), often competing with phosphorylation (Wang et al., 2008).  
The Biosynthetic Pathway of N-glycosylation 
In all eukaryotes, the core pathway for the establishment of N-linked glycosylation is well 
conserved (Stanley et al., 2009b). This process mainly takes place in the endoplasmic reticulum 
(ER) and further processing and rebuilding of the N-glycans occurs in the Golgi compartment 
generating a large diversity of possible structural outcomes (Dennis et al., 2009; Varki et al., 
2009c). N-glycosylation is considered an important protein posttranslational modification in 
eukaryotic cells given the high occurrence of N-glycans in glycoproteins. It is estimated that about 
90 % of all glycoproteins carry N-linked glycans with an average of 1.9 N-linked glycans per 
polypeptide chain (Apweiler et al., 1999). 
Sugars that constitute N-glycan structures are covalently attached to the proteins at asparagine 
(Asn) residues by an N-glycosidic bond, and five different N-glycan linkages have been reported, of 
which N-acetylglucosamine to asparagine (GlcNAcβ1-Asn) is the most common (Stanley et al., 
2009b). This N-glycosylation process starts in the ER and is characterized by a linkage to Asn 
residue, via a common trimannosyl chitobiosyl pre-assembled core sugar structure. The 
assembled of this core structure can occur whenever a consensus sequence Asn-X-Ser/Thr is 
present in the nascent protein, where X can be any amino acid with the exception of proline. Less 
commonly, the sequence Asn-X-Cys can also be used to construct N-glycan structures (Gavel et 
al., 1990; Sato et al., 2000).  
The biosynthesis of the core trimannosyl chitobiosyl structure, starts in the cytosolic surface of 
the ER membrane, and is characterized by a stepwise addition of two N-acetylglucosamines (2 
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GlcNAc) and five mannoses (5xMan) to dolichylphosphate (Dol-P) giving rise to Dol-P-P-
GlcNAc2Man5 (Helenius et al., 2001; Helenius et al., 2004). Thereafter, the Dol-P-P-GlcNAc2Man5 
structure is "flipped" to the luminal side of ER membrane where four mannose and three glucose 
additional residues are added forming the final core structure Dol-P-P-GlcNAc2Man9Gluc3. The 
substrate donors for the addition of the last four Man and three Glc are the Dol-P-Man and Dol-P-
Glc, also made on the cytoplasmic face of the ER and “flipped” onto the luminal face. Each of the 
sugar additions is catalyzed by a specific glycosyltransferase located on both sides of the ER 
membrane (Helenius et al., 2001; for a review see Stanley et al., 2009b).  
The transfer of the complex core structure from the Dol-P-P-GlcNAc2Man9Gluc3 donor to the 
nascent polypeptide backbone takes place in the ER lumen and is catalyzed by the 
oligosaccharyltransferase (OST) enzyme complex (Helenius et al., 2001; Helenius et al., 2004; 
Stanley et al., 2009b). Following the covalent attachment of the core oligosaccharide to Asn 
residues, a series of processing reactions trims the N-glycan in the ER. First, the three Glc 
residues (the terminal α1–2Glc and the two inner α1–3Glc) are removed sequentially by α-
glucosidases I and II, followed by one mannose removal by ER α-mannosidade which specifically 
removes the terminal α1–2Man from the central arm of Man9GlcNAc2. These initial steps are 
known to be important in regulating glycoprotein folding, a process that is mediated by the 
interaction between enzymes and chemical chaperons in the ER that recognize specific features 
of the trimmed glycan. At this point, misfolded proteins can be recognized and targeted for ER 
degradation by two different quality control processes, the calnexin/calreticulin system and the ER 
degradation-enhancing α-mannosidase I–like protein (EDEM). Calnexin (membrane-bound) and 
calreticulin (soluble) sequester the newly synthesized glycoprotein and act as molecular 
chaperones by a deglucosylation reglucosylation cycle promoting correct folding, preventing 
aggregation of folding intermediates, blocking premature oligomerization, and by facilitating 
formation of native disulfide bonds (Stanley et al., 2009b). Another group of proteins that are 
believed to interact with the deglucosylated chain and help in the correct folding of glycoproteins 
are EDEMs. Little is known about EDEMs functions, however evidence suggests that EDEMs have 
catalytic activity and that overexpression enhances misfolded glycoprotein degradation (Freeze et 
al., 2009). During this quality control process, if glycoproteins fail to fold or oligomerize properly 
they are eventually retrotranslocated to the cytoplasm and destroyed by N-deglycosylation and 
proteasomal degradation, a process called ER-associated degradation (ERAD). 
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When correctly folded, glycoproteins leave the ER and travel through the Golgi compartment 
where several steps of removal and addition of sugars occur by the action of several glycosidases 
and glycosyltransferases, creating a variety of glycan structures. In the majority of the multicellular 
organisms, glycoproteins entered in the cis-Golgi compartment and trimming of α1–2Man 
residues is carry on by the action of α1–2 mannosidases, originating the Man5GlcNAc2 
intermediate glycan structure for the synthesis of hybrid and complex N-glycans. Further 
processing reactions for the biosynthesis of hybrid and complex N-glycans are initiated in the 
medial-Golgi and are pursued in the trans-Golgi (Helenius et al., 2001). In the end, N-glycan 
structures share a common pentasaccharide core region (Manα1–6(Manα1-3)Manβ1–
4GlcNAcβ1–4GlcNAcβ1-Asn) that can be classified into three main classes: high-mannose 
type, complex type and hybrid type (Figure 3).  
The biosynthesis of these three different glycan structures occurs in a stepwise manner by the 
action of several enzymes such as N-acetylglucosaminyltransferases, galactosyltransferases, 
sialyltransferases and fucosyltransferases, in a very well-orchestrated fashion (Stanley et al., 
2009b). In brief, the high mannose type structure is characterized by the presence of only 
mannose residues attached to the pentasaccharide core structure; complex type has two 
antennae or branches initiated by the addition of two GlcNAc residues catalyzed by N-
acetylglucosaminyltransferases (GnTs); and hybrid type in which mannose residues are attached 
to the Manα1–6 arm and a GlcNAc residue to the Manα1–3 arm of the core structure (Helenius 
et al., 2001; Helenius et al., 2004; Stanley et al., 2009b). 
 
 
Figure 3: Types of N-glycans. N-glycans added to protein at Asn-X-Ser/Thr sequons, that shear a common core 
Man3GlcNAc2Asn, are of three general types in a mature glycoprotein: High mannose, Complex, and Hybrid. 
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The enzymes responsible for the synthesis of complex structures in N-glycans are common to 
the elongation process of the mucin type O-glycosylation, and occur both in the Golgi 
compartment. For this reason, the terminal protein glycosylation can be very similar between N- 
and O-glycans. 
Biosynthesis of Mucin Type O-glycosylation 
In contrast to N-glycosylation, the O-glycosylation is a stepwise process with monosaccharide 
added incrementally, beginning with the addition of a single sugar residue to either a Ser or Thr 
amino acids in the protein backbone and then to the nascent sugars in a process called 
elongation. O-linked glycosylation is a relatively late-stage event in the protein maturation, and 
involves a large set of enzymes localized at the Golgi compartment (Hanisch 2001).  
The most ubiquitous type of initial O-glycosylation is the one formed by the addition of GalNAc 
(O-GalNAc) to Ser or Thr, also described as mucin type glycosylation. The addition of the first 
monosaccharide residue on protein backbones is mediated by a family of UDP-
GalNAc:polypeptide GalNAc-transferases (ppGalNAc-Ts) and occurs in the Golgi 
compartment (Roth et al., 1994; Clausen et al., 1996; Rottger et al., 1998; Bennett et al., 2012; 
Gerken et al., 2013). Although most protein glycosylation events are controlled by one or two 
genes encoding the enzymes responsible for the initiation step of glycosylation, human mucin-
type O-glycosylation is controlled by a large family of up to 20 homologous genes encoding 
ppGalNAc-Ts, fifteen of which were confirmed to be expressed and functionally active (Clausen et 
al., 1996; Ten Hagen et al., 2003; Tian et al., 2009; Bennett et al., 2012). The addition of 
GalNac residues by ppGalNAc-Ts is not dependent on a defined consensus recognition sequence 
and in theory, any Ser or Thr residues can be O-glycosylated. However, some aspects have been 
identified that allow an improved prediction of the polypeptide O-glycosylation sites (Hansen et al., 
1995; Julenius et al., 2005; Gerken et al., 2011). Some authors claimed that the initiation of 
GalNAc glycosylation by ppGalNAc-Ts is ruled by the sequence context of putative O-glycosylation 
sites. Each ppGalNAc T isoform may be uniquely sensitive to peptide sequence and overall 
charge, which together dictates the substrate sites that will be glycosylated (Clausen et al., 1996; 
Kato et al., 2001; Gerken et al., 2006; Wandall et al., 2007; Gerken et al., 2011). Moreover, 
there are evidences for a dynamic regulatory mechanism of the initial GalNAc addition, either by 
competition for different substrate sites or by competition of ppGalNAc-Ts with the 
glycosyltransferases responsible for the formation of core glycans (Hanisch et al., 1999; Gill et al., 
2011). Also very interesting is that tissues show specific ppGalNAc-Ts enzyme expression 
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(Bennett et al., 1998; Bennett et al., 1999; Mandel et al., 1999; Gomes et al., 2009). Overall, the 
cellular repertoire of glycosyltransferases, with their distinct donor and acceptor sugar 
specificities, their localizations in sub-compartments of the Golgi and their sequential action will 
dictate the cell's specific O-glycosylation profile.  
In mucin type glycosylation the addition of the first monossacharide residue by ppGalNAc-Ts, 
which transfer a GalNAc residue from a sugar donor UDP-GalNAc to Ser/Thr residues of the 
acceptor protein, gives rise to the formation of the Tn antigen (GalNAc-Ser/Thr) (Figure 4). A 
two-step model of O-GalNAc biosynthesis is proposed, where a subset of GalNAc-Ts add GalNAc at 
low density to the polypeptide chain, preferentially with unglycosylated Ser/Thr residues or those 
containing GalNAc-Ser/Thr flanking the active site; and another subset of GalNAc-Ts that catalyze 
the addition of GalNAc residues to Ser/Thr adjacent to the existing GalNAc-Ser/Thr sites 
(reviewed in Gill et al., 2011). This initial step regulates the site and level of occupancy of total O-
glycan modification in the target proteins, which will be then further elongated giving rise to the 
global final glycan chain structure. Extension of the GalNAc residue can generate eight different 
cores (Figure 4) and cores 1 to 4 are the most common in humans. Elongation of the GalNAc 
residue can be employed by C1GalT enzyme or T synthase, originating the core 1 structure, also 
known as T antigen (Galβ1-3GalNAc-Ser/Thr); or by C3GnT making the core 3 structure 
(GlcNAcβ1-3GalNAc-Ser/Thr) (Figure 4). Further elongation of these core 1 and core 3 
structures is performed by C2GnT family of enzymes that catalyze the specific addition of a 
β1,6GlcNAc originating the corresponding core 2 and core 4 structures (Figure 4). Therefore, 
the C2GnT1 and C2GnT3 function to synthesize the core 2 structure, whereas C2GnT2 catalyzes 
the core 4 synthesis (reviewed in Gill et al., 2011). 
Additional core extension can occur in the GlcNAc moiety of the core 2 and core 4 O-glycans in 
two different ways: addition of a simple Gal alone by β3/4GalT enzymes or by addition of poly-
lactosamine repeats (Gal-GlcNAc) through the concerted action of β3/4GalT and β3/4GnT 
enzymes. Conversely, the core 3 GlcNAc moiety is only extended through the addition of Gal by 
β4GalT4 or β3GalT5. The extension of core structures by the action of β3/4 Gal-Ts and β3/4 Gn-
Ts leads to type 1 and type 2 chains formation, where type 1 chains are characterized by the β1,3 
linkage of the Gal residue to the GalNAc, while in type 2 chains this linkage is β1,4. Both chains 
are frequently terminated by Lewis-type blood group-related antigens. Finally, all O-glycan are 
capped to terminate O-glycosylation through addition of sialic acid by ST3Gal- and ST6Gal-
sialyltransferases.  
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Figure 4: Schematic representation of mucin type O-glycosylation biosynthesis pathway. The image 
depicts the biosynthetic pathway of mucin type glycosylation that can generate eight different cores structures (with 
cores 1 to 4 the most common in humans), and are extended giving rise to a vast diversity of structures. For image 
simplicity only representative enzymes were included. Gray boxes correspond to cancer-associated antigens. 
As mentioned above, there are four additional core O-glycans structures (core 5–8) that have 
been biochemically characterized in tissues. They are thought to be generated through direct 
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modification of the nascent GalNAc O-glycan but the enzymatic machinery necessary to generate 
these O-glycans is not known.  
Furthermore, some of these branching reactions, like the formation of Type 1 and Type 2, are 
common to other O- and N-glycans and glycolipids. For instance, once N-glycans are produced in 
the ER and early Golgi, and O-glycan and glycosphingolipids core structures are generated within 
the Golgi apparatus, each can be modified with outer extensions, which can be highly similar 
among these three classes of glycans (Stanley et al., 2009a). Moreover, the same 
glycosyltransferases can compete for extending the termini of these three types of glycan chains, 
highlighting the importance of the Golgi compartment in generating glycan diversity (Varki 2011).  
More recently, it has been suggested a new alternative model of GalNAc addition based on the 
subcellular localization of GalNAc-Ts (Gill et al., 2010). Despite the fact that many studies 
reported that enzymes responsible for O-GalNAc addition are expressed in the Golgi compartment, 
this work clearly demonstrates the possible localization of GalNAc-Ts in the ER depending of 
physiological status of the cells. It was shown that GalNAc-Ts from the Golgi compartment can be 
relocated to the ER by COP-I coat vesicles retrograde trafficking, a process that is regulated by the 
Src tyrosine kinase, driving a significant increase in O-glycosylation initiation. This increase in O-
GalNAc addition impairs the activity of downstream enzymes resulting in increased short glycan 
synthesis, such as STn, Tn and T (reviewed in Gill et al., 2011). It is important to note that Src is 
a proto-oncogene often implicated in cancer (Guarino 2010), and concurrently cancer cells 
commonly express short truncated glycans, including Tn, sialyl-Tn and T antigens, that are usually 
absent in normal tissues (Springer 1984; David et al., 1992; Werther et al., 1996; Baldus et al., 
2000; Leivonen et al., 2001). 
ABERRANT GLYCOSYLATION IN CANCER 
Glycosylation is a feature that enhances the functional diversity of proteins and influences their 
biological activity. Dysfunction of glycans at the cell surface or in secreted proteins is recognized 
as a factor that can cause or contribute to the development of several diseases, with alterations in 
glycosylation being frequently observed in patients suffering from congenital diseases, 
immunodeficiency and cancer (Hakomori 2002; Ohtsubo et al., 2006; Drake et al., 2010; Tabak 
2010). Particularly during carcinogenesis, glycans are recognized to be involved in different 
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stages of tumor progression, being key players in the proliferation, invasion, metastasis and 
angiogenesis processes (Fuster et al., 2005).  
In cancer, glycans structures are different from their normal counterpart, making glycosylation 
changes a hallmark of malignant cell transformation. The most frequently reported tumor-
associated glycosylation alterations are the increased sialylation and polysialic acid synthesis, the 
appearance of sialylated Lewis antigens in glycolipids and glycoproteins, the formation of 
truncated O-glycan chains and the increase in branching of N-glycans (David et al., 1992; Reis et 
al., 2010; Kang et al., 2011; Pinho et al., 2011; Dall'Olio et al., 2012). Some of the glycosylation 
changes that are frequently observed in cancer are summarized in Figure 4 grey boxes. 
One of the underlying causes of glycosylation changes observed in cancer is the deregulated 
expression or localization of glycosyltransferases and associated proteins within the tumor cell 
(Hakomori 2002; Gill et al., 2011; Meany et al., 2011; Harduin-Lepers et al., 2012). Several 
different glycosyltransferases have been described to present altered expression during the 
carcinogenesis process. Among the best characterized glycosyltransferases are N-
acetylglucosaminyltransferase V (GnT-V), which is overexpressed through regulation by the Ets-1 
transcription factor in malignant cancer cells (Ko et al., 1999) and is responsible for the increased 
expression of branched N-glycans (Pinho et al., 2009; Taniguchi et al., 2011; Pinho et al., 2012); 
and sialyltransferases (Dall'Olio et al., 2001; Harduin-Lepers et al., 2012), which are at least 
partially responsible for the generation of the polylactosamine residues, polysialic acid, terminal 
and truncated sialylated structures and some gangliosides.  
Altered expression of sialyltransferases and their associated products have been widely studied 
in cancer (Harduin-Lepers et al., 2012). Sialylated glycan structures, that result from the 
increased expression of sialyltransferases (STs) (Harduin-Lepers et al., 2012), include sialyl Lewis 
antigen (SLe) and sialyl-Tn (STn). These structures are commonly observed on glycoproteins and 
gangliosides in various cancers, which are frequently associated with poor prognosis in patients 
with breast (Cazet et al., 2010b), colon (Itzkowitz et al., 1990) and stomach (David et al., 1992; 
Ma et al., 1993; Marcos et al., 2011) cancer. Up to 20 different sialyltransferases have been 
described to catalyze the transfer of sialic acid residues from a donor substrate CMP-sialic acid to 
the oligosaccharide side chain of the glycoconjugates. This sialic acid generally occupies the 
terminal non-reducing position on glycan chains (Harduin-Lepers et al., 2005). Different 
sialyltransferases show a cell and tissue specific expression pattern and differ in substrate 
specificities and types of linkage formed (Harduin-Lepers et al., 2005). Depending on these 
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characteristics, STs are classified in four families - ST3Gal, ST6Gal, ST6GalNAc and ST8Sia. 
ST3Gal transferases are α2,3-STs and are partially responsible for the biosynthesis of sialylated 
Lewis structures since they can act on both type 1 (Gal β1,3 GlcNAc) or type 2 (Gal β1,4 GlcNAc) 
disaccharide sequences. The sialyltransferase ST3Gal III preferentially acts on type 1 rather than 
on type 2 disaccharides and is involved in the synthesis of SLea (Kitagawa et al., 1993). 
Alternatively, ST3Gal IV and ST3Gal VI mainly catalyze the α2,3 sialylation of type 2 
disaccharides, leading to the biosynthesis of SLeX (Okajima et al., 1999; Ellies et al., 2002; Conze 
et al., 2010; Colomb et al., 2012; Yang et al., 2012). In cancer, the increased expression of 
sialylated Lewis-type blood group antigens, such as SLea and SLeX, mimics their normal 
expression on blood cells (monocytes and neutrophils) potentiating cancer cell migration through 
binding to endothelial cell selectins (Varki 1994; Fuster et al., 2005). Therefore, SLea and SLeX 
overexpression are a common feature of several carcinomas (e.g., lung, colon, gastric and 
pancreas) and are associated with increased metastatic capacity (Fukuoka et al., 1998; Kim et 
al., 1998; Tatsumi et al., 1998; Borsig et al., 2002; Perez-Garay et al., 2013) and poor overall 
patients' survival (Nakamori et al., 1997; Amado et al., 1998; Baldus et al., 1998; Nakamori et 
al., 1999; Grabowski et al., 2000). 
Besides ST3Gal transferases, ST6GalNac transferases also show different expression in 
cancer. The expression of ST6GalNAc transferases, in particular ST6GalNAc I (Marcos et al., 
2004; Sewell et al., 2006; Marcos et al., 2011; Julien et al., 2012; Ferreira et al., 2013), have 
been associated with the expression of STn antigen in cancer. The STn antigen (Neu5Acα2-
6GalNAcα-O-Ser/Thr), is a simple mucin-type carbohydrate antigen that shows limited expression 
in normal tissues but is highly expressed in most gastric (David et al., 1992; Victorzon et al., 
1996; Baldus et al., 2000), colorectal (Itzkowitz et al., 1990), ovarian (Kobayashi et al., 1992), 
breast (Yonezawa et al., 1992; Leivonen et al., 2001; Sewell et al., 2006), pancreatic (Kim et al., 
2002) and bladder (Ferreira et al., 2013) carcinomas. The expression of STn is an established 
indicator of poor prognosis in patients with gastric (Werther et al., 1994; Werther et al., 1996; 
Nakagoe et al., 2002), colorectal (Itzkowitz et al., 1992; Karlen et al., 1998), and ovarian cancer 
(Holmberg et al., 2000) and contributes to the aggressive phenotype of carcinoma cells by 
altering their behavior (Clement et al., 2004; Julien et al., 2005; Julien et al., 2006; Pinho et al., 
2007; Ferreira et al., 2013). Expression of STn is also observed in precursor and early lesions of 
carcinomas of the gastrointestinal tract, such as intestinal metaplasia of the stomach (David et 
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al., 1992; Ferreira et al., 2006), adenomatous polyps (Itzkowitz et al., 1992), chronic ulcerative 
colitis (Karlen et al., 1998) and pancreatic intraepithelial neoplasias (Kim et al., 2002). 
Moreover, expression of truncated O-glycans such as STn and Tn antigens in cancer hs also 
been associated to dysfunction of proteins associated to glycosyltranferases and all the 
glycosylation process. One example is the deficiency in Cosmc chaperon protein that was 
demonstrated to lead to the synthesis of Tn and STn antigen (Ju et al., 2008b; Wang et al., 
2010). Cosmc protein is known to stabilize T synthase, the enzyme responsible for Core 1 
synthesis. T synthase enzyme is present in most cell types, and in vertebrates it requires Cosmc 
specific chaperone to be correctly exported from endoplasmic reticulum to the Golgi compartment 
ensuring its fully activity (Ju et al., 2008a; Aryal et al., 2010; Ju et al., 2011; Sun et al., 2011). As 
consequence of the presence of these truncated O-glycans at the cell surface of cancer cells, 
antigenic peptide backbones that are not accessible in normal cells are exposed (Burchell et al., 
2001). 
Mucins are the major carriers of cancer-associated carbohydrates, including truncated 
oligosaccharides forms (immature) and sialylated terminal structures. There are many 
descriptions about mucin aberrant glycosylation in cancer. For example, some adenocarcinoma 
cells, such as the case of breast, over-express the cell-membrane mucin MUC1 with truncated 
non-branched O-glycans consisting of Tn and STn antigens as well as of Core 1 glycans such as T 
and sialyl-T (ST) antigens, whereas in the normal cell counterpart branched O-glycans of Core 2 
and to a lesser extent of Core 3 are typical found in glycoproteins (Lloyd et al., 1996; 
Brockhausen 2006; Singh et al., 2007; Cazet et al., 2010a). In gastric cancer it was described 
the presence of T antigen in MUC1 protein (Santos-Silva et al., 2005) and also STn antigens in 
MUC2 protein, and this last is also found in intestinal metaplasia, a gastric precursor lesion 
(Ferreira et al., 2006; Conze et al., 2010). More recently, Pinto et al. demonstrated that, in a 
panel of different carcinoma tissues, several different mucins were abnormally glycosylated (Pinto 
et al., 2012). 
Aberrant Glycosylation In Gastric Cancer 
Many different glycan alterations have been described in gastric lesions and cancer. Recently, 
differences have been observed in the glycosylation of gastric mucins in different gastric lesions 
(Conze et al., 2010; Pinto et al., 2012). As described previously in this chapter, gastric 
carcinogenesis, in most of the cases, is characterized by the development of a chronic 
inflammation upon H. pylori infection that can evolve to gastric cancer. During the gastric 
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carcinogenesis pathway many different alterations occur and interestingly this process is 
accompanied by changes on the gastric mucosa glycosylation profile of glycoconjugates. 
Human gastric tissues express several different mucins representing a very broad family of 
polydisperse high molecular weight glycoproteins that are part of the gastric mucosa and 
glycocalyx. From the more than 20 mucins already described (Rose et al., 2006), MUC1, MUC4, 
MUC5AC, and MUC6 are expressed in gastric tissue (Audie et al., 1993; De Bolos et al., 1995; 
Ho et al., 1995; Byrd et al., 1997; Reis et al., 1997; Reis et al., 1998; Reis et al., 2000), with 
MUC1, MUC5AC, and MUC6 being the most prominent (Ho et al., 1995). Gastric mucins are 
highly glycosylated and from one single several hundred of carbohydrate chains arise. The 
carbohydrate chains covering gastric mucins are extremely diverse contributing to the complexity 
of these molecules. The biosynthesis of the carbohydrate chains present on proteins and lipids on 
cell membranes involve many different glycosyl- and sulfotransferases, resulting in a myriad of 
final sugar structures. In the gastrointestinal tissues, the high levels of C3GnT enzyme favor the 
biosynthesis of the core 3 structures and the downstream core 4 O-glycans (Iwai et al., 2002). 
Thus, the normal gastric mucosa expresses mostly neutral glycans, but upon H. pylori infection 
and inflammation, there is de novo expression of charged sialylated Lewis antigens, including SLeX 
and SLea (Ota et al., 1998; Mahdavi et al., 2003; Kobayashi et al., 2004; Marcos et al., 2008). 
Besides the de novo expression of these sialylated Lewis antigens in gastric lesions, it is also 
described the expression of STn antigen in MUC 2 present in goblet cells in intestinal metaplasia 
tissues (Ferreira et al., 2006; Conze et al., 2010). Briefly, two main types of intestinal metaplasia 
have been described so far according to the mucin expression profile. The complete type, that is 
characterized by loss of expression of the typical gastric mucins MUC1, MUC6 and MUC5AC and 
the de novo expression of MUC2; and the incomplete type that co-expresses gastric mucins 
MUC1, MUC6 and mostly MUC5AC with the intestinal MUC2 mucin (Reis et al., 1999). In 
addition to gastric precursor cancer lesions, it is also observed overexpression of sialylated 
antigens in gastric tumor cells (Baldus et al., 1998), and expression of dimeric SLeX was 
associated with venous invasion and poor disease prognosis (Amado et al., 1998). In addition to 
sialylated glycans, most of the gastric tumors also show high expression of the simple mucin type 
antigens Tn and STn (David et al., 1992; Baldus et al., 2000) and expression of MUC2 (Pinto-de-
Sousa et al., 2002; Mesquita et al., 2003). 
In gastric tissues ST6GalNAc-I was proposed as a major enzyme responsible for controlling 
STn expression (Marcos et al., 2011), and also ST3Gal IV (Carvalho et al., 2010; Jun et al., 
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2012), FUT IV (Petretti et al., 1999) and β3GnT5 (Marcos et al., 2008) have been described to 
be involved in SLeX antigen expression. In gastric carcinoma tissues, the increased expression of 
ST3Gal IV (Petretti et al., 1999; Jun et al., 2012) is associated with increased expression of α2,3 
sialic acids and sialyl Lewis antigens and correlated with poor prognosis and increased metastatic 
capacity (Amado et al., 1998). These reports highlight the role of sialyltransferases and 
demonstrate that the expression of crucial glycan determinants, such SLeX, plays an important 
role in gastric tumor progression. However, the molecular mechanisms underlying this altered 
enzyme expression and aggressive behavior of gastric cancer cells expressing these glycan 
determinants are not fully understood. 
More recently, some studies pointed out the role of the inflammation process and interleukin 
(IL) production in the expression of several glycosyltransferases involved in SLeX biosynthesis 
(Blander et al., 1999; Higai et al., 2006; Marcos et al., 2008; Trinchera et al., 2011). Besides 
sialyltransferases, CMP-sialic acid donors are also transcriptionally regulated during inflammation, 
leading to SLeX glycan biosynthesis (Huopaniemi et al., 2004). Blander and co-workers 
demonstrated that ST3Gal IV and FUT VII are up-regulated upon CD4 T cell activation by IL-12 or 
IL-4, and this activation leads to SLeX expression on Th1 activated cells (Blander et al., 1999). In 
addition, IL-1β was reported to induce SLeX via enhanced expression of ST3Gal IV and FUT VI 
gene on hepatocellular carcinoma HuH-7 cells (Higai et al., 2006). In gastric carcinoma cells, IL-
1β and IL-6 were reported to induce significant increases in the mRNA levels of FUT1, FUT2 and 
FUT4 with no alterations in ST3Gal IV expression (Padro et al., 2011). Thus, this increased 
expression of FUT enzymes with no alterations in ST3Gal enzymes leads to decreased expression 
of SLeX in a mouse xenograph model, in opposition to its expression on gastric intestinal type 
carcinoma tissues (Padro et al., 2011). This fact highlights the already described association of 
increased expression of ST3Gal IV and induction of SLeX in gastric carcinoma tissues (Petretti et 
al., 1999; Jun et al., 2012), that was not observed in this IL-1β and IL-6 inductive cellular model. 
Conversely, Rudd and co-workers described the expression of SLeX in acute phase proteins from 
serum of individuals with gastric carcinoma as a possible result of increased IL-6 signaling (Bones 
et al., 2011).  
Furthermore, the role of tyrosine kinase receptor activation and downstream effectors have 
been reported in some ST overexpression studies (Cazet et al., 2009; Cazet et al., 2010b; Cazet 
et al., 2012). In different studies, Cazet and co-workers demonstrated that expression of GD2 
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ganglioside, due to overexpression of ST8SIA1, induces c-Met activation enhancing breast cancer 
cell increased proliferation and migration (Cazet et al., 2009; Cazet et al., 2012).  
Aberrant glycosylation is a functional marker that can be used to estimate the clinic-pathogenic 
process in cancer, and is a good starting point for cancer biomarker discovery. 
BIOMARKERS FOR CANCER DETECTION 
By definition biomarker is “a characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes or pharmacologic responses to a 
therapeutic intervention” (Glassman et al., 2009).  
In medicine the use of biomarkers lays on the principle that an observation or measurement 
can be used to establish a biological process and as an indicator that a specific disease is 
present. Most recent biomarker related studies, especially those for cancer biomarkers, have 
largely reported the incapability to validate the biomarker for clinical use, rather than successful 
validation (Diamandis 2010). Moreover, the majority of cancer biomarkers currently used in 
clinical practice are mainly recommended for monitoring response to treatment among patients 
with advanced disease and are not suitable for population screening or for early diagnosis.  
In the last decades, many new studies have reported a handful of new cancer biomarkers. 
Still, very few are validated as efficient cancer biomarkers suitable for screening and early 
diagnosis (Manne et al., 2005). The reason behind the ineffective validation of new cancer 
biomarkers cannot be attributed to the lack of pathophysiological knowledge, powerful techniques, 
or investment of funds but in inherent difficulties that are associated with biomarker discovery 
which have been underestimated. Deficiencies in the study design are a major reason for the 
difficulties found during biomarkers discovery and validation contributing for the short life span of 
many “newly discovered” biomarkers (Diamandis 2010). Some of the problems within the study 
design include aspects that may play a role before sample analysis (pre-analytical phase), during 
sample analysis (analytical phase) and/or after sample analysis (post-analytical phase). Prior to 
sample analysis, in the pre-analytical phase, aspects such as examination of various individual 
characteristics (such as sex, age and drugs) or sample collection and storage could independently 
affect biomarker levels. Moreover, in the analytical phase all the methodology employed in the 
study should be highly specific, sensitive and accurate to avoid introducing measurements bias or 
artifacts. In addition, in the post-analytical phase the important aspect to take in consideration is 
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the data interpretation, so the results can be extended to general population and replicated by 
independent studies. Therefore, careful validation in independent datasets by independent in-
vestigators and publication of the findings are probably the best way to identify a good biomarker. 
Finally, in order to validate a tumor biomarker for clinical practice some requirements are 
needed such as: 1) a molecule to be effective in early diagnose must be released into circulation 
in appreciable amounts by a small asymptomatic tumor; 2) the biomarker should be highly 
specific for the tissue of origin; 3) the level of a biomarker should not be affected by a non-cancer 
disease. To overcome most of these problems, post-translational modifications such as 
glycosylation, can contribute to distinguish molecules that are only expressed in cancer tissues 
when compared with normal tissues or other diseases.  
Glycoprotemic Advances in Gastric Cancer Biomarker Discovery 
In the last two decades, several different proteomic approaches have been developed leading 
to new glycoproteomic advances, mainly in serum glycoproteome.  
Many different biological matrices have been used in different studies, and in the case of 
gastric cancer biomarker discovery the majority of reported proteomic investigations used gastric 
tissues (Lee et al., 2012), serum (Qiu et al., 2009; Bones et al., 2011; Liu et al., 2012), saliva 
(Wu et al., 2009) and gastric juice (Lee et al., 2004; Hsu et al., 2007). In addition, cell culture 
(Tomlinson et al., 2002; Takikawa et al., 2006) and mouse xenograft (Chong et al., 2010; Florou 
et al., 2010; Zhang et al., 2010) models have also been employed in order to obtain some insight 
into new cancer biomarker finding. 
Different strategies have been used to assist in the identification of new biomarkers such as 
several serological protein depletion approaches (Andersen et al., 2010; Holewinski et al., 2013), 
reduction of protein concentration range with equalization methods (Thulasiraman et al., 2005), 
lectin affinity chromatography enrichments (Abbott et al., 2010), antibody microarrays (Haab 
2003), immunohistochemistry analysis (Ansari et al., 2011; O Leary et al., 2013), ELISA 
protocols (Scholler et al., 2006; Zhou et al., 2012), two-dimensional (2-D) gel electrophoresis 
(Rabilloud 2002), dimensional difference in-gel electrophoresis (2D-DIGE) (Kondo et al., 2006), 
several mass spectrometry technologies SELDI-TOF-MS, MALDI-TOF-MS, LC-MS (Srinivas et al., 
2002), and many others.  
Despite all of these new advances in the glycoproteome analysis, to date very few studies were 
able to identify new cancer biomarkers regarding alterations in the glycome and glycoproteome of 
patients bearing stomach cancer. Most of the studies that report the role of glycans in gastric 
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carcinogenesis are focused on the involvement of carbohydrate determinants in the interaction 
and binding of H. pylori to stomach epithelial cells (Peek et al., 2002; Marcos et al., 2008; 
Kobayashi et al., 2009; Magalhaes et al., 2009). In addition, identification of glycan alterations in 
gastric cancer has been limited to few descriptions on mucin glycoproteins (Conze et al., 2010) or 
in glycosyltransferases and their associated glycans that show increased expression in cancer 
(Gretschel et al., 2003; Marcos et al., 2003; Kim et al., 2004; Marcos et al., 2004; Conze et al., 
2010; Marcos et al., 2011; Jun et al., 2012).  
Although serum biomarker discovery has attracted increased attention in the last years, few 
studies have succeeded in the detection of alterations in serum proteins' glycosylation and 
identification of new biomarkers in stomach cancer. In 1998, Goodarzi and Turner characterized 
the N-glycosylation pattern of haptoglobin in a set of different diseases and verified that in gastric 
cancer that is a difference in the glycosylation pattern of this protein, claiming a potentially clinical 
application of haptoglobin glycosylation changes in patient's samples (Goodarzi et al., 1998). 
More recently, Bones et al. showed that an increase in the levels of SLeX present on triantennary 
glycans and also increased levels of core fucosylated agalactosyl biantennary glycans present on 
IgG, were associated with increasing disease pathogenesis (Bones et al., 2011). Further, 2D gel 
electrophoresis analysis of the depleted serum showed a number of differentially expressed 
protein candidates (e.g. clusterin, leucine-rich-R2-glycoprotein, and kininogen-1), and some were 
validated to carry triantennary SLeX using subsequent glycoproteomic approaches (Bones et al., 
2011). Prior to this finding, Bones et al. was able to demonstrate a new ultra performance liquid 
chromatography (UPLC) technology for fast and efficient identification of cancer associated 
alterations in the serum N-glycome of patients bearing stomach adenocarcinoma (Bones et al., 
2010). In this study the authors evaluated the contribution of the glycosylation present on four 
highly abundant serum glycoproteins IgG, haptoglobin, transferrin, and α1-acid glycoprotein and 
they found an increase in sialylation of haptoglobin, transferrin, and α1-acid glycoprotein and 
increased levels of core fucosylated biantennary glycans and decreased levels of 
monogalactosylated core fucosylated biantennary glycans on IgG with progressing cancer state 
(Bones et al., 2010). 
Despite the association between glycan expression alterations in tumor tissues and clinical 
prognosis has been documented, its application in the clinical setting has been limited to 
serological assays that detect glycoconjugates shed by the tumors into circulation. 
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Glycan-Based Serological Biomarker Assays In Cancer 
Glycosylation changes on glycoconjugates either present on the surface or secreted by cancer 
cells are a major potential source of cancer biomarkers. Presently, most serological assays used 
for cancer detection, prognosis and monitoring are based on quantifying glycoconjugates in the 
serum of patients with cancer. These serological assays detect carbohydrate antigens such as 
SLea (CA19-9) and STn (CA72-4) or mucin glycoproteins such as MUC1 (CA15-3) and MUC16 
(CA125) (Nustad et al., 1996; Yin et al., 2001; Yin et al., 2002; Drake et al., 2010; Reis et al., 
2010).  
The use of these biomarkers for cancer screening limits the identification of the organ of origin 
since their broad expression in various different cancer types (Chang et al., 2004; Baskic et al., 
2007). In addition, the presence of these biomarkers can also be found in some non-neoplastic 
and inflammatory diseases (Sevinc et al., 2007), reducing the specificity of the assays for cancer 
screening (Harris et al., 2007). Therefore, currently the clinical application of these makers is 
mostly for monitoring treatment and relapses with no consensual application in cancer diagnosis.  
Nevertheless, sound data support the use of the CA125 assay for detection of ovarian cancer. 
The CA125 is detected in 80% of patients with ovarian cancer (Nustad et al., 1996) and 
preoperative evaluation of CA125 has been shown to aid in the evaluation of prognosis for 
patients with ovarian cancer (Gostout et al., 2006). Moreover, increased CA125 levels were found 
in 50% of patients with stage I ovarian cancer and in 25% of serum samples collected 5 years 
before diagnosis of ovarian cancer, stressing a possible application in early detection of cancer 
(Zurawski et al., 1988). Similarly to CA125, increased levels of aberrant glycosylated MUC1 
mucin, which is produced by cancer cells and shed into the circulation to be detected by the 
CA15-3 assay, have also been shown to be useful for prognosis evaluation in early stage breast 
cancer and for monitoring the course of the disease (Ebeling et al., 2002; Kumpulainen et al., 
2002; Uehara et al., 2008). 
In addition to mucin expression in cancer, the aberrant expression of other carbohydrate 
antigens on glycoconjugates has also been shown to be useful for evaluating prognosis and for 
monitoring purposes in cancer. The CA19-9 serological assay detects the expression of SLea on 
glycolipids and glycoproteins and is usually used to evaluate the clinical response to therapy in 
patients with various cancer types such as pancreatic, colorectal, gastric or biliary cancer (Safi et 
al., 1997; Locker et al., 2006; Harder et al., 2007; Pan et al., 2011). In colon cancer, CA19-9 is 
a prognostic marker since patients presenting increased CA19-9 concentrations before surgery 
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had a fourfold increase in death rate at three years (Diez et al., 1994). In gastric carcinoma, 
preoperative CA19-9 concentration remains one of the best prognostic factors (Reiter et al., 1997; 
Ychou et al., 2000), and preoperative positivity for CA19-9 is an independent risk factor for 
recurrence of gastric carcinoma (Marrelli et al., 1999). Another carbohydrate antigen, STn, which 
is expressed in glycoproteins such as mucins, can be detected by the CA72-4 assay. Increased 
concentration of CA72-4 has been shown in patients with gastric, colorectal and pancreatic 
carcinomas (Ychou et al., 2000; Gaspar et al., 2001; Carpelan-Holmstrom et al., 2004). In gastric 
carcinoma, CA72-4 assay can be used for monitoring disease recurrence (Ychou et al., 2000) and 
has been shown to be an independent prognostic factor since patients positive for CA72-4 show a 
3.8-fold higher risk of death (Louhimo et al., 2004).  
Besides mucins and aberrant expression of carbohydrate antigens, several other markers are 
used in clinical practice such as the case of prostate specific antigen (PSA) and carcinoembryonic 
antigen (CEA). CEA is highly expressed in colorectal, stomach, and several other cancers, and 
shed into the circulation (Bakalakos et al., 1999; Goldstein et al., 2005). Also, patients with 
prostate cancer show high levels of PSA in serum, making PSA the golden standard for prostate 
cancer diagnose and monitoring (Gann et al., 1995; Draisma et al., 2003; Hong et al., 2012). 
However increase in serum concentration of both CEA and PSA can also have non-cancer-related 
causes (Yi et al., 2013). The differential diagnostic application of benign and malignant lesions 
remains a hurdle that can be eventually overcome by taking into consideration the type and level 
of glycosylation. This feature has been previously observed in colonic tissues, where normal 
colonic mucosa and preneoplastic lesions display CEA molecules with different molecular weights 
due to glycosylation when compared to colon cancer cells (Garcia et al., 1991). More recently, 
CEA was reported to display abnormal glycosylation in colon cancer (Saeland et al., 2012). 
Regarding PSA, several reports have demonstrated altered PSA glycosylation in benign and 
malignant prostate lesions, highlighting the importance in considering the glycan composition of 
this biomarker for the clinical diagnosis of the disease (Peracaula et al., 2003; Tajiri et al., 2008; 
Meany et al., 2009; White et al., 2009; Dwek et al., 2010; Li et al., 2011; Gilgunn et al., 2012; 
Vermassen et al., 2012).  
The glycosylation alterations observed in cancer should be taken in consideration, and 
constitute a key target for the development of novel serological- based assays for early cancer 
detection with major screening and clinical implications. 
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Cancer is a leading cause of death worldwide and the development of new approaches for 
early diagnosis, treatment and prevention is a main concern to improve health.  
Gastric cancer is the fourth most common cancer worldwide, being the second cause of 
cancer related deaths. The high mortality rate of gastric carcinoma is mainly due to the lack of 
early diagnosis of the disease. The failure in the early diagnosis of gastric cancer is closely 
associated with the lack of specific symptoms, with patients most of the times being diagnosed 
in advanced stages of disease where the five year survival rate is less than 15%. In clinical 
practice, endoscopy remains the gold standard for diagnosis of gastric cancer that fails the early 
diagnose since patients that do not display symptoms are generally not selected for endoscopic 
investigation. In addition, the clinical serological assays used nowadays also lack the specificity 
and sensitivity necessary for patient screening, being used mostly for monitoring disease. 
Therefore, the discovery of new biomarkers for detection of cancerous lesions in the stomach at 
the early developmental stage of the tumor is a main goal for a better outcome of gastric 
carcinoma.  
Glycan alterations are a common feature of cancer, and during gastric carcinogenesis many 
different alterations occur, in particular changes on the gastric mucosa glycosylation profile of 
glycoconjugates. In addition, an increased body of evidence supports the role of glycan 
alterations in cancer, principally in cancer cell biology.  
The general aim of the present work was to identify proteins carriers of cancer associated 
glycan antigens that can be possible new biomarkers in gastric cancerous lesions, and 
characterize the role of these glycans in gastric cancer cell biology.  
Specific objectives 
1. To identify glycoproteins, presenting cancer associated O-glycan structures, in 
serum from individuals with gastric lesions including gastric cancer, as potential 
new biomarkers. 
The use of serum for the identification of cancer biomarkers is an extremely important goal 
since sampling is minimally invasive, and the ease with which assays could be translated to the 
clinic should mean a rapid take up. Most biomarkers are based on the expression of novel 
antigens by cells. Cancer cells have frequent alterations in the glycosylation pattern, which 
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normally results in expression of truncated O-glycans attached to the protein. The detection, in 
the serum, of these glycoproteins depends on the production by cancer cells and shedding into 
the blood stream. Nowadays, many of the clinical biological assays used in cancer diagnose and 
monitoring are based on glycoproteins expressing different glycan structures that are released 
into serum. In light of these we first aimed to assess the expression of truncated glycans, such 
as STn and T antigens, in tissues and serum of patients with gastric lesions including cancer, 
and identify the proteins carriers of these glycan structures. In Chapter 3.1, we present a 
glycoproteomic approach that was developed in order to identify proteins carriers of truncated 
glycans produced in different gastric pathological conditions and released into circulation. We 
further validated the glycan structure and glycosylation sites present in the identified 
glycoproteins by de-O-glycosylation with reductive β-elimination followed by nano-HPLC-MALDI-
TOF/TOF, and by sialoglycopeptides enrichment with titanium dioxide chromatography and 
mass spectra data crossing with MSBridge software. 
2. To disclose the biological role of ST3Gal IV and its associated carbohydrate 
determinant SLeX in gastric cancer cell behavior. 
Expression of cancer associated glycans relays in the altered expression of 
glycosyltransferases. Many different glycosyltransferases are deregulated in cancer, in particular 
sialyltransferases. Increased expression of sialyltransferases, for instance ST3Gal III and ST3Gal 
IV have been associated with increased expression of sialylated Lewis-type blood groups such as 
SLea and SLeX. In addition, the increase expression of SLea and SLeX in cancer is known to mimic 
their normal expression on blood cells (monocytes and neutrophils) potentiating cancer cell 
migration through binding to endothelial cell selectins. Therefore, SLea and SLeX overexpression 
are a common feature of several carcinomas, and in gastric cancer have been associated with 
increased metastatic capacity and poor overall patients survival. In chapter 3.2, we aimed to 
unveil the role of ST3Gal III and ST3Gal IV in the biosynthesis of SLeX antigens in a gastric 
carcinoma cell line MKN45. Furthermore, we intended to evaluate the biological role of SLeX 
expression on gastric cancer cell behavior in vitro and in vivo using the chicken chorioallantoic 
membrane (CAM) model. 
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3. To evaluate the role of tyrosine kinase receptor activation and downstream 
effectors in cancer cell behavior of cells expressing SLeX. 
The expression of SLeX antigens, due to overexpression of sialyltransferases, plays an 
important role in gastric tumor progression and behavior. The molecular mechanisms 
underlying this altered enzyme expression and aggressive behavior of gastric cancer cells 
expressing these glycan determinants is a hurdle that still need further investigations. The 
involvement of signaling pathways with activation of receptors and downstream effectors that 
enhance cell biological functions have been reported as possible effect to expression of such 
cancer glycan determinants. In Chapter 3.2, we aimed to assess the role of tyrosine kinase 
receptor activation and downstream evaluation of effectors in gastric cancer cells expressing 
SLeX antigens.  
4. To identify the SLeX expressing glycoproteins in a gastric carcinoma cell line and 
to validate in gastric carcinoma tissues. 
Aberrant glycosylation is a functional marker that can be used to estimate the clinic-
pathogenic process in cancer, and is a good starting point for cancer biomarker discovery. 
Increased expression of ST3Gal IV and SLeX antigen have been reported in gastric carcinoma 
tissues and also in association with venous invasion and poor prognosis for the patients. One of 
the current clinical biomarker used for diagnose of gastric cancer is the carbohydrate antigen 
SLea (CA19-9). Nevertheless, this serological assay lacks the levels of sensitivity and specificity 
required to make it clinically useful for the early detection of gastric carcinoma and is mainly 
used to monitor the disease after treatment, rather than diagnostic purposes. In chapter 3.3, we 
intended to identify the proteins carriers of SLeX in the gastric carcinoma cell line overexpressing 
ST3Gal IV and validate the protein target and the molecular complex protein/SLeX in gastric 
carcinoma tissues as a potential new cancer biomarker.  
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ABSTRACT 
Gastric cancer is preceded by a carcinogenesis pathway which includes gastritis caused by 
Helicobacter pylori infection, chronic atrophic gastritis that may progress to intestinal metaplasia 
(IM), dysplasia and ultimately gastric carcinoma of the more common intestinal subtype. The 
identification of glycosylation changes in circulating serum proteins in patients with precursor 
lesions of gastric cancer is of high interest and represents a source of putative new biomarkers for 
early diagnosis and intervention. 
This study applies a glycoproteomic approach to identify altered glycoproteins expressing the 
simple mucin-type carbohydrate antigens T and STn in the serum of patients with gastritis, IM 
(complete and incomplete sub-types) and in control healthy individuals. The 
immunohistochemistry analysis of the gastric mucosa of these patients showed expression of T 
and STn antigens in gastric lesions, with STn being expressed only in IM. The serum 
glycoproteomic analysis using 2D-gel electrophoresis, Western blot, and MALDI-TOF/TOF mass 
spectrometry led to the identification of circulating proteins carrying these altered glycans. One of 
the glycoproteins identified was plasminogen, a protein that has been reported to play a role in H. 
pylori chronic infection of the gastric mucosa and is involved in extracellular matrix modeling and 
degradation. Plasminogen was further characterized and showed to carry STn antigens in patients 
with gastritis and IM. 
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These results provide evidence of serum proteins displaying abnormal O-glycosylation in 
patients with precursor lesions of gastric carcinoma and include a panel of putative targets for the 
non-invasive clinical diagnosis of individuals with gastritis and IM. 
INTRODUCTION 
The development of gastric cancer is associated with a long carcinogenesis pathway that is 
initiated by Helicobacter pylori (H. pylori), a Gram-negative bacterium that causes gastritis, and 
may lead to the development of a chronic atrophic gastritis, intestinal metaplasia (IM) and 
ultimately gastric adenocarcinoma (Parsonnet et al., 1991; Correa 1992; Suerbaum et al., 1998; 
Wang et al., 1998; Mesquita et al., 2006; Correa et al., 2007). H. pylori infects more than 70% of 
the population in some countries (Atherton 2006) but only a fraction of those individuals develop 
more severe gastric conditions, such as atrophic gastritis and IM, a pre-cancerous lesion (Correa 
1992; Mesquita et al., 2006). The current diagnosis for these precursor lesions relies almost 
exclusively in endoscopy followed by biopsy, which is both invasive and costly to apply for 
screening strategies. Therefore, biomarkers which can aid in the screening and identification of 
individuals with silent gastric pathologies are highly needed. 
Glycosylation is a common post-translational modification of proteins with more than 50% of 
eukaryotic proteins thought to be glycosylated (Apweiler et al., 1999). The pattern of protein 
glycosylation is cell and tissue specific and closely reflects the physiological status of the cell. 
Thereby, changes in glycan expression are frequently observed in several pathological conditions 
(Reis et al., 2010) and in particular in the gastric context (David et al., 1992; Silva et al., 2002; 
Ferreira et al., 2006). In gastric pathologies the glycosylation alterations include aberrant 
expression of simple mucin type carbohydrate antigens, namely T (Galβ1–3GalNAcα-O-Ser/Thr), 
Tn (GalNAcα-O-Ser/Thr), and sialyl-Tn (Neu5Acα2-6GalNAcα-O-Ser/Thr) (David et al., 1992; 
Ferreira et al., 2006; Conze et al., 2010; Marcos et al., 2011). An over-expression of sialylated 
Lewis antigens (Amado et al., 1998) and the decreased expression of terminal α1,4-linked N-
acetylglucosamine residues (αGlcNAc) has also been reported (Zhang et al., 2001; Ferreira et al., 
2006; Karasawa et al., 2012). 
The biosynthesis of the carbohydrate structures in glycoproteins relies on a number of 
competitive and concerted processes involving several glycosyltransferases. Mucin (GalNAc)-type 
O-glycosylation (hereafter called O-glycosylation) is one of the most common types of glycosylation 
found in glycoproteins and consists of a glycan O-linked to a serine or a threonine residue. The 
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first step in O-glycosylation is the transfer of GalNAc from a sugar donor UDP-GalNAc to a serine 
or threonine residue and is controlled by UDP-GalNAc: polypeptide N-
acetylgalactosaminyltransferases (GalNAc-Ts) (Clausen et al., 1996; Bennett et al., 2012). These 
Golgi enzymes control the site of O-glycosylation. After the first glycan (GalNAc) is added forming 
the Tn antigen, the action of other glycosyltranferases leads to the synthesis of the various core 
structures depending on the cell context. In gastric epithelial cells, a Gal-transferase (C1GalT-1) 
leads to the biosynthesis of the core 1 (T antigen), which can be further branched, extended and 
terminated by Lewis and ABO blood group antigens. Alternatively, Tn and T antigens can be 
sialylated by sialyltransferases forming the sialyl-Tn (STn), sialyl-T (ST) and disialyl-T (Figure 1) 
(for a review see Reis et al., 2010). 
 
 
 
Figure 1: Schematic representation 
of the biosynthesis of Core O-glycan 
structures and formation of simple 
type carbohydrate antigens Tn, STn, 
T and ST.  
 
 
The alterations in glycosylation observed in pathologic conditions are mostly due to 
modifications at the glycosylation cell machinery, disorganization of secretory pathway organelles 
(ER and Golgi) and altered glycosyltransferase expression. The aberrant expression of 
glycoconjugates bearing these glycans either present on the surface or secreted by cells are a 
major potential source of biomarkers representing most serological assays used for cancer 
detection and monitoring. These serological assays detect carbohydrate antigens such as SLea 
(CA19-9) and STn (CA72-4) or mucin glycoproteins such as MUC1 (CA15-3) and MUC16 (CA125) 
(Reis et al., 2010). 
The glycoproteins carrying immature glycans, such as simple mucin type O-glycan antigens, 
can be present in circulating proteins in pathological conditions and are being targeted for early 
CHAPTER 3 | Results 
 
 88 
detection approaches. In this study we assess the immunohistochemical presence of truncated O-
glycans STn and T antigens in gastric tissues, including normal gastric mucosa, gastritis and IM. 
We have further screened sera from the same patients searching to identify proteins bearing 
these truncated glycans. This approach resulted in the identification of fine alterations in the O-
glycosylation of serum glycoproteins, such as the presence of STn, which is known to be 
aberrantly expressed in the gastric lesions under study. Specifically, we identified serum proteins 
carrying abnormal O-glycans that can be candidate targets for the non-invasive diagnosis of 
precursor lesions of gastric cancer.  
MATERIALS AND METHODS 
Tissue samples and Histology 
Stomach biopsies and serum from individuals without gastric lesions and H. pylori infection 
(n=6), gastritis (n=5), complete (n=5) and incomplete (n=3) IM were used. The individuals are 
part of a cohort from northern Portugal (Viana do Castelo) working in a shipyard that have been 
study and characterized as previously described for gastric pathologies and H. pylori infection 
(Almeida et al., 2003). 
Paraffin sections were used for histochemistry and immunohistochemistry. Tissue sections 
were stained with hematoxylin and eosin (H&E) for histopathology. Clinical data, including H. 
pylori infection status of every case was considered for selection of the cases and controls. 
Immunohistochemistry 
Paraffin sections were dewaxed and rehydrated. Endogenous peroxidase activity was blocked 
with 3% H2O2 in methanol for 30 min, and then sections were incubated with normal rabbit serum 
diluted 1:5 in PBS containing 10% BSA. Incubation with the monoclonal antibodies was performed 
overnight at 4ºC. Slides were washed in PBS and incubated for 30 min with secondary 
biotinylated rabbit anti-mouse antibody (E0354-DakoCytomation, Glostrup, Denmark) diluted 
1:200 in PBS containing 5% of BSA. The slides were subsequently washed in PBS and incubated 
for 30 min with avidin-biotin complex (Vectastain Elite ABC kit, Burlingame, CA, USA) according to 
manufacturer’s recommendations. Staining was performed with 3,3'-diaminobenzidine 
tetrahydrochloride (Sigma, St. Louis, MO, USA) containing 0.02% hydrogen peroxide. Counter 
staining of the nucleus was done with Mayer’s hematoxylin. Monoclonal antibodies used in this 
study, their specificity and their references are listed in Table 1.  
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Table 1: Specificity of monoclonal antibodies used for immunohistochemistry. 
MoAbs Isotype Dilution Antigen and reference 
TKH2 IgG1 1:20 STn (Kjeldsen et al., 1988) 
3C9 IgM 1:50 T (Bohm et al., 1997) 
CLH2 IgG2 1:750 MUC5AC (Reis et al., 1997) 
PMH1 IgM 1:40 MUC2 GalNAc (Reis et al., 1998) 
Sera sample collection and protein equalization by combinatorial peptide ligand 
library 
Sera sample from the same individuals as the biopsies were pooled according to the clinical 
data (without gastric lesions and H. pylori infection, gastritis, complete and incomplete IM). 
Equalization of the amount of proteins within each serum sample group was done using a 
combinatorial peptide ligand library – CPLL (ProteoMiner, BioRad, CA) (Thulasiraman et al., 
2005) according to manufacturer’s recommendations. 
2D gel electrophoresis 
Equalized protein samples from CPLL were precipitated (ProteoExtract, Calbiochem), 
resuspended in rehydration buffer (7M Urea, 2M Thiourea, 4% (v/v) CHAPS and 0.0002% 
Bromophenol Blue) with 0.2% of ampholyte and quantified (2D Quant Kit from GE Healthcare). 
Passive rehydration of the strips was performed overnight with 100µg of sample using IPG strips 
of pH 3-10 NL (ReadyStrip; 0.5 x3 x70 mm, Bio-Rad, Hercules, CA) at room temperature. 
Isoelectric focusing was performed on Protean IEF cell (Bio-Rad) with an initial voltage of 250 V 
for 15 min, and then by applying a voltage gradient up to 4000V with limiting current of 50 µA 
per strip and temperature set at 20ºC. The first dimension was concluded at 14-20 kVh. 
Following the isoelectric focusing proteins were reduced and alkylated by incubation with 2% 
DL-dithiothreitol (DTT) followed by 2.5% Iodoacetamide in an equilibration buffer (6M Urea, 2% 
SDS, 0.002% Bromophenol Blue, 75mM Tris pH 8.8, 29.3% Glycerol) for 10 min each under 
gentle agitation. The strips were then packed in a 1% low gelling (1% agarose in running buffer - 
25 mM Tris, 192 mM Glycine, and 0.1% (w/v) SDS, pH 8.3; Bio-Rad) on top of a 10% acrylamide 
gel (acrylamide/bisacrylamide 37.5:1, 2.6% from Bio-Rad). Second dimension electrophoresis 
was performed in a Mini-Protean tetra cell system (Bio-Rad) using 1xTris/Glycine/SDS buffer at 
constant voltage of 125 V. 
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Western blot analysis 
Gels were transferred to nitrocellulose membranes (Amersham) in a semi-dry system 
according to manufacturer’s recommendations (TE 77 PWR Amersham) and were blocked with 
5% BSA in PBS-Tween (PBS-T) 0.05%. Primary antibodies were incubated overnight at 4ºC with 
5% BSA in PBS-T 0.05%. Membranes were washed three times with PBS-T 0.05% before 
secondary antibody incubation. Secondary antibodies were isotype specific (Jackson 
immunoresearch) anti-IgM (dilution 1:100000) and anti-IgG1 (dilution 1:50000) and were 
incubated for 1 h in 1% BSA in PBS-T 0.05%. Signal detection was obtained by enhanced 
chemiluminescence (ECL plus, Amersham). The primary antibodies were the same as those used 
for immunohistochemistry (Table 1) and used undiluted. 
Protein selection and in-gel tryptic digestion. 
2D gels were stained with Coomassie Blue (Bio-Safe Coomassie from Bio-Rad, CA) overnight 
and images were acquired with a Gel Doc XR system (Bio-Rad, CA).  
The spots highlighted in the Western blots were matched in the Coomassie Blue gels and 
proteins excised with a spotpicker (OneTouch 2D gel spotpicker, 1.5 mm diameter, Gel Company, 
USA). The selected protein spots were then processed for MALDI MS analysis in agreement with 
the trypsin manufacturer instructions (Promega, USA): the protein gel plugs were washed with 
water, destained with methanol:50 mM NH4HCO3 and acetonitrile:50 mM NH4HCO3 (1:1 v/v 
each), reduced with 25 mM DTT in 50 mM NH4HCO3 for 20 min at 56ºC, alkylated with 55 mM 
IAA in 50 mM NH4HCO3 for 20 min in the dark, in gel digested with 10 µL of  2 ng/µL trypsin for 
3 h at 37ºC in presence of 0.01% surfactant (ProteaseMAX, Promega) and the resulting peptides 
were extracted with 20 µL of TFA 2.5% for 15 min.  
Protein identification by MALDI-TOF/TOF 
Protein digests were desalted, concentrated and spotted onto a MALDI plate using ZipTips 
(Millipore, USA) following the manufacturer’s instructions. For the matrix preparation, a solution of 
6-8 mg/mL α-cyano-4-hydroxycinnamic acid in 50% ACN/0.1% TFA was used. Samples were 
analyzed using a 4700 Proteomics Analyzer MALDI-TOF/TOF (AB SCIEX, Framingham, MA). 
Peptide mass fingerprint (PMF) data were collected in positive MS reflector mode in the range of 
m/z 700–4000 and was calibrated with external standards and internally calibrated using trypsin 
autolysis peaks. If necessary, several of the highest intensity non-tryptic peaks were selected for 
MS/MS analysis. The MS and MS/MS spectra were processed and analyzed using the software 
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GPS Explorer (Version 3.6, AB SCIEX, Framingham, MA), and were searched together against the 
UniProt (release 2012_09)  protein sequence database using the Mascot search engine (Version 
2.1.04, Matrix Science, UK) limited to Homo sapiens taxonomy. The search included 65 peaks 
with a signal-to-noise ratio greater than 10 and allowed for up to two missed trypsin cleavage 
sites. The MS tolerance was 50 ppm for PMF analysis and 1.0 Da for MS/MS analysis; fixed 
modifications, carbamidomethylation of cysteine; variable modifications, oxidation of methionin; 
keratins were filtered out. To be considered a match, a confidence interval (CI), calculated by the 
AB SCIEX GPS Explorer/Mascot software, of at least 99% was required. 
Data mining for glycosylation sites in glycoproteins 
N-Glycosylation in human proteins was predicted by the NetNglyc 1.0 server 
(http://www.cbs.dtu.dk/services/NetNGlyc), an artificial neural network that examines the 
sequence context of Asn-Xaa-Ser/Thr (where Xaa is not Pro) sequences. O-glycosylation was 
predicted by NetOglyc 3.1 server (http:// www.cbs.dtu.dk/services/NetOGlyc) that produces 
neural network predictions of mucin- type GalNAc O-glycosylation sites in mammalian proteins 
(Julenius et al., 2005). 
Plasminogen sialoglycopeptides enrichment and characterization 
Plasminogen spots from the centre of a 2D gel from each clinical situation were excised and 
processed as described above. For the enrichment of plasminogen sialoglycopeptides the 
plasminogen peptide extract was subjected to titanium dioxide chromatography (Larsen et al., 
2007) as described by manufacturer (GE Healthcare, USA). The sialoglycopeptides were eluted 
with the MALDI matrix 2',4',6'-Trihydroxyacetophenone monohydrate (THAP). The mass spectra 
acquisition was performed in linear positive mode in the instrument MALDI-TOF/TOF 4700 
Proteomics Analyzer (AB SCIEX, USA). In order to search for sialoglycopeptides the mass spectra 
raw data was submitted to the software Glycomod (http://web.expasy.org/glycomod/) and 
MSBridge, ProteinProspector (http://prospector.ucsf.edu/prospector/cgi-
bin/msform.cgi?form=msbridgestandard). The mass error tolerance was 0.4 Da. Mass spectra 
were internally calibrated by mass plasminogen sialoglycoforms previously described (Hayes et 
al., 1979a; Hayes et al., 1979b; Hortin 1990; Pirie-Shepherd et al., 1997). 
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In gel O-deglycosylation and permethylation  
Enrichment of plasminogen from serum samples of individuals without gastric lesions and H. 
pylori infection, gastritis, complete and incomplete IM cases were performed using Lysine-
sepharose affinity chromatography (Deutsch et al., 1970). The enriched plasminogen samples 
were run in SDS-PAGE gel and stained with Coomassie Blue. The plasminogen bands were 
removed from SDS-PAGE gels and the protein identity was confirmed by MALDI MS. Equivalent 
amounts of plasminogen previously digested with neuraminidase from Clostridium perfringens 
(Sigma-Aldrich; Karlsruhe, Germany) were used as a control. 
Plasminogen was then in-gel de-O-glycosylated by reductive β-elimination upon incubation with 
50 mM NaOH and 1 M NaBH4 at 45ºC for 16 h.  The reaction was stopped with glacial acetic 
acid until no fizzing was observed and the samples were subsequently filtered using 10-kDa 
molecular weight cutoff (MWCO; Millipore). The filtrate, containing low molecular weight peptides, 
O-glycans and borate salts, was recovered and incubated several times with methanol containing 
5% (v/v) acetic acid under a stream of nitrogen to remove borates as methyl esters.  
The O-glycans enriched fractions were then permethylated adopting a modification of the 
method by Ciucanu and Kerek (Ciucanu et al., 1984). Briefly, the samples were dissolved in 100 
µL of anhydrous DMSO, and powdered NaOH was added. The mixture was sonicated for 30 min 
and frozen prior to the addition of 100 µL of CH3I and then incubated under mild stirring for 1 h. 
The permethylated samples were recovered from the reaction mixture by extraction with 
dichloromethane and extensively washed with acidified water (pH 2.0) to avoid base-induced 
hydrolysis of the carboxymethyl group of permethylated sialic acids. The samples were then de-
salted using Dowex ion-exchange resin (Dowex 50W-X8, Dow, USA). 
Nano-HPLC-MALDI-TOF/TOF 
The permethylated samples were separated in a nano-HPLC Ultimate 3000 system (Dionex, 
Amsterdam) equipped with a capillary column (Pepmap100 C18; 3 μm particle size, 0.75 μm 
internal diameter, 15 cm in length). The samples were dissolved in 5% acetonitrile (ACN) aqueous 
solution containing 0.1% formic acid (phase A). The separation was performed using a linear 
gradient of 32-50 % B for 45 min, 50-70 % B for 10 min and 70-32% A for 5 min. The eluted 
glycans were applied directly on a MALDI plate in 10 sec fractions using an automatic fraction 
collector Probot (Dionex, Amsterdam, Netherlands) under a continuous flow rate of 270 nL of 
DHB matrix solution (10 mg/mL in 70% acetonitrile/0.1% TFA and internal standard Glu-Fib at 
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15ftmol). Mass spectra were obtained on a MALDI TOF/TOF mass spectrometer (4800 
Proteomics Analyzer, Applied Biosystems, Foster City, CA, USA) in the positive ion reflector mode 
and obtained in the mass range from 600-4500 Da with 1200 laser shots. For the experiment, 
Glu-Fib was used for internal calibrations. The MALDI-MS data from each chromatographic run 
was combined into a three dimensional data array (LC fraction, m/z, total ionic current). A survey 
of plausible analytical signals at 691.36 [STn+Na]+, was performed by determining the most 
prominent peaks occurring within 0.2 Da of the reference peak. The analysis of the distribution of 
the STn MS signals allowed the identification of chromatographic profiles. MS2 were acquired 
under high-energy collisional ionization dissociation (CID) conditions. Peak assignments MS2 
spectra and database searches were performed using the GlycoWorkBench platform (Ceroni et 
al., 2008). 
RESULTS  
The proteomic strategy applied in this study is schematically represented in Figure 2.  
 
Figure 2: Schematic representation of the proteomic strategy applied in this study. 
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Expression of aberrant simple mucin-type carbohydrate antigens in gastric tissues 
The pattern of expression of STn and T antigens was assessed in normal gastric mucosa, in 
gastric mucosa with gastritis, and in IM (complete and incomplete types). The pattern of mucin 
expression (MUC5AC and MUC2) allowed the classification of IM in the gastric mucosa as 
previously described (Reis et al., 1999). Table 2 show the overall results of STn and T antigen 
expression and Figure 3 displays representative cases. 
Table 2: In situ analysis of mucins and simple mucin-type carbohydrate antigens by 
immunohistochemistry in gastric tissues. 
Cases 
Immunostaining 
MUC2 MUC5AC STn T 
 
Control (n=5) 0 5 0 1 
 
Gastritis (n=6) 0 6 0 1 
 
Complete intestinal metaplasia (n=4) 4 0 4 1 
 
Incomplete intestinal metaplasia (n=3) 3 3 3 0 
 
Normal gastric mucosa showed absence of expression of STn and T antigens, with the 
exception of a single case that displayed a faint staining for T antigen in few cells. As expected, 
mucin expression in normal mucosa was limited to MUC5AC detection in the foveolar superficial 
epithelium of the gastric mucosa. No expression of MUC2 was observed in normal gastric 
mucosa (Table 2, Figure 3). 
Gastric mucosa displaying gastritis showed no expression of STn but staining for the T antigen 
was observed in one case (Table 2, Figure 3). Mucosa with gastritis showed expression of 
MUC5AC with a strong cytoplasmic staining detected in every case. Mucosa with gastritis showed 
absence of MUC2 expression (Table 2, Figure 3). 
Among the seven cases with IM, three showed a mixed expression of MUC5AC and MUC2 
characteristic of the incomplete type of IM. Four cases showed only positive staining for MUC2 
consistent with the complete type of IM. Both types of IM showed high levels of STn antigen 
expression detected mostly in the vacuole of goblet cells (Table 2, Figure 3) of the metaplastic 
glands. Absence of expression of T antigen was observed in IM with the exception of one case of 
the complete type that displayed expression of T antigen in few cells (Table 2).  
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Figure 3: Immunohistochemical staining of normal mucosa and gastric lesions with MUC5AC, MUC2 
and the truncated glycoforms T and STn antigens. The figure shows normal expression of MUC5AC and 
absence of expression of MUC2 in mucosa from healthy individuals, as well as lack of truncated glycoforms (except 
one normal case that also expressed T antigen – Table 2, not shown in Figure). In gastric lesions we see the 
presence of truncated glycans (although T antigen was also seen in only one case – Table 2 and Figure 3), and also 
de novo expression of MUC2 in intestinal metaplasia. 
Serum protein equalization by combinatory peptide ligand library (CPLL) 
Serum is a highly complex biofluid comprehending proteins spanning a wide range of dynamic 
concentrations (Anderson et al., 2002). In addition, a few proteins account for approximately 70-
90% of the overall proteome, which is known to mask subtle alterations associated with 
pathological events (Chan et al., 2004). To overcome this limitation, the proteome of each clinical 
group was equalized by CPLL. This proteome equalization resulted in the gel electrophoretic 
profile presented in Figure 4, which displays the bound and unbound fractions of the CPLL. The 
equalized fractions of the different clinical groups showed a normalized amount of proteins 
characterized by an increased ratio of low abundant proteins and a decreased ratio of high 
abundant proteins (Figure 4). 
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Figure 4: SDS-PAGE of sera before and after CPLL treatment. In the gel are represented serum samples of 
the four different groups before and after protein equalization using the CPLL technique. Lanes 2, 4, 6 and 8 
represent the eluted sample of the ligand library for healthy, gastritis, complete and incomplete intestinal metaplasia 
sera, respectively. Lanes 3, 5, 7 and 9 represent the unbound fraction of the same samples in the same order. Lane 
one shows molecular weight standards. 
Serum protein separation by two-dimensional gel electrophoresis and simple 
carbohydrate antigen detection 
To identify proteins in the serum displaying simple mucin type carbohydrate antigens a 
glycoproteomic analysis was performed. This approach included protein separation by two-
dimensional (2D) gel electrophoresis combined with a Western blotting directed for the detection 
of simple mucin type carbohydrate antigens using specific monoclonal antibodies. 
The equalized serum protein samples from the different clinical groups were subjected to two-
dimensional gel electrophoresis with a first dimension separation according to the protein 
isoelectric point and a second dimension based on the protein molecular weight.  The patterns of 
protein distribution in 2D gels were similar among the different clinical groups as revealed by 
Coomassie Blue staining of the gels (Figure 5, left panel). These protein maps showed profiles 
compatible with a good resolution separation of protein isoforms. 2D gels replicates of the same 
clinical groups that were immunoblotted for simple mucin type carbohydrate antigens showed 
reactivity for T and STn antigens. This immunoreactivity was restricted to few proteins in the 
proteomic map (Figure 5, center and right panels). 
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Figure 5: 2D gel electrophoresis and Western blot analysis for T and STn antigens of serum from 
healthy individuals, individuals with gastritis and individuals with intestinal metaplasia (complete and 
incomplete type). In the left side of the figure are represented coomassie blue gels of serum samples equalized 
with CPLL and in the middle and right sides are represented Western blots against T and STn antigens respectively. 
The spots that were highlighted in the Western blots were matched on Coomassie blue gels and excised for protein 
identification by MALDI-TOF TOF analysis.  
The 2D immunobloting revealed that the immunoreactivity for the T antigen was higher in the 
gastritis group with lower detection in IM groups. Furthermore, STn antigen immunoreactivity 
showed to be higher in proteins from the 2D gel maps of the IM groups and in gastritis when 
compared with normal control group (Figure 5, right panel). 
Protein identification by MALDI-TOF/TOF mass spectrometry 
Identification of the proteins that were labeled in Western blots for simple mucin type 
carbohydrate antigens was obtained using the excised spots from the Coomassie Blue stained 2D 
CHAPTER 3 | Results 
 
 98 
gel (Figure 5). Table 3 shows the list of identified proteins by MALDI-TOF/TOF mass 
spectrometry. Proteins identified due to T antigen detection in samples from gastritis patients 
were plasminogen (Spot ID 1) and Histidine-rich glycoprotein (Spot ID 2). Plasminogen was also 
identified based on T antigen immunoreactivity in both types of IM (Spot ID 10 and 21). Proteins 
identified according to the immunoreactivity with STn antigen included plasminogen which was 
detected in all disease groups (Spot ID 1, 10, 21). Vitronectin was also identified based on STn 
immunoreactivity in incomplete IM (Spot ID 19 and 20). Other proteins indentified in the 2D maps 
showing immunoreactivity with STn are displayed in Table 3. 
Table 3: Proteins identified in sera of gastritis, complete intestinal metaplasia and incomplete 
intestinal metaplasia according to the immunoreactivity with antibodies for T and STn antigens. 
Spot ID Protein description Accession number 
MASCOT Protein 
C.I. % 
Peptide 
count 
% cov 
Peaks 
matched 
MOWSE 
score 
1 Plasminogen  PLMN_HUMAN  100 44 58 49 454 
2 Histidine-rich glycoprotein  HRG_HUMAN  100 21 36 21 156 
3 IGH protein  Q6GMX6_HUMAN 99.8 9 22 9 79 
4 Complement factor H  F8WDX4_HUMAN 100 18 44 18 133 
5 Complement factor H-related protein 1  FHR1_HUMAN  100 13 40 14 95 
6 Complement factor H-related protein 1  FHR1_HUMAN  99.4 7 21 9 66 
7 Complement factor H-related protein 1  FHR1_HUMAN  99.3 10 30 11 74 
8 Complement factor H-related protein 1  FHR1_HUMAN  99.4 11 37 12 74 
9 Complement C4 gamma chain B4DDH0_HUMAN  100 17 34 18 105 
10 Plasminogen  PLMN_HUMAN  100 43 59 49 442 
11 Histidine-rich glycoprotein  HRG_HUMAN  100 22 40 22 169 
12 IGH protein Q6GMX6_HUMAN  99.1 11 27 11 72 
13 Complement factor H  CFAH_HUMAN  100 27 65 32 262 
14 Complement factor H-related protein 1  FHR1_HUMAN  100 14 43 15 107 
15 Complement factor H-related protein 1  FHR1_HUMAN  100 15 42 17 119 
16 Complement factor H-related protein 1 FHR1_HUMAN  100 15 37 16 118 
17 Complement C4-B gamma chain B4DDH0_HUMAN  99.8 15 25 15 79 
18 Complement C4-B gamma chain B4DDH0_HUMAN  100 20 31 22 133 
19 Vitronectin  VTNC_HUMAN 100 17 36 19 121 
20 Vitronectin  VTNC_HUMAN 99.8 13 30 15 79 
21 Plasminogen  PLMN_HUMAN  100 42 54 48 424 
22 Complement C4-B  B4DIE5_HUMAN 100 25 30 25 170 
23 Complement C4-B  B4DIE5_HUMAN  100 10 13 10 86 
24 IGH protein Q6GMX6_HUMAN 99.9 9 24 9 83 
25 IGH protein Q6GMX6_HUMAN 100 10 17 11 106 
Glycosylation characterization of the identified proteins 
Table 4 depicts the simple mucin type carbohydrate antigens detected by Western blotting in 
the identified proteins from the sera in the different clinical groups, as well as the bioinformatical 
prediction of glycosylation in these proteins. Additionally, Table 4 shows available information on 
the N- and O- glycosylation of these proteins previously described, as well as the sites of O-
glycosylation and N-glycosylation predicted bioinformaticaly by NetOGlyc and NetNGlyc, 
respectively.  
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We observed expression of T antigen in plasminogen from all clinical groups and a strong STn 
immunoreactivity in gastritis and IM. Conversely, the expression of T antigens was considerably 
decreased in the plasminogen from patients with IM. The sites of O-glycosylation known to date 
for plasminogen include Thr346 (Hayes et al., 1979b), Ser248 (Pirie-Shepherd et al., 1997), and 
Ser339 (Hortin 1990), as well as N-glycosylation in Asn289 (Hayes et al., 1979a). NetOGlyc 
(Table 4) has further highlighted Thr290, Thr359, and Thr365 as putative O-glycosylation sites.  
Table 4: Glycosylation information of the identified proteins. 
Protein 
Glycosylation* Predicted glycosylation T and STn expression in serum by Western blot 
O-linked N-linked Net -O-Glyc Net -N-Glyc Healthy Gastritis 
Complete 
IM 
Incomplete IM 
Plasminogen 
Ser248 
Ser339 
Thr346 
Asn289 
Thr171 
Thr340 
Thr346 
No T T/STn T/STn T/STn 
Vitronectin No 
Asn86 
Asn169 
Asn242 
Thr113 
Ser137 
Thr141 
Asn86 
Asn169 
- - - STn 
Complement 
factor H 
No 
Asn511 
Asn700 
Asn784 
Asn804 
Asn864 
Asn893 
Asn1011 
Asn1077 
No 
Asn529 
Asn882 
Asn1029 
Asn1095 
- STn STn STn 
Histidine-rich 
glycoprotein 
No 
Asn45 
Asn69 
Asn107 
Asn184 
Asn326 
Asn327 
Ser307 
 
Asn63 
Asn125 
Asn344 
- T - - 
* Glycosylation sites reported in previous studies. 
Vitronectin, which has been described until now as an N-glycosylated protein (Ogawa et al., 
1995), was also found among the proteins showing simple mucin-type O-glycans 
immunoreactivity. Still, its expression was restricted to STn in the context of incomplete IM. In 
agreement with these observations, NetOGlyc has also predicted possible O-glycosylation sites for 
Vitronectin.  
Additionally, we observed STn antigen reactivity in Complement factor H in sera from gastritis 
and IM. No sites of O-glycosylation have been described but at least eight sites of N-glycosylation 
have been shown in Complement factor H (Fenaille et al., 2007). Histidine-rich glycoprotein was 
identified as displaying T antigen reactivity. No sites of O-glycosylation have been described but at 
least six sites of N-glycosylation have been described in this protein (Jones et al., 2005) (Table 
4). Noteworthy, despite the absence of reports of O-glycosylation in Histidine-rich glycoprotein, 
theoretically this protein can carry this type of post-translational modification as predicted by 
NetOGlyc.  
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In summary, among the proteins found carrying simple mucin type carbohydrate antigens, 
plasminogen showed the most differentiated pattern of O-glycosylation for IM. Namely, it 
presented decreased levels of T antigen accompanied by the abnormal overexpression of STn.  
Structural characterization of STn antigen from Plasminogen and glycosylation site 
determination 
Structural analysis was performed in order to validate immunoblotting assignments regarding 
the expression of STn in plasminogen. The protein purified by affinity chromatography using 
Lysine-sepharose, further separated by SDS-PAGE electrophoresis was chemically de-O-
glycosylated in gel. The released O-glycans from plasminogen were then permethylated to avoid 
desialylation by MALDI in-source and metastable decay and analyzed by MALDI-TOF/TOF. This 
allowed the distinction of a chromatographic profile for the ion at m/z 691.36 corresponding to 
the sodium adduct of STn antigen (Figure 6A and B). This assignment was further supported by 
the absence of the signal upon desialylation of plasminogen with a α-neuraminidase. Moreover, 
the product ion spectrum exhibited the ions at m/z 107.1 resulting from B10,2X1 fragmentations, at 
m/z 358.1 from C11,3X1, and at m/z 416.2 from 2,5X1 or C1 (nomenclature according to Domon and 
Costello (Domon et al., 1988) (Figure 6C), therefore confirming the presence of STn in 
plasminogen. The prevalence of cross-ring fragmentations are in keeping with previous 
observations for high CID conditions (Zaia 2004). In agreement with previous reports concerning 
the O-glycosylation of plasminogen (Hayes et al., 1979b; Hortin 1990; Pirie-Shepherd et al., 
1997), low abundant ions belonging to mono- (m/z 895.5) and di-sialylated T (m/z 1256.6) 
antigens have also been detected (data not shown).  
In order to characterize the plasminogen glycosylation sites containing STn, sialoglycopeptides 
from plasminogen of the different clinical groups were enriched by titanium dioxide 
chromatography (Larsen et al., 2007) as described in materials and methods. The methodology 
was optimized for human plasminogen using a commercial plasminogen sample. Using this 
method we have detected the three O-glycosylation sites and one N-glycosylation site previously 
described in human plasminogen (Hayes et al., 1979a; Hayes et al., 1979b; Hortin 1990; Pirie-
Shepherd et al., 1997) (Supplementary Table 1 and Supplementary Figure 1). Using this 
approach we found one STn-containing glycopeptide in healthy controls, five in gastritis, four in 
complete IM and eight in incomplete IM (Table 5). 
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Figure 6: Positive mode MALDI-TOF/TOF identification of permethylated STn in serum plasminogen isolated from 
patients with intestinal metaplasia. A) Relative Ionic Current of nano-HPLC fractions for the ion at m/z 691.36 
corresponding to the monoisotopic mass of [STn+Na]+, before and after desialylation. The analytical signals in each 
plot were normalized to allow the comparison of both sets of data. A chromatographic envelop was observed in the 
samples for fractions 80-100, that is absent after desialylation. B) MS spectrum showing the ion at m/z 691.36 
corresponding to the monoisotopic mass of [STn+Na]+. C) MS2 spectrum of the ion at m/z 691.36 highlighting 
reporter ions resulting from combined sialic acid cross-ring fragmentations (X1) and glycosidic bound cleavages B1 
and C1 fragments (nomenclature according to Domon et al., 1988) and symbology  adapted from Glycoworkbench. 
“*” overlapping signals resulting from cross-ring fragmentations at the sialic moiety, and/or at the reduced GalNAc 
residue, and/or the loss of methoxy groups (Morelle et al., 2004), induced by high CID conditions (Zaia 2004). 
Table 5: Characterization of serum plasminogen1 sialoglycopeptides.  
 
Experimental 
mass (Da) 
Theoretical 
mass (Da) 
Number of 
STn 
glycoforms 
Glycoform 
Mass 
Tryptic 
missed 
cleavages 
Sialoglycopeptides2 
Control 2782.59 2782.80 3 1483.36 0 494-504 HSIFTPETNPR 
Gastritis 
3189.28 3189.15 4 1977.81 0 108-117 WSSTSPHRPR 
4656.01 4656.00 1 494.45 0 330-367IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR 
2382.30 2382.46 2 988.91 0 379-389 C*QSWSSM§TPHR 
2782.40 2782.80 3 1483.36 0 494-504 HSIFTPETNPR 
 2319.88 2319.56 1 494.45 2 777-791 VSRFVTWIEGVM§RNN 
Complete 
IM 
2352.49 2352.68 1 494.45 2 71-85 DVVLFEKKVYLSEC*K 
2783.07 2782.80 3 1483.36 0 494-504 HSIFTPETNPR 
855.63 855.88 1 494.45 0 777-779 VSR 
2814.02 2814.02 2 988.91 2 777-791 VSRFVTWIEGVM§RNN 
Incomplete 
IM 
1528.63 1528.54 2 988.91 0 94-98 GTM§SK 
3189.50 3189.15 4 1977.81 0 108-117 WSSTSPHRPR 
4656.33 4656.00 1 494.45 0 330-367IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR 
2382.46 2382.46 2 988.91 0 379-389 C*QSWSSM§TPHR 
2782.59 2782.80 3 1483.36 0 494-504 HSIFTPETNPR 
4723.11 4722.93 3 1483.36 0 720-750 VQSTELC*AGHLAGGTDSC*QGDSGGPLVC*FEK 
3187.30 3187.62 1 494.45 0 753-776 YILQGVTSWGLGC*ARPNKPGVYVR 
855.49 855.87 1 494.45 0 777-779 VSR 
1: Plasminogen aminoacid numbering excludes the 19 amino acid signal peptide. 
2: C* - carbamidomethylation of cysteine; M§ = methionine oxidation 
 
CHAPTER 3 | Results 
 
 102 
DISCUSSION 
Alterations of glycosylation are commonly observed in pathological conditions, including gastric 
cancer (David et al., 1992; Amado et al., 1998), constituting a major source of biomarkers (Reis 
et al., 2010). These changes in glycosylation are also observed during the process of gastric 
carcinogenesis, such as in gastritis and in IM, a precursor lesion of gastric carcinoma 
characterized by the expression of simple mucin type carbohydrate antigens, such as T and STn 
(David et al., 1992; Ferreira et al., 2006; Conze et al., 2010; Marcos et al., 2011). 
Serum remains the ideal biofluid for biomarker identification due to the easy collection and 
because it frequently displays proteins expressed by pathological tissues. The present study 
identified serum proteins displaying altered O-glycosylation as determined by the expression of the 
antigens T and STn in patients with gastric pathologies, such as gastritis, IM of the complete and 
incomplete types, as compared with control individuals without any gastric mucosa lesion.  
In order to perform this glycoproteomic analysis we applied an equalizing tool for serum 
protein content. The CPLL (Thulasiraman et al., 2005) equalized sera from the different clinical 
groups showed a normalized amount of proteins characterized by an increased ratio of low 
abundant proteins and a decreased ratio of high abundant proteins. This tool showed to be quite 
efficient in avoiding the overrepresentation of serum albumin, immunoglobulins, as well as the 
other 20 most abundant serum proteins (Farrah et al., 2011). The search for serum proteins 
bearing T and STn antigens was performed using a combination of 2-D gel electrophoresis for 
protein separation and further detection by Western blotting of T and STn using specific 
monoclonal antibodies. This strategy directed this serum O-glycoproteome search for the protein 
targets displaying altered simple mucin type carbohydrate antigens T and STn in the different 
clinical groups.  The first dimension of the 2D gel electrophoresis using separation gradients of 
pH 3-10 and pH 4-7 were applied in the present study, however the pH 3-10 gradient allowed 
better resolution of proteins localized in the upper limit of the gradient and showing 
immunoreactivity with the monoclonal antibodies against the STn and T glycan antigens. 
The patterns of total protein distribution in 2D gel electrophoresis were similar among the 
different clinical groups, with protein maps showing good resolution separation of various protein 
isoforms (Figure 5, left panel). The Western blotting analysis showed T and STn antigens 
detection in few proteins (Figure 5, center and right panel) of the different clinical groups. T 
antigen detection was observed in all groups with higher reactivity observed in gastritis whereas 
STn antigen detection was observed in gastritis, and in complete and incomplete IM groups.  
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The detection of serum proteins expressing truncated glycans may reflect the aberrant 
glycosylation observed in proteins expressed by pathological tissues. This is the case in most 
serological assays that detect circulating glycoproteins derived from malignant tumors or benign 
lesions (Reis et al., 2010; Pan et al., 2011). Our results showing the detection of truncated 
glycans STn and T in the glycoproteomic profiling of patients with gastritis and IM are in 
agreement with our previous findings that the STn and T antigens are expressed in the gastric 
mucosa of the patients displaying pre-neoplastic pathological conditions of the stomach (David et 
al., 1992; Carneiro et al., 1994; Ferreira et al., 2006), particularly in IM, and in contrast to the 
absence (or almost absence) of expression of these truncated glycans in the normal gastric 
mucosa of control individuals.  
The glycosylation modifications observed in gastric pathologic tissues may stem from altered 
expression of glycosyltransferases, previously shown in gastric epithelial cells induced by H. pylori 
infection (Marcos et al., 2008), and particular increased expression of specific 
glycosyltransferases (Marcos et al., 2011). The reasons underlying such glycosylation 
modifications are still largely unknown but hypothesis such as deregulation of the glycosylation 
machinery in the Golgi apparatus of the cells (Gill et al., 2011), or as consequence of altered 
differentiation program observed in IM are being tested (Almeida et al., 2003). 
The proteomic mining of the serum for STn and T antigens expression in the different clinical 
groups tested in the present work has resulted in the identification of relatively abundant 
circulating proteins, namely plasminogen, vitronectin, complement factor H, and histidine-rich 
glycoprotein. Even though the amount of these proteins did not vary significantly between groups, 
the pattern of simple mucin type O-glycans immunoreactivity showed considerable alterations.  
Plasminogen was identified due to the immunoreactivity for T and STn antigen in all disease 
groups, but showed no immunoreactivity in healthy controls. Interestingly, among the identified 
proteins carrying simple mucin type carbohydrate antigens, plasminogen showed the most 
differentiated pattern of O-glycosylation in IM, displaying decreased levels of T antigens 
accompanied by an increased expression of STn when compared with the other clinical groups. 
The detailed analysis of the O-glycans from purified plasminogen from IM patients was performed 
in order to validate the STn glycan detection at the molecular level. Plasminogen O-glycans 
released by reductive β-elimination were permethylated and analysed by MALDI mass 
spectrometry.  Our results showed the detection of ions compatible with STn antigens (Figure 6). 
Further MALDI-MS2 analysis of the ion at m/z 691.4 Da exhibited glycosidic bond cleavages B, C 
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and Z, and cross-ring fragmentation A and X product ions characteristic of STn glycan, therefore 
demonstrating the presence of STn in plasminogen from serum of incomplete IM patients. 
In addition, the MALDI structural analysis of sialoglycopeptides from plasminogen enriched by 
titanium dioxide chromatography showed the presence of glycopeptides containing STn in all 
disease groups. The use of the sialoglycopeptides enrichment method by titanium dioxide 
followed by MALDI showed to be quite efficient with the identification of the three O-glycosylation 
sites and one N-glycosylation site previously described in human plasminogen (Hayes et al., 
1979a; Hayes et al., 1979b; Hortin 1990; Pirie-Shepherd et al., 1997) (Supplementary Figure 
1 and Supplementary Table 1). Based on this approach the analysis of the clinical groups lead 
to the identification of one STn-containing glycopeptide in healthy control, five STn-containing 
glycopeptides in gastritis, four in complete IM and eight in incomplete IM (Table 5). Some of the 
sites identified have not been described for plasminogen and may constitute potential novel 
biomarkers of pre-cancerous gastric lesions.  
Further analysis of enriched for sialic acid containing glycoproteins from gastritis, intestinal 
metaplasia, and carcinoma patients confirmed STn reactivity of plasminogen in an independent 
set of samples (Supplementary Figure 2 and Supplementary Table 2). These results using 
alternative glycoprotein enrichment approaches and different sample cohorts further demonstrate 
the potential application of the altered plasminogen STn glycosylation as a biomarker in these 
pathologies. 
Plasminogen is released as a zymogen from the liver into circulation where it adopts a closed, 
activation resistant, conformation. Upon binding to blood clots, or to cell surfaces, plasminogen 
can adopt an open form that can be converted into active plasmin by a variety of enzymes, 
including tissue plasminogen activator and urokinase plasminogen activator (Miles et al., 2005; 
Law et al., 2012). Plasmin is a serine protease that acts dissolving fibrin clots and in other 
proteolysis functions in diverse systems. Two major glycoforms of plasminogen have been 
described in humans - type I plasminogen containing two glycosylation moieties (N-linked to 
Asn289 and O-linked to Thr346), and type II plasminogen containing a single O-linked sugar on 
Thr346 (Hayes et al., 1979a; Hayes et al., 1979b).  However, additional sites of O-glycosylation of 
plasminogen have been reported in Ser248 (Pirie-Shepherd et al., 1997), and Thr339 (Hortin 
1990). Type II plasminogen has been shown to be preferentially recruited to the cell surface 
whereas type I plasminogen appears more readily recruited to blood clots (Takada et al., 1985). 
Nevertheless, only one (Thr346) of these glycosylation sites could be theoretically predicted using 
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the bioinformatics platform NetOGlyc. On the other hand this approach retrieved other putative 
glycosylation sites that are still lacking in vivo confirmation. The discrepancy between these 
findings has been previous highlighted for serum proteins (Ferreira et al., 2011) and suggests 
that in vivo processing and pathophysiological states may play a determinant role in the definition 
of the glycosylation of circulating glycoproteins. 
The X-ray crystal structure analysis of closed plasminogen has revealed that O-glycosylation 
alter the position of a Kringle domain, partially explaining the functional differences observed 
between the type I and type II plasminogen glycoforms (Law et al., 2012). In closed plasminogen, 
the O-linked sugar on Thr346 is one of the requirements for the blocking of the cleavage by tissue 
plasminogen activator and urokinase plasminogen activator (Law et al., 2012). 
Liver is the primary tissue for plasminogen synthesis (Raum et al., 1980) but other tissue 
sources, including the gut, have been described in animal models (Zhang et al., 2002). The 
truncated O-glycans observed in circulating plasminogen from gastritis and in IM patients may 
either reflect altered glycosylation in the liver response to inflammatory cytokines or altered 
glycosylation of locally expressed plasminogen. Pro-inflammatory cytokines produced within the 
gastric disease context (Goll et al., 2007; Chang et al., 2008; Haghazali et al., 2011), may induce 
differential expression of glycosyltranferases in hepatocytes leading to alteration of glycosylation of 
circulating proteins (Gabay et al., 1999). This is in agreement with previous studies that have 
shown that modification of glycosylation characterized by increased expression of sialylated glycan 
structures, are observed in hepatocyte derived proteins during acute and chronic inflammatory 
diseases (De Graaf et al., 1993; Brinkman-van der Linden et al., 1998; Peracaula et al., 2010; 
Sarrats et al., 2010). In addition, alterations of plasminogen may also be related with the infection 
by H. pylori. Plasminogen-binding proteins in H. pylori with subsequent activation to plasmin 
(Pantzar et al., 1998; Jonsson et al., 2004) may provide proteolytic capacity and may contribute 
for the virulence of this bacterium (Pantzar et al., 1998; Jonsson et al., 2004). Also, the increased 
expression of urokinase plasminogen activator has been described in H. pylori-associated gastritis 
(Gotz et al., 1996; Goto et al., 2011). These findings altogether may point towards an important 
role of plasminogen activation in pathological conditions of the gastric mucosa. 
Vitronectin was also identified based on STn immunoreactivity in the incomplete type of IM. 
Vitronectin is a glycoprotein known to be glycosylated. Human vitronectin has been shown to 
contain N-glycans but no O-glycans have been described, contrary to vitronectin of other 
mammals that have been shown to contain both types of glycosylation (Kitagaki-Ogawa et al., 
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1990). Furthermore, it was demonstrated that despite the homology of about 73% between 
human and rat vitronectin, the sites of glycosylation are highly conserved and have been shown to 
be important for the protein function (Sano et al., 2007). 
Vitronectin is a multifunctional glycoprotein produced mainly by hepatocytes that is present 
mostly in plasma and extracellular matrix of many tissues (Schvartz et al., 1999). Vitronectin is 
involved in many functions such as the regulation of coagulation and fibrinolysis, cell adhesion 
and invasion, as well as in matrix remodeling and humoral defense mechanisms (Preissner 
1991). Glycosylation has been reported to be important in the interaction of vitronectin with other 
molecules and on its functional activities (Yoneda et al., 1998). Additionally, vitronectin 
oligosaccharide moiety was suggested to be relevant in H. pylori binding and in the mechanism of 
the bacterial immune escape (Ringner et al., 1994; Singh et al., 2010). Furthermore, vitronectin 
was shown to be important in the adhesion and migration of tumor-infiltrating lymphocytes 
(Edwards et al., 2006). 
Our results showed STn antigen immunoreactivity for vitronectin in the context of incomplete 
IM. Despite the lack of reports on vitronectin O-glycosylation in humans we could predict three 
possible O-glycan sites (Thr113, Ser137, Thr141) using the NetOGlyc tool. Taking into 
consideration the importance of vitronectin glycosylation on its function and the reported bacterial 
interactions (Ringner et al., 1994; Singh et al., 2010), our findings may point towards a possible 
role in the context of gastric lesions development. 
The present study also indicated the histidine-rich glycoprotein as a target expressing 
truncated O-glycans, presenting reactivity with T antigen in the gastritis group. Histidine-rich 
glycoprotein is a plasma glycoprotein produced by the liver and known to bind to a number of 
ligands in circulation, such as heparin, heparan sulfate, thrombospondin, and plasminogen. 
Histidine-rich glycoprotein acts as an adapter protein and has been implicated in regulating many 
processes such as immune complex and pathogen clearance, cell adhesion, angiogenesis, 
coagulation and fibrinolysis (Ohta et al., 2009). Even though regarded as an N-glycosylated 
protein (six described sites and three predicted) our study has found Western blotting reactivity for 
the T antigen in gastritis and the NetOGlyc tool identified Ser307 as a putative glycosylation site. 
This indicates that this type of glycosylation could also be present in Histidine-rich glycoprotein 
and suggests that further structural insights on the O-glycan moiety may be required to 
complement previous studies focused on the analysis of the N-glycans (Ohta et al., 2009). 
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Similarly, our results showed immunoreactivity to STn antigen in all pathological conditions in 
proteins from the complement system, namely complement factor H, complement H-related 
protein and complement C4-B. The human complement pathway is a highly controlled effector 
mechanism of the immune system. Over 30 plasma proteins and membrane bound molecules 
are involved in the complement system and the most of these proteins are glycosylated. The 
complement factor H, complement factor H-related protein and the complement C4-B are 
proteins that have been described to be N-glycosylated (Ritchie et al., 2002). Our results 
indicating that aberrant O-glycosylation can be detected in these members of the complement 
system warrants further structural characterization of the glycans in these proteins. Most of the 
protein modules that form the complement system have been crystallized and structural data 
provides evidence for the role of N-glycans in this system. However, the structure and role of 
glycans in the resistance to proteolysis and functionality activation within pathological conditions 
is still incomplete. As these data become available, the glycans can be modeled at the 
appropriate locations and give further insights into the interaction between complement proteins 
and cofactors. 
Our results provide novel glycobiomarkers in serum from patients with gastric pathologies, 
including gastritis, intestinal metaplasia and gastric carcinoma. The present work opens new 
avenues for future targeted evaluation of these specific glycobiomarkers in additional 
immunoassay-based approaches enabling large scale individual analysis. 
In summary, this work present a set of proteins displaying altered O-glycosylation as detected 
by antibodies directed to STn and T antigens in the serum from patients with gastritis and IM in 
opposition to minor or no reactivity in the same proteins of healthy individuals without any gastric 
disease. We further demonstrated that circulating serum plasminogen from IM patients carry the 
truncated O-glycan STn antigen. These results warrant further studies to address the application 
of plasminogen STn glycosylation pattern as a serum biomarker of gastric pathologies. 
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SUPPLEMENTARY DATA 
Supplementary data 1 – Characterization of plasminogen glycosylation by MALDI-TOF/TOF 
mass spectrometry 
 
Supplementary Table 1: List of plasminogen glycopeptides detected by MALDI-MS. Serum plasminogen 
from a commercial sample was subjected to tryptic digestion followed by titanium dioxide enrichment of 
sialoglycopeptides (described in material and methods). MALDI mass spectra were acquired in linear positive mode 
using THAP (2',4',6'-Trihydroxyacetophenone monohydrate) as a matrix with a mass error tolerance of 0.06 %. 
Different already described plasminogen glycoforms have been detected. 
Peak 
nº 
Experimental 
mass (Da) 
Theoretical 
mass (Da) 
Glycosylation 
type 
Glycoform(s) Sialoglycopeptides # Reference 
1 2451.99 2451.65 O ST 243-258 C*TTPPPSSGPTYQC*LK(G) (Pirie-Shepherd et 
al., 1997) 
2 4605.11 4606.87 O T + Pi 330-367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR(G)  
3 4697.11 4698.75 N Hex2HexNAc2NeuAC1 + 
Man3GlcNAc2 
266-290 GNVAVTVSGHTCQHWSAQTPHTHNR(T) (Hayes et al., 
1979a) 
4 4815.91 4818.15 O ST 330-367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR(G) (Hayes et al., 
1979b; Pirie-
Shepherd et al., 
1997) 
5 4896.60 4898.13 O ST + Pi 330-367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR(G) (Pirie-Shepherd et 
al., 1997) 
6 4989.98 4987.07 N Hex2HexNAc2NeuAC2 + 
Man3GlcNAc2 
266-290 GNVAVTVSGHTCQHWSAQTPHTHNR(T) (Hayes et al., 
1979a) 
7 5188.48 5189.39 O diST + Pi 330-367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR(G) (Pirie-Shepherd et 
al., 1997) 
8 5554.99 5554.61 O diST + T + Pi 330-367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR(G) (Hortin 1990) 
 
Supplementary Figure 1: MALDI MS spectrum of human plasminogen after titanium dioxide enrichment. The 
detected sialoglycopeptides are presented in the Supplementary Table 1. 
Supplementary data 2 - Identification of STn in Plasminogen from gastritis, intestinal 
metaplasia and gastric carcinoma of independent set of samples 
Supplementary Material and methods 
Sera sample collection, glycoprotein enrichment by lectin affinity chromatography and identification 
of STn containing proteins 
A second set of sera sample from Hospital Santo António and Hospital São João were used for the identification 
of proteins carrying STn structures. Sera sample from ten individuals within each of the following clinical groups were 
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used: without gastric lesions, gastritis, intestinal metaplasia and from two types of gastric carcinoma (intestinal and 
atypical). Sera sample were pooled and subjected to albumin and IgG depletion by a commercial kit (ProteoPrep from 
Sigma Aldrich). For the enrichment of STn containing glycoproteins, depleted sera were subjected to Sambucus nigra 
agglutinin (Vector laboratories) affinity chromatography that specifically recognizes and capture α2,6 sialic acids 
containing glycoproteins. The affinity chromatography eluted proteins were further subjected to 2D gel 
electrophoresis, Western blot analysis to detect STn containing proteins, and MALDI-TOF/TOF mass spectrometry 
protein identification was performed as described in materials and methods of this paper.  
 
Supplementary Figure 2: Glycoproteomic approach to reveal serum proteins carrying STn antigen. 
Serum samples from healthy, gastric precursor lesions (gastritis and  intestinal metaplasia) and two types of gastric 
carcinoma (intestinal and atypical type) individuals were subjected to albumin and IgG removal and lectin affinity 
chromatography to capture α2,6 sialic acid containing proteins. Affinity captured proteins were separated by 2D gel 
electrophoresis and STn highlighted by Western blot. The results show the presence of STn containing proteins in 
serum from individuals with gastric percursor lesions and with gastric carcinoma, and Plasminogen was identified by 
MALDI-TOF/TOF as STn protein carrier. Black highlighted areas indicate selected protein dots, reactive for STn 
antigen, and identified as plasminogen (see Supplementary Table 2).   
Supplementary Table 2: Proteins identified in sera of control, gastritis, metaplasia, intestinal type carcinoma and 
atypic type carcinoma according to the immunoreactivity with antibodies for STn antigen. 
Spot ID 
Protein 
description 
Accession number 
MASCOT Protein 
C.I. % 
Peptide 
count 
% cov 
Peaks 
matched 
MOWSE 
score 
Control Plasminogen PLMN_HUMAN 100 31 32 34 243 
Gastritis Plasminogen PLMN_HUMAN 100 32 35 32 259 
Metaplasia Plasminogen PLMN_HUMAN 100 28 32 30 202 
Intestinal Type Carcinoma Plasminogen PLMN_HUMAN 100 33 37 37 273 
Atypic type carcinoma Plasminogen PLMN_HUMAN 100 30 33 34 232 
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ABSTRACT 
Sialyl-Lewis X (SLeX) is a sialylated glycan antigen expressed on the cell surface during 
malignant cell transformation and is associated with cancer progression and poor prognosis. The 
increased expression of sialylated glycans is associated with alterations in the expression of 
sialyltransferases.  
In this study we determined the capacity of ST3GAL3 and ST3GAL4 sialyltransferases to 
synthesize the SLeX antigen in MKN45 gastric carcinoma cells and evaluated the effect of SLeX 
overexpression in cancer cell behavior both in vitro and in vivo using the chicken chorioallantoic 
membrane (CAM) model. The activation of tyrosine kinase receptors and their downstream 
molecular targets was also addressed. 
Our results showed that the expression of ST3GAL4 in MKN45 gastric cancer cells leads to the 
synthesis of SLeX antigens and to an increased invasive phenotype both in vitro and in the in vivo 
CAM model. Analysis of phosphorylation of tyrosine kinase receptors showed a specific increase 
in c-Met activation. The characterization of downstream molecular targets of c-Met activation, 
involved in the invasive phenotype, revealed increased phosphorylation of FAK and Src proteins 
and activation of Cdc42, Rac1 and RhoA GTPases. Inhibition of c-Met and Src activation abolished 
the observed increased cell invasive phenotype.  
In conclusion, the expression of ST3GAL4 leads to SLeX antigen expression in gastric cancer 
cells which in turn induces an increased invasive phenotype through the activation of c-Met, in 
association with Src, FAK and Cdc42, Rac1 and RhoA GTPases activation. 
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INTRODUCTION 
Alterations in cell surface glycosylation are considered a hallmark during carcinogenesis. 
These alterations usually lead to the expression of tumor-associated carbohydrates on 
glycoproteins or glycolipids that decorate cell surfaces (Reis et al., 2010). One of the most 
common glycan alterations is the increase of sialylated Lewis-type blood group antigens, such as 
sialyl Lewis A (SLea (NeuAcα2,3Galβ1-3[Fucα1-4]GlcNAc-R) and sialyl Lewis X (SLeX 
(NeuAcα2,3Galβ1-4[Fucα1-3]GlcNAc-R)). SLea and SLeX are expressed in cancer cells, mimicking 
their normal expression on blood cells (monocytes and neutrophils) potentiating cancer cell 
migration through binding to endothelial cell selectins (Varki 1994; Fuster et al., 2005). 
Therefore, SLea and SLeX overexpression are a common feature of several carcinomas (e.g., lung, 
colon, gastric and pancreas) and are associated with increased metastatic capacity (Fukuoka et 
al., 1998; Kim et al., 1998; Tatsumi et al., 1998; Borsig et al., 2002) and poor overall patients' 
survival (Nakamori et al., 1997; Amado et al., 1998; Baldus et al., 1998; Nakamori et al., 1999; 
Grabowski et al., 2000).  
The increased expression of sialylated glycans associated to carcinogenesis is the result of 
altered expression of sialyltransferases (STs) genes which encode for enzymes involved in the 
biosynthesis of the glycan antigens above described (Harduin-Lepers et al., 2012). Up to 20 
different sialyltransferases have been described to catalyse the transfer of sialic acid residues 
from a donor substrate CMP-sialic acid to the oligosaccharide side chain of the glycoconjugates. 
This sialic acid generally occupies the terminal non-reducing position on glycan chains (Harduin-
Lepers et al., 2005). Different STs show cell and tissue specific expression pattern and differ in 
substrate specificities and types of linkage formed (Harduin-Lepers et al., 2005). Depending on 
these characteristics, STs are classified in four families - ST3Gal, ST6Gal, ST6GalNAc and ST8Sia. 
ST3Gal family are α2,3-STs which catalyze the transfer of sialic acid residues to terminal 
galactopyranosyl (Gal) residues and include six members from ST3Gal I to ST3Gal VI (Harduin-
Lepers et al., 2001). 
Among the six ST3Gal sialyltransferases, ST3Gal III, IV and VI have been described to 
contribute to SLeX formation (Kono et al., 1997; Okajima et al., 1999), with a substantial role 
attributed to ST3Gal IV (Ellies et al., 2002; Sperandio et al., 2006). 
The sialyl-Lewis antigens are synthesized on type 1 (Gal β1,3 GlcNAc) or type 2 (Gal β1,4 
GlcNAc) disaccharide sequences. The sialyltransferase ST3Gal III preferentially acts on type 1 
rather than on type 2 disaccharides and is involved in the synthesis of SLea (Kitagawa et al., 
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1993). ST3Gal IV mainly catalyzes the α2,3 sialylation of type 2 disaccharides, leading to the 
biosynthesis of SLeX (Ellies et al., 2002; Colomb et al., 2012). 
We previously demonstrated the contribution of different ST3Gal sialyltransferases to the 
synthesis of sialyl Lewis antigens in gastric carcinoma cells, and described that ST3Gal IV is 
involved in the synthesis of SLeX antigen (Carvalho et al., 2010). In line with this report, other 
studies also found that high expression of ST3Gal IV, contributes to the expression of α2,3-linked 
sialic acid residues, and is associated with the malignant behavior of gastric cancer cells (Jun et 
al., 2012).  
In gastric carcinoma tissues, the increased expression of ST3Gal IV (Petretti et al., 1999) and 
of sialyl Lewis antigens have been associated with poor prognosis and metastatic capacity 
(Amado et al., 1998). These reports highlight the role of STs and evidenced that the expression of 
crucial glycan determinants, such SLeX, play an important role in tumor progression. However, the 
molecular mechanisms underlying the aggressive behavior of gastric cancer cells expressing SLeX 
are not fully understood. Some studies pointed to the importance of tyrosine kinase receptor 
activation in ST overexpression models (Cazet et al., 2009; Cazet et al., 2010; Cazet et al., 
2012). In the present study we assessed the effect of ST3GAL IV overexpression in the synthesis 
of SLeX in gastric carcinoma cells and we evaluated the functional role of SLeX in vitro 
(proliferation, invasion and adhesion) and in vivo (angiogenesis, tumor growth and invasion). We 
further evaluated the contribution to cell behavior of tyrosine kinase receptors activation and 
identified the downstream effectors in the context of a ST3Gal IV/SLeX overexpressing gastric 
carcinoma cells.  
MATERIALS AND METHODS 
Cell culture 
The gastric cancer cell line MKN45 was obtained from the Japanese Cancer Research Bank 
(Tsukuba, Japan) and was stably transfected with full length human gene for ST3GAL3 (MST3Gal 
III), ST3GAL4 (MST3Gal IV) and the empty vector pcDNA3.1 (Mock) as shown previously (Carvalho 
et al., 2010). The cells were grown in monolayer culture in T75cm2 flasks and maintained at 
37°C in an atmosphere of 5% CO2, in Roswell Park Memorial Institute (RPMI) 1640 GlutaMAX, 
HEPES medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin 
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(P/S) and in the presence of 0.5 mg/mL G418 (all from Invitrogen). Culture medium was 
replaced every two days. 
RNA isolation, cDNA synthesis and real-time PCR analysis 
Total RNA was extracted from cell lysates of Mock, MST3Gal III and MST3Gal IV cell lines 
using TRI Reagent (Sigma) and converted to cDNA using the SuperScript® II Reverse 
Transcriptase (Invitrogen). Reverse transcription was performed using 3 µg of total RNA, random 
oligonucleotides primers and SuperScript II RT (Invitrogen) in a total volume of 20 µL as 
described by the manufacturer. For real-time PCR analysis, cDNA samples were diluted 50-fold 
with water and PCR amplified in triplicate with 10.0 µL Power SYBRGreen Master Mix (Applied 
Biosystems), 0.48 µL of each 10 µM primer and 4 µL cDNA using an ABI Prism 7000 Sequence 
Detection System (Applied Biosystems). The primers used were the following: ST3GAL3 for 5'-
ggtggcagtcgcaggattt-3'; rev 5'-catgcgaacggtctcatagtagtg-3'; and ST3GAL4 for 5'-
cctggtagctttcaaggcaatg-3'; rev 5'-cctttcgcacccgcttct-3'. Expression of 18S (for 5'-
cgccgctagaggtgaaattc-3'; rev 5'-cattcttggcaaatgctttcg-3') and GAPDH (for 5'-agtccctgccacactcag-3'; 
rev 5'-tactttattgatggtacatgacaagg-3') was also measured in triplicate for each sample and used for 
normalization of target gene abundance. Specificity of amplification was confirmed by melting 
curve analysis. Standard curves were determined for each gene, and results are presented as 
ratio between target gene and housekeeping genes, 18S  and GAPDH. 
Proliferation assays 
Cell growth was analyzed using the BrdU reagent (Roche) according to the manufacturer's 
directions. Cells (1 × 105) were seeded in slides on 24-well plates (Thermo Fisher Scientific) and 
grown in RPMI containing 10% FBS, 1% P/S in the presence of 0.5 mg/mL G418. When cells 
reached 50% of confluence, BrdU was incorporated in cell culture medium and incubated for 20 
minutes. After incorporation cell culture medium was removed and cells fixed with methanol for 
30 min. Cell labeling with anti-BrdU antibody and FITC secondary antibody was performed 
according to manufacturer's instructions. Three independent assays were performed and each 
assay was done in quadruplicates for all the cell lines. Percentage of dividing cells was calculated 
by measuring positive BrdU cells in relation to total cells with the help of ImageJ software. Results 
are presented as means ± SD for each sample, and proliferation levels obtained were compared 
with the Mock control cell line. 
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Invasion assay 
Invasion assays were performed in a BD Biocoat Matrigel invasion chamber with an 8-µm 
diameter pore size membrane and a thin layer of Matrigel, in a 24-well plate. Inserts were 
rehydrated for at least 1 h in RPMI medium. After detachment of confluent cells with 
trypsin/EDTA, cells (5 × 104) were seeded in the upper surface of Transwell plates and cultured in 
RPMI containing 10% FBS, 1% P/S in the presence of 0.5 mg/mL G418 for 6 h, and the same 
culture medium was added in the lower part of the insert. After incubation, non-invading cells in 
the upper part of the insert were carefully removed, cells were fixed with methanol and 
membranes were removed from the inserts and mounted in a slide using Vectashield with DAPI 
(Vector labs). Three independent assays were performed and cells were seeded in duplicate for 
each cell line. Invading cells were counted under a fluorescence microscope, and measurement 
was done by counting cells in three different fields in each sample, with application of ImageJ 
software. Results are presented as means ± SD for each sample, and invasion levels obtained 
were compared with the Mock control cell line. 
Cell-substrate adhesion assay 
Cell adhesion assays were performed in a 96-well plate coated overnight at 4ºC with 50 µL of 
different extracellular matrix (ECM) proteins: collagen IV, fibronectin and vitronectin in the 
concentration of 20 µg/mL, while bovine serum albumin (BSA) (Sigma-Aldrich) was used as 
negative control. After coating, the plate was incubated for 1 hour with 0.5% of BSA in phosphate 
buffer saline (PBS) and viable cells (2 x 104 cells/well) were introduced into the plate and allowed 
to adhere for 30 min in RPMI serum-free medium at 37ºC and 5% CO2. Removal of non-adherent 
cells was performed by washing the plate with PBS and adherent cells were fixed with methanol 
for 30 min. Cells were subjected to 0.5% crystal violet dissolved in 20% of methanol for 1 h, and 
then washed several times with water and allowed to air dry. Crystal violet dye was solubilized 
with 10% acetic acid and absorbance was measured at  = 560 nm. Results are presented as 
means ± SD for each sample, and adhesion levels obtained were compared with the Mock control 
cell line. 
Phospho-RTK array analysis 
Cells were cultured until reached confluence on T75cm2 flasks with RPMI medium 
supplemented with 10% FBS and 100 units/mL penicillin-streptomycin in the presence of 0.5 
mg/mL G418. Cells were then lysed in NP40 lysis buffer (1% NP40, 20 mM Tris-HCl (pH 8.0), 
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137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM sodium orthovanadate, and protease inhibitor 
cocktail tablet (Roche)), protein concentration was determined by the bicinchoninic acid (BCA) 
protein assay (Pierce) and 300 µg of total protein was used for the human Phospho-RTK array kit 
(R&D Systems). Phospho-RTK array protocol was performed according to manufacturer's 
instructions. Activated receptors were matched according to the phospho-RTK array coordinates: 
a1, a2: EphA6; a3, a4: EphA7; a5, a6: EphB1; a7, a8: EphB2; a9, a10: EphB4; a11, a12: 
EphB6; a13, a14: mouse IgG1 negative control; a15, a16: mouse IgG2A negative control; a17, 
a18: mouse IgG2B negative control; a19, a20: goat IgG negative control; a21, a22: PBS negative 
control; b1, b2: Tie-2; b3, b4: TrkA; b5, b6: TrkB; b7, b8: TrkC; b9, b10: VEGFR1; b11, b12: 
VEGFR2; b13, b14: VEGFR3; b15, b16: MuSK; b17, b18: EphA1; b19, b20: EphA2; b21, b22: 
EphA3; b23, b24: EphA4; c1, c2: Mer; c3, c4: c-Met; c5, c6: MSPR; c7, c8: PDGFRα; c9, c10: 
PDGFRβ; c11, c12: SCFR; c13, c14: Flt-3; c15, c16: M-CSFR; c17, c18: c-Ret; c19, c20: ROR1; 
c21, c22: ROR2; c23, c24: Tie-1; d1, d2: EGFR; d3, d4: ErbB2; d5, d6: ErbB3; d7, d8: ErbB4; 
d9, d10: FGFR1; d11, d12: FGFR2α; d13, d14: FGFR3; d15, d16: FGFR4; d17, d18: insulin R; 
d19, d20: IGF-IR; d21, d22: Axl; d23, d24: Dtk. Black dots represent phospho-tyrosine positive 
controls. 
c-Met and Src inhibition assay 
c-Met and Src inhibitors were used to evaluate the invasive capacity of the cells upon 
inhibition. c-Met inhibition was performed with 0.1 µM of PHA-665752 (Sigma) and Src inhibition 
with 20 µM of PP2 (Sigma) both during 10h. Inhibition was assessed by Western blot for the 
phosphorylation status of c-Met and Src, and invasion capacity of cells was evaluated as 
described above, after 10h of inhibitors incubation 
Immunoblotting 
Proteins were obtained from total cell lysates of each cell line. Briefly, confluent T75cm2 flasks 
were incubated with NP40 lysis buffer and cells were scraped. Total cell lysates were centrifuge at 
14000 rpm for 10 min to remove pellet cell debris. Protein concentration was determined by the 
bicinchoninic acid (BCA) protein assay (Pierce). Proteins from cell lysates were separated 
accordingly to protein molecular weight by gel electrophoresis in 7.5% acrylamide/bis acrylamide 
(Sigma) SDS-PAGE. For c-Met, phospho-Met, phospho-AKT, phospho-STAT3 and phospho-ERK 
detection, 25 µg of total protein extract were used and for phospho-Src and phospho-FAK 
detection we used 50 µg of total protein extract. Gels were then transferred onto a nitrocellulose 
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membrane (Amersham) in a semi-dry system. Membranes were then blocked with 5% non-fat 
milk, washed three times with Tris buffer saline (TBS), and incubated overnight at 4ºC with 
primary antibodies. After incubation, membranes were washed three times with TBS and 
incubated 1 h with secondary antibodies. Analysis was done by chemiluminescence using the 
ECL Western blotting detection reagent and films (both from GE Healthcare). 
Antibodies: anti-phosphorylated Akt Ser473, anti-phosphorylated FAK Tyr397, anti-
phosphorylated Src Tyr416, anti-phosphorylated ERK Thr202/Tyr204 and anti-phosphorylated 
MET Tyr1234/1235, anti-phosphorylated STAT3 Tyr705 (all rabbit polyclonal antibody from Cell 
Signaling Technology) were  used at 1:1000 dilution. Mouse monoclonal IgG2a antibody directed 
against human MET (Invitrogen) was used at 1:2000. Anti-SLeX clone KM93 (Millipore) was used 
at 1:500 dilution. Goat anti-actin and rabbit anti-actin (Santa Cruz Biotechnology) were used at 
1:8000 dilution. Secondary anti-rabbit and anti-goat antibodies, conjugated with horseradish 
peroxidase (DAKO), were used at 1:2000, while anti-mouse IgG2a and IgM antibodies, conjugated 
with horseradish peroxidase (Jackson immunoresearch) were used at 1:25000 and 1:10000, 
respectively.  
Cdc42, Rac1 and RhoA GTPases pull down assay 
Cells were cultured in serum free medium for 24 h, and proteins were obtained from total cell 
lysates. Pull-down assays, using RhoA / Rac1 / Cdc42 Activation Assay Combo Biochem Kit 
(Cytoskeleton, inc), were performed according to manufacturer’s instructions, using 600 µg of 
total protein lysates. Briefly, rhotekin-RBD effector domain affinity beads were used to bind RhoA 
active (GTP-bound) protein and PAK-PBD effector domain affinity beads for Cdc42 and Rac1 
active proteins. Total proteins were incubated with these beads for 2 h, and pull down proteins 
were eluted with Laemmli buffer and separated on 12% acrilamide/bis acrilamide gels. Pull down 
negative and positive controls were performed according to manufacturer’s instructions; briefly 
total cell lysates were incubated with GTPases inhibitors or activators prior to pull down. To 
confirm the presence of GTPases in the cell protein extract, a 5% input control were also runned 
in the gels. Gels were transferred to nitrocellulose membranes and antibodies against Cdc42, 
RAC1 and RhoA (included in the kit) were incubated overnight with gentle agitation. Proteins were 
analyzed by chemiluminescence using the ECL Western blotting detection reagent and films (both 
from GE Healthcare). 
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Chicken embryo in vivo tumorigenesis and angiogenic assay 
The chicken embryo chorioallantoic membrane (CAM) model was used to evaluate the 
angiogenic response and growth capability of Mock and MST3Gal IV cells (n=13 for each group). 
According to the European Directive 2010/63/EU, ethical approval is not required for 
experiments using embryonic chicken. Correspondingly, the Portuguese law on animal welfare 
does not restrict the use of chicken eggs. Briefly, fertilized chick (Gallus gallus) eggs obtained 
from commercial sources were incubated horizontally at 37.8°C in a humidified atmosphere and 
referred to embryonic day (E). On E3 a square window was opened in the shell after removal of 
1.5-2 mL of albumin to allow detachment of the developing CAM. The window was sealed with a 
transparent adhesive tape and the eggs returned to the incubator. The window in the egg shell 
does not interfere in any way with the normal development of the chick embryo. Cells, re-
suspended in 10 µL of complete medium (1x106 cells per embryo), were placed on top of E10 
growing CAM into a 3 mm nylon ring under sterile conditions. The eggs were re-sealed and 
returned to the incubator for an additional 3 days. At this point the embryos are at embryonic 
development day 13, thus still in the first 2/3 of development. The embryos were euthanized by 
adding 2 mL of fixative in the top of the CAM which is a very efficient and fast method. After 
removing the ring, the CAM was excised from the embryos, photographed ex ovo under a 
stereoscope, at 20x magnification (Olympus, SZX16 coupled with a DP71 camera). The number 
of new vessels (less than 15 µm diameter) growing radial towards the ring area was counted in a 
blind fashion manner. The area of CAM tumors was determined using the Cell A (Olympus) 
software.  
Immunohistochemistry analysis and tumor invasive phenotype 
Excided CAMs were fixed in 10% neutral-buffered formalin, paraffin-embedded for slide 
sections and stained with hematoxilin-eosin for histological examination. Slides with clear view of 
the CAM tumors were also processed for cytokeratin, SLeX and p-Met immunohistochemical 
detection in order to characterize the phenotype of CAM tumors. Briefly, sections were dewaxed, 
rehydrate and the endogenous peroxidase activity was blocked with 3% H2O2 in methanol for 30 
min. Then, sections were incubated with normal rabbit or swine serum diluted 1:5 in PBS 
containing 10% BSA for 30 min followed by incubation with the monoclonal antibodies overnight 
at 4ºC. Incubation with both biotinylated rabbit anti-mouse and swine anti-rabbit secondary 
antibodies (DAKO) was done during 30 min at room temperature followed by avidin/biotin 
complex detection (Vectastain). Staining was performed with 3,3′-diaminobenzidine 
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tetrahydrochloride (Sigma) containing 0.02% hydrogen peroxide and counter staining of the 
nucleus was done with Mayer’s hematoxylin. Monoclonal antibodies used were KM93 1:60, p-Met 
1:100 and cytokeratins AE1/AE3 1:300, and for both antigen retrieval was achieved with citrate 
buffer pH 6.0. Evaluation of tumor invasion was performed in a blind fashion way by two 
independent observers. The semi-quantitative evaluation took into consideration the quantity of 
human AE1/AE3 labeled cells present in the CAM mesenchyme. 
Statistical analysis 
Statistical analysis was performed using Graph Pad program. ANOVA tests were used to 
calculate significance in an interval of 95% confidence level. All statistics were compared with 
Mock group and values of p<0.05 were considered to be statistically significant. 
RESULTS 
Induction of SLeX by overexpression of ST3GAL4 in gastric carcinoma cells 
To evaluate the role of ST3GAL3 and ST3GAL4 sialyltransferases in the synthesis of SLeX 
structures, the previously established MKN45 cell line model stably transfected with full length of 
either ST3GAL3 (MST3Gal III), ST3GAL4 (MST3Gal IV) genes, or an empty vector as control 
(Mock) were used (Carvalho et al., 2010). The evaluation of the expression levels of ST3GAL3 and 
ST3GAL4 genes by Real Time-PCR (Figure 1A), showed approximately 4 fold increase of 
ST3GAL3 gene in MST3Gal III cells in comparison with Mock and MST3Gal IV cells, and a 160 
fold increase of ST3GAL4 gene expression in MST3Gal IV cells in comparison with Mock and 
MST3Gal III cells. 
The biosynthesis of SLeX antigen was further assessed by immunofluorescence and by Western 
blot analysis of total cell lysates and secreted proteins (secretome). Immunofluorescence results 
showed expression of SLeX in MST3Gal IV cells when compared with Mock and MST3Gal III cell 
lines (Figure 1B). Consistently, Western blot results demonstrated the expression of SLeX in 
MST3Gal IV cells, both in total cell lysates as previously described (Carvalho et al., 2010) and 
secreted proteins (Figure 1C). No expression of SLeX was detected in total protein extracts or 
secreted proteins from Mock and MST3Gal III cells.  
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Figure 1: Induction of SLeX expression by ST3Gal IV transfection in gastric carcinoma cells. A – Relative 
quantification of ST3GAL3 and ST3GAL4 mRNA expression in MOCK, MST3Gal III and MST3Gal IV transfected cells 
showing a significant overexpression of ST3GAL3 gene in MST3Gal III cells and ST3GAL4 in MST3Gal IV cells when 
comparing gene expression levels in Mock cells; ***p < 0.001 Mock versus MST3Gal III for ST3GAL3 gene and ***p 
< 0.001 MST3Gal IV versus Mock for ST3GAL4 gene. Results are presented as means ± SD. B – 
Immunofluorescence detection of SLeX expression in Mock, MST3Gal III and MST3Gal IV cells evidencing the 
presence of SLeX in MST3Gal IV (magnification 200x); C – Western blot detection of SLeX in proteins from total cell 
lysate and secreted proteins from Mock, MST3Gal III and MST3Gal IV cells. SLeX expression was observed on cell 
lysates and secretome from ST3GAL4 transfected cells (MST3Gal IV).  
Glycan structural characterization of glycolipids were also performed with mass spectrometry 
technology and no differences were observed in the pattern of glycosylation in the different cell 
lines, and no SLeX structures were found in all the cell lines (Supplemented Figure 1). 
Since only MST3Gal IV transfected cells were able to produce SLeX antigen, further experiments 
were performed using the MST3Gal IV and Mock cells.  
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In vitro biological behavior of SLeX expressing cells - MST3Gal IV  
Cell growth, invasive capacity and adhesion properties of cells transfected with the ST3Gal IV 
gene were evaluated in order to characterize these cellular phenotypes, and also to address the 
biological role of SLeX expression. MST3Gal IV cells showed no statistical differences when 
compared to Mock cells in terms of BrdU incorporation (Figure 2A), suggesting that the 
expression of ST3Gal IV sialyltransferase and of SLeX do not affect the proliferation rate of these 
cells.   
 
Figure 2: SLeX overexpression induces cell invasion and increases matrix-cell adhesion in vitro. A –  
BrdU proliferation assay in transfected cells. After 50% confluence, cells were incubated for 30 min with BrdU reagent 
and fluorescent labeled for proliferative index measurement. No differences were found between the different cell 
lines. B – Cell invasion assay on Matrigel chambers. Cells were seeded on Matrigel-coated filters inserted into two-
compartment chambers and invading capacity was measured by counting the number of cells that invade, through 
the Matrigel-coated filter, 6 h after incubation. MST3Gal IV cells demonstrated an invasive phenotype presenting a 
significant increased number of invasive cells when compared with MOCK cells (***p < 0.001). C –  Cell adhesion to 
ECM proteins. Adhesion potential of cells was assessed by incubating cells 30 min in pre-coated plates with collagen 
IV, fibronectin and vitronectin. Results demonstrate an increased adhesion of SLeX expressing cells to collagen IV (*p 
< 0.05 MST3Gal IV versus Mock) and vitronectin (*p < 0.05 MST3Gal IV versus Mock) matrix proteins. No statistical 
difference was found in the adhesion capacity of cells to fibronectin. Results are presented as means ± SD. 
Cell invasion was analyzed by counting the number of invasive cells on Transwell Matrigel 
invasion chambers. This analysis revealed that cells overexpressing ST3Gal IV sialyltransferase 
presented 3 fold increased ability to invade in vitro, when compared with Mock control cells 
(Figure 2B). This result evidence the importance of SLeX expression for the invasive phenotype of 
MST3Gal IV cells.  
In addition, the adhesion to extracellular matrix proteins was also evaluated by seeding cells in 
plates pre-coated with collagen type IV, fibronectin or vitronectin. Interestingly, SLeX expressing 
cells (MST3Gal IV) present an increase capacity to adhere to collagen IV and to vitronectin when 
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compared with Mock control cells (Figure 2C). In contrast, no statistical differences were found 
in the adhesion capacity of these cells to fibronectin. 
In vivo evaluation of angiogenesis, tumor growth and invasion capacity of MST3Gal 
IV cell line using chicken embryo chorioallantoic membrane model 
Transfected cells were inoculated into the chicken embryo chorioallantoic membrane (CAM) 
and different parameters were evaluated after 3 days of inoculation, specifically, the angiogenic 
response, tumor size and tumor cell invasive capacity (Table 1).  
Table 1: Parameters evaluated in the CAM model: Angiogenesis, tumor growth and invasion potential 
of cells. 
 
MOCK MST3Gal IV p-value 
Angiogenesis (vessel number)  20.15 ± 4.06 19.31±4.05 n.s. 
Tumour growth (total area mm
2
)  4.13± 1.45 4.29± 1.24 n.s. 
Cell invasion on CAM (% cases)  1/7 (14.3%) 5/7 (71.43%) * (0.0308) 
n.s.(non-significant) p≥0.05 
* p<0.05 
The angiogenic potential was assessed by counting the number of vessels with less than 20 
µm diameter growing radially towards the inoculation area. The results show no statistical 
differences in vessel number between Mock control cells and MST3Gal IV indicating that ST3Gal 
IV and SLeX expression do not influence the angiogenic response. Tumor size was assessed by 
measuring the area (mm2) of the tumor in the different groups. The results show no statistical 
differences in tumor size arising from the different cell lines, indicating no influence of ST3Gal IV 
and SLeX expression in tumor growth potential. 
For the evaluation of tumor cell invasive capacity, CAMs were excised from the embryos, fixed 
with formalin and paraffin-embedded. Invasion of inoculated cells was evaluated in sections of 
CAM tumors immunostained for human citokeratins. The results show an increased invasive 
capacity of MST3Gal IV cells inoculated in CAM in comparison to Mock cells (Table 1). To assess 
if cells invading the CAM expressed SLeX antigens, CAM sections were immunostained for SLeX. 
The results show that MST3Gal IV invasive cells expressed SLeX antigens, contrary to the observed 
in Mock control cells (Figure 3).  
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Figure 3: SLeX expressing cells present an invasive phenotype in vivo chicken embryo chorioallantoic 
membrane (CAM) model. Transfected cells were inoculated in CAM and different parameters were evaluated after 
3 days of inoculation. Invasive capacity of inoculated cells was evaluated by immunolabeling CAM tumors with human 
cytokeratin and SLeX to assess the presence of human epithelial cells expressing SLeX. Human cytokeratins 
immunostaining was used to prove the presence of inoculated human gastric carcinoma cells. SLeX expression and 
the invasive capacity of cells were match up to cytokeratins expression. Immunostained tissues evidence the 
presence of SLeX structures in CAM tumors from MST3Gal IV cells that, in contrast with Mock cells, invaded the CAM 
tissue.  
Increased activation of c-Met receptor in SLeX expressing cells - MST3GalIV 
To evaluate the possible effects of SLeX expression on the activation of cell surface receptors 
and on the induction of the cancer cell invasive phenotype, a receptor tyrosine kinase array was 
performed using total cell lysates from Mock and MST3Gal IV cells. The results show consistently 
that MST3Gal IV cells induce increased activation of hepatocyte growth factor receptor (HGFR/c-
Met) (Figure 4A). 
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Figure 4: Tyrosine kinase receptors activation evaluation in gastric carcinoma cells; increased c-Met 
in MST3GAL IV cells. A – phospho-RTK array of transfected Mock and MST3Gal IV cells. Total cell lysates were 
collected and 300 µg of total protein were incubated into a phospho-RTK membrane array. The array shows an 
increased activation of c-Met (HGFR) in MST3Gal IV cells. Activated receptors were matched according to the 
phospho-RTK array coordinates indicated in the material and methods section. c3, c4 correspond to c-Met ; B – 
Analysis of c-Met activation in MOCK and MST3Gal IV cells by Western blot; Cell lysates were analyzed by Western 
blot with antibodies directed against human c-Met and the phosphorylated tyrosine residues 1234/1235 of the 
kinase domain to confirm the activation of c-Met in MST3GAL IV cells. The results show an increase expression of 
phosphorylated c-Met (p-Met) in MST3Gal IV cell line with no differences in c-Met total protein levels in both cell lines. 
Anti-tubulin antibody was used to assess protein loading. C – Expression of phosphorylated c-Met was assessed in 
CAM tissues. The evaluation of c-Met activation in CAM tumors show that MST3Gal IV/SLeX expressing cells present 
positive staining for phospho c-Met and that the resulting invading cells are also positive for the phosphorylated form 
of this receptor.  
The increased level of c-Met receptor tyrosine phosphorylation (p-Met) was further evaluated by 
Western blot, and the results confirmed that phosphorylation of c-Met is increased in MST3Gal IV 
cells, with no differences in total c-Met protein expression levels (Figure 4B). To assess if the 
CAM invading cells are expressing the activated c-Met, CAM sections were immunostained for 
phospho c-Met, demonstrating that MST3Gal IV invasive cells are indeed expressing activated c-
Met (Figure 4C).  
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Evaluation of downstream effectors of c-Met activation 
c-Met activation relies on stereotypical signaling modulators common to many RTKs (Liu et al., 
2010; Organ et al., 2011). To evaluate possible downstream effectors of c-Met activation, we 
analyzed the activation of Src, FAK, STAT3, AKT and ERK, proteins involved in different c-Met 
downstream pathways. Our results show that MST3Gal IV cells present increased activation of Src 
and FAK proteins which are known to be involved in cell motility and invasion (Figure 5A, B).  
Figure 5: Evaluation of downstream effectors of c-Met activation. A – Increased levels of p-FAK and p-Src 
proteins in MST3Gal IV cells. The contribution of other effector proteins, such as AKT, ERK, FAK and Src was 
evaluated by Western blot for their phosphorylated forms in Mock and MST3Gal IV cell lines, and expression of β-
actin protein was used as protein loading control. Results show increased levels of phophorylated FAK and Src 
supporting their involvement as downstream effectors of phosphorylated c-Met (p-Met). B – Analysis of 5 independent 
Western blot of c-Met, STAT3, AKT, ERK, FAK and Src phosphorylated forms in MOCK and MST3 Gal IV cells showing 
statistically significant increased levels of p-FAK and p-Src, concomitantly with increased phosphorylated c-Met. 
Results are presented as means ± SD. C – Evaluation of Cdc42, Rac1 and RhoA GTPases as potential modulators of 
c-Met activation by pull-down assay of their activated forms. Western blot analysis of pull-down proteins evidence an 
increased activation of Cdc42, Rac1 and RhoA in MST3Gal IV cell line. A-GTPase WB protein positive control (His-
Cdc42, His-Rac1 and His-RhoA); B-Mock total cell protein pull down; C-MST3Gal IV total cell protein pull down; D-
Mock total cell protein pull down with previous GTPases activation (pull down positive control); E-Mock total cell 
protein pull down with previous GTPases inhibitors (pull down negative control); F-Mock total cell protein input; G-
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MST3Gal IV total cell protein input. Highlighted areas represent regions of interest regarding the specific protein 
migration. 
The small GTPases of the Rho family, such as Rac1, Cdc42, and RhoA were also evaluated as 
possible downstream modulators of c-Met activation by pull-down of activated GTPases. Our 
results demonstrate that in MST3Gal IV cells, the expression of ST3Gal IV and SLeX induce 
activation of Rac1, Cdc42 and RhoA (Figure 5C). 
Inhibition of invasion in SLeX expressing cells using c-Met and Src activation 
inhibitors 
In order to confirm the biological role of c-Met and Src activation in the invasive capacity of 
SLeX expressing cells, inhibition of phosphorylation of c-Met, Src and both in combination were 
performed. The inhibition was tested using different concentration of each inhibitor, and different 
time-points of incubation (data not shown). Longer incubations with 0.1 µM of PHA-665752 c-Met 
inhibitor (24h and 48h) led to decrease in cell proliferation and cell death (data not shown), 
therefore a 10h incubation time-point, showing no alteration in cell proliferation, was used for the 
evaluation of cell invasion. Src inhibition occurred after 10h of incubation with 20 µM of PP2 and 
no differences in cell death and proliferation was observed after longer incubation periods (data 
not shown). The activation status of c-Met and Src was assessed by Western blot analysis, and 
results confirmed the decreased in activation of both proteins after 10 h incubation with the 
inhibitors (Figure 6A). Given the observation that SLeX expressing cells present increased cell 
invasive capacity resulting from the activation of c-Met and Src, invasion of cells was evaluated 
after c-Met and Src inhibition. The results confirmed the increased invasion of SLeX expressing 
cells in DMSO control treatment, and demonstrated the abolishment of this invasion capacity 
upon inhibition of c-Met, Src and both proteins in combination (Figure 6B). Moreover, the results 
showed that inhibition of Src or both Src and c-Met in combination were more effective in 
precluding cell invasion (Figure 6B). 
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Figure 6: Inhibition of invasion in SLeX expressing cells by targeting c-Met and Src activation. A –  
Evaluation by Western blot of the activation of c-Met and Src in the MST3Gal IV  and Mock cells with or without the 
presence of inhibitors of c-Met (PHA-665752) and Src (PP2). B –  Cell invasion assay on Matrigel chambers after 
inhibition of c-Met and Src activation. Cells were seeded on Matrigel-coated filters after incubation with inhibitors for 
10 h. Invading capacity was measured by counting the number of cells that invade, through the Matrigel-coated filter, 
after 6 h. MST3Gal IV cells demonstrated an invasive phenotype presenting a significant increased number of 
invasive cells when compared with MOCK cells. Inhibition of c-Met, Src, and both in combination led to abolishment 
of cell invasion capability of the MST3Gal IV cells  (*p<0.05; **p<0.01; ***p < 0.001). 
DISCUSSION 
Aberrant glycosylation has been described for many years as a hallmark of cancer, and many 
of the resulting altered glycosyl epitopes are tumor associated antigens (Hakomori 2002; Drake et 
al., 2010). These cancer-related antigens are caused by disease-specific alterations in the glycan 
synthesis pathway such as changes in the Golgi and Endoplasmic Reticulum compartments, 
mutations in enzymes or chaperons, altered expression of enzymes and biochemical competition, 
and even variations in sugar donor availability (for a review see Reis et al., 2010). A common 
alteration is the abnormal expression of sialyltransferases, responsible for adding sialic acids 
residues to cell surface molecules and to secreted proteins, and which have been involved  in the 
oncogenic transformation, as well as in invasion and metastasis (Hakomori 2002; Dube et al., 
2005; Drake et al., 2010). Sialic acids are typically attached to the outermost ends of 
glycoproteins and glycolipids that can mediate and modulate a wide variety of physiological and 
pathological processes (Varki 2008). 
The SLeX antigen is a sialylated glycan structure which expression has been associated with 
cancer progression and aggressiveness as well as poor overall patient survival (Nakamori et al., 
1997; Amado et al., 1998; Baldus et al., 1998; Fukuoka et al., 1998; Kim et al., 1998; Tatsumi 
et al., 1998; Nakamori et al., 1999; Grabowski et al., 2000; Borsig et al., 2002). The expression 
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of SLeX in cancer results from the altered expression of sialyltransferases, that adds the sialic acid 
in a α2,3 linkage to Galactose residues on type-II chains (Harduin-Lepers et al., 2012). 
In this study, we have characterized the role ST3Gal IV sialyltransferase in the synthesis of 
SLeX antigen. Expression analyzes of SLeX in stably transfected gastric carcinoma cells by 
immunofluorescence and Western blot confirmed that ST3Gal IV leads to the biosynthesis of SLeX. 
Moreover, our results indicate that SLeX antigen is expressed on proteins from total cell lysates as 
well as on secreted proteins from MST3Gal IV cells. These results confirm previous observations 
that described the importance of ST3Gal IV in the synthesis of SLeX, the glycan ligand of selectins 
(Ellies et al., 2002; Sperandio et al., 2006). In addition, our results are in agreement with recent 
reports showing an increased mRNA level of ST3Gal IV and α2,3 sialic acid residues expression in 
gastric cancer tissues (Jun et al., 2012). 
The carbohydrate SLeX functions as a ligand for cell adhesion molecules of the selectin family, 
usually expressed on vascular endothelial cells. The expression of SLeX on cancer cells is known 
to facilitate tumor cell spreading by mediating tumor-endothelial cell interactions (Takada et al., 
1993; Kannagi 1997). The SLeX antigen is known to be important in selectin interactions 
participating in the adhesion of cancer cells to vascular endothelium and contributing to 
hematogenous metastasis (Kannagi et al., 2004). These previous observations further support 
that SLeX antigen plays a functional role in malignant cancer cell behavior. Noteworthy, the 
crosstalk between cancer cells and host mechanisms like cell-cell adhesion and cell-matrix 
adhesion interactions, tumor cell growth and motility are known to be important in modulating the 
process of cancer cell invasion. In the present study we performed a comprehensive evaluation of 
the biological role of SLeX in gastric cancer cells using in vitro and in vivo models. The in vitro 
analysis showed that SLeX expressing cells display a similar proliferative rate when compared with 
Mock transfected cells. However, SLeX expressing cells demonstrated a higher capacity to invade 
in vitro in Matrigel chambers, demonstrating the active role of this sialylated glycan structure in 
tumor cell motility and invasion. Concomitant to this invasive capacity, SLeX expressing cells 
evidenced higher capacity to adhere to collagen IV and vitronectin extracellular matrix proteins. 
These findings highlight the importance of this sialylated glycan in the malignant invasive 
phenotype. Furthermore, this invasive phenotype was also confirmed in vivo where cells 
transfected with ST3Gal IV and expressing SLeX antigen presented increased capacity to invade 
the chorioallantoic membrane of the chicken embryo. Our results are in keeping with studies that 
associate SLeX expressing tumors with more aggressive phenotypes (Nakamori et al., 1993; 
CHAPTER 3 | Results 
 
 135 
Amado et al., 1998; Ichikawa et al., 2000). In the gastric carcinoma context it has also been 
described that SLeX antigen expression correlates with liver metastasis (Tatsumi et al., 1998). The 
modulation of cancer cell biological behavior by sialylated glycans has been previously described 
in human pancreatic cells. In this pancreatic model the restoration of α1,2 fucosyltransferase 
activity, a enzymatic competitor of ST3Gal transferases, reduces the expression of Sialyl Lewis 
antigens and decreases the adhesive and metastatic properties of these cells (Aubert et al., 
2000). 
In addition, previous reports have shown that increased cellular sialylation leads to  receptor 
and signaling pathways activation and that the hypersialylation contributes to cancer progression 
and increased cell motility (Seales et al., 2005a; Seales et al., 2005b). Moreover, it has been 
described that TNF-α can induce SLeX and 6-sulfo-SLeX expression in human cancer cells, by 
increasing the expression of ST3GAL4 (Colomb et al., 2012). This mechanism has also been 
shown to be mediated by neutrophils expressing TNF-α leading to cancer cells invasiveness and 
metastasis (St Hill et al., 2011).  
In order to clarify the potential implication of ST3Gal IV and of its product SLeX in the biological 
behavior of gastric cancer cells, we evaluated the expression of activated tyrosine kinase 
receptors and downstream modulators involved in cancer cell invasion. The tyrosine kinase 
receptor array allowed the identification of a constitutive activation of c-Met in SLeX expressing 
cells. The activation of tyrosine receptors, directly or indirectly by glycan antigens has previously 
been observed in other cancer cell models. Singh and colleagues described that the Thomsen-
Friedenreich antigen (T antigen) present in CD44v6 promotes the activation of c-Met and mitogen-
activated protein kinase (MAPK) signaling leading to cancer cell proliferation (Singh et al., 2006). 
Furthermore, activation of c-Met receptor has been described in a breast cancer cell model that 
overexpress glycosyltransferases and this activation has been implicated in proliferation and 
invasion of cancer cells (Cazet et al., 2009; Cazet et al., 2010; Cazet et al., 2012). The MKN45 
cell line model has been reported to have a high level of expression and dependence on c-Met 
(Smolen et al., 2006) and therefore modulation of cellular glycosylation can have implications in 
this c-Met dependent cells. 
c-Met overexpression has been considered a hallmark of cancer, playing a role in many tumors 
and in metastatic progression (Sierra et al., 2011). In gastric cancer, c-Met expression alterations 
have been reported, such as the Tpr/Met rearrangement (Soman et al., 1991; Yu et al., 2000) 
and c-Met copy number amplification (Lee et al., 2011), as well as increased c-Met activation 
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(Inoue et al., 2004; Dua et al., 2011). We evaluated the c-Met activation in a series of gastric 
carcinoma tissues (data not shown). The variability in tissue sample processing is known to lead 
to loss of protein phosphorylation which precluded the detection of phosphorylated c-Met in these 
samples. However, sections analyzed from the chicken chorioallantoic membrane tumors, derived 
from either Mock or SLeX expressing gastric carcinoma cells, confirmed phosphorylated c-Met 
positive staining in SLeX cancer invading cells. This result further supports the hypothesis that SLeX 
expressing cells exhibit invasive capacity through the activation of c-Met. 
The activation of c-Met is well known to induce docking sites for proteins that mediate 
downstream signaling leading to the activation of the MAPK, phosphatidylinositol 3-kinase (PI3K)-
AKT, v-src oncogene homolog (Src), signal transducer and activator of transcription (STAT), which 
are signaling pathways that are involved in increased cell growth, scattering, motility, invasion, 
protection from apoptosis, branching morphogenesis, and angiogenesis (Liu et al., 2010; Organ 
et al., 2011). Taking that into consideration, we evaluated the downstream effectors of c-Met 
activation and found that FAK and Src proteins showed increased activation in cells expressing 
ST3Gal IV. In combination with our invasion assays results (in vitro and in vivo), these results 
strongly suggest that c-Met activation mediates tumor cell motility and invasion, also in gastric 
cancer cells. These results are in agreement with previous studies that associate Src-FAK 
signaling pathway with the metastization process (Peng et al., 2009; Lim et al., 2012; Sanchez-
Bailon et al., 2012; Shen et al., 2012). Furthermore, our results show that inhibition of c-Met and 
Src could preclude the increased invasion observed in SLeX expressing cells supporting the 
importance of this glycosylation alteration in the activation of this invasive related pathways. 
Oncogenic transformation is often associated with changes in organization of the cytoskeleton, 
which can influence cell migration, adhesion and invasion. The c-Met activation can cause 
changes in gene expression of cell-cycle regulators (Cdk6 and p27), extracellular matrix 
proteinases (such as matrix metalloproteinases and urokinase plasminogen activator), and in 
alterations of cytoskeleton functions that control migration, invasion and proliferation (Birchmeier 
et al., 2003). The cytoskeleton is composed of a complex and organized network of various 
fibrous proteins within the cytoplasm, playing an essential structural and regulatory role in the 
maintenance of cell structure and strength, in cell division, proliferation, motility, invasion and 
also in signaling functions (Tapon et al., 1997; Machesky et al., 1999; de Curtis et al., 2012). 
The activation of tyrosine kinase receptors can modify the phosphorylation status of cytoskeleton 
regulatory and structural proteins. Signaling pathways initiated by the activation of cell surface 
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receptors can promote distinct membrane protrusions by converging onto the Rho family of 
GTPases (Hall 1999; Kjoller et al., 1999). Rho proteins are small (21-25 kDa) molecules that 
share structural homology and become activated only when bound to GTP. One of the best 
characterized Rho GTPase family members is RhoA regulating the formation of stress fibers and 
focal adhesion assembly, while Rac1 and Cdc 42 are mainly involved in membrane ruffling and 
formation of filopodia, respectively (Pertz 2010). Estimation of GTPases activation is frequently a 
molecular marker in the evaluation of cytoskeleton alterations during cell migration (Evers et al., 
2000; Parri et al., 2010; Wessler et al., 2011). Here we showed the activation of Rho GTPases, 
specifically RhoA, Rac1 and Cdc42. These results further supports the evidence that SLeX 
expression leads to cytoskeleton protein alterations in cancer cells, underlying the observed 
increased cell motility and invasion of these cells. Our findings are in keeping with previous 
reports showing the importance of RhoA, Rac1 and Cdc42 in cancer progression (Kamai et al., 
2004), and also the crosstalk between these GTPases and other signaling pathways like Src-FAK 
in the migratory phenotype of cancer cells (Leve et al., 2011). Our present findings support the 
hypothesis that increased expression of SLeX on the surface of malignant cells plays an important 
role in tumor invasion and metastasis. Overall, our study showed that tumor cell invasion is 
induced by SLeX expression on gastric cancer cells through the activation of c-Met in association 
with downstream signaling effectors Src, FAK and RhoA GTPases activation (Figure 7). 
These results open new avenues for the designing of intervention strategies that target ST3Gal 
IV/SLeX in cancer cells as well as the inhibition of c-Met and Src in order to improve gastric cancer 
treatment by targeting invasion and metastasis. 
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Figure 7: Schematic representation of the alterations induced by increased expression of SLeX and 
activation of c-Met. Increased transcription of ST3GAL 4 leads to increased expression of the ST3Gal IV enzyme in 
the Golgi apparatus of the cells. This enzyme will glycosylate type-2 terminal oligosaccharide chains leading to the 
presence of SLeX in glycoproteins targeted for the membrane or to be secreted by the cells. The expression of SLeX in 
membrane-associated and secreted proteins can promote the interactions between these proteins and c-Met leading 
to its activation. c-Met activation leads to downstream signaling activation target proteins Src, FAK and Rho GTPAses 
leading to a modified cell-matrix adhesion and an increased cell invasion. 
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SUPPLEMENTARY DATA 
Mass spectrometry analysis of glycosphingolipids 
Prior to mass spectrometry analysis, glycosphingolipids were permethylated according to Ciucanu and Kerek 
(Ciucanu et al., 1984). Briefly, compounds were incubated 2 h in a suspension of 200 mg/mL of NaOH in dry 
dimethyl sulfoxide (300 μL) and ICH3 (200 μL). The methylated derivatives were extracted in CHCl3 and washed 
several times with water. The reagents were evaporated and the sample was dissolved in CHCl 3 in the appropriate 
dilution. Mass spectrometry analysis of permethylated GSLs was performed by matrix-assisted laser desorption-
ionization (MALDI) time-of-flight (TOF) on a Voyager Elite reflectron mass spectrometer (PerSeptive Biosystems, 
Framingham, MA), equipped with a 337-nm UV laser. Samples were prepared by mixing on a tube 5 μL of diluted 
permethylated derivatives solution in CHCl3 and 5 μL of 2,5-dihydroxybenzoic acid matrix solution [10 mg/mL 
dissolved in CHCl3/CH3OH(1:1, v/v)]. The mixtures (2 μL) were then spotted on the target plate and air-dried. 
 
Supplementary Figure 1: MALDI-TOF analysis of permethylated glycosphingolipids isolated from MKN45 Mock 
and transfected cells. Permethylated GSLs isolated from (A) MKN45 transfected with empty vector - Mock, (B) 
MKN45 transfected with ST3Gal III, (C) and MKN45 transfected with ST3Gal IV. No differences were observed in the 
type of gangliosides expressed in the three different cell lines.  Blue circle, Glc; yellow circle, Gal; blue square, 
GalNAc; red triangle, Fuc. 
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ABSTRACT 
Glycosylation alterations are common features of cancer cells, constituting a main source of 
cancer biomarkers. These alterations in cancer are consequence of the deregulated expression of 
glycosyltransferases such as α2,3 sialyltransferases that lead to expression of the SLeX antigen.  
In this work, we demonstrated in a gastric carcinoma cell line that overexpression of ST3Gal IV 
leads to the biosynthesis of SLeX and identified by mass spectrometry carcinoembryonic antigen 
glycoprotein as a major carrier of SLeX. We validated this result by immunoprecipitation and 
proximity ligation assay. The analysis of CEA and SLeX expression in a series of gastric carcinoma 
cases demonstrated that 83.9% of the total cases co-expressed both CEA and SLeX. This 
association was further validated by demonstrating CEA/SLeX molecular in situ expression in 
80.6% of the cases as determined by PLA. The presence of CEA/SLeX molecular complexes in the 
tumor tissues was correlated with the pattern of tumor growth and venous invasion.  
In conclusion we identified CEA as a glycoprotein carrier of SLeX antigen in gastric carcinoma 
cells, and demonstrated a co-expression and presence of molecular complexes of SLeX and CEA in 
gastric carcinoma tissues. The co-expression of CEA/SLeX may contribute to improve gastric 
cancer specific diagnosis and monitoring.   
INTRODUCTION 
Multiple molecular alterations are involved in the transition of healthy to tumor tissues, and 
these include changes in the pattern of protein glycosylation. Most membrane-associated and 
secreted cellular proteins are glycosylated, containing N- or O-linked glycans that decorate the cell 
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surfaces. The glycan composition of glycoproteins play various functions in the cell, such as 
protein conformation and trafficking, cell-cell and cell-matrix interactions and recognition (Varki 
1993). Aberrant glycosylation is a common feature associated with cancer, constituting an 
important source of cancer biomarkers (Drake et al., 2010; Reis et al., 2010).  
Deregulated expression or localization of glycosyltransferases and associated proteins within 
the tumor cell, are underlying causes of glycosylation changes observed in cancer (Hakomori 
2002; Gill et al., 2011; Meany et al., 2011; Harduin-Lepers et al., 2012). Altered expression of 
sialyltransferases and their associated products have been widely studied in cancer (Harduin-
Lepers et al., 2012). The most frequently reported tumor-associated glycosylation alterations are 
the increased sialylation and polysialic acid synthesis, the appearance of sialylated Lewis antigens 
in glycolipids and glycoproteins, the formation of truncated O-glycan chains and the increase in 
branching of N-glycans, (David et al., 1992; Reis et al., 2010; Kang et al., 2011; Pinho et al., 
2011; Dall'Olio et al., 2012). The expression of Sialyl Lewis X (SLeX (NeuAcα2,3Galβ1-4[Fucα1-
3]GlcNAc-R)) is significantly upregulated in cancer and has been shown to correlate with more 
aggressive phenotype and poor prognosis (Nakamori et al., 1993; Nakamori et al., 1997; 
Fukuoka et al., 1998; Kim et al., 1998; Julien et al., 2011). Several glycosyltransferases have 
been described to be involved in the synthesis of SLeX structures in cancer cells, such as the α1,3 
fucosyltransferases (FucT-VI and FucT-VII) (Britten et al., 1998; Liu et al., 2008; Trinchera et al., 
2011) and the α2,3 sialyltransferase IV (ST3Gal IV) (Ellies et al., 2002; Carvalho et al., 2010; 
Colomb et al., 2012). In gastric carcinomas increased expression of SLeX (Amado et al., 1998) 
and ST3Gal IV (Jun et al., 2012) have been described and associated with an aggressive cancer 
cell behavior. 
Although association between glycan expression alterations in tumor tissues and clinical 
prognosis has been documented, its application in the clinical setting has been limited to 
serological assays that detect glycoconjugates shed by the tumors into circulation. Among these, 
various serological assays have been approved such as carcinoembryonic antigen (CEA) for 
colorectal cancer, cancer antigen 125 (CA125) for ovarian cancer, CA19.9 for pancreatic and 
gastric cancer, and prostate-specific antigen (PSA) for prostate cancer (Drake et al., 2010; Reis et 
al., 2010; Pan et al., 2011). 
Currently the clinical application of these makers is mostly for monitoring treatment and 
relapses with no consensual application in early diagnosis. This limited diagnosis application is 
mostly due to the low tumor specificity of these biomarkers. 
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In the present work our main goal was the identification of proteins in gastric carcinoma cells 
that carry the SLeX glycan antigen. For this intend, we used a gastric carcinoma cell line 
expressing SLeX due to the overexpression of the ST3Gal IV enzyme, and indentified by mass 
spectrometry analysis carcinoembryonic antigen (CECAM5; CEA) as a SLeX protein carrier. This 
result was further validated by CEA immunoprecipitation and Proximity Ligation Assays, and the 
presence of this molecular complex was also verified in gastric carcinoma tissues and associated 
with venous invasion. 
MATERIALS AND METHODS 
Cell culture 
MKN45 gastric carcinoma cell line (Japanese Cancer Research Bank, Tsukuba, Japan) was 
stably transfected with a full length human gene for ST3GAL4 (MST3Gal IV) and the empty vector 
(Mock) (Carvalho et al., 2010). The cells were routinely grown in monolayer in T75 cm2 flasks 
using RPMI 1640 GlutaMAX, HEPES medium, supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin-streptomycin (P/S) in the presence of 0.5 mg/mL G418 (all from Invitrogen. 
Cell culture was done at 37°C in a 5% CO2 atmosphere and culture medium was replaced every 
two days. 
SDS-PAGE and Western blot analysis 
Transfected cells were collected at high confluence, incubated and scrapped with NP40 lysis 
buffer (1% NP40, 20 mmol/L Tris-HCl (pH 8.0), 137 mmol/L NaCl, 10% glycerol, 2 mmol/L 
EDTA, 1 mmol/L sodium orthovanadate, and protease inhibitor cocktail tablet (Roche)) to obtain 
total protein cell lysates. For secretome protein collection, cells in approximately 80% of 
confluence were carefully washed with phosphate buffer saline (PBS) and RPMI followed by a 24 
h cell culture in serum free RPMI medium. The culture medium was collected and concentrated 
in 10 MW cutoff filters according to manufacturer's instructions (Millipore). Protein concentration 
was determined by the bicinchoninic acid (BCA) protein assay (Pierce), and 50 µg of total protein 
were loaded on 7.5% acrylamide/bisacrylamide gel (Bio-Rad). After electrophoresis gels were 
stained or transferred to nitrocellulose membranes (GE Healthcare). Gels were stained with 
Coomassie blue (Imperial Protein Stain from Thermo Scientific) or with periodic acid-Schiff (PAS) 
method (Glycoprotein Staining Kit from Thermo Scientific Pierce) that specifically detects 
glycosylated proteins having sialic acid and other oxidizable carbohydrate groups according to 
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manufacturer's instructions (Pierce) and images were acquired with a GS800 scanner (Bio-Rad). 
Membranes were blocked with 5% BSA in PBS with 0.05% Tween 20 (PBST), incubated with 
primary antibody followed by incubation with horseradish peroxidase-conjugated goat anti-mouse 
IgM and goat anti-mouse IgG1 (Jackson ImmunoResearch) secondary antibodies and ECL 
detection (GE Healthcare). For lectin blots, after membrane blocking with 5% BSA PBST, 
biotinylated SNA lectin was incubated for 1 h at room temperature followed by avidin/biotin 
detection reagents (Vectastain) incubation and ECL detection. 
Antibodies and Lectin: Anti- SLeX clone KM93 was purchased from Millipore and used at 1:500 
dilution, rabbit monoclonal IgG1 antibody directed against human CEA was purchased from Cell 
Signaling Technology and used in 1:3000 dilution and biotinylated SNA from Vector labs was 
used in 1:600 dilution. 
Protein selection and identification by MALDI-TOF/TOF mass spectrometry 
The spots highlighted in the Western blots were matched in the stained gel and proteins 
excised with a spotpicker (OneTouch 2D gel spotpicker, 1.5 mm diameter, Gel Company, USA). 
After reduction and alkylation, the selected protein bands were in-gel digested with trypsin and the 
respective peptidic mass spectra were acquired by MALDI-TOF/TOF (4700 Proteomics Analyzer 
MALDI-TOF/TOF, AB SCIEX, CA) as previously described (Gomes et al., 2013a). Proteins were 
identified using the combined information of Peptide Mass Fingerprint (PMF) and MS/MS peptide 
sequencing approaches by the Mascot protein search software (Matrix Science, UK), integrated in 
the GPS Explorer software (AB SCIEX, CA).  
CEA Immunoprecipitation 
CEA immunoprecipitation was performed in Mock and MST3Gal IV total cell proteins. Briefly, 2 
µL of mouse anti-CEA antibody (Cell Signaling) was coupled to 60 µL of ProteinG Sepharose 
(Sigma) for 2 h at 4ºC, followed by BS3 (Sigma) crosslink of the antibody and total cell proteins 
(600 µg) were incubated overnight at 4ºC. Bead’s washes were performed with PBS and after 
protein incubation 1% of Triton X-100 (Sigma) was added. The immunoprecipitated proteins were 
eluted in 60 µL of SDS Laemmeli buffer and 10 µL was used for CEA Western blot and 25 µL for 
both SLeX and SNA Western blot. 
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Immunofluorescence staining 
MKN45 transfected cells were seeded and cultured on glass coverslips in 24-well plates 
(Orange Scientific). Cells were washed and fixed 30 min with methanol. After fixation, cells were 
washed and blocked with swine or rabbit serum in 10% BSA PBS for 30 min at room temperature 
followed by primary antibody incubation overnight at 4ºC. Then, cells were washed and incubated 
for 30 min with both rabbit anti-mouse 1:100 and swine anti-rabbit 1:70 FITC-conjugated 
secondary antibodies (DAKO). Nuclear counter staining was done with DAPI and coverslips were 
mounted in a microscope slide with vectashield (Vector Labs). Fluorescence was examined in a 
fluorescence microscopy and images were acquired using a Zeiss Axio cam MRm and the 
AxioVision Rel. 4.8 software (Carl ZEISS) and in some cases immersion oil was used. Monoclonal 
antibodies used: mouse monoclonal KM93 1:60, mouse monoclonal antibody anti-CEA 1:600. 
Tissue samples and Immunohistochemistry analysis 
Gastric carcinomas and gastric mucosa adjacent to carcinomas were obtained from individuals 
undergoing surgery at Centro Hospitalar São João (CHSJ), University of Porto Medical Faculty 
(Porto, Portugal).  Study was performed with the approval of the local CHSJ ethical committee. 
Gastric carcinoma tissues (n=31) formalin-fixed parafin-embedded were used for slide sections 
and stained with hematoxilin-eosin for histological examination. Hematoxylin and eosin-stained 
sections were used to classify gastric carcinomas according to the classifications of Carneiro et al. 
(1995), Laurén (1965), Ming (1977), and the World Health Organization (WHO). 
Clinicopathological characteristics of the cases (lymphatic invasion, venous invasion, pTNM 
staging) were also recorded in every case.  
Paraffin sections were dewaxed, rehydrated and blocked for endogenous peroxidase activity 
with 3% H2O2 in methanol for 30 min. Sections were then incubated with normal rabbit or swine 
serum diluted 1:5 in PBS containing 10% BSA for 30 min followed by incubation with the 
monoclonal antibodies overnight at 4ºC. Incubation with biotinylated rabbit anti-mouse (DAKO) 
was done during 30 min at room temperature followed by avidin/biotin complex detection 
(Vectastain). Staining was performed with 3,3′- diaminobenzidine tetrahydrochloride from Sigma 
containing 0.02% hydrogen peroxide and counter staining of the nucleus was done with Mayer’s 
hematoxylin. Mouse monoclonal antibodies used KM93 1:60, anti-CEA (CB30) 1:300 with antigen 
retrieval with citrate buffer pH 6.0. 
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Proximity ligation assay (PLA) 
PLA assay was performed in cultured cells on glass coverslips and on gastric carcinoma tissue 
sections for detection of ligation dependent SLeX on CEA glycoproteins, according to previous 
studies showing that PLA is an appropriate approach for glycoproteins identification in tissue 
sections (Pinto et al., 2012). Briefly, paraffin tissue sections were dewaxed and rehydrated 
followed by antigen retrieval with citrate buffer pH6.0. Tissue sections and cells on glass 
coverslips were then incubated with normal goat serum diluted 1:5 in PBS containing 10% BSA 
for 30 min followed by incubation with the two monoclonal antibodies in the same solution 
overnight at 4ºC. Proximity ligation assays (PLA) were performed using the DuoLink® II 
Fluorescence Kit (Olink® Bioscience, Uppsala, Sweden) according to the manufacturer’s 
instructions. PLA probes anti-IgG plus and anti-IgM minus were incubated 1 h at 37ºC, followed 
by ligation step 30 min at 37ºC and amplification step 100 min at 37ºC. Nuclei were stained with 
DAPI and slides were mounted in an appropriated medium (Duolink II). PLA products are seen as 
fluorescent red dots. Fluorescence was examined in a fluorescence microscopy and images were 
acquired using a Zeiss Axio cam MRm and the AxioVision Rel. 4.8 software (Carl ZEISS) and in 
some cases immersion oil was used. 
RESULTS 
Identification of SLeX protein carriers in MKN45 ST3Gal IV gastric carcinoma cell 
line 
The expression of SLeX on proteins from Mock and ST3Gal IV overexpressing cells were 
evaluated by Western blot. We observed expression of SLeX antigen exclusively on total cell lysates 
and secretome from MST3Gal IV cells (Figure 1). 
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Figure 1: ST3Gal IV induces expression of SLeX in proteins of MKN45 gastric cancer cells. Gastric 
carcinoma cells stably transfected with ST3Gal IV show SLeX expression. A – Coomassie blue gel of proteins from 
total cell lysates and secretome from Mock and MST3Gal IV cells; B – Western blot analysis of SLeX expression in 
Mock and MST3Gal IV. This evaluation shows expression of SLeX antigen in proteins from MST3Gal IV cell line. 
In order to detect high molecular weight proteins labeled in the SLeX western blot, we 
separated total cell lysates in SDS-PAGE and stained glycoproteins using the PAS method that 
specifically stains glycan residues (Figure 2A). The SLeX bands in the Western blot (Figure 2B) 
were matched with the glycan stained gel and the proteins identified by MALDI-TOF/TOF mass 
spectrometry analysis.  
Figure 2: Glycoprotein analysis of Mock and MST3Gal IV cells. A – Glycan staining using the periodic acid-
Schiff (PAS) method of SDS-PAGE glycoproteins present in Mock and MST3Gal IV; Horseradish peroxidase was used 
as positive staining control; B – SLeX expression on glycoproteins from Mock and MST3Gal IV cells; C – α2-6 sialic 
acid expression detected using the SNA lectin in glycoproteins from Mock and MST3Gal IV cells. The results show 
SLeX expression (B) and reduced α2-6 sialic acids expression (C) in MST3Gal IV cells. The PAS staining method (A) 
allowed the detection of glycoproteins in Mock and MST3Gal IV cells. Arrows 1 and 2 indicate the selected proteins 
for MALDI-TOF/TOF identification. 
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Two proteins were identified (Table 1), and among them the Carcinoembryonic antigen 
(CEACAM5; CEA) was the only previously described to be glycosylated. In addition, the detection 
of α2,6 sialic acids in total cell lysate proteins shows a loss of α2,6 sialic acids expression 
(Figure 2C) in SLeX positive proteins from MST3Gal IV cells (Figure 2B). 
Table 1: Proteins identified in MST3Gal IV cells according to SLex antigen detection by western blot  
Spot 
ID  
Protein description  Accession 
number  
MASCOT 
Protein 
C.I. % 
Peptide 
count 
% 
cov 
Peaks 
matched 
MOWSE 
score 
1 
Carcinoembryonic antigen-related 
cell adhesion molecule 5 
CEAM5_HUMAN 99 4 8 5 92 
2 
Ras GTPase-activating-like protein 
IQGAP1 
Carcinoembryonic antigen-related 
cell adhesion molecule 5 
IQGA1_HUMAN 100 39 21 40 268 
CEAM5_HUMAN 100 5 10 7 234 
Attempts to obtain a protein separation in 2D gel electrophoresis were performed, but 
Coomassie blue and SLeX staining (Supplementary Figure 1) did not allow the visualization of 
high molecular weight proteins that were observed in 1D SDS-PAGE. 
Characterization of SLeX glycan antigen in CEA  
In order to validate that CEA is a carrier of SLeX we performed CEA immunoprecipitation of 
total cell lysates from Mock and MST3Gal IV cells, followed by Western blot analysis for SLeX 
antigen. The results confirmed that gastric carcinoma cells express CEA (Figure 3A), and that 
CEA glycan structure from ST3Gal IV transfected cells contains the SLeX antigen (Figure 3B). 
Furthermore, it was observed a shift in the type of sialylation with a reduced α2,6 sialic acids and 
an increase in α2,3 sialylation present in CEA from ST3Gal IV cells (Figure 3C). Our results also 
show that CEA glycoprotein molecules from MST3Gal IV cells display a slightly higher molecular 
weight when compared with CEA protein molecules from Mock cells. These differences can be 
due to the alteration of the glycan structures in CEA protein molecules from MST3Gal IV cells.  
To further confirm the expression of SLeX in CEA molecules, Mock and MST3Gal IV gastric 
cells were evaluated by PLA, which indicates close proximity of the two molecules. The PLA 
results show positive expression signals in MST3GAl IV cells confirming that SLeX and CEA are in 
molecular proximity (Figure 3D).  
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Figure 3: SLeX expression in CEA molecules from MST3Gal IV. To assess expression of SLeX in CEA 
molecules immunoprecipitation of proteins and PLA was performed in Mock and MST3Gal IV cells. A – CEA Western 
blot analysis to confirm CEA expression in Mock and MST3Gal IV cells. The results show that CEA is expressed in 
both cell lines; B – SLex expression analysis in CEA immunoprecipitated proteins from Mock and MST3Gal IV cells 
confirming the expression of SLeX in MST3Gal IV CEA protein; C – α2-6 sialic acids expression analysis in CEA 
immunoprecipitated proteins from Mock and MST3Gal IV showing reduced expression of α2-6 sialic acids in CEA. 
Lanes: 1-molecular weight; 2-Mock CEA immunoprecipitated proteins; 3- Mock IgG immunoprecipitated proteins 
(immunoprecipitation control); 4- MST3Gal IV CEA immunoprecipitated proteins; 5- MST3Gal IV IgG 
immunoprecipitated proteins (immunoprecipitation control); 6- Mock CEA protein input; 7- Mock IgG protein input; 8- 
MST3Gal IV CEA protein input; 9- MST3Gal IV IgG protein input. D –Immunofluorescence analysis was performed to 
evaluate the expression of CEA and SLeX in Mock and MST3Gal IV gastric carcinoma cells. Both Mock and MST3Gal 
IV cells expressed CEA whereas only MST3Gal IV cells expressed SLeX. To assess if CEA carries SLeX, PLA analyses 
was performed and showed that only MST3Gal IV cells present CEA with SLeX antigen. 
SLex and CEA expression in gastric carcinoma tissues  
We next evaluated the expression of SLeX and CEA in gastric carcinoma. A series of 31 gastric 
carcinoma tissues were screened for the expression of SLeX, CEA and the presence of the 
CEA/SLeX molecular complex. Figure 4 shows representative images of the 
immunohistochemical expression of CEA, SLeX and PLA in two gastric carcinoma cases as well as 
in normal gastric mucosa. 
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Figure 4: CEA is a SLeX carrier in gastric carcinoma tissues. Immunohistochemical evaluation of the 
expression of SLeX and CEA in gastric carcinoma tissues. The figure illustrates a normal gastric mucosa (left column) 
and two gastric carcinomas. The result shows CEA and SLeX expression in gastric carcinoma tissues and no 
expression in normal gastric mucosa. PLA signal was only observed in gastric carcinoma (200x magnification). 
Normal and adjacent mucosa to gastric carcinomas showed no CEA expression whereas few 
cells with a weak immunostaining were observed for SLeX in gastric mucosa. Every gastric 
carcinoma showed CEA expression (100%) with staining varying from less than 25% to more than 
75% of the carcinoma cells. Expression of CEA were associated with lymphatic invasion and 
venous invasion (Table 2). There was also a trend for association between CEA expression and 
more advanced stages of gastric carcinoma (pTNM staging). 
Expression of SLeX was observed in 26 (83.9%) out of 31 gastric carcinoma cases. The 
expression of SLeX was heterogeneous among the cases, with 9 (29%) cases showing more than 
75% positive cells, 17 (54.9%) cases showing 25-75% positive cells, and 5 (16.1%) cases being 
negative or showing few positive cells (Table 2). The levels of SLeX expression were associated 
with Ming´s classification (Table 2). 
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Table 2: Expression of CEA and SLeX in gastric carcinoma tissues, and expression of CEA/SLeX by PLA  
 CEA  SLeX  PLA signal  
 0-25% 25-75% >75% P* 0-25% 25-75% >75% P* Neg. Pos. P* 
Laurén classification            
Intestinal 
(n=13) 
1 
(7.7%) 
2  
(15.4%) 
10 
(76.9%) 
ns 
1 
(7.7%) 
9  
(69.2%) 
3 
(23.1%) 
ns 
1 
(7.7%) 
12 
(92.3%) 
ns 
Diffuse 
(n=2) 
0 
(0%) 
1 
(50%) 
1 
(50%) 
0 
(0%) 
2 
(100%) 
0 
(0%) 
1 
(50%) 
1 
(50%) 
Unclassified  
(n=16) 
1 
(6.2%) 
5 
(31.3%) 
10 
(62.5%) 
5 
(25%) 
6 
(37.5%) 
6 
(37.5%) 
4 
(25%) 
12 
(75%) 
Carneiro classification            
Glandular 
(n=13) 
1  
(7.7%) 
2 
(15.4%) 
10 
(76.9%) 
ns 
1 
(7.7%) 
9 
(69.2%) 
3 
(23.1%) 
ns 
1 
(7.7%) 
12 
(92.3%) 
0.069 
Mixed 
(n=15) 
1 
(6.7%) 
5 
(33.3%) 
9 
(60 %) 
3 
(20%) 
6 
(40%) 
6 
(40%) 
3 
(20%) 
12 
(80%) 
Others  
(Isolated cells  + solid) 
(n=3) 
0 
(0 %) 
1 
(33.3%) 
2 
(66.7%) 
1 
(33.3%) 
2  
(66.7%) 
0 
(0%) 
2 
(66.7%) 
1 
(33.3%) 
Ming classification            
Expansive 
(n=8) 
1 
(12.5%) 
2 
(25%) 
5 
(62.5%) 
ns 
4 
(40%) 
3 
(37.5%) 
1 
(12.5%) 
0.04 
4 
(50%) 
4 
(50%) 
0.038 
Infiltrative 
(n=22) 
1 
(4.5%) 
5 
(22.8%) 
16 
(72.7%) 
1 
(4.5%) 
13 
(59.1%) 
8 
(36.4%) 
2 
(9.1%) 
20 
(90.9%) 
Unclassified 
(n=1) 
0 
(0%) 
1 
(100%) 
0 
(0%) 
0 
(0%) 
1 
(100%) 
0 
(0%) 
0 
(0%) 
1 
(100%) 
OMS classification            
Well-differentiated  
(n=15) 
2 
(13.3%) 
2 
(13.4%) 
11 
(73.3%) 
ns 
2 
(13.3%) 
9 
(60%) 
4 
(26.7%) 
ns 
2 
(13.3%) 
13 
(86.7%) 
ns 
Others 
(n=16) 
0 
(0%) 
6 
(37.5%) 
10 
(62.5%) 
3 
(18.75%) 
8 
(50%) 
5 
(31.25%) 
4 
(25%) 
12 
(75%) 
Lymphatic invasion            
Present 
(n=24) 
1 
(4.2%) 
4 
(16.6%) 
19 
(79.2%) 
0.042 
4 
(16.7%) 
13 
(54.1%) 
7 
(29.2%) 
ns 
4 
(16.7%) 
20 
(83.3%) 
ns 
Absent 
(n=7) 
1 
(14.3%) 
4 
(57.1%) 
2 
(28.6%) 
1 
(14.3%) 
4 
(57.1%) 
2 
(28.6%) 
2 
(28.6%) 
5 
(71.4%) 
Venous invasion            
Present 
(n=19) 
0 
(0%) 
3 
(15.8%) 
16 
(84.2%) 
0.029 
1 
(5.3%) 
12 
(63.1%) 
6 
(31.6%) 
ns 
1 
(5.3%) 
18 
(94.7%) 
0.012 
Absent 
(n=12) 
2 
(16.7%) 
5 
(41.7%) 
5 
(41.7%) 
4 
(33.3%) 
5 
(41.7%) 
3 
(25%) 
5 
(41.7%) 
7 
(58.3%) 
pTNM            
I+II 
(n=16) 
1 
(6.25%) 
7 
(43.75%) 
8 
(50%) 
0.058 
4 
(25%) 
8 
(50%) 
4 
(25 %) 
ns 
5 
(31.25) 
11 
(68.75%) 
0.08 
III+IV 
(n=15) 
1 
(6.7%) 
1 
(6.7%) 
13 
(86.6%) 
1 
(6.7%) 
9 
(60%) 
5 
(33.3%) 
1 
(6.7%) 
14 
(93.3%) 
Total 
2 
(6.5%) 
8 
(25.8%) 
21 
(67.7%) 
 
5 
(16.1%) 
17 
(54.9%) 
9 
(29%) 
 
6 
(19.4%) 
25 
(80.6%) 
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The evaluation of PLA for CEA/SLeX showed no signal in normal or adjacent gastric mucosa. In 
gastric carcinomas, PLA results showed that 25 out of 31 cases (80.6%) were positive. 
Furthermore, 25 out of the 26 cases that were positive for SLeX (displaying from 25-100% of 
positive cells) were also positive in PLA. The evaluation of the association between PLA signal and 
clinicopathological variables of the cases showed that PLA signal was correlated with Ming´s 
classification and venous invasion (Table 2). In addition there was a trend for association 
between PLA signals and Carneiro´s classification and pTNM staging. 
DISCUSSION  
The identification and characterization of molecular markers specific of cells undergoing 
malignant transformation are key steps for the selection of biomarkers that can be used for 
improvement of cancer diagnosis and patient’s monitoring. The cancer cell proteome has been a 
target for many studies in the last years, and post translational modifications of proteins, such as 
glycosylation, can provide key insights and added information to the proteome alterations in 
cancer (Hakomori 2002; Drake et al., 2010). Glycosylation is deregulated in human cancers 
resulting in the expression of distinct carbohydrate profiles in malignant tissues (Hakomori 2002; 
Drake et al., 2010; Reis et al., 2010) and therefore, protein aberrant glycosylation represents an 
important target for novel cancer biomarker discovery. One of the most typical glycosylation 
alterations in cancer is characterized by increased cellular sialylation. Many cancers specifically 
express sialylated structures such as the SLeX antigen (Hakomori 2002), which is known to be 
associated with an increase of ST3Gal IV sialyltransferase activity (Ellies et al., 2002; Sperandio et 
al., 2006; Carvalho et al., 2010; Jun et al., 2012).  
In this study we have confirmed that ST3Gal IV overexpression leads to SLeX biosynthesis in 
membrane-associated proteins (Carvalho et al., 2010), and also demonstrated expression of SLeX 
in secreted proteins from gastric carcinoma cells. The SLeX expression analysis of MST3Gal IV 
cells revealed a restricted expression limited to a set of glycoproteins, demonstrating specificity of 
the SLeX protein carriers. In addition, analysis of α2,6 sialic acid expression in MST3Gal IV cells, 
determined by SNA staining, showed that α2,6-sialylation was reduced in the protein bands that 
were positive for SLeX. This concurrent expression of SLeX (α2,3 sialic acid) and  α 2,6 sialic acid 
in MST3Gal IV and in Mock control cells, respectively, suggests an enzymatic competition in the 
addition of sialic acids to glycoproteins. This can result from the increased expression of ST3Gal 
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IV in the cell and its location in the Golgi compartment that may limit the CMP-sialic acid donor 
and the acceptor substrate availability in the cell due to previous α2,3 sialylation.  
Previous studies have shown that SLeX expression is implicated in the malignant behavior of 
cancer cells and is associated with more aggressive tumors (Nakamori et al., 1993; Nakamori et 
al., 1997; Amado et al., 1998; Fukuoka et al., 1998; Kim et al., 1998). Recently, we evaluated 
the biological role of SLeX in a gastric carcinoma cell model, showing that these cells display 
increased adhesion capacity to extracellular matrix proteins as well as an increased invasive 
phenotype both in vitro and in vivo (Gomes et al., 2013b). This phenotype was also associated 
with an increased activation of c-Met signaling pathways controlling cellular motility and invasion 
(Gomes et al., 2013b). These previous observations highlight the importance of identifying the 
glycoproteins carrying SLeX and determining the biological contribution of such specific protein 
glycosylation to the malignant phenotype of cancer cells. In this regard, and in order to disclose 
new targets for diagnostic and therapeutic applications, in this work we identify the proteins 
carriers of SLeX by MALDI-TOF/TOF mass spectrometry analysis. The protein identification 
revealed CEA as a major SLeX glycoprotein carrier in the ST3Gal IV expressing cells. The SLeX 
expression in CEA was confirmed by immunoprecipitation and PLA assays. The 
immunoprecipitation results showed that MKN45 cells expresses CEA and the SLeX western blot 
analysis confirmed the presence of this glycan structure in CEA molecules in ST3Gal IV 
expressing cells. These observations were further supported with the PLA results showing positive 
signal for CEA/SLeX molecular complexes in ST3Gal IV expressing cells when compared with no 
PLA signal in the Mock cells.  
CEA is a heavily glycosylated protein (Paxton et al., 1987) with 28 possible N-glycosylation 
sites described (Oikawa et al., 1987). CEA shows limited expression in normal adult tissues, most 
restricted to epithelial cells (Frangsmyr et al., 1999; Hammarstrom 1999). The cellular 
expression of CEA is limited to the glycocalyx commonly in the apical membrane domain of the 
cell as a glycophosphatidylinositol-linked surface glycoprotein (Hefta et al., 1988; Takami et al., 
1988; Frangsmyr et al., 1999; Hammarstrom 1999). However, the loss of cell polarity and tissue 
architecture observed in cancer leads to the shedding of CEA into the blood of cancer patients 
which can be detected by the CEA serological assay (Gold et al., 1965; Benchimol et al., 1989). 
Additionally, the increased invasive and metastasis capacity of cancer cells also result in release 
of CEA molecules into the lymph and blood vessels further contributing for the increase CEA 
serum detection.  
CHAPTER 3 | Results 
 
 160 
Currently, CEA serological detection in the cancer clinical setting is mostly limited to 
monitoring the disease with limited application in diagnosis. The differential diagnostic application 
of benign and malignant lesions remains a hurdle which can be eventually overcome by taking 
into consideration the type and level of glycosylation of the CEA protein (Garcia et al., 1991; 
Saeland et al., 2012). In this work, we also observed that SDS-PAGE analysis of the CEA 
immunoprecipitated from MST3Gal IV cells displayed a slightly higher molecular weight than CEA 
from Mock cells. These molecular weight variations in CEA may be attributed to its different 
glycosylation pattern in ST3Gal IV cells. This feature has been previously observed in colonic 
tissues, where normal colonic mucosa and preneoplastic lesions display CEA molecules with 
different molecular weights when compared to colon cancer cells (Garcia et al., 1991). 
In gastric cancer the overexpression of CEA has been well documented (Chevinsky 1991; 
Berinstein 2002) with association between the increased serum levels and poor outcome of the 
patients (Park et al., 2008; Chen et al., 2012). Nevertheless, at the moment there is no 
information on the glycosylation modifications of CEA in gastric tissues. Therefore in order to 
clarify the potential application of CEA glycosylation in gastric carcinoma tissues we evaluated 
possible associations with clinicopathological characteristics of the cases. Our results showed that 
all gastric carcinoma cases evaluated expressed CEA, in contrast with an absence of detection in 
adjacent normal gastric tissue. Furthermore, analysis of SLeX expression in gastric carcinomas 
showed that 83.9% of the cases displayed SLeX antigen. The evaluation of expression of both SLeX 
antigen and CEA molecules in gastric carcinoma tissues by PLA revealed that 80.6% of the cases 
showed CEA/SLeX PLA signal, strongly suggesting that CEA carries SLeX antigens in gastric 
carcinoma. The expression of CEA/SLeX, detected by PLA, was significantly associated with 
clinicopathological features of the cases, including the pattern of tumor growth (Ming's 
classification) and the presence of venous invasion.  
The importance of glycosylation changes during tumorigenesis has been described in other 
cancer biomarkers used in the clinical practice. Some reports have demonstrated altered PSA 
glycosylation in benign and malignant prostate lesions, highlighting the importance in considering 
the glycan composition of this biomarker in the clinical diagnosis of the disease (Peracaula et al., 
2003; Tajiri et al., 2008; Meany et al., 2009; White et al., 2009; Dwek et al., 2010; Li et al., 
2011; Gilgunn et al., 2012; Vermassen et al., 2012). Furthermore, CEA has been also reported 
as displaying abnormal glycosylation in colon cancer (Saeland et al., 2012) and has been 
demonstrated to contribute to the tumor biological behavior and immune evasion due to 
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interactions of CEA glycans with lectins of the immune system (van Gisbergen et al., 2005; 
Nonaka et al., 2008; Saeland et al., 2012). As shown for PSA, the evaluation of CEA glycoforms 
also offers interesting diagnostic perspectives to improve specificity to this serum biomarker. 
In conclusion, we report the identification of CEA as a SLeX protein carrier in the ST3Gal IV 
expressing gastric carcinoma cells, and we validate this association in a series of gastric 
carcinoma tissues. The expression of CEA/SLeX in gastric carcinoma detected by PLA was 
associated with the presence of venous invasion, supporting the role of SLeX for an aggressive 
behavior of the tumor cells. Our results open new avenues for addressing CEA altered 
glycosylation with SLeX in order to improve diagnosis and potential therapeutic decisions in gastric 
cancer. 
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SUPPLEMENTARY DATA 
1) Detection of SLex protein carriers by 2D gel electrophoresis separation  
Material and Methods: 2D gel electrophoresis 
Total cell proteins were precipitated using a ProteoExtract Kit (Calbiochem), resuspended in rehydration buffer 
(7M Urea, 2M Thiourea, 4% (v/v) CHAPS and 0.0002% Bromophenol Blue) with 0.2% of ampholyte and quantified 
using a 2D Quant Kit (GE Healthcare). Passive rehydration of the strips was performed overnight with 200 µg of total 
protein using IPG strips of pH 3-10 NL (ReadyStrip; 0.5 x3 x70 mm, Bio-Rad) at room temperature. Isoelectric 
focusing was performed on Protean IEF cell (Bio-Rad) with an initial voltage of 250 V for 15 min, and then by applying 
a voltage gradient up to 4000 V with limiting current of 50 µA per strip and temperature set at 20ºC. The first 
dimension was concluded at 14-20 kVh. Following the isoelectric focusing proteins were reduced and alkylated by 
incubation with 2% DL-dithiothreitol (DTT)(Sigma) followed by incubation with 2.5% Iodoacetamide (Sigma)  in an 
equilibration buffer (6M Urea, 2% SDS, 0.002% Bromophenol Blue, 75 mM Tris pH8.8, 29.3% Glycerol) for 15 min 
each under gentle agitation. The strips were then packed in a 1% low gelling (1% agarose in running buffer - 25 mM 
Tris, 192 mM Glycine, and 0.1% (w/v) SDS, pH 8.3; Bio-Rad) on top of a 9% acrylamide gel 
(acrylamide/bisacrylamide 37.5:1, 2.6% from Bio-Rad). Second dimension electrophoresis was performed in a Mini-
Protean tetra cell system (Bio-Rad) using 1xTris/Glycine/SDS buffer (Bio-Rad) at constant voltage of 125 V. 
 
Supplementary Figure 1: 2D gel electrophoresis and Western blot analysis of SLeX antigen from Mock 
and MST3Gal IV proteins. Coomassie blue gels from Mock and MST3Gal IV proteins are represented in the left 
side of the figure and Western blot analysis of SLeX antigen is represented in the right side. Proteins from total cell 
lysates of Mock and MST3Gal IV cells were separated in 2D gels and proteins highlighted in the Western blot were 
matched and excised for protein identification by MALDI-TOF/TOF analysis. The 2D methodology difficult the 
separation and identification of high molecular weight proteins that were positive for SLeX antigen. The proteins 
identified were not confirmed to carry SLeX antigen. 
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GENERAL DISCUSSION  
Cancer is a leading cause of death worldwide and a remarkable effort has been made to 
improve cancer diagnosis and cancer patients treatment, in order to reduce cancer related 
deaths.  
Many of the studies on cancer research aim at the discovery of new and appropriate 
biomarkers for cancer detection. Nowadays, various serological assays have been approved in the 
clinics such as carcinoembryonic antigen (CEA) for colorectal cancer, cancer antigen 125 
(CA125) for ovarian cancer, carbohydrate antigen 19-9 (CA19.9) for pancreatic and gastric 
cancer, and prostate-specific antigen (PSA) for prostate cancer (Drake et al., 2010; Reis et al., 
2010; Pan et al., 2011). However, the clinical application of these biomarkers is mostly for 
monitoring treatment and relapses with no consensual application in diagnosis. The limited 
diagnosis application of these biomarkers is mostly due to the low tumor specificity and 
sensitivity, being an imperative the discovery of new cancer biomarkers to improve cancer 
diagnosis.  
Gastric cancer remains one of the most common cancers and is the second leading cause of 
cancer-related death in the world, although the trends in gastric cancer incidence have been 
declining along the last decades (Ferlay et al., 2010). In clinical practice, CA19-9 (SLea antigen) is 
one of the serological markers used in gastric cancer. Nevertheless, this biomarker lacks the level 
of sensitivity and specificity required for the early detection of stomach carcinoma and is mainly 
employed for post resection monitoring rather than diagnostic purposes (Carpelan-Holmstrom et 
al., 2002; Qiu et al., 2009).  
Alterations of glycosylation are commonly observed in pathological conditions, including gastric 
cancer (David et al., 1992; Amado et al., 1998). During carcinogenesis, glycans are recognized to 
be involved in different stages of tumor progression, being key players in the proliferation, 
invasion, metastasis and angiogenesis processes (Fuster et al., 2005). Deregulation of 
glycosylation observed in cancer leads to the expression of distinct carbohydrate profiles in 
malignant tissues (Hakomori 2002; Drake et al., 2010; Reis et al., 2010) and therefore, protein 
aberrant glycosylation represents an important target for novel cancer biomarker discovery. 
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GLYCOPROTEOMICS FOR DISCOVERY OF NEW CANCER BIOMARKERS 
Glycan structures that decorate cell surfaces present a large structural complexity and are 
crucial for a wide variety of cellular processes. The high complexity of glycan structures combined 
with the challenge in the glycan analysis have limited the glycomics, especially when compared to 
genomics or proteomics. In the last years, advantages in glycomic analysis assist to attenuate the 
differences in the different "Omic" fields. The recent progress in understanding the importance of 
glycosylation in both normal and disease conditions have emphasized the value of glycan 
analysis, specially for finding new biomarkers of disease.  
Serum glycoproteomics for biomarker discovery in patients with gastric lesions 
Serum remains the ideal biofluid for biomarker identification due to the easy collection and 
because it frequently displays proteins expressed by pathological tissues. Protein glycosylation 
alterations are a hallmark in cancer progression, and glycoproteins produced during the 
carcinogenesis pathway can be released from cells into circulation acting as biosensors of the 
disease. In the particular case of gastric carcinoma, these changes in glycosylation are also 
observed in gastric cancer precursor lesions, for instance in gastritis and in intestinal metaplasia 
(IM), where we found expression of simple mucin type carbohydrate antigens, such as T and STn 
(David et al., 1992; Ferreira et al., 2006; Conze et al., 2010; Marcos et al., 2011). The 
expression of these truncated glycans modulates protein function and consequently the cell 
behavior and immune recognition (Liotta et al., 2001; Pinho et al., 2007), being important as 
cancer biomarkers (Reis et al., 2010) and presenting potential for immunotherapy (Julien et al., 
2009). In light of this, many efforts have been made to develop new glycoproteomic strategies to 
improve the identification of these glycans and the associated protein carriers in disease. 
In the first part of this work (Chapter 3.1) we have focused our attention in the identification of 
proteins carriers of truncated O-glycans that are known to be expressed in the different steps of 
the gastric carcinogenesis pathway that might be shed into circulation as source for biomarker 
discovery. To achieve this goal we used two different glycoproteomic strategies: 1) serum protein 
equalization using a combinatorial peptide ligand library (CPLL) (Thulasiraman et al., 2005); and 
2) enrichment of serum glycoproteins, after albumin and immunoglobulins depletion, using lectin 
affinity chromatography (Abbott et al., 2010). Followed this two procedures proteins were 
separated according to both their isoelectric point and molecular mass using 2D gel 
electrophoresis, and truncated O-glycans were highlighted using Western blot analysis. The 
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highlighted proteins were matched to Coomassie blue gels and proteins were identified by MALDI-
TOF/TOF analysis.  
The detection of serum proteins expressing truncated glycans may reflect the aberrant 
glycosylation observed in proteins in the pathological tissues. Therefore, the expression of these 
truncated glycans were firstly evaluated in gastric biopsies, confirming the presence of T and STn 
antigens in gastritis and in the two types of IM (Figure 3 and Table 2, Chapter 3.1) in agreement 
with our previous findings (David et al., 1992; Carneiro et al., 1994; Ferreira et al., 2006). Serum 
from the same individuals were used for the serum proteomic screening. Using the different 
glycoproteomic approaches described above, we were able to identify proteins displaying T and 
STn antigens in serum of patients with gastritis, and with both types of IM, comparing with control 
individuals without any gastric mucosa lesion. The Western blot analysis showed T and STn 
antigens detection in few proteins of the different clinical groups (Figure 5, chapter 3.1), with T 
immunoreactivity observed in all groups with higher expression in gastritis whereas STn antigen 
detection was observed in gastritis, and in complete and incomplete IM groups. The mass 
spectrometry analysis of the immunoreactive proteins resulted in the identification of four main 
proteins, namely plasminogen, vitronectin, complement factor H, and histidine-rich glycoprotein. 
Moreover, the amount of these proteins did not vary significantly between groups, except the 
pattern of simple mucin type O-glycans immunoreactivity that showed considerable alterations.  
All of the identified proteins have been described to be glycosylated, however only 
plasminogen has been reported to carry O-glycans. Nevertheless, and according to the NetOGlyc 
search performed in this study, vitronectin and histidine-rich glycoprotein display putative O-glycan 
sites.  
Vitronectin was identified based on STn immunoreactivity in the incomplete type of IM. Despite 
the lack of reports on vitronectin O-glycosylation in humans, contrary to vitronectin of other 
mammals that have been shown to contain both types of glycosylation (Kitagaki-Ogawa et al., 
1990), we could predict three possible O-glycan sites (Thr113, Ser137, Thr141) using the 
NetOGlyc tool. Furthermore, it was demonstrated that despite the homology of about 73% 
between human and rat vitronectin, the sites of glycosylation are highly conserved and have been 
shown to be important for the protein function (Sano et al., 2007). Glycosylation in vitronectin has 
been reported to be important in the interaction of vitronectin with other molecules and on its 
functional activities (Yoneda et al., 1998). Additionally, vitronectin oligosaccharide moiety was 
suggested to be relevant in H. pylori binding and in the mechanism of the bacterial immune 
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escape (Ringner et al., 1994; Singh et al., 2010). Taking into consideration the importance of 
vitronectin glycosylation on its function and the reported bacterial interactions (Ringner et al., 
1994; Singh et al., 2010), our findings may point towards a possible role in the context of gastric 
lesions development. In addition, and taking in consideration the fact that patients with 
incomplete IM present higher risk of developing gastric cancer when compared with complete IM 
(Silva et al., 1990; Rokkas et al., 1991; Tosi et al., 1993), it would be worthy the deeply study of 
the role of altered vitronectin glycosylation in incomplete intestinal metaplasia context.  
Regarding histidine-rich glycoprotein, our study identified it as expressing truncated O-glycans, 
presenting reactivity with T antigen in the gastritis group. Even though regarded as an N-
glycosylated protein (6 described sites and 3 predicted), the NetOGlyc tool identified Ser307 as a 
putative glycosylation site. Histidine-rich glycoprotein is a plasma glycoprotein produced by the 
liver and known to bind to a number of ligands in circulation, such as heparin, heparan sulfate, 
thrombospondin, and plasminogen. Histidine-rich glycoprotein acts as an adapter protein and has 
been implicated in regulating many processes such as immune complex and pathogen clearance, 
cell adhesion, angiogenesis, coagulation and fibrinolysis (Ohta et al., 2009). The predicted O-
glycosylation site indicates that this type of glycosylation could also be present in histidine-rich 
glycoprotein and suggests that further structural insights on the O-glycan moiety may be required 
to complement previous studies focused on the analysis of the N-glycans (Ohta et al., 2009). 
Besides vitronectin and histidine-rich glycoprotein, our results showed immunoreactivity to STn 
antigen in all pathological conditions in proteins from the complement system, namely 
complement factor H, complement H-related protein and complement C4-B. The human 
complement pathway is a highly controlled effector mechanism of the immune system. Over 30 
plasma proteins and membrane bound molecules are involved in the complement system and 
most of these proteins are glycosylated. The complement factor H, complement factor H-related 
protein and the complement C4-B are proteins that have been described to be N-glycosylated 
(Ritchie et al., 2002). Most of the protein modules that form the complement system have been 
crystallized and structural data provides evidence for the role of N-glycans in this system. 
However, the structure and role of glycans in the resistance to proteolysis and functional 
activation within pathological conditions is still incomplete. As these data become available, the 
glycans can be modeled at the appropriate locations and give further insights into the interaction 
between complement proteins and cofactors. 
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Overall, our results indicate that aberrant O-glycosylation can be detected in these three main 
serum glycoproteins (vitronectin, histidine-rich glycoprotein and complement factor H), however 
warrants further structural characterization of the glycans to confirm the presence of these 
aberrant glycosylation in gastric lesions. Nevertheless, in this study from the four main proteins 
identified, plasminogen has been described as being O-glycosylated, and the respective glycan 
composition has been demonstrated to be important for its function (Santos et al., 2010). Taking 
this fact in consideration, we decided to deepen with the structural characterization of glycans in 
plasminogen from serum of individuals with IM. 
Serum plasminogen glycan characterization in gastric lesions 
The identification of glycan alterations in gastric cancer has been limited to alterations on 
mucin glycoproteins (David et al., 1992; Carneiro et al., 1994; Amado et al., 1998; Reis et al., 
1998; Conze et al., 2010) or in glycosyltransferases and their associated glycans that show 
increased expression in cancer (Gretschel et al., 2003; Kim et al., 2004; Marcos et al., 2011; Jun 
et al., 2012). In addition, most of the proteomic studies in serum of gastric cancer patients are 
based in the differential expression of proteins compared with serum from normal individuals 
(Aburatani 2005; Miki et al., 2007; Lam et al., 2008; Liu et al., 2010a; Liu et al., 2012) with few 
reports about serum protein altered glycosylation (Adamczyk et al., 2012; Lin et al., 2012). To 
our knowledge, very few studies have succeeded in the detection of alterations in serum proteins 
glycosylation and identification of new biomarkers in stomach cancer. One of the first studies was 
performed by Goodarzi and Turner in 1998, which detected differences in the N-glycosylation 
pattern of a specific protein, haptoglobin, in gastric cancer claiming a potentially clinically 
application of haptoglobin glycosylation changes in patient samples (Goodarzi et al., 1998). In 
2010, Bones et al. were able to identify cancer associated alterations in serum of patients bearing 
stomach adenocarcinoma (Bones et al., 2010). In this study the authors evaluated the 
contribution of N-glycosylation present on four highly abundant serum glycoproteins as they found 
an increase in sialylation of haptoglobin, transferrin, and α1-acid glycoprotein and increased levels 
of core fucosylated biantennary glycans and decreased levels of monogalactosylated core 
fucosylated biantennary glycans on IgG (Bones et al., 2010). More recently, Bones et al. showed 
an increase in the levels of SLeX present on triantennary glycans of clusterin, leucine-rich-R2-
glycoprotein, and kininogen-1 and also an increased levels of core fucosylated agalactosyl 
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biantennary glycans present on IgG which were associated with increasing disease pathogenesis 
(Bones et al., 2011).  
In our study, plasminogen was identified due to the immunoreactivity for T and STn antigen in 
patients with preneoplastic lesions in the gastric mucosa as well as in gastric carcinoma, with no 
immunoreactivity in healthy controls. Interestingly, among the identified proteins carrying simple 
mucin type carbohydrate antigens, plasminogen showed the most differentiated pattern of O-
glycosylation in IM and gastric cancer, displaying decreased levels of T antigens accompanied by 
an increased expression of STn when compared with the other clinical groups.  
Liver is the primary tissue for plasminogen synthesis (Raum et al., 1980) but other tissue 
sources, including the gut, have been described in animal models (Zhang et al., 2002). The 
truncated O-glycans observed in circulating plasminogen from gastritis, IM and gastric cancer 
patients may either reflect altered glycosylation in the liver response to inflammatory cytokines or 
altered glycosylation of locally expressed plasminogen. Pro-inflammatory cytokines produced 
within the gastric disease context (Goll et al., 2007; Chang et al., 2008; Haghazali et al., 2011), 
may induce differential expression of glycosyltranferases in hepatocytes leading to alteration of 
glycosylation of circulating proteins (Gabay et al., 1999). This is in agreement with previous 
studies that have shown that modification of glycosylation characterized by increased expression 
of sialylated glycan structures, are observed in hepatocyte derived proteins during acute and 
chronic inflammatory diseases (De Graaf et al., 1993; Brinkman-van der Linden et al., 1998; 
Peracaula et al., 2010; Sarrats et al., 2010). Moreover, modification of glycosylation in gastric 
cancer has been observed in hepatocyte derived proteins and in immune system glycoproteins 
such as immunoglobulins (Bones et al., 2010; Bones et al., 2011). In addition, alterations of 
plasminogen may also be related with the gastric mucosa infection by H. pylori. Plasminogen-
binding proteins expressed in H. pylori leads to subsequent activation of plasminogen in plasmin 
(Pantzar et al., 1998; Jonsson et al., 2004) that may provide proteolytic capacity and may 
contribute for the pathogenesis of this bacterium (Pantzar et al., 1998; Jonsson et al., 2004). 
Also, the increased expression of urokinase plasminogen activator has been described in H. 
pylori-associated gastritis (Gotz et al., 1996; Goto et al., 2011). These findings may point towards 
an important role of plasminogen activation in pathological conditions of the gastric mucosa. 
In this study, and in order to obtain new insights about plasminogen glycosylation in the serum 
of individuals with gastric lesions, we performed a detailed analysis of the O-glycans from purified 
plasminogen from IM patients to validate the STn glycan detection at the molecular level. 
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Plasminogen O-glycans released by reductive β-elimination were permethylated and analyzed by 
MALDI mass spectrometry. Our results showed the detection of ions compatible with STn 
antigens (Figure 6, Chapter 3.1). Further MALDI-MS/MS analysis of the ion at m/z 691.4 Da 
exhibited glycosidic bond cleavages B, C and Z, and cross-ring fragmentation A and X product 
ions characteristic of STn glycan, therefore demonstrating the presence of STn in plasminogen 
from serum of incomplete IM patients.  
Two major glycoforms of plasminogen have been described in humans: type I plasminogen 
containing two glycosylation moieties (N-linked to Asn289 and O-linked to Thr346), and type II 
plasminogen containing a single O-linked sugar on Thr346 (Hayes et al., 1979a; Hayes et al., 
1979b). However, additional sites of O-glycosylation of plasminogen have been reported in 
Ser248 (Pirie-Shepherd et al., 1997), and Thr339 (Hortin 1990). In this study we further 
performed a MALDI structural analysis of sialoglycopeptides from plasminogen enriched by 
titanium dioxide chromatography demonstrating the presence of STn containing glycopeptides in 
all disease groups. The use of the sialoglycopeptides enrichment method by titanium dioxide 
followed by MALDI showed to be quite efficient with the identification of the three O-glycosylation 
sites and one N-glycosylation site previously described in human plasminogen (Hayes et al., 
1979a; Hayes et al., 1979b; Hortin 1990; Pirie-Shepherd et al., 1997) (Supplementary Figure 1 
and Supplementary Table 1, Chapter 3.1). Based on this approach the analysis of the clinical 
groups lead to the identification of one STn-containing glycopeptide in healthy control, five STn-
containing glycopeptides in gastritis, four in complete IM and eight in incomplete IM (Table 5, 
Chapter 3.1). Some of the sites identified have not been described for plasminogen and may 
constitute potential novel biomarkers of pre-cancerous gastric lesions and gastric cancer. 
Nevertheless, only one (Thr346) of these glycosylation sites could be theoretically predicted using 
the bioinformatics platform NetOGlyc. On the other hand this approach retrieved other putative 
glycosylation sites that are still lacking in vivo confirmation. The discrepancy between these 
findings has been previous highlighted for serum proteins (Ferreira et al., 2011) and suggests 
that in vivo processing and pathophysiological states may play a determinant role in the definition 
of the glycosylation of circulating glycoproteins. 
Furthermore, in our study we were also able to identify STn reactivity in plasminogen from an 
independent set of serum samples (Supplementary Figure 2 and Supplementary Table 2, Chapter 
3.1), enriched for sialic acid containing glycoproteins with SNA lectin from gastritis, intestinal 
metaplasia, and carcinoma patients. These results using alternative glycoprotein enrichment 
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approaches and different sample cohorts further demonstrate the potential application of the 
altered plasminogen STn glycosylation as a biomarker in these pathologies. 
In summary, this work present a set of proteins displaying altered O-glycosylation as detected 
by antibodies directed to STn and T antigens in the serum from patients with gastritis, IM and 
gastric cancer in opposition to minor or no reactivity in the same proteins of healthy individuals 
without any gastric disease. We further demonstrated that circulating serum plasminogen from IM 
patients carry the truncated O-glycan STn antigen. Altogether these data provide putative novel 
glycobiomarkers in serum from patients with gastric pathologies, including gastritis, intestinal 
metaplasia and gastric carcinoma. These results warrant further studies to address the 
application of plasminogen STn glycosylation pattern as a serum biomarker of gastric pathologies.  
MODULATION OF GASTRIC CELLULAR GLYCOPHENOTYPE BY 
SIALYLTRANSFERASES OVEREXPRESSION: BIOLOGICAL BEHAVIOR AND 
BIOMARKER IDENTIFICATION 
Aberrant glycosylation has been described for many years as a hallmark of cancer, and many 
of the resulting altered glycosyl epitopes are tumor associated antigens (Hakomori 2002; Drake et 
al., 2010). These cancer-related antigens are caused by disease-specific alterations in the glycan 
synthesis pathway such as changes in the Golgi and Endoplasmic Reticulum compartments, 
mutations in enzymes or chaperons, altered expression of enzymes and biochemical competition, 
and even variations in sugar donor availability (Reis et al., 2010; Wang et al., 2010; Gill et al., 
2013).  
A common alteration observed in cancer is the abnormal expression of sialyltransferases, 
responsible for adding sialic acids residues to cell surface molecules and to secreted proteins, 
which have been involved in the oncogenic transformation, as well as in invasion and metastasis 
(Hakomori 2002; Dube et al., 2005; Drake et al., 2010). The identification and characterization of 
molecular markers specific of cells undergoing malignant transformation are key steps for the 
selection of biomarkers that can be used for improvement of cancer diagnosis and patient’s 
monitoring. 
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Biological role of SLeX expression, due to overexpression of ST3Gal IV, in gastric 
cancer cells  
Sialic acids are typically attached to the outermost ends of glycoproteins and glycolipids that 
can mediate and modulate a wide variety of physiological and pathological processes (Varki 
2008). The SLeX antigen is a sialylated glycan structure which expression has been associated 
with cancer progression and aggressiveness (Nakamori et al., 1997; Baldus et al., 1998; Fukuoka 
et al., 1998; Kim et al., 1998; Nakamori et al., 1999; Grabowski et al., 2000; Borsig et al., 
2002). In the gastric carcinoma context, it has also been described that increased expression of 
SLeX is associated with an aggressive cancer cell behavior as well as poor overall patient survival 
(Amado et al., 1998; Tatsumi et al., 1998). The expression of SLeX in cancer results from the 
altered expression of sialyltransferases, that adds the sialic acid in a α2,3 linkage to Galactose 
residues on type-II chains (Harduin-Lepers et al., 2012). 
In the second part of this study (Chapter 3.2), we evaluate the capacity of two 
sialyltransferases, ST3Gal III and ST3Gal IV, to produce SLeX both in glycoproteins and in 
glycolipids in gastric carcinoma cells. Expression analyzes of SLeX, in both ST3Gal III and ST3Gal 
IV stably transfected gastric carcinoma cells, by immunofluorescence and Western blot confirmed 
that ST3Gal IV leads to the biosynthesis of SLeX antigens (Figure 1, Chapter 3.2). Moreover, our 
results indicate that SLeX antigen is expressed on proteins from total cell lysates as well as on 
secreted proteins from cells expressing ST3Gal IV. Furthermore, glycolipidic component analysis 
by mass spectrometry demonstrated that the pattern of glycosylation did not change in both 
ST3Gal III and ST3GalIV transfected cells when compared with Mock cells (Supplementary 
results, Chapter 3.2). These results demonstrated that  ST3Gal IV participate in SLeX biosynthesis, 
preferentially in glycoproteins. Overall, these results confirm previous observations that described 
the importance of ST3Gal IV in the synthesis of SLeX (Ellies et al., 2002; Sperandio et al., 2006), 
and are in agreement with recent reports showing an increased mRNA level of ST3Gal IV and 
α2,3 sialic acid residues expression in gastric cancer tissues (Jun et al., 2012).  
The carbohydrate SLeX functions as a ligand for cell adhesion molecules of the selectin family, 
usually expressed on vascular endothelial cells, and the expression of SLeX on cancer cells is 
known to facilitate tumor cell spreading by mediating tumor-endothelial cell interactions 
contributing to hematogenous metastasis (Takada et al., 1993; Kannagi 1997; Kannagi et al., 
2004). These previous observations further support the hypothesis that SLeX antigen plays a 
functional role in malignant cancer cell behavior. Noteworthily, the crosstalk between cancer cells 
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and host mechanisms like cell-cell adhesion and cell-matrix adhesion interactions, tumor cell 
growth and motility are known to be important in modulating the process of cancer cell invasion. 
On light of this, and on the clinical pathological evidence that SLeX expression in gastric cancer 
are associated with invasive carcinomas (Amado et al., 1998), we analyzed the in vitro and in vivo 
biological behavior of SLeX expressing cells. Thus, we performed a comprehensive evaluation of 
the biological role of SLeX in gastric cancer cells using classical in vitro models and the in vivo 
chorioallantoic membrane of the chicken embryo (CAM) model. The in vitro analysis showed that 
SLeX expressing cells display a similar proliferative rate when compared with Mock transfected 
cells. However, SLeX expressing cells demonstrated a higher capacity to invade in vitro in Matrigel 
chambers, demonstrating the active role of this sialylated glycan structure in tumor cell motility 
and invasion. Concomitant to this invasive capacity, SLeX expressing cells evidenced higher 
capacity to adhere to collagen IV and vitronectin extracellular matrix proteins (Figure 2, Chapter 
3.2). Furthermore, this invasive phenotype was also confirmed in vivo where cells transfected with 
ST3Gal IV and expressing SLeX antigen presented increased capacity to invade the chorioallantoic 
membrane of the chicken embryo (Figure 3 and Table 1, Chapter 3.2). These findings, altogether 
highlight the importance of this sialylated glycan in the malignant invasive phenotype, and are in 
keeping with studies that associate SLeX expressing tumors with more aggressive phenotypes 
(Nakamori et al., 1993; Amado et al., 1998; Tatsumi et al., 1998; Ichikawa et al., 2000). In 
conclusion, these results support the role of ST3Gal IV in the biosynthesis of SLeX glycan antigen 
and evidenced an important role in gastric tumor invasion. However, the molecular mechanisms 
underlying this altered enzyme expression and aggressive behavior of gastric cancer cells 
expressing these glycan determinants are not fully understood. 
Role of signaling pathways in gastric cancer cells expressing SLeX structures 
Previous reports have shown that increased cellular sialylation leads to receptor and signaling 
pathways activation and that the hypersialylation contributes to cancer progression and increased 
cell motility (Seales et al., 2005a; Seales et al., 2005b). Moreover, it has been described that 
TNF-α can induce SLeX and 6-sulfo-SLeX expression in human cancer cells, by increasing the 
expression of ST3GAL4 (Colomb et al., 2012). This mechanism has also been shown to be 
mediated by neutrophils expressing TNF-α leading to cancer cells invasiveness and metastasis (St 
Hill et al., 2011).  
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Having as starting point the hypothesis that expression of SLeX can induce activation of 
signaling pathways involved in cancer cell invasion, we intended to evaluate the possible role of 
tyrosine kinase receptors activation and downstream signaling effectors in ST3Gal IV expressing 
cells. To assess receptors activation we used a tyrosine kinase receptor array that allowed the 
identification of increased activation of c-Met in SLeX expressing cells (Figure 4, Chapter 3.2). In 
MKN45 cell line model it has been reported a high level of expression and dependence on c-Met 
(Smolen et al., 2006) and therefore modulation of cellular glycosylation can have implications in 
this c-Met dependent cells. In addition, we evaluated the in vivo c-Met activation in gastric cancer 
cells in the CAM model and observed the expression of phosphorylated c-Met on cancer invading 
cells expressing SLeX (Figure 4, Chapter 3.2). This result further supports the hypothesis that SLeX 
expressing cells exhibit invasive capacity through the activation of c-Met.  
In general, c-Met overexpression has been considered a hallmark of cancer, playing a role in 
many tumors and in metastatic progression (Sierra et al., 2011). In gastric cancer, alterations in 
c-Met expression have been reported, such as the Tpr/Met rearrangement (Soman et al., 1991; 
Yu et al., 2000), c-Met copy number amplification (Lee et al., 2011), as well as increased c-Met 
activation (Inoue et al., 2004; Dua et al., 2011).  
The activation of tyrosine receptors, directly or indirectly, by glycan antigens has previously 
been observed in other cancer cell models. Singh and colleagues described that the Thomsen-
Friedenreich antigen (T antigen) present in CD44v6 promotes the activation of c-Met and mitogen-
activated protein kinase (MAPK) signaling leading to cancer cell proliferation (Singh et al., 2006). 
Furthermore, activation of c-Met receptor has been described in a breast cancer cell model that 
overexpress glycosyltransferases and this activation has been implicated in proliferation and 
invasion of cancer cells (Cazet et al., 2009; Cazet et al., 2010; Cazet et al., 2012).  
The activation of c-Met is well known to induce docking sites for proteins that mediate 
downstream signaling leading to the activation of the MAPK, phosphatidylinositol 3-kinase (PI3K)-
AKT, v-src oncogene homolog (Src), signal transducer and activator of transcription (STAT), which 
are signaling pathways that are involved in increased cell growth, scattering, motility, invasion, 
protection from apoptosis, branching morphogenesis, and angiogenesis (Liu et al., 2010b; Organ 
et al., 2011). Taking that into consideration, we evaluated the downstream effectors of c-Met 
activation and found that FAK and Src proteins showed increased activation in cells expressing 
ST3Gal IV (Figure 5, Chapter 3.2). In combination with our invasion assays results (in vitro and in 
vivo), these data strongly suggest that c-Met and downstream FAK and Src activation mediates 
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tumor cell motility and invasion, also in gastric cancer cells. These results are in agreement with 
previous studies that associate Src-FAK signaling pathway with the metastization process (Peng et 
al., 2009; Lim et al., 2012; Sanchez-Bailon et al., 2012; Shen et al., 2012). Furthermore, our 
results show that inhibition of c-Met and Src could preclude the increased invasion observed in 
SLeX expressing cells supporting the role of this glycosylation alteration in the activation of this 
invasive related pathway (Figure 6, Chapter 3.2). 
Oncogenic transformation is often associated with changes in organization of the cytoskeleton, 
which can influence cell migration, adhesion and invasion. The c-Met activation can cause 
changes in gene expression of cell-cycle regulators (Cdk6 and p27), extracellular matrix 
proteinases (such as matrix metalloproteinases and urokinase plasminogen activator), and in 
alterations of cytoskeleton functions that control migration, invasion and proliferation (Birchmeier 
et al., 2003). The cytoskeleton is composed of a complex and organized network of various 
fibrous proteins within the cytoplasm, playing an essential structural and regulatory role in the 
maintenance of cell structure and strength, in cell division, proliferation, motility, invasion and 
also in signaling functions (Tapon et al., 1997; Machesky et al., 1999; de Curtis et al., 2012). 
The activation of tyrosine kinase receptors can modify the phosphorylation status of cytoskeleton 
regulatory and structural proteins. Signaling pathways initiated by the activation of cell surface 
receptors can promote distinct membrane protrusions by converging onto the Rho family of 
GTPases (Hall 1999; Kjoller et al., 1999). Rho proteins are small (21-25 kDa) molecules that 
share structural homology and become activated only when bound to GTP. One of the best 
characterized Rho GTPase family members is RhoA that regulates the formation of stress fibers 
and focal adhesion assembly, while Rac1 and Cdc42 are mainly involved in membrane ruffling 
and formation of filopodia, respectively (Pertz 2010). Estimation of GTPases activation is 
frequently a molecular marker in the evaluation of cytoskeleton alterations during cell migration 
(Evers et al., 2000; Parri et al., 2010; Wessler et al., 2011). In this study we showed the 
activation of Rho GTPases, specifically RhoA, Rac1 and Cdc42 (Figure 5, Chapter 3.2). These 
results further supports the evidence that SLeX expression leads to cytoskeleton protein alterations 
in cancer cells, underlying the observed increased cell motility and invasion of these cells. Our 
findings are in keeping with previous reports showing the importance of RhoA, Rac1 and Cdc42 in 
cancer progression (Kamai et al., 2004), and also the crosstalk between these GTPases and other 
signaling pathways like Src-FAK in the migratory phenotype of cancer cells (Leve et al., 2011).  
CHAPTER 4 | General Discussion 
 
 
 181 
Our present findings support the hypothesis that increased expression of SLeX on the surface 
of malignant cells plays an important role in tumor invasion and metastasis. Overall, our study 
showed that tumor cell invasion is induced by SLeX expression on gastric cancer cells through the 
activation of c-Met in association with downstream signaling effectors Src, FAK and RhoA GTPases 
activation (Figure 7, Chapter 3.2). These results open new avenues for the designing of 
intervention strategies that target glycosyltransferases leading to the biosynthesis of SLeX in 
cancer cells as well as the inhibition of c-Met and Src in order to improve gastric cancer treatment 
by targeting invasion and metastasis. 
Gastric cancer cell model expressing SLeX as a source for cancer biomarkers 
discovery 
One of the most typical glycosylation alterations in cancer is characterized by increased 
cellular sialylation. Many cancers specifically express sialylated structures such as the SLeX 
antigen (Hakomori 2002), which is known to be associated with an increase of ST3Gal IV 
sialyltransferase activity (Ellies et al., 2002; Sperandio et al., 2006; Carvalho et al., 2010; Jun et 
al., 2012). 
In Chapter 3.2 we show expression of SLeX antigens in proteins from ST3Gal IV overexpressing 
cells, and this expression revealed to be restricted to a set of glycoproteins, demonstrating 
specificity of the SLeX protein carriers. In addition, SLeX expression was associated with increased 
invasive capacity of cancer cells, and this result was in accordance to previous studies that 
demonstrated an association between SLeX expression with more aggressive tumors (Nakamori et 
al., 1993; Nakamori et al., 1997; Amado et al., 1998; Fukuoka et al., 1998; Kim et al., 1998). All 
of these previous observations highlight the importance of identifying the glycoproteins carrying 
SLeX and determining the biological contribution of such specific protein glycosylation to the 
malignant phenotype of cancer cells. In this regard, and in order to disclose new targets for 
diagnostic and therapeutic applications, in this work (Chapter 3.3) we identify the proteins carriers 
of SLeX by MALDI-TOF/TOF mass spectrometry analysis. The protein identification revealed 
carcinoembryonic antigen (CEA) as a major SLeX glycoprotein carrier in the ST3Gal IV expressing 
cells (Figure 2 and Table 1, Chapter 3.3). The SLeX expression in CEA was confirmed by 
immunoprecipitation and proximity ligantion assays (PLA). The immunoprecipitation results 
showed that MKN45 cells expresses CEA and the SLeX Western blot analysis confirmed the 
presence of this glycan structure in CEA molecules in ST3Gal IV expressing cells (Figure 3, 
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Chapter 3.3). These observations were further supported by the PLA results showing positive 
signal for CEA/SLeX molecular complexes in ST3Gal IV expressing cells when compared with no 
PLA signal in the Mock cells (Figure 3, Chapter 3.3).  
CEA is a heavily glycosylated protein (Paxton et al., 1987) with 28 possible N-glycosylation 
sites described (Oikawa et al., 1987). CEA shows limited expression in normal adult tissues, most 
restricted to epithelial cells (Hammarstrom 1999). The cellular expression of CEA is limited to the 
glycocalyx commonly in the apical membrane domain of the cell as a glycophosphatidylinositol-
linked surface glycoprotein (Hefta et al., 1988; Takami et al., 1988; Hammarstrom 1999). 
However, the loss of cell polarity and tissue architecture observed in cancer leads to the shedding 
of CEA into the blood of cancer patients which can be detected by the CEA serological assay (Gold 
et al., 1965; Benchimol et al., 1989). Additionally, the increased invasive and metastasis capacity 
of cancer cells also result in release of CEA molecules into the lymph and blood vessels further 
contributing for the increase CEA serum detection.  
The use of CEA serological test was first described as a circulating tumor-specific antigen in 
colon and rectum cancers (Thomson et al., 1969). Currently, CEA serological detection in the 
cancer clinical setting is mostly limited to monitoring the disease with limited application in 
diagnosis. In gastric carcinoma, CEA serological test is also used, however its application is 
mainly to the detection of cancer recurrence (Tamada et al., 1982; Chen et al., 2012) and CEA 
increased expression has been associated with poor patients' prognosis (Park et al., 2008). The 
identification of the different CEA glycoforms can contribute to the improvement of the diagnostic 
application of this biomarker (Garcia et al., 1991; Saeland et al., 2012). In this work, we also 
observed that SDS-PAGE analysis of the CEA immunoprecipitated from MST3Gal IV cells 
displayed a slightly higher molecular weight than CEA from Mock cells. These molecular weight 
variations in CEA may be attributed to its different glycosylation pattern in ST3Gal IV cells. This 
feature has been previously observed in colonic tissues, where normal colonic mucosa and 
preneoplastic lesions display CEA molecules with different molecular weights when compared to 
colon cancer cells (Garcia et al., 1991). 
In gastric cancer the overexpression of CEA has been well documented (Chevinsky 1991; 
Berinstein 2002) with association between the increased serum levels and poor outcome of the 
patients (Park et al., 2008; Chen et al., 2012). Nevertheless, at the moment there is no 
information on the glycosylation modifications of CEA in gastric tissues. Therefore in order to 
clarify the potential application of CEA glycosylation in gastric carcinoma tissues we evaluated 
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possible associations with clinicopathological characteristics in gastric carcinoma cases. Our 
results showed that all gastric carcinoma cases evaluated expressed CEA, in contrast with an 
absence of detection in adjacent normal gastric tissue. Furthermore, analysis of SLeX expression 
in gastric carcinomas showed that 83.9% of the cases displayed SLeX antigen. The evaluation of 
expression of both SLeX antigen and CEA molecules in gastric carcinoma tissues by PLA revealed 
that 80.6% of the cases showed CEA/SLeX PLA signal, strongly suggesting that CEA carries SLeX 
antigens in gastric carcinoma. The expression of CEA/SLeX, detected by PLA, was significantly 
associated with clinicopathological features of the cases, including the pattern of tumour growth 
(Ming's classification) and the presence of venous invasion (Figure 4 and Table 2, Chapter 3.3).  
The importance of glycosylation changes during tumorigenesis has been described in other 
cancer biomarkers used in the clinical practice. Some reports have demonstrated altered PSA 
glycosylation in benign and malignant prostate lesions, highlighting the importance in considering 
the glycan composition of this biomarker in the clinical diagnosis of the disease (Peracaula et al., 
2003; Tajiri et al., 2008; Meany et al., 2009; White et al., 2009; Dwek et al., 2010; Li et al., 
2011; Gilgunn et al., 2012; Vermassen et al., 2012). Furthermore, CEA has been also reported 
as displaying abnormal glycosylation in colon cancer when compared with normal colonic mucosa 
and preneoplastic lesions (Saeland et al., 2012) and has been demonstrated to contribute to the 
tumor biological behavior and immune evasion due to interactions of CEA glycans with lectins of 
the immune system (van Gisbergen et al., 2005; Nonaka et al., 2008; Saeland et al., 2012). 
Overall, and as shown for PSA, the evaluation of CEA glycoforms offers interesting diagnostic 
perspectives to improve specificity of this serum biomarker. 
In conclusion, we report the identification of CEA as a SLeX protein carrier in the ST3Gal IV 
expressing gastric carcinoma cells, and we validate this association in a series of gastric 
carcinoma tissues. The expression of CEA/SLeX in gastric carcinoma, detected by PLA, was 
associated with the presence of venous invasion, supporting the role of SLeX for an aggressive 
behavior of the tumor cells. Our results open new avenues for addressing CEA altered 
glycosylation with SLeX in order to improve diagnosis and potential therapeutic decisions in gastric 
cancer. 
In summary, we performed a comprehensive characterization of aberrant protein glycosylation 
in gastric carcinogenesis, both using serum samples from patients and cell line models, that 
allows the identification of putative new targets that can be used in clinical practice. The identified 
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proteins may be particularly valuable for the development of novel glycan-based strategies for 
cancer diagnosis. 
FUTURE PERSPECTIVES IN GLYCAN-BASED SEROLOGICAL ASSAYS IN 
GASTRIC CANCER 
Currently, the clinical application of the existing serological assays in gastric cancer screening 
lacks the specificity and sensitivity necessary for its application in early diagnosis, being used 
mostly for monitoring treatment and relapses. Considering the role of glycans during gastric 
carcinogenesis, the design of new glycan-based approaches constitute a distinct starting point for 
the identification of newly identified serological targets for cancer detection at the early stages of 
the disease. 
Based on the results presented in this thesis, we intend to validate the glycan structures, 
namely STn and SLeX, and the glycan sites on the identified proteins plasminogen and CEA, 
respectively. Ultimately, we will consider the development of glycan-based assays that specifically 
recognize the identified proteins and the associated glycan antigens in patients with gastric 
preneoplastic lesions and with gastric carcinoma. 
Recently, it was reported an efficient model to study protein O-glycosylation using zinc-finger 
nuclease-glycoengineered SimpleCell lines technology (Steentoft et al., 2011; Steentoft et al., 
2013a; Steentoft et al., 2013b). Using this approach it is possible to knock out Cosmc chaperone 
that will impair O-glycosylation elongation resulting in the synthesis of Tn and STn antigens in O-
glycoproteins. Taking advantage of this technology we propose to use gastric carcinoma cell lines 
knock out for Cosmc chaperone to study plasminogen sites of O-glycosylation. To achieve this, 
gastric carcinoma cell lines knocked out for Cosmc can be further transfected with the full length 
human plasminogen gene, and plasminogen protein enriched by SNA (recognizes α2,6SA 
residues) and VVA (recognizes Tn antigens) lectin affinity chromatography. Further plasminogen 
purification steps can be performed, and the specific O-glycosylation sites can be determined by 
mass spectrometry. This strategy will be useful for validating the glycosylation sites identified in 
serum plasminogen from gastric disease patients. The ultimate goal will be to develop a 
monoclonal antibody that specifically recognizes one site-specific STn antigen in plasminogen to 
be used in a ELISA serological assay for screening of patients with gastric lesions. 
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Regarding our results on CEA, to our knowledge there are no descriptions about SLeX 
expression in CEA molecules in gastric cancer. In addition, the relevance of CEA glycosylation in 
cancer has been described for colon cancer. So, as future work we envision to confirm by mass 
spectrometry technology the presence of SLeX in CEA molecules using both cell models and CEA 
from serum samples. Particularly interesting would be to isolate and characterize the 
glycosylation of CEA molecules from gastric carcinoma vs non-neoplastic gastric mucosa and 
define the presence of SLeX. Finally, we want to evaluate the presence of CEA/SLeX in serum from 
gastric cancer patients vs normal individuals, and to develop a novel serological assay for gastric 
cancer diagnosis. 
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SUMMARY AND CONCLUSIONS 
Gastric cancer incidence and mortality have remained high over the last past decades, and 
gastric cancer persists as one of the leading causes of cancer-related death worldwide. This high 
mortality rate reflects the late diagnosis due to the lack of early screening biomarkers and the 
appearance of clinical symptoms only when the cancer has already progressed.  
Glycosylation alterations of glycoconjugates are a hallmark of cancer, and in gastric cancer 
many alterations have been described during gastric carcinogenesis. The development of new 
glycoproteomic strategies to detect glycan alterations observed in cancer has contributed to the 
improvement of biomarker identification. 
This work aimed to identify new possible glycobiomarkers in gastric cancer, based on 
alterations in the normal glycosylation pattern of glycoproteins. In order to accomplish this aim, 
we have employed different strategies that allowed us to reach the following conclusions: 
1) We have developed a glycoproteomic approach that specifically detected cancer associated 
truncated O-glycans in serum glycoproteins from patients with percursor lesions of gastric cancer 
nad in patients with gastric cancer. The employed glycoproteomic strategies allowed the 
identification of glycoproteins presenting truncated O-glycans, namely plasminogen. 
2) We have characterized the STn structure present on plasminogen in the serum of patients with 
intestinal metaplasia. Furthermore, we have shown that enriched sialopeptides exhibit mass peak 
that matched with peak of plasminogen peptides containing STn structures. The sialopeptides 
analysis has also demonstrated the presence of STn-containing glycopeptides in gastritis, in 
complete and in incomplete intestinal metaplasia. 
These findings highly suggest that plasminogen display O-glycosylation modifications 
during gastric carcinogenesis, and this altered glycosylation may be particularly 
important for future development of new glycan-based serological assays. 
3) We have demonstrated, in a gastric carcinoma cell model, the role of ST3Gal IV in the 
biosynthesis of SLeX structures on glycoproteins. Furthermore, we have performed a 
comprehensive characterization of the biological role of SLeX expression on gastric carcinoma 
cells, and have demonstrated the increased invasive capacity of these cells both in vitro and in 
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vivo, and an enhanced adhesion capacity to extracellular matrix proteins such as collagen IV and 
vitronectin. 
4) We have evaluated the contribution of SLeX expression in tyrosine kinase receptor activation, 
and demonstrated an increased activation of c-Met and downstream effectors such as Src, FAK 
and GTPases (RhoA, Rac and Cdc42). In addition, inhibition of c-Met and Src activation 
completely abolished the increased invasive capacity on SLeX expressing cells. 
5) We have identified the glycoproteins expressing SLeX in our cell model and found that CEA is a 
protein carrier of SLeX. Moreover, this co-expression was also demonstrated in gastric carcinoma 
tissues by PLA, and was correlated with venous invasion of cells.   
These results show the involvement of SLeX in the invasive capacity of gastric cancer 
cells through activation of c-Met and downstream effectors, and demonstrate the 
potential application of CEA altered glycosylation as a potential biomarker of 
invasive gastric carcinomas.  
Overall, our results have extended the current knowledge on altered glycosylation observed in 
gastric cancer as source for biomarker discovery and understanding cancer cell behavior. The 
identification of glycobiomarkers is opening new avenues for the development of new glycan-
based assays leading to the improvement of cancer diagnosis.   
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Alterations in glycosylation as biomarkers for
cancer detection
Celso A Reis,1,2 Hugo Osorio,1 Luisa Silva,1 Catarina Gomes,1 Leonor David1,2
ABSTRACT
Glycoconjugates constitute a major class of biomolecules
which include glycoproteins, glycosphingolipids and
proteoglycans. Glycans are involved in several
physiological and pathological conditions, such as
hostepathogen interactions, cell differentiation,
migration, tumour invasion and metastisation, cell
trafficking and signalling. Cancer is associated with
glycosylation alterations in glycoproteins and glycolipids.
This review describes various aspects of protein
glycosylation with the focus on alterations associated
with human cancer. The application of these
glycosylation modifications as biomarkers for cancer
detection in tumour tissues and serological assays is
summarised.
INTRODUCTION
Glycosylation is a common post-translational
modification of proteins, and variation in oligosac-
charide structures is associated with many normal
and pathological events: hostepathogen interac-
tions, differentiation, migration, tumour invasion
and metastisation, cell trafficking and signalling.
Cancer is associated with aberrations in glycolipids
and glycoproteins.1 2 In glycoproteins, about half
of which are glycosylated in eukaryotes, both
N-glycans and O-glycans can be synthesised, and
both can be affected during cancer progression.
N-glycans have a functional role in cell adhesion,
and modifications in cancer cells are associated
with invasion and metastisation.3 O-Glycosylation
of glycoproteins, of which mucin glycoproteins are
a major component because of their high content of
serine and threonine and the fact that they are
highly overexpressed in carcinomas, contributes to
a substantial part of cancer biomarkers and will be
the focus of the present review. The review is
directed to non-specialised scientific readers
assumed to be familiar with cancer nomenclature
and concepts. It is intended to give an overview of
the normal process of glycosylation and the alter-
ations associated with cancer and their usefulness
as tumour markers.
GLYCOSYLATION IN HUMAN CELLS
Glycosylation is the covalent attachment of
a carbohydrate to a protein, lipid, carbohydrate or
other organic compound, catalysed by glycosyl-
transferases, using specific sugar donor substrates.
Glycans are found in several types of biomolecule
which can be classified into different families of
glycoconjugates: glycoproteins, glycosphingolipids,
proteoglycans and glycosylphosphatidylinositol-
linked proteins (figure 1).
As mentioned above, there are two types of
glycan in glycoproteins: N-glycans and O-glycans.
Both types of glycosylation often coexist in the
same protein and in the same cell. N-Glycosylation
consists of an oligosaccharide chain N-linked to
asparagine in the sequence context Asn-X-Ser/Thr,
where X is any amino acid except proline. In rare
cases, the sequence Asn-X-Cys is also used.
N-Glycosylation requires the production of an
oligosaccharide precursor which is transferred en
bloc to nascent proteins in the endoplasmic retic-
ulum (ER). After the transfer of the oligosaccha-
ride precursor structure to the nascent protein,
several subsequent processing reactions occur in
the ER, including cycles of glucose removal and
addition, which contribute to protein folding. In
addition, N-glycan chains can be further diversified
in the Golgi apparatus, with terminal saccharide
residues.
O-Glycosylation is the other type of glycosylation
found in glycoproteins and consists of a glycan
O-linked to a serine or a threonine residue (figure 2).
The frequency of O-glycosylation on glycoproteins
is high, particularly on secreted or membrane-bound
mucins, which are rich in serine and threonine. The
first step in mucin-type O-glycosylation is the
transfer of GalNAc from a sugar donor UDP-GalNAc
to serine and threonine residues and is controlled by
UDPGalNAc-polypeptide N-acetylgalactosaminyl-
transferases (ppGalNAc-Ts).4e6 To date, more than
15 distinctmembers of themammalian ppGalNAc-T
family have been identified and characterised,7e20
and in silico analysis indicates that as many as 20
ppGalNAc-Ts may exist.6 They control the first level
of complexity of mucin glycosylationdthat is, the
sites and density of O-glycan occupancy of
themucin tandemrepeat.This is because ppGalNAc-
Ts, although catalysing the same enzymatic step,
display different tissue expression specificity21 22
and have different kinetic properties and accep-
tor substrate specificities.5 11 23 This enzymatic
specificity may lead to different functions
depending on the cell type and organ in which it is
expressed.9 10 24e26 Altered expression of ppGalNAc-
Ts may be one of the mechanisms involved in
changes in mucin O-glycosylation during malignant
transformation.21 22 27e30
A second level of complexity in mucin O-glyco-
sylation is the processing of carbohydrate chains by
other glycosyltransferases. After the first glycan
(GalNAc) is added forming the Tn antigen, the core
1 structure is synthesised by Gal-transferase
(C1GalT-1), which adds Gal to GalNAc, forming
the core 1 (T antigen). Alternatively, Tn and
T antigens can be sialylated by sialyltransferases
forming the sialyl-Tn, sialyl-T and disialyl-T
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Figure 1 Schematic representation of
common classes of glycoconjugates
expressed in human cells. Protein
O-glycosylation and N-glycosylation can
occur in both membrane-associated and
secreted glycoproteins.
Figure 2 Schematic representation of the biosynthetic pathways of most common mucin-type O-glycans. Glycosyltransferases involved in the
enzymatic steps are indicated. The major tumour-associated antigens are highlighted. b3Gal-T, b1-3-galactosyltransferase; b4Gal-T,
b1-4-galactosyltransferase; b3Gn-T, b1,3-N-acetylglucosaminyltransferase; C1Gal-T1, core 1 b1-3-galactosyltransferase; C2GnT, core 2 b1e6
N-acetylglucosaminyltransferase; ppGalNAc-T, UDPGalNAc-polypeptide N-acetylgalactosaminyltransferase; ST3Gal, a2,3-sialyltransferase;
ST6GalNAc-I, GalNAc a2,6-sialyltransferase.
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antigens.31e34 Formation of the sialyl-Tn antigen stops any
further processing of the oligosaccharide chain31 32 35 (figure 2).
Another common core structure present in normal cells
contains a branching GlcNAc attached to core 1 and is termed
core 2 (figure 2).36 Core 2 is produced in many epithelial and
haematopoietic cells. The enzyme responsible for core 2
synthesis is core 2 b1e6 N-acetylglucosaminyltransferase
(C2GnT).37 At least three genes encode this subfamily (C2GnT1
to C2GnT3) of a larger family of b1e6 N-acetylglucosaminyl-
transferases.38 There are two major types of C2GnTs. The L type
(leucocyte type, C2GnT1 and C2GnT3) synthesises only the
core 2 structure, whereas the M type (mucin type, C2GnT2) is
also involved in the synthesis of core 4 and other GlcNAcb1e6-
linked branches (figure 2). The C2GnT1 and C2GnT3 enzymes
are active in many tissues and cell types, but the C2GnT2
enzyme is found only in mucin-secreting cell types.38 39 The
expression and activity of C2GnTs are altered in certain
tumours. Because of their branched nature, core 2 O-glycans can
block the exposure of mucin peptide epitopes. There are other
types of core structures, and most of them show tissue speci-
ficity expression.
The extension of the core structures is catalysed by b3/4
Gal-Ts and b3/4 Gn-Ts (figure 2) leading to the formation of type
1 and type 2 chains. The Lewis and ABO glycan-based blood
group antigens are common terminal structures which are
present in mucins as in other glycoconjugates. The families of
glycosyltransferases that catalyse the addition of these terminal
structures are described in detail below. In contrast with
N-glycans, O-glycans do not have sialic acid a2-6Gal linkages,
although the sialic acid a2-6GalNAc moiety is common, for
example, in the sialyl-Tn antigen. Thus, in most mammalian
mucin-producing cells, a2e6 sialyltransferases act on GalNAc,
and a2e3 sialyltransferases act on galactose. Some of the sialyl-
transferases preferO-glycans as their substrate, butmany of these
enzymes have an overlapping specificity and also act onN-glycan
structures as acceptor substrates. There are other types of non-
mucin O-glycans, such as O-GlcNAc in proteins found in the
cytoplasm and nucleus; these are not the focus of this review.
Another important group of glycoconjugates are proteogly-
cans. These consist of a core protein and covalently attached
glycosaminoglycan chains, which are linear polysaccharides
(figure 1). Proteoglycans are expressed in a tissue-specific manner
and have been shown to participate in several cellular and
extracellular interactions.
ALTERATIONS IN GLYCOPROTEIN O-GLYCOSYLATION IN
CANCER AND PRENEOPLASTIC LESIONS
Altered glycosylation of cell surface glycolipids, membrane-
associated glycoproteins and secreted glycoproteins is a quasi-
universal modification in cancer.40 This was first demonstrated
by showing that antibodies raised against cancer cells often
recognise abnormal glycan structures.41 Despite there being no
evidence for a role of altered glycosylation in cancer initiation,
and despite information on the mechanisms that generate
abnormal glycosylation still being limited, it is well established
that it can contribute from early stages to invasion and metas-
tisation.2 42e44
We will focus on glycan alterations of glycoproteins, in
particular mucins that are major carriers of glycan structures
in carcinomas, characterised by O-glycosylation initiated by
addition of a GalNAc on serine or threonine residues. Of the
various changes, the two most important ones from the stand-
point of biomarker signatures are generation of truncated
versions of normal oligosaccharides and generation of unusual
forms of terminal structures, namely sialylated versions of the
normal counterparts (figure 2). Most modifications are generated
by upregulation/downregulation of glycosyltransferases, and
one study has implicated a mutation in the Cosmc chaperone
protein as the underlying mechanism for the absence of a func-
tional enzyme, leading to accumulation of cancer-associated
precursors.45 Therefore it is reasonable to assume that the glycan
signature at the cancer cell surface is unstable, at variance with
what happens to most cancer-associated alterations, which are
clonal because of their genetic origin. This fits into the mosai-
cism of glycan expression in tissue sections, reflecting variations
in differentiation along cancer progression.46 However, despite
their non-clonal nature, it is clear that they stabilise during
cancer progression,47 probably because of the positive selective
properties they confer on the cell populations, by facilitating
invasion and metastisation.
It is relevant in considering altered glycosylation central to the
cancer biomarker field that it is visible on the cell surface of
cancer cells (and therefore easily accessible to antibodies or
lectins as tissue biomarkers) and often expressed in the circula-
tion, either on secreted products or by shedding from cell
surfaces (and therefore identifiable as serum biomarkers).
As mentioned above, mucins are major carriers of cancer-
associated carbohydrates and they amplify alterations at the
surface of the cancer cell because they are highly overexpressed
in cancer and have repetitive sequences rich in serine and thre-
onine, the potential O-glycosylation sites.48 They are major
carriers of the modified glycans secreted or anchored at cancer
cell membranes. However, they can themselves be biomarkers
due to modifications induced by altered glycosylation. Such an
example is the differential recognition of the MUC1 mucin by
different monoclonal antibodies according to glycosylation.49
Mucins can be either secreted or membrane-bound and contain
both O-linked and N-linked oligosaccharides and share
a common structural feature, the presence of a tandem repeat
(VNTR) domain.50e59 Tandem repeats are rich in serine and
threonine, which can be O-glycosylated. The polymorphic
nature of mucins at the VNTR was first recognised in 198750
and later shown, for the MUC1 mucin, to have implications for
the risk of gastric cancer development,60 partly by modulating
glycosylation.61 Mucins show restricted, tissue-specific, expres-
sion in normal epithelial cells, but are overexpressed and aber-
rantly expressed in cancer. As an example, MUC2 mucin, which
is expressed in normal intestine, can be aberrantly expressed in
intestinal metaplasia, a precursor lesion of gastric carcinoma,62
and in 25% of gastric carcinomas.63 Also MUC4 is expressed in
premalignant and malignant lesions of the pancreas despite it
not being expressed in normal pancreatic cells.64 In some cases,
modifications of mucin expression are strictly linked to
modified glycosylation. For example, MUC2 mucin in intestinal
metaplasia colocalises with expression of sialyl-Tn in goblet
cells.47 65 66 Future studies should address the putative coordi-
nation of mucin/glycosyltransferase regulation to clarify if, at
least to some extent, mucin expression can ‘instruct’ glycosyla-
tion or if they are independently but coordinately regulated.
SIMPLE MUCIN-TYPE CARBOHYDRATE ANTIGENS
One of the most common cancer-associated modifications is
poor glycosylation of glycoproteins, leading to expression of
truncated O-glycans at the cell surface67e69 (figure 1). These are
Tn, sialyl-Tn and Tantigens (figure 2), which are pan-carcinoma
antigens.70 71 Many studies have identified aberrant expression
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of these so-called simple mucin-type antigens in carcinomas
from breast,72 oesophagus,73 colon,74 pancreas,75 76 stomach,47
lung,77 endometrium,78 79 ovary80 and bladder.81 Other studies
have shown an association of expression of these antigens with
poor prognosis in patients with breast,82 colon83 and stomach84 85
carcinoma.
Modifications stem from disorganisation of secretory
pathway organelles (ER and Golgi) in cancer cells and altered
glycosyltransferase expression. As mentioned above, these
modifications can also occasionally depend on mutations in
a chaperone essential for glycosyltransferase function.45
Another, more common, mechanism for cancer-associated
expression of truncated O-glycans is absence of glycosyl-
transferases responsible for the synthesis of core structures used
as substrates for chain elongation.31 Alternatively, or in combi-
nation with the previous mechanism, is overexpression of
sialyltransferases responsible for the synthesis of sialyl-Tn
and sialyl-T antigens.35 86 In fact, transfection of cells that do
not express sialyl-Tn with the ST6GalNAc I (GalNAc a2,6-
sialyltransferase) is induced to express sialyl-Tn,33 87 and, in
human breast cancer, expression of ST6GalNAc I colocalises
with expression of sialyl-Tn.34 Furthermore, induced expression
of sialyl-Tn in cell lines increases their tumorigenicity.88 89
Future studies will be directed at identifying specific
O-glycan/core-protein combinations to increase the specificity
of the biomarkers for cancer detection. In the case of MUC1, it
has been shown that specific glycopeptide combinations
can generate antibodies with increased specificity in cancer
reactivity.90
LEWIS CARBOHYDRATE ANTIGENS (BIOSYNTHESIS AND
EXPRESSION)
Lewis-type blood group antigens, such as sialyl Lewis A (SLea)
and sialyl Lewis X (SLex) (figure 3), are expressed in cancer cells,
mimicking their normal expression on blood cells (monocytes
and neutrophils) and also mimicking their potential for migra-
tion through binding to endothelial cell selectins. They are
expressed on carbohydrate chains, type 1 and type 2, according
to the linkage between the galactose residue and the GlcNAc
residue, b1,3 and b1,4, respectively. The presence or absence of
type 1 Lewis antigens in a given individual depends initially on
the presence of active enzymes responsible for the addition of
the fucose monosaccharide. The a1,2-fucosyltransferase,
product of the secretor gene (Se), acts on the terminal galactose
and produces the H type 1 structure which forms the substrate
for the a1,4-fucosyltransferase, the product of the Lewis gene
(Le), which synthesises the difucosylated Leb antigen (figure 3).
People with inactivating mutations of the Se gene are unable to
synthesise H type 1 and Leb antigen; they are called non-secre-
tors and constitute 20% of the human population. The secretor
and Lewis status of individuals are implicated in susceptibility to
several diseases, mostly infections, with almost complete
absence of gastrointestinal infections from calicivirus in non-
secretors91 and an implication of BabA+ Helicobacter pylori
infection.92
The relevance of Lewis sialylated structures in cancer was first
revealed in the 1980s, when monoclonal antibodies raised
against cancer cells were shown to recognise SLea/x.93e95 The
biosynthetic basis for sialylated Lewis antigens also started to be
Figure 3 Schematic representation of
the biosynthesis of Lewis antigens. R
represents precursor carbohydrate
chain. Fuc-T, fucosyltransferase; Lea,
Lewis A; Leb, Lewis B; Lex, Lewis X;
Ley, Lewis Y; SLea, sialyl Lewis A; SLex,
sialyl Lewis X; ST3Gal, a2,3-
sialyltransferase.
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determined in the 1980s,96 97 and it is now recognised as
depending on increased a2,3-sialyltransferase and/or a1,3/4-
fucosyltransferase activities.98 99 In leukaemias, a viral gene
product of human T-cell lymphotropic virus type 1 trans-
activates fucosyltransferase VII, an a1,3-fucosyltransferase with
rate-limiting activity for the synthesis of sialyl-Lex in leucocytes,
and induces strong constitutive expression of sialyl-Lex in
leukaemic cells.100
Mucins can be carriers of these glycan structures,101 and
MUC1 was specifically identified as one such carrier.102 In 1991,
it was demonstrated that SLea and SLex were recognised by
endothelial leucocyte adhesion molecule 1 (ELAM-1) in endo-
thelial cells103 and also that cancer cells use these structures to
adhere to activated endothelial cells104 and facilitate establish-
ment of haematogenous dissemination and metastisation. In
agreement with this, overexpression of SLex and SLea is common
in carcinomas of several origins (eg, lung, colon, gastric and
pancreas) and is associated with increased metastatic abil-
ity105e108 and poor survival of the patients.109e113
The relevance of SLea and SLex to cancer dissemination led
to attempts to use them not only as cancer biomarkers but
also as therapeutic targets. One therapeutic strategy is to
reduce synthesis of SLex by using competitive disaccharide
substrates as decoys.114 Antisense strategies, directed to a1,3/
4-fucosyltransferase, were successful in reducing liver
metastisation in a mouse model.115 Similarly, increased and
cancer-associated expression of these antigens has been used
for in vivo bioimaging.116
Mechanisms controlling gene expression, including methyla-
tion and identification of transcription factors, are under investi-
gation to better understand aberrant expression of Lewis antigens
in cancer and to improve their usefulness as cancer biomarkers.
GLYCAN-BASED SEROLOGICAL ASSAYS IN CANCER
Glycosylation changes on glycoconjugates either present on the
surface or secreted by cancer cells are a major potential source of
cancer biomarkers. At present, most serological assays used for
cancer detection, prognosis and monitoring are based on quan-
tifying glycoconjugates in the serum of patients with cancer.
These serological assays detect carbohydrate antigens such as
SLea (CA19-9) and STn (CA72-4) or mucin glycoproteins such as
MUC1 (CA15-3) and MUC16 (CA125).57 117e119
The use of these biomarkers for cancer screening is limited
because of their broad expression by various types of cancer,
precluding identification of the organ in which the cancer has
originated.120e122 In addition, these biomarkers can also be
produced in some non-neoplastic and inflammatory diseases,123
reducing the specificity of the assays for screening purposes.124
Nevertheless, sound data support the use of the CA125 assay for
detection of ovarian cancer. Raised CA125 concentrations are
found in 50% of patients with stage I ovarian cancer and in 25%
of serum samples collected 5 years before diagnosis of ovarian
cancer.125
In general, the detection of these biomarkers in the serum of
patients with cancer has been shown to be particularly useful for
evaluation of prognosis and for monitoring purposes. This is the
case for the assay of CA125, which is detected in 80% of patients
with ovarian cancer117; furthermore, increases and decreases in
CA125 correlate with regression and progression of the disease. In
addition, preoperative evaluation of CA125 has been shown to aid
evaluation of prognosis for patients with ovarian cancer.126 127
Similarly, the aberrantly glycosylated MUC1 mucin, which is
produced by cancer cells and shed into the circulation, can be
detected by the CA15-3 assay. Raised CA15-3 concentrations
have been shown to be useful for prognosis evaluation in early-
stage breast cancer and for monitoring the course of the
disease,128e130 including monitoring patients with metastatic
disease during active therapy.131 In the absence of readily
measurable disease, an increasing CA15-3 concentration may
indicate treatment failure.124 132 Evaluation of the clinical utility
of CA15-3 in other cancers is under investigation.
The aberrant expression of other carbohydrate antigens on
glycoconjugates has also been shown to be useful for evaluating
prognosis and for monitoring purposes in cancer. Serological
detection of SLea on glycolipids and glycoproteins by the CA19-9
assayhas beenperformed inpatientswith an established diagnosis
of pancreatic, colorectal, gastric or biliary cancer and used to
monitor clinical response to therapy.133 134 In addition, in colon
cancer, a raised CA19-9 concentration before surgery has inde-
pendent prognostic value: patients with increased concentrations
had a fourfold increase in death rate at 3 years compared with
those with lower concentrations. In gastric carcinoma, preopera-
tive CA19-9 concentration remains one of the best prognostic
factors,135 136 and preoperative positivity for CA19-9 is an inde-
pendent risk factor for recurrence of gastric carcinoma.137
Another carbohydrate antigen, sialyl-Tn, which is expressed in
glycoproteins such as mucins, can be detected by the CA72-4
assay. Raised CA72-4 concentration has been shown in patients
with gastric, colorectal and pancreatic carcinomas.136 138 In
gastric carcinoma, CA72-4 has been shown to be useful as an
independent prognostic factor: patients positive for CA72-4
show a 3.8-fold higher risk of death.139 The CA72-4 assay is also
useful for monitoring gastric carcinoma, where positivity is
considered to be a predictor of tumour recurrence.136 CA72-4 has
also been shown to be an independent prognostic factor in
pancreatic cancer.140
Determination of carcinoembryonic antigen (CEA) is another
serological assay widely used in clinics. CEA glycoproteins are
rich in N-glycans, and these glycoproteins are produced by
normal and carcinoma cells. In colorectal and some other
cancers, CEA is expressed at high level and shed into the circu-
lation.129e131 The clinical significance of serum CEA in patients
with colorectal carcinoma is in the evaluation of prognosis and
follow-up of patients.141 142 Increases in serum concentrations of
CEA can also have non-cancer-related causes.140 Because of its
lack of sensitivity in the early stages of colorectal cancer, CEA
measurement is unsuitable for population screening.
The glycosylation alterations observed in cancer, particularly
the putative glycopeptide specificities been identified above,
constitute a major target for the development of novel serolog-
ical-based assays for early cancer detection with major screening
and clinical implications.
PERSPECTIVES
Glycoconjugate modifications are a universal hallmark of
cancer, which makes them important cancer biomarkers. Many
Take-home messages
< Glycoconjugate modifications are a quasi-universal hallmark of
cancer which makes them important cancer biomarkers.
< Some modified glycoconjugates detected in serum are in
clinical use for follow-up of patients.
< New developments are expected to increase the scope of
their clinical application, particularly at the diagnostic level.
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of the current biomarkers used in clinics, in both tissue and
serum assays, are based on these carbohydrate modifications.
Their basis and precise structure are, however, largely not
understood by those who use them in the clinical setting. This
stems from the molecular complexity of the expression of
these biomarkers and the still largely unknown regulatory
pathways. Given the importance of these biomarkers because
of both their high frequency and high accessibility at the cell
surface and in serum, this review is an attempt to give the
clinical/pathological expert a relevant biochemical under-
standing of the field.
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1. ABSTRACT 
 
Sialyl-Tn is a simple mucin-type carbohydrate 
antigen aberrantly expressed in gastrointestinal 
adenocarcinomas and in the precursor lesion intestinal 
metaplasia. Sialyl-Tn tumour expression is an independent 
indicator of poor prognosis. We have previously shown in 
vitro that ST6GalNAc-I and ST6GalNAc-II sialyltransferases 
can synthesize sialyl-Tn. The aim of the present study was to 
establish whether ST6GalNAc-I is the major enzyme 
responsible for the expression of sialyl-Tn. We used a model 
of CHO-ldlD cells producing only MUC1-Tn glycoform and 
showed that ST6GalNAc-I is the key-enzyme leading to sialyl-
Tn biosynthesis. We developed novel monoclonal antibodies 
specific for ST6GalNAc-I and evaluated its expression in 
gastrointestinal tissues. ST6GalNAc-I was detected in normal 
colon mucosa co-localized with O-acetylated sialyl-Tn. 
Expression was largely unaltered in colorectal 
adenocarcinomas. In contrast, we found that ST6GalNAc-I is 
weakly expressed in normal gastric mucosa, but over-
expressed in intestinal metaplasia, co-localized with sialyl-
Tn. In gastric carcinomas ST6GalNAc-I was also 
associated with sialyl-Tn, but with heterogeneous staining 
and partial co-localization.  Our results showed 
ST6GalNAc-I as the major enzyme controlling the 
expression of cancer-associated sialyl-Tn antigen in 
gastrointestinal tissues. 
2. INTRODUCTION 
 
Altered glycosylation is a common feature of 
cancer cells. The sialyl-Tn (STn)  antigen (Neu5Acα2-
6GalNAcα-O-Ser/Thr), also known as CD175s, is a simple 
mucin-type carbohydrate antigen which has attracted much 
attention because it is highly expressed in most gastric (1-
3), colorectal (4), ovarian (5), breast (6, 7) and pancreatic 
(8) carcinomas, but has limited expression in normal 
tissues. The expression of sialyl-Tn is an established 
indicator of poor prognosis in patients with gastric (9-11), 
colorectal (12, 13), and ovarian cancer (14) and contributes 
to the aggressive phenotype of carcinoma cells by altering 
their behaviour (15-18). Sialyl-Tn expression is also 
aberrantly expressed in precursor and early lesions of 
carcinomas of the gastrointestinal tract, such as intestinal 
metaplasia (IM) of the stomach (2), adenomatous polyps 
(12), chronic ulcerative colitis (13) and pancreatic 
intraepithelial neoplasias (8).  
 
The synthesis of the mucin-type carbohydrate 
antigens depends upon expression of the enzymes that 
initiate O-glycosylation: UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferases (GalNAc-transferases) 
(19). GalNAc-transferases control the first step in mucin 
glycosylation and controls the level of complexity of mucin 
glycans, i.e., the sites and density of O-glycan occupancy 
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of the mucin tandem repeats (20, 21).  Processing of 
GalNAcα-O-Ser/Thr, also known as the Tn antigen, by 
different glycosyltransferases is dependent on the cell type 
and tissue of origin. Monosaccharides are added 
sequentially to the GalNAc in the Golgi apparatus, forming 
a variety of O-glycan stuctures that include the Core1 
(Galβ1-3GalNAcα-O-Thr/Ser), also known as T antigen, 
and the Core2 (GlcNAcβ1-6 (Galβ1-3)GalNAcα-O-
Thr/Ser) glycans. These glycoforms may be glycosylated 
further forming larger and more complex structures. A 
common feature in carcinoma cells is the activation of an 
alternative glycosylation pathway that caps the GalNAcα-
O-Thr/Ser structures with α2,6-sialic acid. Once sialylated, 
the resulting sialyl-Tn glycoform, Neu5Acα2-6GalNAcα-
O-Ser/Thr, cannot be glycosylated further thereby 
preventing normal glycan elongation (22-24). The 
underlying mechanisms responsible for the induction of the 
sialyl-Tn glycoform in cancer cells are not fully 
understood. Two α2,6-sialyltransferases have been shown 
to be capable to sialylate the GalNAc residue O-linked on 
proteins: ST6GalNAc-I, and ST6GalNAc-II (25-27). 
However, over-expression of the ST6GalNAc-I 
glycosyltransferase in cells can override the normal O-
glycosylation pathways leading to the formation of sialyl-
Tn O-glycans as the dominant mucin phenotype (28-30). 
We have previously shown that both ST6GalNAc-I and 
ST6GalNAc-II can synthesize sialyl-Tn, in vitro; however, 
only ST6GalNAc-I could create large amounts of sialyl-Tn 
when over-expressed in a cancer cell line (28). Previous 
studies have also correlated the amount of ST6GalNAc-I 
mRNA with the amount of sialyl-Tn expression in breast 
cancer (30) and several cell lines (31), while the level of 
ST6GalNAc-II mRNA did not correlate with the expression 
of sialyl-Tn in gastric (unpublished results) and breast 
cancer cell lines (26) or in breast tumours (30). However, 
the role of each sialyltransferase, ST6GalNAc-I and II, in 
the synthesis of the cancer-associated sialyl-Tn structure in 
cells and pathological tissues remains unclear. 
 
A novel monoclonal antibody (MAb) directed to 
ST6GalNAc-I was used to evaluate its expression in normal 
gastric and colonic mucosa, in intestinal metaplasia of the 
stomach, and in gastric and colorectal adenocarcinomas. 
The results show that over-expression of ST6GalNAc-I in 
intestinal metaplasia of the stomach co-localizes with the 
expression of sialyl-Tn. ST6GalNAc-I was not over-
expressed in colon adenocarcinomas when compared to 
normal mucosa, suggesting that the acetylation status of 
sialyl-Tn may mask this antigen in normal colonic mucosa 
and exposed in adenocarcinomas. In contrast, in gastric 
carcinomas expression of sialyl-Tn was partially, but not 
exclusively, associated with ST6GalNAc-I. Our results 
demonstrate that ST6GalNAc-I is the major regulator of 
expression of cancer-associated sialyl-Tn O-glycosylation. 
 
3. MATERIAL AND METHODS 
 
3.1.Recombinant expression of soluble ST6GalNAc-I 
An expression construct of the human 
ST6GalNAc-I were designed to encode an enzyme lacking 
the cytoplasmic and the transmembrane region. This 
soluble construct of ST6GalNAc-I encoding amino acid 
residues 43–601was prepared as described previously 
(28).  The soluble construct of ST6GalNAc-I was 
expressed in Sf9 cells using the Baculo-virus expression 
system, and purified to near homogeneity (28). 
 
3.2. Generation of monoclonal antibodie 
The recombinant ST6GalNAc-I enzyme was used 
as immunogen. Balb/c mice were immunized with one 
subcutaneous injection of 10 µg native protein in Freunds 
complete adjuvant, followed by two injections with 
Freunds incomplete adjuvant, and finally an intravenous 
boost without adjuvant. Eye bleeds were taken 7 days after 
the third immunization, and the titre and specificity of 
antibodies were evaluated by immunocytology with baculo-
virus infected Sf9 cells expressing recombinant human 
ST6GalNAc-I or irrelevant enzymes. Spleen cells from one 
immunized mouse were fused to NS-1 myeloma cells to 
produce hybridomas and the cloning procedure was 
performed as described previously (32, 33). Hybridomas 
were selected by initial screening on baculo-virus infected 
Sf9 cells expressing either one of the following human 
sialyltransferases: ST6GalNAc-I, ST6GalNAc-II or 
ST3Gal-I. Further characterization of the hybridoma clones 
was done on human cell lines expressing full-length coding 
ST6GalNAc-I or ST6GalNAc-II enzymes as previously 
described (28). Antibodies were also tested by SDS-PAGE 
Western blot analysis. 
 
3.3. CHO ldlD-MUC1F cells stably transfected with 
ST6GalNAc-I or ST6GalNAc-II 
CHO ldlD cells were kindly provided by M. 
Krieger (MIT, USA) (34). Stable CHOldlD cell line 
expressing full length FLAG-epitope tagged MUC1 
(MUC1F) has been previously established (CHO ldlD-
MUC1F) (35). Based on existing cDNA constructs (28, 
30), full length human ST6GalNAc-I and ST6GalNAc-
II-Myc constructs were produced by PCR, using 
PfuUltra™ polymerase (Stratagene). Regions encoding 
the membrane anchoring (ST6GalNAc-I; aa 1-293 and 
ST6GalNAc-II; aa 1-80) and catalytic domains 
(ST6GalNAc-I; aa 294-601 and ST6GalNAc-II; aa81-374) 
were generated using two sets of primers. For ST6GalNAc-
I membrane anchor ST6I-1 (5´-GCG GAT CCA CCA TGA 
GGT CCT GCC TGT GGA GAT GCA GGC-3´)/ST6I-3 
(5´-GAG CGC  TCT AGA CCA CAG CGA CTT GGA 
GGC TTT GAT CTT C-3´) and catalytic domain ST6I-2 
(5´-GAG CGC TCT AGA AAA CTC TTT CTG CCC 
AAC CTC ACT CTC-3´)/ST6I-4 (5´-GCG GCG GCC 
GCT CAG TTC TTG GCT TTG GCA GTT CCG GG-3´) 
were used. For ST6GalNAc-II membrane anchor ST6II-1 
(5´-GCG GGA TCC ACC ATG GGG CTC CCG CGC 
GGG TCG TTC TTC-3´)/ST6II-3 (5´-GAG CGC TCT 
AGA GTG GGG GTG CCG CTG AAT GGC CAG-3´) and 
catalytic domain ST6II-2 (5´-GAG CGC TCT AGA GGC 
CTG TTC AAT CTC TCC ATT CCA GTG-3´)/ST6II-4 
(5´-GGC GGC CGC GCG CTG GTA CAG CTG AAG 
GAT GCC GGC C-3´). Single XbaI sites were introduced 
in the membrane anchoring domain preceding the catalytic 
domain leading to L293S and Q294R mutations in 
ST6GalNAc-I and F80S mutation in ST6GalNAc-II-Myc, 
sites underlined in primers shown above. Dual insert 
(membrane anchor and catalytic domain) were cloned 
ST6GalNAc-I controls sialyl-Tn expression in gastrointestinal tissues 
1445 
Table 1. Monoclonal antibodies, their specificity and 
references 
MAb Specificity Dilution Reference 
2C3 ST6GalNAc-I 1:2 This paper 
1C9 ST6GalNAc-I 1:2 This paper 
HB-STn sialyl-Tn 1:15 Dako 
B72.3 sialyl-Tn 1:50  (38) 
TKH2 sialyl-Tn 1:10  (39) 
PMH1 MUC 2 1:10  (40) 
CLH2 MUC 5AC 1:10  (41) 
5E5 MUC1-Tn/STn 1:10  (42, 43) 
 
directionally into the BamHI and NotI sites of the 
pcDNA3-zeo (Invitrogen™). For ST6GalNAc-II the C-
terminal Myc-tag construct was introduced by inserting a 
double stranded Myc-oligo into the Not-I site of 
ST6GalNAc-II-pCDNA3-zeo. All constructs were 
sequence verified using an ABI Avant sequenator. CHO 
ldlD-MUC1F cells were transfected with full length 
human ST6GalNAc-I or ST6GalNAc-II-Myc and grown 
in the presence of GalNAc.  
 
3.4. Patients and tissues 
Gastric carcinomas and gastric mucosa adjacent 
to carcinomas were obtained from individuals undergoing 
surgery at Hospital S. João, Medical Faculty (Porto, 
Portugal). Study was performed with the approval of the 
local HSJ ethical committee (from 05-09-2007). Specimens 
were frozen at – 80oC. Serial sections were cut and used for 
immunofluorescence. We evaluated 22 gastric mucosas 
with normal morphology, 24 IM lesions adjacent to the 
carcinoma cases that were classified as complete IM (n 
=14) and incomplete IM (n =10) according to the pattern of 
mucin expression (described below) and 31 cases of gastric 
carcinoma. Gastric carcinomas were classified according to 
Laurén’s classification (36). Colorectal adenocarcinoma 
cases were obtained from the KAM cohort based on the 
screening group of the Norwegian Colorectal Cancer 
Prevention study in the county of Telemark, Norway (37) 
and a series of colorectal cancer cases recruited to the 
KAM cohort from routine clinical work at Telemark 
Hospital, Skien and Ulleval University Hospital, Oslo. The 
KAM study is approved by the Regional Ethical Committee 
and the Norwegian Data Inspectorate. We evaluated 15 
colorectal adenocarcinomas. A sample of control tissue was 
taken from the surgically removed tissue close to the 
adenocarcinoma or as far away from the tumor as possible. 
The histology of adjacent normal tissue was examined 
independently by two specialist histopathologists, and 
found to be normal. The histology of the adenocarcinomas 
was also examined independently by two specialist 
histopathologists in order to determine the tumor stage. All 
colon cancer cases were histomorphologically classified as 
moderately differentiated. 
 
3.5. Immunofluorescence 
Details of MAbs used are shown in Table 1. Cells 
were fixed in ice-cold acetone for 5 min and kept at -20ºC 
before staining. Tissue slides were preserved at -80ºC and 
fixed in 4% paraformaldehyde for 15 min at RT, prior to 
procedure.  
 
Double staining was used for co-localization of 
ST6GalNAc-I (MAb 2C3) and sialyl-Tn (MAb TKH2 and 
HB-STn) and ST6GalNAc-I and MUC2 (MAb PMH1). 
MUC5AC and MUC2 staining was performed for the 
characterization of IM types (44). Deacetylation 
(saponification) of selected samples was accomplished by 
treating slides immediately after fixation with 0.1N NaOH 
for 20 min at RT prior to performing the 
immunofluorescence (45). Samples designed for MUC2 
detection with PMH1 were pre-treated with neuraminidase 
as previously described (40). 
 
Samples were washed twice in PBS and 
incubated for 20 min with rabbit non-immune serum 
(DAKO) diluted 1:5 in PBS/10%BSA. Samples were 
incubated overnight at 4ºC with the monoclonal antibodies 
2C3 or CLH2 (Table 1) diluted in PBS/5%BSA. Sections 
were washed in PBS and incubated with FITC-conjugated 
rabbit anti-mouse immunoglobulin (DAKO) diluted 1:70 in 
PBS/5%BSA, for 45 min. Then the samples were washed 
in PBS and blocked with non-immune goat serum (DAKO) 
diluted 1:5 in PBS/10%BSA for 20 min. Sections were 
incubated with the monoclonal antibody PMH1 or TKH2 
(Table 1) diluted in PBS/5%BSA overnight at 4ºC. 
Sections were washed with PBS and incubated for 30 min 
with Texas-Red-conjugated goat anti-mouse IgM (in the 
case of PMH1) or Texas-Red-conjugated goat anti-mouse 
IgG1-specific (in the case of TKH2) (Jackson 
Immunoresearch) diluted 1:70 in PBS/5%BSA and DAPI 
diluted 1:100, for 30 min in the dark. Samples were washed 
in PBS and mounted in Vectashield (Vector Laboratories, 
Inc). 
 
Results are based on assays analyzed by two 
independent observers. Statistical analysis was performed 
using the chi-square test with Yates correction using 
Statview 4.01 software. 
 
4. RESULTS 
 
4.1 Monoclonal antibodies to ST6GalNAc-I 
Two monoclonal antibodies 2C3 (IgG2a) and 
1C9 (IgG1) were selected for their specific reactivity with 
ST6GalNAc-I. MAb 2C3 reacted with Sf9 cells expressing 
ST6GalNAc-I but no reactivity was observed with Sf9 cells 
expressing ST6GalNAc-II. MAb 2C3 was also found to 
react with the human cell line K562, which expresses high 
levels of ST6GalNAc-I transcripts and sialyl-Tn antigen 
(31) (Figure 1, Panel II G, J). MAb 2C3 did not show 
reactivity with the denatured form of ST6GalNAc-I when 
analyzed by SDS-PAGE Western blot (not shown). On the 
other hand MAb 1C9 was selected for their specific of the 
reactivity with ST6GalNAc-I in reduced SDS-PAGE 
Western blot analysis (Figure 1, Panel I). These results are 
in agreement with our previous findings that MAbs to 
glycosyltransferases tend to react either with the native 
conformation of the protein or with the denatured protein 
(32, 46). We have generally been unable to produce MAbs 
that react with both the native protein in unfixed cells or 
tissues and by SDS-PAGE Western blot analysis. 
 
Further analysis of MAb 2C3 showed some 
immunoreactivity in immunocytology with the human 
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Figure 1. Characterization of monoclonal antibodies to ST6GalNAc-I. Panel-I: SDS-PAGE and Western blot analysis of the 
immunoreactivity of monoclonal antibody 1C9 with total cell lysate of transfected Sf9 cells expressing a secreted construct of 
ST6GalNAc-I (b). Molecular weight markers are indicated as (a) in the figure. Arrow indicates the detection ST6GalNAc-I. 
Additional band corresponds to N-glycosylated form of the protein. Panel-II: Expression of ST6GalNAc-I and sialyl-Tn in cell 
lines. MAb 2C3 reacts exclusively with MKN45 cells transfected with ST6GalNAc-I (MST6-I) (E) and shows no reactivity with 
wt MKN45 (D) nor with MKN45 cells transfected with ST6GalNAc-II (MST6-II) (F). The same pattern is observed for Hela 
cells (K, L). K562 hematopoietic cell line naturally expresses ST6GalNAc-I (J). Sialyl-Tn staining with MAb TKH2 correlates 
with ST6GalNAc-I (A-C, G-I). Panel-III: Expression of ST6GalNAc-I and sialyl-Tn in minor salivary glands from oral cavity. 
PAS&E staining (A).  MAb 2C3 to ST6GalNAc-I stains salivary glands (B) and co-localizes in the same regions as sialyl-Tn, 
MAb  HB-STn (C). Magnification 200x.  
 
tumour cell lines MKN45 (31) and Hela, which express low 
levels of endogenous ST6GalNAc-I. However, we 
observed strong immunoreactivity with these cells when 
transfected with full coding human ST6GalNAc-I (Figure 
1, Panel II). The staining pattern observed in these cells 
was a distinct perinuclear punctuate staining typical of 
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Figure 2. Stably transfected CHO ldlD-MUC1F cells with full coding human ST6GalNAc-I and ST6GalNAc-II-MYC grown in 
the presence of GalNAc. Cell staining images from CHO ldlD-MUC1F +ST6GalNAc-I (A-F) or +ST6GalNAc-II (G-L) are 
shown in left and right panels, respectively.  Primary antibodies used are shown in the figure. 
 
Golgi vesicles. MAb 2C3 furthermore produced the same 
staining pattern in glandular epithelial cells of salivary 
glands (Figure 1, Panel III), which are known to express 
ST6GalNAc-I mRNA. 
 
4.2 Glycophenotype of CHO ldlD-MUC1F cells stably 
transfected with ST6GalNAc-I and ST6GalNAc-II 
Glycosylation-defective CHO ldlD cells lack the 
epimerase that transforms UDP-Glc and -GlcNAc to UDP-
Gal and -GalNAc, respectively (34). This defect blocks O-
linked glycosylation of proteins. However, the addition of 
exogenous Gal or/and GalNAc to the media of ldlD cells 
overcame this defect and corrected the abnormal 
glycosylation phenotype (34). Addition of only GalNAc to 
the cells produced a truncated mucin limited to Tn. No 
sialyl-Tn was observed. This indicated that CHO ldlD cells 
have no competing glycosylation pathway after the Tn 
glycoform was produced. Interestingly, both the parental 
cell line CHO K1 and the CHO ldlD cell line grown in the 
presence of Gal and GalNAc are known to produce mono- 
and to a lesser extent di-sialylated T-antigen glycoforms 
(47), and indicates that an ST6GalNAc-transferase activity 
must be present. Stably transfectanted cells (CHO ldlD-
MUC1F) of a full coding MUC1 have been produced and 
shown to express MUC1 on the cell membrane (35, 42). 
 
CHO ldlD-MUC1F cells cultured in the presence 
of GalNAc expressed the Tn antigen (GalNAc-O-Ser/Thr) 
(Figure 2).  There was no sialyl-Tn found indicating that 
the endogenous sialyltransferases were not capable of 
producing sialyl-Tn. A lack of the presence of the sialyl-T 
antigen was confirmed by treating the cells with 
neuraminidase and then staining the cells using controlled 
conditions with an anti-T antibody. Stable transfection of 
ST6GalNAc-I into these cells resulted in production of the 
sialyl-Tn glycoform as detected by B72.3 (Figure 2) and 
other sialyl-Tn Mabs (not shown). In contrast, stable 
transfection with ST6GalNAc–II did not result in 
substantial production of sialyl-Tn, although a few faint 
cells (<25%) could be visualized (Figure 2). Interestingly, 
while the cytolocalization of ST6GalNAc-I detected by 
MAb 2C3 was clearly supranuclear and Golgi-like, the 
staining of myc-tagged ST6GalNAc-II was localized 
throughout the cell with no apparent Golgi localization. 
While tagged constructs may mislocalize recombinant 
proteins, previously we have shown co-localisation of 
native and tagged constructs of several other 
glycosyltransferases. A 6X His tagged ST6GalNAc-II 
construct has also been expressed as a secreted functional 
enzyme in insect cells (unpublished). We are currently 
trying to develop Mabs to ST6GalNAc-II and characterize 
the cytolocalization in more detail.     
 
4.3 Expression of ST6GalNAc-I and sialyl-Tn in normal 
gastric mucosa 
Gastric mucosa with normal morphology showed
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Table 2. Immunoreactivity of MAb 2C3 in normal gastric mucosa, intestinal metaplasia,gastric carcinoma, and colon carcinoma 
 ST6GalNAc-I (Mab 2C3 immunoreactivity) 
Gastric mucosa and Intestinal metaplasia Negative Weakly positive Strongly positive 
Normal gastric mucosa (n=22) 0  21 1  
IM complete a (n=14) 0 0 14 
IM incomplete a (n=10) 0 0 10 
 ST6GalNAc-I (Mab 2C3 immunoreactivity) 
Gastric Carcinomas (n=31) Negative < 50% of pos. cells > 50% of pos. cells P  value 
Histologic type b     
     Intestinal (n=18) 4 10 4 0.600 
     Diffuse (n=9) 2 6 1  
     Atypical (n=4) 1 1 2  
     
Sialyl-Tn expression     
   Negative (n=4) 3 1 0 0.009 
   < 50% of positive cells (n=9) 1 8 0  
   > 50% of positive cells (n=18) 3 8 7  
 ST6GalNAc-I (Mab 2C3 immunoreactivity) 
Colon Carcinomas (n=15) Negative < 50% of pos. cells > 50% of pos. cells P  value 
Clinical stage     
     A (n=4) 0 2 2 0.897 
     B (n=4) 0 3 1  
     C (n=7) 0 3 4  
Sialyl-Tn expression     
   Negative (n=1) 0 1 0 0.005 
   < 50% of positive cells (n=7) 0 7 0  
   > 50% of positive cells (n=7) 0 0 7  
 (a) Classification based on MUC2 and MUC5AC mucin expression,  (b) Classification according to Laurén (34) 
 
a complete absence of expression of sialyl-Tn antigen, as 
expected. Immunodetection of ST6GalNAc-I was observed 
in all normal gastric mucosa (Table 2) and was 
characterised by a weak immunofluorescence signal limited 
to the perinuclear area of cells from the foveolar 
epithelium, corresponding to a Golgi-like staining (Figure 
3A-G). The process of deacetylation did not alter the 
expression of sialyl-Tn in normal gastric mucosa, which 
remained negative after treatment (data not shown). 
 
4.4 Expression of ST6GalNAc-I and sialyl-Tn in 
intestinal metaplasia 
The 24 foci of IM, 14 of complete IM and 10 of 
incomplete IM, were classified according to the pattern of 
expression of mucins (44). Cases with metaplastic areas 
which co-expressed gastric mucin MUC5AC together with 
intestinal mucin MUC2 were classified as incomplete IM, 
whereas cases with MUC2 but lacking MUC5AC were 
classified as complete IM.  
 
Expression of sialyl-Tn antigen was observed in 
the mucin vacuoles of goblet cells of all cases of complete 
and incomplete IM (Figure 3C and 3D, respectively). All 
IM cases showed a strong expression of ST6GalNAc-I 
(Table 2, Figure 3A-D), clearly contrasting with the faint 
staining of normal mucosa areas. The staining was also 
restricted to goblet cells and the pattern was perinuclear 
(Golgi-like). Therefore, both in complete and incomplete 
IM, ST6GalNAc-I showed increased staining and co-
localized with MUC2 (Figure 3A and 3B) and sialyl-Tn 
(Figure 3C and 3D). 
 
4.5 Expression of ST6GalNAc-I and sialyl-Tn in gastric 
carcinoma 
Expression of ST6GalNAc-I was observed in 
24/31 (77%) of cases of gastric carcinoma (Table 2; Figure 
3 E-G).The expression levels of enzyme (intensity) could 
not be assessed due to the heterogenous intensity 
observed within each gastric carcinoma case. However, 
differences were observed between the pattern of 
expression in gastric carcinoma and normal mucosa. A 
punctuated Golgi-like staining restricted to foveolar 
epithelium was seen in normal mucosa, opposite to the 
widespread perinuclear and diffuse cytoplasmic staining 
observed in gastric carcinoma. Due to this fact and to 
the focal and patchy nature of sialyl-Tn and 
ST6GalNAc-I expression in carcinomas, a semi-
quantitative scale of percentage of positive cells was 
used to achieve a more informative classification. 
 
We observed a significant association between 
ST6GalNAc-I expression and sialyl-Tn expression, but not 
with the histopathologic type of gastric carcinoma (Table 
2). In the majority of carcinoma cases where co-expression 
of sialyl-Tn and ST6GalNAc-I was observed, both sialyl-
Tn and ST6GalNAc-I were largely expressed in the same 
cells. However, in 8 cases the score for sialyl-Tn 
expression exceeded the score observed for ST6GalNAc-I. 
In addition, there were 4 cases with expression of sialyl-Tn 
where we did not observe ST6GalNAc-I (Table 2). 
 
4.6 Expression of ST6GalNAc-I and sialyl-Tn in normal 
colorectal mucosa 
In all 15 cases, normal appearing colorectal 
mucosa showed a strong perinuclear, Golgi-like, staining 
pattern of ST6GalNAc-I throughout all compartments of 
the colonic crypts (Figure 4B). Before deacetylation with 
sodium hydroxide, sialyl-Tn was only expressed 
sporadically in lower compartments of the crypts in about 
half of the cases (Figure 4C). After deacetylation, all cases 
expressed sialyl-Tn intracellularly in lower compartments; 
however, in some cases the expression of sialyl-Tn was 
also observed in goblet cells throughout the crypts (Figure 
4D).
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Figure 3. Double labelling of ST6GalNAc-I (Mab 2C3) and sialyl-Tn (Mab TKH2) or MUC2 (MAb PMH1) in gastric tissues. 
Normal gastric mucosa adjacent to intestinal metaplasia and carcinomas shows weak expression of ST6GalNAc-I in the foveolar 
epithelium (A, C, E, F, G, arrows). MUC2 (red) and ST6GalNAc-I (green) are overexpressed in the goblet cells in complete 
intestinal metaplasia (A, double arrowheads) and incomplete intestinal metaplasia (B, double arrowheads). Sialyl-Tn (red) and 
ST6GalNAc-I (green) are overexpressed in the goblet cells in complete intestinal metaplasia (C, arrowhead) and incomplete 
intestinal metaplasia (D, arrowhead). Gastric carcinoma of the intestinal type showing co-localization of sialyl-Tn and 
ST6GalNAc-I (E, arrowhead). Gastric carcinoma of the intestinal type showing expression of sialyl-Tn and absence of expression 
of ST6GalNAc-I (F). Gastric carcinoma of the diffuse type showing co-expression of sialyl-Tn and ST6GalNAc-I (G, 
arrowhead). Magnification 200x. 
 
4.7. Expression of ST6GalNAc-I and sialyl-Tn in 
colorectal adenocarcinoma 
ST6GalNAc-I was observed in 15 cases of 
colorectal adenocarcinoma (Table 2, Figure 4E and 4F). 
Expression of ST6GalNAc-I was observed in 50% of cases 
and in >50% of the tumour cells. Generally the staining 
intensity was weaker in tumour cells than in the normal 
cells. Exceptionally strong staining of both ST6GalNAc-I 
and sialyl-Tn was observed in transitional tissue, a tissue 
which is immediately adjacent to tumour edge but with no 
histological features of malignancy. Transitional tissue was 
observed in 4 of the colon biopsies (not shown).  
 
Sialyl-Tn was expressed in the same cases as 
ST6GalNAc-I controls sialyl-Tn expression in gastrointestinal tissues 
1450 
 
 
Figure 4. Normal colon stained with H&E (A), with MAb 2C3 (ST6GalNAc-I) (B) and MAb TKH2 (Salyl-Tn) before 
deacetylation (C) and after deacetylation by treatment with NAOH (D) as described in Mat. & Methods. Colon carcinoma stained 
with MAb 2C3 (ST6GalNAc-I) (E) and MAb TKH2 (Sialyl-Tn) (F). ST6GalNac-I and sialyl-Tn co-localize in colon carcinomas. 
In normal colon this co-localization is observed only when the tissue sample is submitted to deacetylation, exposing the Sialyl-Tn 
antigen. Magnification 200x. 
 
ST6GalNAc-I and in the same areas. Deacetylation of the 
tissue enhanced the staining of sialyl-Tn in most of the 
cases, but this effect was far less pronounced than in 
normal colon samples. Sialyl-Tn was observed in the apical 
cell membranes, cytoplasm, and luminal contents of the 
colorectal adenocarcinomas. There was no correlation of 
Duke’s clinical staging with the expression of ST6GalNAc-
I; however, a strong association with sialyl-Tn expression 
was observed (Table 2). We could not detect tumour cells 
that expressed sialyl-Tn and does not express ST6GalNAc-
I. On the other hand we could occasionally detect few 
tumour cells that expressed ST6GalNAc-I and lacking 
expression of sialyl-Tn. 
 
5. DISCUSSION 
 
Sialyl-Tn antigen is a simple mucin-type 
carbohydrate antigen whose aberrant expression is common 
in several human carcinomas and precursor lesions of 
cancer (1-8, 12, 13). Sialyl-Tn antigen is the product of an 
abnormal glycosylation pathway, corresponding to the 
early α2,6-sialylation of GalNAcα-O-Ser/Thr. The 
molecular mechanism leading to the activation of this 
pathway in carcinomas remains to be clarified.  
 
We have previously shown in vitro that 
ST6GalNAc-I and ST6GalNAc-II can synthesize sialyl-Tn, 
but only ST6GalNAc-I can induce high amounts of sialyl-
Tn when over-expressed in cancer cell lines (28). In most 
cells multiple glycosylation pathways compete for the same 
substrate and hence concordance between in vitro activity 
and in vivo function may not be evident. We used the CHO 
ldlD cell system to determine if the function of 
ST6GalNAc-II was inhibited by other glycosyltransferases 
competing for the same substrate. Indeed, ST6GalNAc-II 
did not produce substantial amounts of sialyl-Tn in a cell 
capable of only producing the enzymes substrate, the Tn 
glycoform as part of the abundant MUC1 mucin. In 
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contrast, ST6GalNAc-I produced sialyl-Tn under the same 
conditions. Therefore, it may be concluded that the low 
activity of ST6GalNAc-II at producing sialyl-Tn in cells 
was not due to competing glycosylation. Different 
molecular mechanisms leading to sialyl-Tn biosynthesis 
have been previously described. In the LS174T colon 
carcinoma cell line model, Brockhausen and co-workers 
demonstrated that the expression of sialyl-Tn in a subset of 
cells is associated with a lack of core1 β3Gal-transferase 
activity, and not with α2,6Sialyl-transferase activity (22). 
Whereas in the LMCR colon carcinoma cell line, they 
showed that the reverse was true, i.e., sialyl-Tn expressing 
cells had increased α2,6Sialyl-transferase activity (23). 
Therefore, using two cell lines from colonic origin, it was 
shown two different mechanisms leading to sialyl-Tn 
synthesis: one due to ST6GalNAc-transferase activity 
overexpression, and another due to the inability of 
synthesizing the core1 glycoform (T-antigen), as a result of 
inactivation of the molecular chaperone, Cosmc (48). The 
Cosmc chaperone is required for expression of an active 
β3Gal-transferase and, subsequently, core1 synthesis and 
proper O-glycosylation (49). Cosmc mutations have been 
found in cancer cell lines and primary cervical cancers 
where its inactivation has been associated with sialyl-Tn 
expression (48, 49). Cosmc mutations in gastric carcinomas 
remain unidentified. In fact, the action of competing 
glycosyltransferases, namely core 1 β3Gal-transferase that 
uses the same substrate as ST6GalNAc-I (GalNAc-O-
Ser/Thr), and core 3 (β3GnT6), may be a mechanism 
interfering with sialyl-Tn biosynthesis. Another factor may 
be the sub cellular localization and Golgi compartment 
localization of these glycosyltransferases. Previous studies 
have shown that sialyl-Tn synthesis in colorectal 
adenocarcinoma was localized throughout the Golgi 
apparatus, including the early compartments (50). This 
result was further supported by another study showing that 
ST6GalNAc-I was found in all Golgi sections in carcinoma 
cells (30). In fact, the biosynthetic pathway leading to the 
production of disialyl-T structures (27-29) involves the 
assembly of the monosialyl-T glycoform (NeuAcα2-
3Galβ1-3GalNAcα-O-Thr/Ser) prior to the action of 
ST6GalNAc-transferase. This sequence of glycan addition 
to the T-antigen is supported by the topological location of 
ST6GalNAc-I in the Golgi compartment; whereas, core 1 
β3Gal-transferase and α2,3sialyltransferases, are located in 
earlier cellular compartments. Studies showing that 
transfection of cells with ST6GalNAc-I can result in 
overriding of the natural O-glycosylation pathway with 
resulting truncated sialyl-Tn O-glycans therefore suggest 
that it is the overexpression and likely the resulting altered 
topology of the enzyme that drives the premature 
α2,6sialylation of Tn before core 1 extension (30). This 
interpretation would be in agreement with the recent 
finding that ST6GalNAc-II, while capable in vitro of using 
Tn substrates, is incapable of inducing substantial amounts 
of sialyl-Tn synthesis in cells with abundant Tn substrates 
and without competitive alternative glycosylation pathways 
(28). Presumably this is due to an entirely different 
subcellular topology (Figure 2). 
 
In the present study, we have produced and 
characterized two novel MAbs that specifically react with 
either the native or the denatured ST6GalNAc-I enzyme 
protein and have utility in immunohistology applications 
and SDS-PAGE Western blot. Although the homologous 
enzymes ST6GalNAc-I and ST6GalNAc-II share a degree 
of sequence similarity we did not identify clones with 
cross-reactivity between the enzymes. This result is similar 
to our past experience with the immunogenicity of 
homologous glycosyltransferases (32). In agreement with 
previous studies we have observed the absence of sialyl-Tn 
expression in normal gastric mucosa. Nevertheless, weak 
immunoreactivity for the ST6GalNAc-I enzyme was 
observed in the foveolar epithelium of gastric mucosa. The 
ST6GalNAc-I staining was restricted to the perinuclear 
region suggesting Golgi localization (Table 2; Figure 3). A 
recent study has shown that ST6GalNAc-I mRNA is 
weakly expressed in various normal tissues despite that 
these tissues generally do not express the sialyl-Tn antigen 
(30). In addition, we have previously shown that gastric 
cell lines devoid of sialyl-Tn, still express basal levels of 
ST6GalNAc-I transcripts (31). It is therefore clear that 
expression of low levels of ST6GalNAc-I mRNA as well as 
basal enzyme levels, as shown here, may not be sufficient 
per se to induce sialyl-Tn expression and further supports 
the importance of the levels of expression of the 
ST6GalNAc-I enzyme as well as the Golgi compartment 
localization.  
 
The expression of sialyl-Tn in colonic mucosa 
appears to represent a different scenario.  ST6GalNAc-I is 
expressed in normal colon both at the mRNA and protein 
levels. Nevertheless, sialyl-Tn is not normally detectable at 
the surface colon cells, being restricted to perinuclear 
staining at the base of the crypt in few cases (Figure 4). In 
normal colonic epithelial cells, sialic acid residues are often 
modified by O-acetyl groups, thereby precluding antibody 
recognition of the sialyl-Tn antigen. Deacetylation leads to 
sialyl-Tn exposure and consequent detection, and MAb 
staining largely increases after this procedure, as can be 
seen in Figure  4. Yet, this mechanism is not true for 
normal gastric mucosa. We observed no sialyl-Tn 
expression after deacetylation of normal gastric mucosa 
(data not shown). O-acetylation in the human stomach is 
very rare and limited to pathological conditions (51) so the 
absence of sialyl-Tn detection in normal gastric mucosa 
cannot be explained by such mechanism. 
 
In the human stomach, Intestinal Metaplasia is a 
pre-malignant lesion characterized by a global trans-
differentiation of gastric epithelium into intestinal 
epithelium and is associated with an increased risk for 
gastric carcinoma development.  Intestinal metaplasia 
expresses several intestinal markers that are foreign to 
normal gastric epithelial cells, such as MUC2 and sialyl-
Tn, which co-localize at the mucinous vacuoles of goblet 
cells (44, 52). We observed that ST6GalNAc-I was 
expressed in all intestinal metaplasia cases (24/24), and this 
expression co-localizes both with MUC2 and sialyl-Tn 
(Figure 3). The ST6GalNAc-I staining was in the 
perinuclear area of goblet cells observed in all metaplastic 
glands, regardless of the histological sub-type, and was 
noticeably more intense than in normal gastric mucosa 
(Figure 3). It is therefore clear that an overexpression of 
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ST6GalNAc-I exists in intestinal metaplasia when 
compared to normal gastric mucosa, and supports the 
hypothesis that overexpression of ST6GalNAc-I is a 
mechanism leading to sialyl-Tn antigen expression in 
intestinal metaplasia. 
 
In the present study, the abundant sialyl-Tn 
expression observed in intestinal metaplasia without 
deacetylation indicated that O-acetylation did not interfere 
with sialyl-Tn detection in intestinal metaplasia as it does 
on normal colon (51). Nevertheless, our results showed that 
the intestinal metaplasia model recapitulates normal colon 
as ST6GalNAc-I and sialyl-Tn are co-expressed in the 
same cells. 
 
In gastric carcinoma, sialyl-Tn expression was 
detected in 87% of the cases similarly to previously 
published series (2), and ST6GalNAc-I expression was 
found on 77% of gastric carcinoma cases.  ST6GalNAc-I 
showed a heterogeneous staining, either clustered in focal 
areas or widely dispersed, and showed variable intensity of 
staining within each case, thus justifying for a different 
classification criteria than in intestinal metaplasia cases, 
based on the percentage of positive cells in the tumour. 
Using this classification, ST6GalNAc-I expression was 
significantly associated with sialyl-Tn expression, 
independent of the histologic type of the tumour. 
Expression of ST6GalNAc-I in >50% of tumour cells was 
observed in 7/31 cases, all of which also expressed sialyl-
Tn in >50% of cells. This equals saying that all gastric 
carcinoma cases that were high enzyme expressers were 
also so for sialyl-Tn. However, the inverse was not true, i.e. 
there were several cases that expressed sialyl-Tn in >50% 
of their tumour cells but have <50% cells with 
ST6GalNAc-I (8/18) or are even negative (3/18). This 
means that, although the majority of gastric carcinoma 
cases expressed sialyl-Tn and ST6GalNAc-I in the same 
cells, there were areas/cases where sialyl-Tn was expressed 
without ST6GalNAc-I detection. Therefore, although there 
was an association between sialyl-Tn and ST6GalNAc-I at 
the case level, the expression of both did not always co-
localize at the cellular level. This apparent discrepancy at 
the cellular level may be explained by different hypothesis. 
One possibility is that ST6GalNAc-I may be present but 
technically undetectable due to low levels of expression. 
Supporting this hypothesis, Sewell and co-workers have 
found that, in breast carcinomas, ST6GalNAc-I expression 
correlated at the mRNA level with sialyl-Tn expression. 
Nevertheless, cases that were weak to moderate positives 
for sialyl-Tn (50% of cases) did not express any detectable 
ST6GalNAc-I RNA by Northern Blot analysis, but were 
positive by RT-PCR (30). These results suggest that 
enzyme detection at the protein level may only occur in 
cases with abundant sialyl-Tn expression. Another 
possibility is that ST6GalNAc-I may not be constitutively 
expressed in the tumour cells, resulting in a temporary 
presence of the enzyme and longer expression of sialyl-Tn 
bearing glycoprotein. Finally, we could not exclude the 
possibility that ST6GalNAc-II, which was demonstrated to 
be enzymatically capable of synthesizing sialyl-Tn in this 
study and in a previous one (28), may co-adjuvate 
ST6GalNAc-I in tumour cells. 
A clear scenario was observed in colon 
adenocarcinomas where a major overlap of enzyme and 
glycan staining was observed. Colon adenocarcinomas 
showed a significant association between ST6GalNAc-I 
expression and sialyl-Tn expression that is independent of 
the clinical stage (Table 2). The presence of both enzyme 
and product was similar to normal colon mucosa with the 
difference that for a complete overlap, deacetylation 
procedures must be applied. In line with this, a previous 
study has shown that normal and cancerous colon tissues 
have similar ST6GalNAc enzymatic activity (53). 
Interestingly enough, transitional tissues have been shown 
to display increased enzymatic activity when compared to 
normal mucosa and cancer (54). We found identical results 
reflected by the exceptionally strong staining of 
ST6GalNAc-I in our transitional colon tissues. 
 
In conclusion our results demonstrate that the novel 
monoclonal antibody 2C3 is highly specific for the 
ST6GalNAc-I enzyme and detects this protein in cells and 
tissues expressing it. We also demonstrate that ST6GaNAc-
I expression is associated with sialyl-Tn expression in 
gastrointestinal tissues supporting the ST6GalNAc-I as the 
major regulator of expression of cancer-associated sialyl-
Tn antigen on O-linked carbohydrate chains. 
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Challenging the Limits of Detection of 
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Short Communication
Challenging the limits of detection of
sialylated Thomsen–Friedenreich antigens
by in-gel deglycosylation and
nano-LC-MALDI-TOF-MS
The identification of sialylated Thomsen–Friedenreich antigens in proteins poses much
interest in the context of cancer research. MALDI-TOF-MS is a powerful technique for
this purpose; still it shows considerable low sensitivity for sialylated molecules due to
in-source and metastable decomposition. Herein, we report a target-driven strategy to
identify these antigens in minute amounts of glycoproteins isolated in polyacrylamide
gels. The glycans were recovered from gel spots by reductive -elimination, permethylated
and analyzed by nano-LC-MALDI-TOF-MS. A computational algorithm was developed to
filter spectral noise and enhance/isolate the signals of interest. Sialylated antigens were
identified inminute amounts of fetuin (0.1g) and plasminogen (1.0g) by this approach.
MS assignments were further validated by enzymatic methods. This methodology allowed
a fivefold decrease in the current LOD of fetuin sialylated O-glycans by MALDI-TOF-MS.
Keywords:
Nano-LC-MALDI-TOF-MS / Permethylation / Sialic acids / Simple mucin-type
antigens / Thomsen–Friedenreich antigens DOI 10.1002/elps.201300148
 Additional supporting information may be found in the online version of thisarticle at the publisher’s web-site
Sialylated Thomsen–Friedenreich-related antigens are a
class of short-chain glycans that result from a prema-
ture stop in the O-glycosylation of proteins [1]. It in-
cludes the sialyl Tn (Neu5Ac2–6GalNAc-O-Ser/Thr; sTn),
sialyl T (Neu5Ac2–3Gal1–3GalNac-O-Ser/Thr and/or
Gal1–3[NeuAc2–6]GalNAc-O-Ser/Thr; sT), and di sia-
lyl T (NeuAc2–3Gal1–3[NeuAc2–6]GalNAc-O-Ser/Thr;
dsT). These antigens are often overexpressed by human can-
cers, reflecting alterations in glycosylation pathways [2]. Its
Correspondence: Dr. Jose´ A. Ferreira, Department of Chemistry,
Mass Spectrometry Centre, University of Aveiro, Campus Univer-
sita´rio de Santiago, 3810-193 Aveiro, Portugal
E-mail: a20025@ua.pt
Abbreviations: dsT, di sialyl T; NEIC, normalized extracted
ionic current; sT, sialyl T; sTn, sialyl Tn; TIC, total ionic current
expression modulates protein function and consequently the
cell behavior and immune recognition [3, 4]. They are also
important cancer biomarkers [1] and present potential for
immunotherapy [5]. Thus, major efforts have been put in the
identification of these glycans in proteins.
MALDI-MS is a powerful, highly sensitive, tool for the
structural analysis of complex glycans [6,7] and glycopeptides
[8]. However, this type of ionization induces a high degree of
vibrational excitation in the generated ions leading to a signif-
icant dissociation of sialic acids [9, 10]. Sialylated molecules
also experience metastable decay [7, 11], particularly in the
reflector mode [12]. Thus, high amounts of the targeted
∗Additional corresponding author: Dr. Rui Vitorino,
E-mail: rvitorino@ua.pt
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Scheme 1. (A) Overview on
the analytical approach devel-
oped for the analysis of trace
amounts of sialylated Thomsen–
Friedenreich-related and (B) the
“in house” algorithm used to
enhance/identify the signals of
interest.
glycoproteins are needed to achieve structural assignments,
making the introduction of enrichment strategies mandatory
[13].
The permethylation of the glycans is considered the
best strategy to overcome these limitations [4, 14–21].
Permethylation reduces the liability of sialic acids [7], al-
lowing their detection together with neutral sugars by
MALDI-MS in positive ion mode [14]. By equalizing their
chemical properties it also allows a semiquantitative compar-
ison between glycans [15]. Most laboratories use a modifi-
cation of the method described by Ciucanu and Kerek [16]
introduced by Ciucanu and Costello [17]. This involves the re-
action of glycanswithmethyl iodide in the presence of sodium
hydroxide in dimethyl sulfoxide in nonanhydrous conditions,
which significantly reduces the oxidative degradation of gly-
cans [17]. Permethylation in small/capillary columns packed
with sodiumhydroxide (solid-phase permethylation) has been
shown capable of improving sample recovery, a critical mat-
ter when dealing with trace samples [18]. This approach has
enabled the identification by MALDI-TOF-MS of sT and dsT
antigens in 0.5 g of fetuin from fetal bovine serum [19].
In a recent study, we combined in-gel de-O-glycosylation
followed by permethylation with nano-LC-MALDI-TOF-MS
to identify sTn antigens in plasminogen of individuals with
gastric precancerous lesions [20]. However, this was done
with about 10 g of plasminogen previously isolated from
human serum by Lysine-sepharose affinity chromatography.
Herein, we challenge the LOD of this technique using fetuin
from bovine serum, which is known to express mainly the sT
antigen [21, 22] and lower amounts of dsT and other glycans
[23]. Since fetuin is themost usedmodel protein for glycomics
studies, this allows a comparison with previous reports.
Briefly, 0.1, 0.5, and 1.0 g of fetuin were separated by
SDS-PAGE and the corresponding bands (50 and 75 kDa)
were revealed with Coomassie Colloidal Blue thereafter. The
bands were then excised from the gels and incubated with
50mMNaOHand 1MNaBH4 at 45C for 16 h to promote the
release of O-glycans (Scheme 1A). The reaction was stopped
with a few drops of glacial acetic acid. The reducing agent
kept the glycan from “peeling” after being released and al-
lowed tagging the nonreductive end. The samples were then
prepurified with 10 kDa MWCO filters (Millipore) to remove
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Figure 1. (A) MALDI-MS spectra of reduced and permethylated O-glycans isolated from 1.0 g of fetuin, highlighting the ions at m/z
895.5 ± 0.2 [sT + Na]+ and 1256.6 [dsT + Na]+. The other signals in the MALDI-MS spectrum did not match the O-glycans deposited
in CFG, Carbbank, GlycomeDB, and Glycosciences databases has shown by the GlycoWorkBench 2 software [24]. (B) S/N of these ions
for different amounts of fetuin. The MS spectra of desialylated samples did not exhibit these ions, which confirmed the structural
assignment (data not shown). The results are presented as average ± SD of three independent replicates. “**” p < 0.01; “**” p < 0.001
versus preceding concentration. The S/N was calculated according to the standard definition: S/N = Psignal/PNoise; where P stands for the
average TIC in the named region of the mass spectra.
proteins and high molecular weight peptides, generated by
the harshness of the deglycosylation conditions. The filtrate,
containing the reduced O-glycans but also low molecular
weight peptides, was incubated several times with methanol
containing 5% (v/v) acetic acid under a stream of nitrogen to
remove borates as methyl esters. The samples were perme-
thylated adopting a modification of the method by Ciucanu
and Costello [17]. Briefly, native O-glycans were dissolved in
78.0 L of DMSO containing trace amounts of water (0.3 L)
and fine grinded NaOH was added to the reaction medium.
The mixture was sonicated for 10 min and frozen prior to
the addition of 10 L of CH3I and then incubated under
mild stirring for 10 min at room temperature. The perme-
thylated glycans were then dissolved in dichloromethane and
extensively washed with 10 mM HCl solution to avoid the
base-induced hydrolysis the permethylated sialic acids car-
boxymethyl groups. The organic phase was evaporated under
vacuum. Equivalent amounts of fetuin previously digested
with neuraminidase from Clostridium perfringens to remove
sialic acids that were used as controls. All experiments were
performed in triplicates.
The permethylated samples were then analyzed in a
MALDI TOF/TOF mass spectrometer (4800 Proteomics An-
alyzer, AB SCIEX, Foster City, CA, USA) in the positive ion
reflector mode. The mass spectra were obtained in the mass
range from 600–4500 Da with 1200 laser shots using as a
matrix 2,5-dihydroxybenzoic acid (DHB; 10 mg/mL in 70%
ACN/0.1% TFA). The MS spectra for 0.5 and 1.0 g of fe-
tuin exhibited the ions at m/z 895.7 and 1256.6 consistent
with [sT+Na]+ and [dsT+Na]+, respectively (Fig. 1A and B).
The higher signal-to-noise ratio (S/N) of sT in comparison to
dsT (Fig. 1B) was in agreement with its abundance in fetuin
[22, 23]. Due to the low abundance of the ions it was not pos-
sible to runMS/MS experiments. Nevertheless, these species
were not observed in samples digested with neuraminidase,
suggesting that the ions atm/z 895.7 and 1256.6 belong to sia-
lylated species, which reinforces our structural assignments.
However, none of these ions were detected using 0.1 g of
fetuin (Fig. 1B).
In an attempt to decrease the LOD, 0.1 g of fetuin sam-
ples were dissolved in 70% ACN and separated in a nano-
HPLC Ultimate 3000 system (Dionex, Amsterdam) equipped
with a C18 reverse phase capillary column (Pepmap100 C18;
3 m particle size, 0.75 m internal diameter, 15 cm in
length). The separation was performed using a linear gra-
dient of 3–50% B (90% ACN, 0.1% TFA) for 45 min, 50–70%
B for 10 min, and 70–32% A (0.1% TFA) for 5 min. The
eluted glycans were applied directly on a MALDI plate in
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Figure 2. (A) Plots of the sparse matrix for 0.1 g of fetuin (nano-LC fraction versus m/z versus NEIC) for the signals at m/z 873.5 ± 0.2
[sT + H]+ and 895.5 ± 0.2 [sT+Na]+ (plots I and III) andm/z 1234.7 [dsT + H]+ and 1256.6 [dsT + Na]+ (plots II and IV). The top part of each
graph represents the NEIC of each extraction window, whereas the lower part represents the combined NEIC of protonated and sodiated
species as a function of the nano LC fraction. Plots I and II refer to reduced and permethylated glycans recovered from native fetuin,
while III and IV result from desialyated fetuin. A chromatographic envelop, characterized by a cluster of high-intensity signals and lesser
dispersion of m/z over the envelope region, is visually detected in plot I, spanning fractions 105–115, and in plot II, spanning fractions
115–125. This chromatographic profile is absent from desialylated samples (plots III and IV). (B) Signal average and S/N for NEIC of the
combined sodiated and protonated species presented in Fig. 2A). In all cases, LC factions 20–40 where used to sample the background
noise. The signal window considered for sT spanned LC fractions 105–115 and for dsT LC fractions 115–125. The S/N was calculated
according to the standard definition: S/N = Psignal/PNoise; where P stands for the average NEIC in the named region of the mass spectra.
10 s fractions using an automatic fraction collector Probot
(Dionex, Amsterdam) under a continuous flow rate of 270 nL
of DHB with 15 fentmole of Glu-1-Fibrinopeptide B (Protea
Biosciences) as an internal standard.
An “in house” algorithm (Scheme 1B) was applied to
nano-LC-MALDI-MS spectra to filter noise and reduce the
original dataset to a sparse matrix containing only candi-
date signals. This algorithm combined the MALDI-MS data
from each chromatographic run into a 3D data array compre-
hending the nano-LC fractions versusm/z versusMALDI-MS
normalized extracted ionic current (NEIC). The NEIC results
from a normalization of the total ionic currents (TIC) of each
run. The distribuition of the signals within 0.2 Da of the ions
of interest were comprehensively analyzed. The surveyed ions
included both protonated and sodiated forms of sT (m/z 873.5
and 895.7) and dsT (m/z 1234.7 and 1256.6).
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As shown by the plots in Fig. 2A, all the surveyed ions
presented sparse matrix plots with clusters of high-intensity
signals. These patterns showed a lesser dispersion of m/z
values over these particular regions, thus consistent with
chromatographic envelopes, which strongly suggests the
presence of the targeted compounds. This also allowed the
identification of LC fractions enriched in the species of in-
terest that were not evident in the original spectra (data not
shown). The averageNEIC for the species of interest was then
evaluated and compared with the corresponding intensity of
the background signals (nano-LC fractions 40–20; Fig. 2B).
The NEIC of the combined signals of both protonated and
sodiated was 0.74 ± 0.18 (S/N 10.6) and 0.58 ± 18 (S/N 7.6),
for sT and dsT, respectively. The desialylation of fetuin led to
the disaperance of the chromatographic envelopes, as high-
lighted by the decrese in combined NEIC to 0.22 ± 0.18
(S/N 1.5) for sT and 0.32 ± 0.18 (S/N 1.3) for dsT (Fig. 2B),
which reinforced the structural assignments. Having estab-
lished the technique, we attempted to decrease the amount
of fetuin required for analysis, however without success. This
strategy was then applied to plasminogen isolated from the
serum of healthy individuals as described by Gomes et al.
[20]. This allowed a tenfold decrease in the amount of protein
required for analysis (Supporting Information Fig. 1S).
In summary, in-gel de-O-glycosylation, permethylation
and nano-LC-MALDI-MS backed by comprehensive data
mining allows the detection of sialylated T-related antigens
in trace amounts of glycoprotein isolated in SDS-PAGE gels.
The LOD of sialylated T-related antigens recovered from fe-
tuin was decreased approximately 5 times in comparison to
previous reports [18]. To our knowledge, this is the first at-
tempt to analyze such low amounts of glycans recovered from
gel spots. This approach may now be adopted to study other
classes of glycans.
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ABSTRACT: Gastric cancer is preceded by a carcinogenesis
pathway that includes gastritis caused by Helicobacter pylori infection,
chronic atrophic gastritis that may progress to intestinal metaplasia
(IM), dysplasia, and ultimately gastric carcinoma of the more
common intestinal subtype. The identification of glycosylation
changes in circulating serum proteins in patients with precursor
lesions of gastric cancer is of high interest and represents a source
of putative new biomarkers for early diagnosis and intervention.
This study applies a glycoproteomic approach to identify altered
glycoproteins expressing the simple mucin-type carbohydrate
antigens T and STn in the serum of patients with gastritis, IM
(complete and incomplete subtypes), and control healthy individuals.
The immunohistochemistry analysis of the gastric mucosa of these
patients showed expression of T and STn antigens in gastric lesions,
with STn being expressed only in IM. The serum glycoproteomic
analysis using 2D-gel electrophoresis, Western blot, and MALDI-
TOF/TOF mass spectrometry led to the identification of circulating
proteins carrying these altered glycans. One of the glycoproteins identified was plasminogen, a protein that has been reported to
play a role in H. pylori chronic infection of the gastric mucosa and is involved in extracellular matrix modeling and degradation.
Plasminogen was further characterized and showed to carry STn antigens in patients with gastritis and IM. These results provide
evidence of serum proteins displaying abnormal O-glycosylation in patients with precursor lesions of gastric carcinoma and include a
panel of putative targets for the non-invasive clinical diagnosis of individuals with gastritis and IM.
KEYWORDS: biomarkers, O-glycosylation, gastritis, intestinal metaplasia, sialyl-Tn, T antigen, plasminogen
■ INTRODUCTION
The development of gastric cancer is associated with a long
carcinogenesis pathway that is initiated by Helicobacter pylori
(H. pylori), a Gram-negative bacterium that causes gastritis, and
may lead to the development of a chronic atrophic gastritis,
intestinalmetaplasia (IM), andultimately gastric adenocarcinoma.1−6
H. pylori infects more than 70% of the population in some
countries,7 but only a fraction of those individuals develop more
severe gastric conditions, such as atrophic gastritis and IM, a
precancerous lesion.1,3 The current diagnosis for these precursor
lesions relies almost exclusively in endoscopy followed by biopsy,
which is both invasive and costly to apply for screening strategies.
Therefore, biomarkers that can aid in the screening and
identification of individuals with silent gastric pathologies are
highly needed.
Glycosylation is a common post-translational modification of
proteins with more than 50% of eukaryotic proteins thought to
be glycosylated.8 The pattern of protein glycosylation is cell- and
tissue-specific and closely reflects the physiological status of
the cell. Thereby, changes in glycan expression are frequently
observed in several pathological conditions9 and in particular in
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the gastric context.10−12 In gastric pathologies the glycosylation
alterations include aberrant expression of simple mucin-type
carbohydrate antigens, namely, T (Galβ1−3GalNAcα-O-Ser/Thr),
Tn (GalNAcα-O-Ser/Thr), and sialyl-Tn (Neu5Acα2−6GalNAcα-
O-Ser/Thr).10,11,13,14 An overexpression of sialylated Lewis
antigens15 and the decreased expression of terminal α1,4-linked
N-acetylglucosamine residues (αGlcNAc) has also been
reported.11,16,17
The biosynthesis of the carbohydrate structures in glyco-
proteins relies on a number of competitive and concerted processes
involving several glycosyltransferases. Mucin (GalNAc)-type
O-glycosylation (hereafter called O-glycosylation) is one of the
most common types of glycosylation found in glycoproteins and
consists of a glycan O-linked to a serine or a threonine residue.
The first step inO-glycosylation is the transfer of GalNAc from a
sugar donor UDP-GalNAc to a serine or threonine residue and is
controlled by UDP-GalNAc: polypeptideN-acetylgalactosaminyl-
transferases (GalNAc-Ts).18,19 These Golgi enzymes control the
site of O-glycosylation. After the first glycan (GalNAc) is added
forming the Tn antigen, the action of other glycosyltranferases
leads to the synthesis of the various core structures depending
on the cell context. In gastric epithelial cells, a Gal-transferase
(C1GalT-1) leads to the biosynthesis of the core 1 (T antigen),
which can be further branched, extended, and terminated by Lewis
and ABO blood group antigens. Alternatively, Tn and T antigens
can be sialylated by sialyltransferases forming the sialyl-Tn (STn),
sialyl-T (ST), and disialyl-T (Figure 1) (for a review see Reis et al.9).
The alterations in glycosylation observed in pathologic
conditions are mostly due to modifications at the glycosylation
cell machinery, disorganization of secretory pathway organelles
(ER and Golgi), and altered glycosyltransferase expression. The
aberrant expression of glycoconjugates bearing these glycans
either present on the surface or secreted by cells are a major
potential source of biomarkers representing most serological
assays used for cancer detection and monitoring. These
serological assays detect carbohydrate antigens such as SLea
(CA19−9) and STn (CA72−4) or mucin glycoproteins such as
MUC1 (CA15−3) and MUC16 (CA125).9
The glycoproteins carrying immature glycans, such as simple
mucin-type O-glycan antigens, can be present in circulating
proteins in pathological conditions and are being targeted for early
detection approaches. In this study we assess the immunohis-
tochemical presence of truncatedO-glycans STn and T antigens in
gastric tissues, including normal gastric mucosa, gastritis, and IM.
We have further screened sera from the same patients searching
to identify proteins bearing these truncated glycans. This
approach resulted in the identification of fine alterations in the
O-glycosylation of serum glycoproteins, such as the presence of
STn, which is known to be aberrantly expressed in the gastric
lesions under study. Specifically, we identified serum proteins
carrying abnormal O-glycans that can be candidate targets for the
noninvasive diagnosis of precursor lesions of gastric cancer.
■ MATERIALS AND METHODS
Tissue Samples and Histology
Stomach biopsies and serum from individuals without gastric
lesions and H. pylori infection (n = 6), gastritis (n = 5), and
complete (n = 5) and incomplete (n = 3) IM were used. The
individuals are part of a cohort from northern Portugal (Viana do
Castelo) that have been studied and characterized as previously
described for gastric pathologies and H. pylori infection.20
Paraffin sections were used for histochemistry and immuno-
histochemistry. Tissue sections were stained with hematoxylin
and eosin (H&E) for histopathology. Clinical data, including
H. pylori infection status, of every case was considered for selection
of the cases and controls.
Immunohistochemistry
Paraffin sections were dewaxed and rehydrated. Endogenous
peroxidase activity was blocked with 3% H2O2 in methanol for
30 min, and then sections were incubated with normal rabbit
serum diluted 1:5 in PBS containing 10% BSA. Incubation with
the monoclonal antibodies was performed overnight at 4 °C.
Slides were washed in PBS and incubated for 30 min with
secondary biotinylated rabbit anti-mouse antibody (E0354-
DakoCytomation, Glostrup, Denmark) diluted 1:200 in PBS
containing 5% of BSA. The slides were subsequently washed in
PBS and incubated for 30 min with avidin−biotin complex
(Vectastain Elite ABC kit, Burlingame, CA, USA) according to
the manufacturer’s recommendations. Staining was performed
with 3,3′-diaminobenzidine tetrahydrochloride (Sigma, St. Louis,
MO, USA) containing 0.02% hydrogen peroxide. Counter-
staining of the nucleus was done with Mayer’s hematoxylin.
Monoclonal antibodies used in this study, their specificities, and
their references are listed in Table 1.
Serum Sample Collection and Protein Equalization by
Combinatorial Peptide Ligand Library
Serum samples from the same individuals as the biopsies were
pooled according to the clinical data (without gastric lesions and
H. pylori infection, gastritis, and complete and incomplete IM).
Equalization of the amount of proteins within each serum sample
Figure 1. Schematic representation of the biosynthesis of core O-glycan
structures and formation of simple type carbohydrate antigens Tn, STn,
T, and ST.
Table 1. Specificity of Monoclonal Antibodies Used for
Immunohistochemistry
MoAbs isotype dilution antigen and ref
TKH2 IgG1 1:20 STn73
3C9 IgM 1:50 T74
CLH2 IgG2 1:750 MUC5AC75
PMH1 IgM 1:40 MUC2 GalNAc76
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group was done using a combinatorial peptide ligand library,
CPLL (ProteoMiner, BioRad, CA),21 according to the manu-
facturer’s recommendations.
2D Gel Electrophoresis
Equalized protein samples from CPLL were precipitated
(ProteoExtract, Calbiochem), resuspended in rehydration buffer
(7 M urea, 2 M thiourea, 4% (v/v) CHAPS, and 0.0002%
bromophenol blue) with 0.2% of ampholyte and quantified (2D
Quant Kit from GE Healthcare). Passive rehydration of the
strips was performed overnight with 100 μg of sample using IPG
strips of pH 3−10 NL (ReadyStrip; 0.5 mm × 3 mm × 70 mm,
Bio-Rad, Hercules, CA) at room temperature. Isoelectric
focusing was performed on Protean IEF cell (Bio-Rad) with an
initial voltage of 250 V for 15 min and then by applying a voltage
gradient up to 4000 V with limiting current of 50 μA per strip and
temperature set at 20 °C. The first dimension was concluded at
14−20 kVh.
Following the isoelectric focusing proteins were reduced and
alkylated by incubation with 2% DL-dithiothreitol (DTT) fol-
lowed by 2.5% iodoacetamide in an equilibration buffer (6 M
urea, 2% SDS, 0.002% bromophenol blue, 75 mM Tris pH 8.8,
29.3% glycerol) for 10 min each under gentle agitation. The
strips were then packed in a 1% low gelling (1% agarose in
running buffer: 25 mM Tris, 192 mM glycine, and 0.1% (w/v)
SDS, pH 8.3; Bio-Rad) on top of a 10% acrylamide gel
(acrylamide/bisacrylamide 37.5:1, 2.6% from Bio-Rad). Second
dimension electrophoresis was performed in a Mini-Protean
tetra cell system (Bio-Rad) using 1xTris/glycine/SDS buffer at
constant voltage of 125 V.
Western Blot Analysis
Gels were transferred to nitrocellulose membranes (Amersham)
in a semidry system according to manufacturer’s recommenda-
tions (TE 77 PWRAmersham) and were blocked with 5% BSA in
PBS-Tween (PBS-T) 0.05%. Primary antibodies were incubated
overnight at 4 °Cwith 5% BSA in PBS-T 0.05%.Membranes were
washed three times with PBS-T 0.05% before secondary antibody
incubation. Secondary antibodies were isotype-specific (Jackson
immunoresearch) anti-IgM (dilution 1:100,000) and anti-IgG1
(dilution 1:50,000) and were incubated for 1 h in 1% BSA in
PBS-T 0.05%. Signal detection was obtained by enhanced chemi-
luminescence (ECL plus, Amersham). The primary antibodies
were the same as those used for immunohistochemistry (Table 1)
and used undiluted.
Protein Selection and In-Gel Tryptic Digestion
2D gels were stained with Coomassie Blue (Bio-Safe Coomassie
from Bio-Rad, CA) overnight, and images were acquired with a
Gel Doc XR system (Bio-Rad, CA).
The spots highlighted in the Western blots were matched in
the Coomassie Blue gels, and proteins were excised with a
spotpicker (OneTouch 2D gel spotpicker, 1.5 mm diameter, Gel
Company, USA). The selected protein spots were then
processed for MALDI MS analysis in agreement with the trypsin
manufacturer instructions (Promega, USA): the protein gel plugs
were washed with water, destained with methanol/50 mM
NH4HCO3 and acetonitrile/50 mM NH4HCO3 (1:1 v/v each),
reduced with 25 mM DTT in 50 mM NH4HCO3 for 20 min at
56 °C, alkylated with 55 mM IAA in 50 mM NH4HCO3 for
20 min in the dark, and in-gel digested with 10 μL of 2 ng/μL
trypsin for 3 h at 37 °C in the presence of 0.01% surfactant
(ProteaseMAX, Promega), and the resulting peptides were
extracted with 20 μL of TFA 2.5% for 15 min.
Protein Identification by MALDI-TOF/TOF
Protein digests were desalted, concentrated, and spotted onto
a MALDI plate using ZipTips (Millipore, USA) following the
manufacturer’s instructions. For thematrix preparation, a solution
of 6−8 mg/mL α-cyano-4-hydroxycinnamic acid in 50%
ACN/0.1% TFA was used. Samples were analyzed using a 4700
Proteomics Analyzer MALDI-TOF/TOF (AB SCIEX, Framing-
ham,MA). Peptidemass fingerprint (PMF) data were collected in
positive MS reflector mode in the range of m/z 700−4000 and
was calibrated with external standards and internally calibrated
using trypsin autolysis peaks. If necessary, several of the highest
intensity nontryptic peaks were selected forMS/MS analysis. The
MS and MS/MS spectra were processed and analyzed using the
software GPS Explorer (Version 3.6, AB SCIEX, Framingham,
MA) and were searched together against the UniProt (release
2012_09) protein sequence database using the Mascot search
engine (Version 2.1.04, Matrix Science, U.K.) limited to Homo
sapiens taxonomy. The search included 65 peaks with a signal-
to-noise ratio greater than 10 and allowed for up to two missed
trypsin cleavage sites. The MS tolerance was 50 ppm for PMF
analysis and 1.0 Da for MS/MS analysis; fixed modifications,
carbamidomethylation of cysteine; variable modifications, oxida-
tion of methionin; keratins were filtered out. To be considered a
match, a confidence interval (CI), calculated by the AB SCIEX
GPS Explorer/Mascot software, of at least 99% was required.
Data Mining for Glycosylation Sites in Glycoproteins
N-Glycosylation in human proteins was predicted by the
NetNglyc 1.0 server (http://www.cbs.dtu.dk/services/NetNGlyc),
an artificial neural network that examines the sequence context
of Asn-Xaa-Ser/Thr (where Xaa is not Pro) sequences.
O-Glycosylation was predicted by the NetOglyc 3.1 server
(http://www.cbs.dtu.dk/services/NetOGlyc) that produces neu-
ral network predictions of mucin- type GalNAc O-glycosylation
sites in mammalian proteins.22
Plasminogen Sialoglycopeptides Enrichment and
Characterization
Plasminogen spots of a 2D gel from each clinical situation were
excised and processed as described above. For the enrichment of
plasminogen sialoglycopeptides the plasminogen peptide extract
was subjected to titaniumdioxide chromatography23 as described by
the manufacturer (GE Healthcare, USA). The sialoglycopeptides
were eluted with the MALDI matrix 2′,4′,6′-trihydroxyacetophe-
none monohydrate (THAP). The mass spectra acquisition was
performed in linear positive mode in the instrumentMALDI-TOF/
TOF 4700 Proteomics Analyzer (AB SCIEX, USA). In order to
search for sialoglycopeptides the mass spectra raw data was
submitted to the software Glycomod (http://web.expasy.org/
glycomod/) and MSBridge, ProteinProspector (http://prospector.
ucsf.edu/prospector/cgi-bin/msform.cgi?form=msbridgestandard).
The mass error tolerance was 0.4 Da. Mass spectra were internally
calibrated by mass plasminogen sialoglycoforms previously
described.24−27
In-Gel O-Deglycosylation and Permethylation
Enrichment of plasminogen from serum samples of individuals
without gastric lesions and H. pylori infection, gastritis, and
complete and incomplete IM cases were performed using lysine-
sepharose affinity chromatography.28 The enriched plasminogen
samples were run in SDS-PAGE gels and stained with Coomassie
Blue. The plasminogen bands were removed from the SDS-
PAGE gels, and the protein identity was confirmed by MALDI
MS. Equivalent amounts of plasminogen previously digested
Journal of Proteome Research Article
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with neuraminidase fromClostridium perf ringens (Sigma-Aldrich;
Karlsruhe, Germany) were used as a control.
Plasminogen was then in-gel O-deglycosylated by reductive
β-elimination upon incubation with 50 mM NaOH and 1 M
NaBH4 at 45 °C for 16 h. The reaction was stopped with glacial
acetic acid until no fizzing was observed, and the samples were
subsequently filtered using 10-kDa molecular weight cutoff
(MWCO; Millipore). The filtrate, containing low molecular
weight peptides, O-glycans, and borate salts, was recovered and
incubated several times withmethanol containing 5% (v/v) acetic
acid under a stream of nitrogen to remove borates as methyl
esters.
The O-glycans-enriched fractions were then permethylated
adopting a modification of the method by Ciucanu and Kerek.29
Briefly, the samples were dissolved in 100 μL of anhydrous
DMSO, and powdered NaOH was added. The mixture was
sonicated for 30 min and frozen prior to the addition of 100 μL
of CH3I and then incubated under mild stirring for 1 h. The
permethylated samples were recovered from the reactionmixture
by extraction with dichloromethane and extensively washed with
acidified water (pH 2.0) to avoid base-induced hydrolysis of the
carboxymethyl group of permethylated sialic acids. The samples
were then desalted using Dowex ion-exchange resin (Dowex
50W-X8, Dow, USA).
Nano-HPLC-MALDI-TOF/TOF
The permethylated samples were separated in a nano-HPLC
Ultimate 3000 system (Dionex, Amsterdam) equipped with a
capillary column (Pepmap100 C18; 3 μm particle size, 0.75 μm
i.d., 15 cm in length). The samples were dissolved in 5%
acetonitrile (ACN) aqueous solution containing 0.1% formic
acid (phase A). The separation was performed using a linear
gradient of 32−50% B for 45 min, 50−70% B for 10 min, and
70−32% A for 5 min. The eluted glycans were applied directly on
a MALDI plate in 10 s fractions using an automatic fraction
collector Probot (Dionex, Amsterdam, Netherlands) under a
continuous flow rate of 270 nL of DHB matrix solution
(10 mg/mL in 70% acetonitrile/0.1% TFA and internal standard
Glu-Fib at 15 ftmol). Mass spectra were obtained on a MALDI
TOF/TOF mass spectrometer (4800 Proteomics Analyzer,
Applied Biosystems, Foster City, CA, USA) in the positive
ion reflector mode and obtained in the mass range from 600 to
4500 Da with 1200 laser shots. For the experiment, Glu-Fib was
used for internal calibrations. The MALDI-MS data from each
chromatographic run was combined into a three-dimensional
data array (LC fraction, m/z, total ionic current). A survey of
plausible analytical signals at 691.36 [STn +Na]+, was performed
by determining the most prominent peaks occurring within
0.2 Da of the reference peak. The analysis of the distribution of
the STn MS signals allowed the identification of chromato-
graphic profiles. MS2 were acquired under high-energy collisional
ionization dissociation (CID) conditions. Peak assignments
MS2 spectra and database searches were performed using the
GlycoWorkBench platform.30
■ RESULTS
The proteomic strategy applied in this study is schematically
represented in Figure 2.
Expression of Aberrant Simple Mucin-Type Carbohydrate
Antigens in Gastric Tissues
The pattern of expression of STn and T antigens was assessed
in normal gastric mucosa, in gastric mucosa with gastritis, and
in IM (complete and incomplete types). The pattern of mucin
expression (MUC5AC and MUC2) allowed the classification of
IM in the gastric mucosa as previously described.31 Table 2
shows the overall results of STn and T antigen expression, and
Figure 3 displays representative cases. Normal gastric mucosa
showed absence of expression of STn and T antigens, with the
exception of a single case that displayed a faint staining for
T antigen in few cells. As expected, mucin expression in normal
mucosa was limited to MUC5AC detection in the foveolar
Figure 2. Schematic representation of the proteomic strategy applied in this study.
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superficial epithelium of the gastric mucosa. No expression of
MUC2was observed in normal gastricmucosa (Table 2, Figure 3).
Gastric mucosa displaying gastritis showed no expression of
STn, but staining for the T antigen was observed in one case
(Table 2, Figure 3). Mucosa with gastritis showed expression of
MUC5AC with a strong cytoplasmic staining detected in every
case. Mucosa with gastritis showed absence of MUC2 expression
(Table 2, Figure 3).
Among the seven cases with IM, three showed a mixed expres-
sion of MUC5AC and MUC2 characteristic of the incomplete
type of IM. Four cases showed only positive staining for MUC2
consistent with the complete type of IM. Both types of IM
showed high levels of STn antigen expression detected mostly in
the vacuole of goblet cells (Table 2, Figure 3) of the metaplastic
glands. Absence of expression of T antigen was observed in IM
with the exception of one case of the complete type that displayed
expression of T antigen in few cells (Table 2).
SerumProtein Equalization by Combinatory Peptide Ligand
Library
Serum is a highly complex biofluid comprehending proteins
spanning a wide range of dynamic concentrations.32 In addition,
a few proteins account for approximately 70−90% of the
overall proteome, which is known to mask subtle alterations
associated with pathological events.33 To overcome this limitation,
the proteome of each clinical group was equalized by CPLL. This
proteome equalization resulted in the gel electrophoretic profile
presented in Figure 4, which displays the bound and unbound
fractions of the CPLL. The equalized fractions of the different
clinical groups showed a normalized amount of proteins
characterized by an increased ratio of low abundant proteins and
a decreased ratio of high abundant proteins (Figure 4).
Serum Protein Separation by Two-Dimensional Gel
Electrophoresis and Simple Carbohydrate Antigen
Detection
To identify proteins in the serum displaying simple mucin-type
carbohydrate antigens a glycoproteomic analysis was performed.
This approach included protein separation by two-dimensional
(2D) gel electrophoresis combined with a Western blotting
directed for the detection of simple mucin-type carbohydrate
antigens using specific monoclonal antibodies.
The equalized serum protein samples from the different clinical
groups were subjected to two-dimensional gel electrophoresis
with a first dimension separation according to the protein
isoelectric point and a second dimension based on the protein
molecular weight. The patterns of protein distribution in 2D gels
were similar among the different clinical groups as revealed by
Coomassie Blue staining of the gels (Figure 5, left panel). These
protein maps showed profiles compatible with a good resolution
separation of protein isoforms.
2D gels replicates of the same clinical groups that were
immunoblotted for simple mucin-type carbohydrate antigens
showed reactivity for T and STn antigens. This immunoreactivity
was restricted to few proteins in the proteomic map (Figure 5,
center and right panels).
The 2D immunobloting revealed that the immunoreactivity
for the T antigen was higher in the gastritis group with lower
detection in IM groups. Furthermore, STn antigen immunor-
eactivity showed to be higher in proteins from the 2D gel maps of
the IM groups and in gastritis when compared with normal
control group (Figure 5, right panel).
Protein Identification by MALDI-TOF/TOF Mass
Spectrometry
Identification of the proteins that were labeled in Western
blots for simple mucin-type carbohydrate antigens was obtained
using the excised spots from the Coomassie Blue stained 2D gel
(Figure 5). Table 3 shows the list of identified proteins by
Table 2. In Situ Analysis of Mucins and Simple Mucin-Type
Carbohydrate Antigens by Immunohistochemistry in Gastric
Tissues
immunostaining
cases MUC2 MUC5AC STn T
control (n = 5) 0 5 0 1
gastritis (n = 6) 0 6 0 1
complete intestinal metaplasia (n = 4) 4 0 4 1
incomplete intestinal metaplasia (n = 3) 3 3 3 0
Figure 3. Immunohistochemical staining of normal mucosa and gastric
lesions with MUC5AC, MUC2, and the truncated glycoforms T and
STn antigens. The figure shows normal expression of MUC5AC and
absence of expression of MUC2 in mucosa from healthy individuals, as
well as lack of truncated glycoforms (except one normal case that also
expressed T antigen; Table 2, not shown in figure). In gastric lesions we
see the presence of truncated glycans (although T antigen was also seen
in only one case; Table 2 and Figure 3) and also de novo expression of
MUC2 in intestinal metaplasia.
Figure 4. SDS-PAGE of sera before and after CPLL treatment. In the gel
are represented serum samples of the four different groups before and
after protein equalization using the CPLL technique. Lanes 2, 4, 6, and 8
represent the eluted sample of the ligand library for healthy, gastritis,
complete, and incomplete intestinal metaplasia sera, respectively. Lanes
3, 5, 7, and 9 represent the unbound fraction of the same samples in the
same order. Lane one shows molecular weight standards.
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Figure 5. 2D gel electrophoresis and Western blot analysis for T and STn antigens of serum from healthy individuals, individuals with gastritis, and
individuals with intestinal metaplasia (complete and incomplete type). In the left side of the figure are represented Coomassie Blue gels of serum samples
equalized with CPLL, and in the middle and right side are represented Western blots against T and STn antigens, respectively. The spots that were
highlighted in the Western blots were matched on Coomassie blue gels and excised for protein identification by MALDI-TOF TOF analysis.
Table 3. Proteins Identified in Sera of Gastritis, Complete IntestinalMetaplasia and Incomplete IntestinalMetaplasia According to
the Immunoreactivity with Antibodies for T and STn Antigens
spot ID protein description accession no. mascot Protein C.I. % peptide count % cov peaks matched MOWSE score
1 plasminogen PLMN_HUMAN 100 44 58 49 454
2 histidine-rich glycoprotein HRG_HUMAN 100 21 36 21 156
3 IGH protein Q6GMX6_HUMAN 99.8 9 22 9 79
4 complement factor H F8WDX4_HUMAN 100 18 44 18 133
5 complement factor H-related protein 1 FHR1_HUMAN 100 13 40 14 95
6 complement factor H-related protein 1 FHR1_HUMAN 99.4 7 21 9 66
7 complement factor H-related protein 1 FHR1_HUMAN 99.3 10 30 11 74
8 complement factor H-related protein 1 FHR1_HUMAN 99.4 11 37 12 74
9 complement C4 gamma chain B4DDH0_HUMAN 100 17 34 18 105
10 plasminogen PLMN_HUMAN 100 43 59 49 442
11 histidine-rich glycoprotein HRG_HUMAN 100 22 40 22 169
12 IGH protein Q6GMX6_HUMAN 99.1 11 27 11 72
13 complement factor H CFAH_HUMAN 100 27 65 32 262
14 complement factor H-related protein 1 FHR1_HUMAN 100 14 43 15 107
15 complement factor H-related protein 1 FHR1_HUMAN 100 15 42 17 119
16 complement factor H-related protein 1 FHR1_HUMAN 100 15 37 16 118
17 complement C4-B gamma chain B4DDH0_HUMAN 99.8 15 25 15 79
18 complement C4-B gamma chain B4DDH0_HUMAN 100 20 31 22 133
19 vitronectin VTNC_HUMAN 100 17 36 19 121
20 vitronectin VTNC_HUMAN 99.8 13 30 15 79
21 plasminogen PLMN_HUMAN 100 42 54 48 424
22 complement C4-B B4DIE5_HUMAN 100 25 30 25 170
23 complement C4-B B4DIE5_HUMAN 100 10 13 10 86
24 IGH protein Q6GMX6_HUMAN 99.9 9 24 9 83
25 IGH protein Q6GMX6_HUMAN 100 10 17 11 106
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MALDI-TOF/TOF mass spectrometry. Proteins identified due
to T antigen detection in samples from gastritis patients were
plasminogen (spot ID 1) and histidine-rich glycoprotein (spot
ID 2). Plasminogen was also identified based on T antigen
immunoreactivity in both types of IM (spot ID 10 and 21).
Proteins identified according to the immunoreactivity with STn
antigen included plasminogen, which was detected in all disease
groups (spot ID 1, 10, 21). Vitronectin was also identified based
on STn immunoreactivity in incomplete IM (spot ID 19 and 20).
Other proteins indentified in the 2D maps showing immuno-
reactivity with STn are displayed in Table 3.
Glycosylation Characterization of the Identified Proteins
Table 4 depicts the simple mucin-type carbohydrate antigens
detected by Western blotting in the identified proteins from the
sera in the different clinical groups, as well as the bioinformatical
prediction of glycosylation in these proteins. Additionally, Table 4
shows available information on the N- and O-glycosylation
of these proteins previously described, as well as the sites of
O-glycosylation and N-glycosylation predicted bioinformaticaly
byNetOGlyc andNetNGlyc, respectively.We observed expression
of T antigen in plasminogen from all clinical groups and a strong
STn immunoreactivity in gastritis and IM. Conversely, the
expression of T antigens was considerably decreased in the
plasminogen from patients with IM. The sites of O-glycosylation
known to date for plasminogen include Thr346,25 Ser248,27 and
Ser339,26 as well as N-glycosylation in Asn289.24 NetOGlyc
(Table 4) has further highlighted Thr290, Thr359, and Thr365 as
putative O-glycosylation sites.
Vitronectin, which has been described until now as an
N-glycosylated protein,34 was also found among the proteins
showing simple mucin-type O-glycans immunoreactivity. Still,
its expression was restricted to STn in the context of incomplete
IM. In agreement with these observations, NetOGlyc has also
predicted possible O-glycosylation sites for Vitronectin.
Additionally, we observed STn antigen reactivity in comple-
ment factor H in sera from gastritis and IM. No sites of
O-glycosylation have been described, but at least 8 sites of
N-glycosylation have been shown in complement factor H.35
Histidine-rich glycoprotein was identified as displaying T antigen
reactivity. No sites of O-glycosylation have been described, but
at least six sites of N-glycosylation have been described in this
protein36 (Table 4). Noteworthy, despite the absence of reports
of O-glycosylation in histidine-rich glycoprotein, theoretically
this protein can carry this type of post-translational modification
as predicted by NetOGlyc.
In summary, among the proteins found carrying simple mucin-
type carbohydrate antigens, plasminogen showed the most
differentiated pattern of O-glycosylation for IM. Namely, it
presented decreased levels of T antigen accompanied by the
abnormal overexpression of STn.
Structural Characterization of STn Antigen from
Plasminogen and Glycosylation Site Determination
Structural analysis was performed in order to validate immuno-
blotting assignments regarding the expression of STn in
plasminogen. The protein purified by affinity chromatography
using lysine-sepharose and further separated by SDS-PAGE
electrophoresis was chemically de-O-glycosylated in gel. The
released O-glycans from plasminogen were then permethylated
to avoid desialylation by MALDI in-source and metastable
decay and analyzed by MALDI-TOF/TOF. This allowed the
distinction of a chromatographic profile for the ion atm/z 691.36
corresponding to the sodium adduct of STn antigen (Figure 6A
and B). This assignment was further supported by the absence
of the signal upon desialylation of plasminogen with a
α-neuraminidase. Moreover, the product ion spectrum exhibited
the ions at m/z 107.1 resulting from B1
0,2X1 fragmentations,
at m/z 358.1 from C1
1,3X1 and at m/z 416.2 from
2,5X1 or C1
(nomenclature according to Domon and Costello37 (Figure 6C),
therefore confirming the presence of STn in plasminogen.
The prevalence of cross-ring fragmentations is in keeping with
previous observations for high CID conditions.38 In agreement
with previous reports concerning the O-glycosylation of
Table 4. Glycosylation Information of the Identified Proteins
glycosylationa predicted glycosylation T and STn expression in serum by Western blot
protein O-linked N-linked Net-O-Glyc Net-N-Glyc healthy gastritis complete IM incomplete IM
plasminogen Ser248 Asn289 Thr171 no T T/STn T/STn T/STn
Ser339 Thr340
Thr346 Thr346
vitronectin no Asn86 Thr113 Asn86 STn
Asn169 Ser137 Asn169
Asn242 Thr141
complement factor H no Asn511 No STn STn STn
Asn700
Asn784 Asn529
Asn804 Asn882
Asn864 Asn1029
Asn893 Asn1095
Asn1011
Asn1077
histidine-rich glycoprotein no Asn45 T
Asn69 Ser307 Asn63
Asn107 Asn125
Asn184 Asn344
Asn326
Asn327
aGlycosylation sites reported in previous studies.
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plasminogen,25−27 low abundant ions belonging to mono- (m/z
895.5) and disialylated T (m/z 1256.6) antigens have also been
detected (data not shown).
In order to characterize the plasminogen glycosylation sites
containing STn, sialoglycopeptides from plasminogen of the
different clinical groups were enriched by titanium dioxide
chromatography23 as described in Materials and Methods. The
methodology was optimized for human plasminogen using a
commercial plasminogen sample. Using this method we have
detected the three O-glycosylation sites and one N-glycosylation
site previously described in human plasminogen24−27 (Supple-
mentary Table 1 and Supplementary Figure 1). Using this
approach we found 1 STn-containing glycopeptide in healthy
controls, 5 in gastritis, 4 in complete IM and 8 in incomplete IM
(Table 5).
■ DISCUSSION
Alterations of glycosylation are commonly observed in patho-
logical conditions, including gastric cancer,10,15 constituting a
major source of biomarkers.9 These changes in glycosylation are
also observed during the process of gastric carcinogenesis, such
as in gastritis and in IM, a precursor lesion of gastric carcinoma
characterized by the expression of simple mucin-type carbohy-
drate antigens, such as T and STn.10,11,13,14
Serum remains the ideal biofluid for biomarker identification
due to the easy collection and because it frequently displays
proteins expressed by pathological tissues. The present study
identified serum proteins displaying altered O-glycosylation as
determined by the expression of the antigens T and STn in
patients with gastric pathologies, such as gastritis and IM of
the complete and incomplete types, as compared with control
individuals without any gastric mucosa lesion.
In order to perform this glycoproteomic analysis we applied an
equalizing tool for serum protein content. The CPLL21 equalized
sera from the different clinical groups showed a normalized
amount of proteins characterized by an increased ratio of low
abundant proteins and a decreased ratio of high abundant
proteins. This tool showed to be quite efficient in avoiding the
overrepresentation of serum albumin, immunoglobulins, as well
as the other 20 most abundant serum proteins.39 The search for
serum proteins bearing T and STn antigens was performed using
a combination of 2-D gel electrophoresis for protein separation
and further detection by Western blotting of T and STn using
specific monoclonal antibodies. This strategy directed this serum
O-glycoproteome search for the protein targets displaying altered
simple mucin-type carbohydrate antigens T and STn in the
different clinical groups. The first dimension of the 2D gel
electrophoresis using separation gradients of pH 3−10 and pH
4−7 were applied in the present study; however, the pH 3−10
gradient allowed better resolution of proteins localized in the
upper limit of the gradient and showing immunoreactivity with
themonoclonal antibodies against the STn and T glycan antigens.
The patterns of total protein distribution in 2D gel electro-
phoresis were similar among the different clinical groups, with
protein maps showing good resolution separation of various
protein isoforms (Figure 5, left panel). The Western blotting
analysis showed T and STn antigens detection in few proteins
(Figure 5, center and right panel) of the different clinical groups.
Figure 6. Positive mode MALDI-TOF/TOF identification of permethylated STn in serum plasminogen isolated from patients with intestinal
metaplasia. (A) Relative ionic current of nano-HPLC fractions for the ion at m/z 691.36 corresponding to the monoisotopic mass of [STn + Na]+,
before and after desialylation. The analytical signals in each plot were normalized to allow the comparison of both sets of data. A chromatographic
envelope was observed in the samples for fractions 80−100 that is absent after desialylation. (B) MS spectrum showing the ion at m/z 691.36
corresponding to the monoisotopic mass of [STn + Na]+. (C) MS2 spectrum of the ion at m/z 691.36 highlighting reporter ions resulting from
combined sialic acid cross-ring fragmentations (X1) and glycosidic bound cleavages B1 and C1 fragments (nomenclature according to ref 37) and
symbology adapted fromGlycoworkbench. Asterisk (*) denotes overlapping signals resulting from cross-ring fragmentations at the sialic moiety and/or
at the reduced GalNAc residue and/or the loss of methoxy groups,72 induced by high CID conditions.38
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T antigen detection was observed in all groups with higher
reactivity observed in gastritis, whereas STn antigen detection
was observed in gastritis, and in complete and incomplete IM
groups.
The detection of serum proteins expressing truncated glycans
may reflect the aberrant glycosylation observed in proteins
expressed by pathological tissues. This is the case in most
serological assays that detect circulating glycoproteins derived from
malignant tumors or benign lesions.9,40 Our results showing the
detection of truncated glycans STn and T in the glycoproteomic
profiling of patients with gastritis and IM are in agreement with our
previous findings that the STn and T antigens are expressed in the
gastric mucosa of the patients displaying preneoplastic pathological
conditions of the stomach,10,11,41 particularly in IM, and in contrast
to the absence (or almost absence) of expression of these truncated
glycans in the normal gastric mucosa of control individuals.
The glycosylation modifications observed in gastric pathologic
tissues may stem from altered expression of glycosyltransferases,
previously shown in gastric epithelial cells induced by H. pylori
infection,42 and particular increased expression of specific
glycosyltransferases.14 The reasons underlying such glycosyla-
tion modifications are still largely unknown, but hypotheses
such as deregulation of the glycosylation machinery in the Golgi
apparatus of the cells43 or as consequence of an altered differentia-
tion program observed in IM are being tested.20
The proteomic mining of the serum for STn and T antigens
expression in the different clinical groups tested in the present
work has resulted in the identification of relatively abundant
circulating proteins, namely, plasminogen, vitronectin, comple-
ment factor H, and histidine-rich glycoprotein. Even though the
amount of these proteins did not vary significantly between
groups, the pattern of simple mucin-type O-glycans immunore-
activity showed considerable alterations. The restricted number
of proteins expressing the altered O-glycans are in agreement
with the known specificity of the glycosyltransferases participat-
ing in O-glycans biosynthesis and that variation of expression of
these enzymes in pathological conditions leads to altered
glycosylation.9,14,19
Plasminogen was identified due to the immunoreactivity for
T and STn antigen in all disease groups, but showed no
immunoreactivity in healthy controls. Interestingly, among the
identified proteins carrying simple mucin-type carbohydrate
antigens, plasminogen showed the most differentiated pattern of
O-glycosylation in IM, displaying decreased levels of T antigens
accompanied by an increased expression of STn when compared
with the other clinical groups. The detailed analysis of the
O-glycans from purified plasminogen from IM patients was
performed in order to validate the STn glycan detection at the
molecular level. Plasminogen O-glycans released by reductive
β-elimination were permethylated and analyzed by MALDI
mass spectrometry. Our results showed the detection of ions
compatible with STn antigens (Figure 6). Further MALDI-MS2
analysis of the ion at m/z 691.4 Da exhibited glycosidic bond
cleavages B, C and Z, and cross-ring fragmentation A and X
product ions characteristic of STn glycan, therefore demonstrating
the presence of STn in plasminogen from serum of incomplete IM
patients.
In addition, the MALDI structural analysis of sialoglycopep-
tides from plasminogen enriched by titanium dioxide chromato-
graphy showed the presence of glycopeptides containing STn in
all disease groups. The use of the sialoglycopeptides enrichment
method by titanium dioxide followed by MALDI showed to be
quite efficient with the identification of the threeO-glycosylation
sites and one N-glycosylation site previously described in human
plasminogen24−27 (Supplementary Figure 1 and Supplementary
Table 1). Based on this approach the analysis of the clinical
groups lead to the identification of 1 STn-containing glycopeptide
in healthy control, 5 STn-containing glycopeptides in gastritis,
4 in complete IM and 8 in incomplete IM (Table 5). Some of
the sites identified have not been described for plasminogen and
may constitute potential novel biomarkers of precancerous gastric
lesions.
Table 5. Characterization of Serum Plasminogena Sialoglycopeptides
exptl mass
(Da)
theor mass
(Da)
no. of STn
glycoforms
glycoform
mass
tryptic missed
cleavages sialoglycopeptidesb
control 2782.59 2782.80 3 1483.36 0 494−504 HSIFTPETNPR
gastritis 3189.28 3189.15 4 1977.81 0 108−117 WSSTSPHRPR
4656.01 4656.00 1 494.45 0 330−367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR
2382.30 2382.46 2 988.91 0 379−389 C*QSWSSM§TPHR
2782.40 2782.80 3 1483.36 0 494−504 HSIFTPETNPR
2319.88 2319.56 1 494.45 2 777−791 VSRFVTWIEGVM§RNN
complete IM 2352.49 2352.68 1 494.45 2 71−85 DVVLFEKKVYLSEC*K
2783.07 2782.80 3 1483.36 0 494−504 HSIFTPETNPR
855.63 855.88 1 494.45 0 777−779 VSR
2814.02 2814.02 2 988.91 2 777−791 VSRFVTWIEGVM§RNN
incomplete IM 1528.63 1528.54 2 988.91 0 94−98 GTM§SK
3189.50 3189.15 4 1977.81 0 108−117 WSSTSPHRPR
4656.33 4656.00 1 494.45 0 330−367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR
2382.46 2382.46 2 988.91 0 379−389 C*QSWSSM§TPHR
2782.59 2782.80 3 1483.36 0 494−504 HSIFTPETNPR
4723.11 4722.93 3 1483.36 0 720−750 VQSTELC*AGHLAGGTDSC*QGDSGGPLVC*FEK
3187.30 3187.62 1 494.45 0 753−776 YILQGVTSWGLGC*ARPNKPGVYVR
855.49 855.87 1 494.45 0 777−779 VSR
aPlasminogen aminoacid numbering excludes the 19 aa signal peptide. bC* = carbamidomethylation of cysteine. M§ = methionine oxidation.
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Further analysis of enriched for sialic acid containing glyco-
proteins fromgastritis, intestinalmetaplasia, and carcinoma patients
confirmed STn reactivity of plasminogen in an independent set of
samples (Supplementary Figure 2 and Supplementary Table 2).
These results using alternative glycoprotein enrichment approaches
and different sample cohorts further demonstrate the potential
application of the altered plasminogen STn glycosylation as a
biomarker in these pathologies.
Plasminogen is released as a zymogen from the liver into
circulation where it adopts a closed, activation resistant,
conformation. Upon binding to blood clots, or to cell surfaces,
plasminogen can adopt an open form that can be converted into
active plasmin by a variety of enzymes, including tissue
plasminogen activator and urokinase plasminogen activator.44,45
Plasmin is a serine protease that acts dissolving fibrin clots and
in other proteolysis functions in diverse systems. Two major
glycoforms of plasminogen have been described in humans - type
I plasminogen containing two glycosylation moieties (N-linked
to Asn289 and O-linked to Thr346), and type II plasminogen
containing a single O-linked sugar on Thr346.24,25 However,
additional sites of O-glycosylation of plasminogen have been
reported in Ser248,27 and Thr339.26 Type II plasminogen has
been shown to be preferentially recruited to the cell surface
whereas type I plasminogen appears more readily recruited to
blood clots.46 Nevertheless, only one (Thr346) of these glyco-
sylation sites could be theoretically predicted using the bio-
informatics platform NetOGlyc. On the other hand this
approach retrieved other putative glycosylation sites that are
still lacking in vivo confirmation. The discrepancy between these
findings has been previous highlighted for serum proteins47 and
suggests that in vivo processing and pathophysiological states
may play a determinant role in the definition of the glycosylation
of circulating glycoproteins.
The X-ray crystal structure analysis of closed plasminogen has
revealed that O-glycosylation alter the position of a Kringle
domain, partially explaining the functional differences observed
between the type I and type II plasminogen glycoforms.44
In closed plasminogen, the O-linked sugar on Thr346 is one of
the requirements for the blocking of the cleavage by tissue
plasminogen activator and urokinase plasminogen activator.44
Liver is the primary tissue for plasminogen synthesis48 but
other tissue sources, including the gut, have been described in
animal models.49 The truncatedO-glycans observed in circulating
plasminogen from gastritis and in IM patients may either reflect
altered glycosylation in the liver response to inflammatory
cytokines or altered glycosylation of locally expressed plasmi-
nogen. Pro-inflammatory cytokines produced within the gastric
disease context,50−52 may induce differential expression of glyco-
syltranferases in hepatocytes leading to alteration of glycosylation
of circulating proteins.53 This is in agreement with previous studies
that have shown that modification of glycosylation characterized
by increased expression of sialylated glycan structures, are
observed in hepatocyte derived proteins during acute and chronic
inflammatory diseases.54−57 In addition, alterations of plasmi-
nogen may also be related with the infection by H. pylori. The
increased expression of urokinase plasminogen activator has been
described in H. pylori-associated gastritis.58,59 Plasminogen-
binding proteins in H. pylori with subsequent activation to
plasmin60,61 may provide proteolytic capacity and may contribute
for the virulence of this bacterium.60,61 These findings altogether
may explain the importance of plasminogen activation in pathological
conditions of the gastric mucosa.
Vitronectin was also identified based on STn immunoreactivity
in the incomplete type of IM. Vitronectin is a glycoprotein known
to be glycosylated. Human vitronectin has been shown to contain
N-glycans, but no O-glycans have been described, contrary to
vitronectin of other mammals that has been shown to contain
both types of glycosylation.62 Furthermore, it was demonstrated
that despite the homology of about 73% between human and rat
vitronectin, the sites of glycosylation are highly conserved and
have been shown to be important for the protein function.63
Vitronectin is a multifunctional glycoprotein produced mainly
by hepatocytes that is present mostly in plasma and the
extracellular matrix of many tissues.64 Vitronectin is involved in
many functions such as the regulation of coagulation and
fibrinolysis, cell adhesion, and invasion, as well as in matrix
remodeling and humoral defense mechanisms.65 Glycosylation
has been reported to be important in the interaction of vitronectin
with other molecules and on its functional activities.66 Addition-
ally, vitronectin oligosaccharide moiety was suggested to be
relevant inH. pylori binding and in themechanism of the bacterial
immune escape.67,68 Furthermore, vitronectin was shown to be
important in the adhesion and migration of tumor-infiltrating
lymphocytes.69
Our results showed STn antigen immunoreactivity for
vitronectin in the context of incomplete IM. Despite the lack
of reports on vitronectin O-glycosylation in humans we could
predict three possible O-glycan sites (Thr113, Ser137, Thr141)
using the NetOGlyc tool. Taking into consideration the
importance of vitronectin glycosylation on its function and the
reported bacterial interactions,67,68 our findings may point toward
a possible role in the context of gastric lesions development.
The present study also indicated the histidine-rich glyco-
protein as a target expressing truncated O-glycans, presenting
reactivity with T antigen in the gastritis group. Histidine-rich
glycoprotein is a plasma glycoprotein produced by the liver and
known to bind to a number of ligands in circulation, such as
heparin, heparan sulfate, thrombospondin, and plasminogen.
Histidine-rich glycoprotein acts as an adapter protein and has
been implicated in regulating many processes such as immune
complex and pathogen clearance, cell adhesion, angiogenesis,
coagulation, and fibrinolysis.70 Even though regarded as an
N-glycosylated protein (6 described sites and 3 predicted) our
study has found Western blotting reactivity for the T antigen in
gastritis and the NetOGlyc tool identified Ser307 as a putative
glycosylation site. This indicates that this type of glycosylation
could also be present in histidine-rich glycoprotein and suggests
that further structural insights on the O-glycan moiety may be
required to complement previous studies focused on the analysis
of the N-glycans.70
Similarly, our results showed immunoreactivity to STn antigen
in all pathological conditions in proteins from the complement
system, namely, complement factor H, complement H-related
protein, and complement C4-B. The human complement
pathway is a highly controlled effector mechanism of the immune
system. Over 30 plasma proteins and membrane-bound
molecules are involved in the complement system, and most of
these proteins are glycosylated. The complement factor H,
complement factor H-related protein, and the complement C4-B
are proteins that have been described to beN-glycosylated.71 Our
results indicating that aberrantO-glycosylation can be detected in
these members of the complement system warrants further
structural characterization of the glycans in these proteins. Most
of the protein modules that form the complement system have
been crystallized and structural data provides evidence for the role
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of N-glycans in this system. However, the structure and role of
glycans in the resistance to proteolysis and functionality activation
within pathological conditions is still incomplete. As these data
become available, the glycans can be modeled at the appropriate
locations and give further insights into the interaction between
complement proteins and cofactors.
Our results provide novel glycobiomarkers in serum from
patients with gastric pathologies, including gastritis, intestinal
metaplasia, and gastric carcinoma. The present work opens
new avenues for future targeted evaluation of these specific
glycobiomarkers in additional immunoassay-based approaches
enabling large scale individual analysis.
In summary, this work presents a set of proteins displaying
altered O-glycosylation as detected by antibodies directed to
STn and T antigens in the serum from patients with gastritis and
IM in opposition to minor or no reactivity in the same proteins
of healthy individuals without any gastric disease. We further
demonstrated that circulating serum plasminogen from IM
patients carries the truncated O-glycan STn antigen. These
results warrant further studies to address the application of
plasminogen STn glycosylation pattern as a serum biomarker of
gastric pathologies.
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 Supplementary Data 
 
Supplementary data 1 – Characterization of plasminogen glycosylation by MALDI-TOF/TOF mass spectrometry 
 
Supplementary Table 1: List of plasminogen glycopeptides detected by MALDI-MS. Serum plasminogen from a commercial sample was subjected to 
tryptic digestion followed by titanium dioxide enrichment of sialoglycopeptides (described in material and methods). MALDI mass spectra were acquired in 
linear positive mode using THAP (2',4',6'-Trihydroxyacetophenone monohydrate) as a matrix with a mass error tolerance of 0.06 %. Different already described 
plasminogen glycoforms have been detected. 
Peak 
number 
Experimental 
mass (Da) 
Theoretical 
mass (Da) 
Glycosylation 
type 
Glycoform(s) Sialoglycopeptides # Reference 
1 2451.99 2451.65 O ST 243-258 C*TTPPPSSGPTYQC*LK(G) 27 
2 4605.11 4606.87 O T + Pi 330-367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR(G)  
3 4697.11 4698.75 N Hex2HexNAc2NeuAC1 
+ Man3GlcNAc2 
266-290 GNVAVTVSGHTCQHWSAQTPHTHNR(T) 24 
4 4815.91 4818.15 O ST 330-367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR(G) 25, 27 
5 4896.60 4898.13 O ST + Pi 330-367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR(G) 27 
6 4989.98 4987.07 N Hex2HexNAc2NeuAC2 
+ Man3GlcNAc2 
266-290 GNVAVTVSGHTCQHWSAQTPHTHNR(T) 24 
7 5188.48 5189.39 O diST + Pi 330-367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR(G) 27 
8 5554.99 5554.61 O diST + T + Pi 330-367 IPSC*DSSPVSTEQLAPTAPPELTPVVQDC*YHGDGQSYR(G) 26 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Figure 1: MALDI MS spectrum of human plasminogen after titanium dioxide enrichment. The detected 
sialoglycopeptides are presented in the supplementary Table 1. 
 
  
Supplementary data 2 - Identification of STn in Plasminogen from gastritis, intestinal metaplasia and gastric carcinoma of independent set of samples 
 
Supplementary Material and methods 
Sera sample collection, glycoprotein enrichment by lectin affinity chromatography and identification of STn containing proteins 
A second set of sera sample from the University Hospital Santo António and Hospital São João were used for the identification of proteins carrying STn 
structures. Sera sample from ten individuals within each of the following clinical groups were used: without gastric lesions, gastritis, intestinal metaplasia and 
from two types of gastric carcinoma (intestinal and atypical). Sera sample were pooled and subjected to albumin and IgG depletion by a commercial kit 
(ProteoPrep from Sigma Aldrich). For the enrichment of STn containing glycoproteins, depleted sera were subjected to Sambucus nigra agglutinin (Vector 
laboratories) affinity chromatography that specifically recognizes and capture α2,6 sialic acids containing glycoproteins. The affinity chromatography eluted 
proteins were further subjected to 2D gel electrophoresis, Western blot analysis to detect STn containing proteins, and MALDI-TOF/TOF mass spectrometry 
protein identification was performed as described in materials and methods of this paper.  
 
 
  
 
Supplementary Figure 2:  Glycoproteomic approach to reveal serum proteins carrying STn antigen. Serum samples from healthy, gastric precursor 
lesions (gastritis and  intestinal metaplasia) and two types of gastric carcinoma (intestinal and atypical type) individuals were subjected to albumin and IgG 
removal and lectin affinity chromatography to capture α2,6 sialic acid containing proteins. Affinity captured proteins were separated by 2D gel electrophoresis 
and STn highlighted by Western blot. The results show the presence of STn containing proteins in serum from individuals with gastric percursor lesions and 
with gastric carcinoma, and Plasminogen was identified by MALDI-TOF/TOF as STn protein carrier. Black highlighted areas indicate selected protein dots, 
reactive for STn antigen, and identified as plasminogen (see supplementary Table 2).   
 Supplementary Table 2: Proteins identified in sera of control, gastritis, metaplasia, intestinal type carcinoma and atypic type carcinoma according to the 
immunoreactivity with antibodies for STn antigen. 
 
  
Spot ID  Protein description Accession number MASCOT Protein C.I. % Peptide count % cov Peaks matched MOWSE score 
Control Plasminogen PLMN_HUMAN 100 31 32 34 243 
Gastritis Plasminogen PLMN_HUMAN 100 32 35 32 259 
Metaplasia Plasminogen PLMN_HUMAN 100 28 32 30 202 
Intestinal Type 
Carcinoma 
Plasminogen PLMN_HUMAN 100 33 37 37 273 
Atypic type 
carcinoma 
Plasminogen PLMN_HUMAN 100 30 33 34 232 
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Abstract
Sialyl-Lewis X (SLex) is a sialylated glycan antigen expressed on the cell surface during malignant cell transformation and is
associated with cancer progression and poor prognosis. The increased expression of sialylated glycans is associated with
alterations in the expression of sialyltransferases (STs). In this study we determined the capacity of ST3GAL3 and ST3GAL4
sialyltransferases to synthesize the SLex antigen in MKN45 gastric carcinoma cells and evaluated the effect of SLex
overexpression in cancer cell behavior both in vitro and in vivo using the chicken chorioallantoic membrane (CAM) model.
The activation of tyrosine kinase receptors and their downstream molecular targets was also addressed. Our results showed
that the expression of ST3GAL4 in MKN45 gastric cancer cells leads to the synthesis of SLex antigens and to an increased
invasive phenotype both in vitro and in the in vivo CAM model. Analysis of phosphorylation of tyrosine kinase receptors
showed a specific increase in c-Met activation. The characterization of downstream molecular targets of c-Met activation,
involved in the invasive phenotype, revealed increased phosphorylation of FAK and Src proteins and activation of Cdc42,
Rac1 and RhoA GTPases. Inhibition of c-Met and Src activation abolished the observed increased cell invasive phenotype. In
conclusion, the expression of ST3GAL4 leads to SLex antigen expression in gastric cancer cells which in turn induces an
increased invasive phenotype through the activation of c-Met, in association with Src, FAK and Cdc42, Rac1 and RhoA
GTPases activation.
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Introduction
Alterations in cell surface glycosylation are considered a
hallmark during carcinogenesis. These alterations usually lead to
the expression of tumor-associated carbohydrates on glycoproteins
or glycolipids that decorate cell surfaces [1]. One of the most
common glycan alterations is the increase of sialylated Lewis-type
blood group antigens, such as sialyl Lewis A (SLea (NeuAca2,3-
Galb1-3(Fuca1-4)GlcNAc-R)) and sialyl Lewis X (SLex (NeuA-
ca2,3Galb1-4(Fuca1-3)GlcNAc-R)). SLea and SLex are expressed
in cancer cells, mimicking their normal expression on blood cells
(monocytes and neutrophils) potentiating cancer cell migration
through binding to endothelial cell selectins [2,3]. Therefore, SLea
and SLex overexpression is a common feature of several
carcinomas (e.g., lung, colon, gastric and pancreas) and it is
associated with increased metastatic capacity [4,5,6,7] and poor
patients survival [8,9,10,11,12].
The increased expression of sialylated glycans associated to
carcinogenesis is the result of altered expression of sialyltrans-
ferases (STs) genes which encode for enzymes involved in the
biosynthesis of the glycan antigens described above [13]. Up to 20
different sialyltransferases have been described to catalyse the
transfer of sialic acid residues from a donor substrate CMP-sialic
acid to the oligosaccharide side chain of the glycoconjugates. This
sialic acid generally occupies the terminal non-reducing position
on glycan chains [14]. Different STs show cell and tissue specific
expression pattern and differ in substrate specificities and types of
linkage formed [14]. Depending on these characteristics, STs are
classified in four families - ST3Gal, ST6Gal, ST6GalNAc and
ST8Sia. ST3Gal family are a2,3-STs which catalyze the transfer
of sialic acid residues to terminal galactopyranosyl (Gal) residues
and include six members from ST3Gal I to ST3Gal VI [15].
Among the six ST3Gal sialyltransferases, ST3Gal III, IV and
VI have been described to contribute to SLex formation [16,17],
with a substantial role attributed to ST3Gal IV [18,19].
The sialyl-Lewis antigens are synthesized on type 1 (Gal b1,3
GlcNAc) or type 2 (Gal b1,4 GlcNAc) disaccharide sequences. The
sialyltransferase ST3Gal III preferentially acts on type 1 rather
than on type 2 disaccharides and is involved in the synthesis of
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SLea [20]. ST3Gal IV mainly catalyzes the a2,3 sialylation of type
2 disaccharides, leading to the biosynthesis of SLex [18,21].
We previously demonstrated the contribution of different
ST3Gal sialyltransferases to the synthesis of sialyl Lewis antigens
in gastric carcinoma cells, and described that ST3Gal IV is
involved in the synthesis of SLex antigen [22]. In line with this
report, other studies also found that high expression of ST3Gal IV,
contributes to the expression of a2,3-linked sialic acid residues,
and is associated with the malignant behavior of gastric cancer
cells [23].
In gastric carcinoma tissues, the increased expression of ST3Gal
IV [24] and of sialyl Lewis antigens have been associated with
poor prognosis and metastatic capacity [8]. These reports
highlight the role of STs and evidenced that the expression of
crucial glycan determinants, such SLex, play an important role in
tumor progression. However, the molecular mechanisms under-
lying the aggressive behavior of gastric cancer cells expressing SLex
are not fully understood. Some studies pointed to the importance
of tyrosine kinase receptor activation in STs overexpression
models [25,26,27]. In the present study we assessed the effect of
ST3GAL IV overexpression in the synthesis of SLex in gastric
carcinoma cells and evaluated the functional role of SLex in vitro
(proliferation, invasion and adhesion) and in vivo (angiogenesis,
tumor growth and invasion). We further evaluated the contribu-
tion to cell behavior of tyrosine kinase receptors activation and
identified the downstream effectors in the context of ST3Gal IV/
SLex overexpressing gastric carcinoma cells.
Materials and Methods
Cell culture
The gastric cancer cell line MKN45 was obtained from the
Japanese Cancer Research Bank (Tsukuba, Japan) and was stably
transfected with full length human gene for ST3GAL3 (MST3Gal
III), ST3GAL4 (MST3Gal IV) and the empty vector pcDNA3.1
(Mock) as shown previously [22]. The cells were grown in
monolayer culture in T75cm2 flasks and maintained at 37uC in an
atmosphere of 5% CO2, in Roswell Park Memorial Institute
(RPMI) 1640 GlutaMAX, HEPES medium supplemented with
10% fetal bovine serum (FBS), 1% penicillin-streptomycin (P/S)
and in the presence of 0.5 mg/mL G418 (all from Invitrogen).
Culture medium was replaced every two days.
RNA isolation, cDNA synthesis and real-time PCR analysis
Total RNA was extracted from cell lysates of Mock, MST3Gal
III and MST3Gal IV cell lines using TRI Reagent (Sigma) and
converted to cDNA using the SuperScriptH II Reverse Transcrip-
tase (Invitrogen). Reverse transcription was performed using 3 mg
of total RNA, random oligonucleotides primers and SuperScript II
RT (Invitrogen) in a total volume of 20 mL as described by the
manufacturer. For real-time PCR analysis, cDNA samples were
diluted 50-fold with water and PCR amplified in triplicate with
10.0 mL Power SYBRGreen Master Mix (Applied Biosystems),
0.48 mL of each 10 mM primer and 4 mL cDNA using an ABI
Prism 7000 Sequence Detection System (Applied Biosystems). The
primers used were the following: ST3GAL3 for5’-ggtggcagtcgcag-
gattt-3’; rev5’-catgcgaacggtctcatagtagtg-3’; and ST3GAL4 for5’-
cctggtagctttcaaggcaatg-3’; rev5’-cctttcgcacccgcttct-3’. Expression
of 18S (for5’-cgccgctagaggtgaaattc-3’; rev5’-cattcttggcaaatgctttcg-
3’) and GAPDH (for5’-agtccctgccacactcag-3’; rev5’-tactttattgatgg-
tacatgacaagg-3’) was also measured in triplicate for each sample
and used for normalization of target gene abundance. Specificity
of amplification was confirmed by melting curve analysis.
Standard curves were determined for each gene, and results are
presented as ratio between target gene and housekeeping genes,
18S and GAPDH.
Proliferation assays
Cell growth was analyzed using the BrdU reagent (Roche)
according to the manufacturer’s directions. Cells (16105) were
seeded in slides on 24-well plates (Thermo Fisher Scientific) and
grown in RPMI containing 10% FBS, 1% P/S in the presence of
0.5 mg/mL G418. When cells reached 50% of confluence, BrdU
was incorporated in cell culture medium and incubated for 20
minutes. After incorporation cell culture medium was removed
and cells fixed with methanol for 30 minutes. Cell labeling with
anti-BrdU antibody and FITC secondary antibody was performed
according to manufacturer’s instructions. Three independent
assays were performed and each assay was done in quadruplicates
for all the cell lines. Percentage of dividing cells was calculated by
measuring positive BrdU cells in relation to total cells with the help
of ImageJ software. Results are presented as means 6 SD for each
sample, and proliferation levels obtained were compared with the
Mock control cell line.
Invasion assay
Invasion assays were performed in a BD Biocoat Matrigel
invasion chamber with an 8-mm diameter pore size membrane and
a thin layer of Matrigel, in a 24-well plate. Inserts were rehydrated
for at least 1 hour in RPMI medium. After detachment of
confluent cells with trypsin/EDTA, cells (56104) were seeded in
the upper surface of Transwell plates and cultured in RPMI
containing 10% FBS, 1% P/S in the presence of 0.5 mg/mL
G418 for 6 hours, and the same culture medium was added in the
lower part of the insert. After incubation, non-invading cells in the
upper part of the insert were carefully removed, cells were fixed
with methanol and membranes were removed from the inserts and
mounted in a slide using Vectashield with DAPI (Vector labs).
Three independent assays were performed and cells were seeded
in duplicate for each cell line. Invading cells were counted under a
fluorescence microscope, and measurement was done by counting
cells in three different fields in each sample, with application of
ImageJ software. Results are presented as means 6 SD for each
sample, and invasion levels obtained were compared with the
Mock control cell line.
Cell-substrate adhesion assay
Cell adhesion assays were performed in a 96-well plate coated
overnight at 4uC with 50 mL of different extracellular matrix
(ECM) proteins: collagen IV, fibronectin and vitronectin in the
concentration of 20 mg/mL, while bovine serum albumin (BSA)
(Sigma-Aldrich) was used as negative control. After coating, the
plate was incubated for 1 hour with 0.5% of BSA in phosphate
buffer saline (PBS) and viable cells (26104 cells/well) were
introduced into the plate and allowed to adhere for 30 min in
RPMI serum-free medium at 37uC and 5% CO2. Removal of
non-adherent cells was performed by washing the plate with PBS
and adherent cells were fixed with methanol for 30 minutes. Cells
were subjected to 0.5% crystal violet dissolved in 20% of methanol
for 1 hour, and then washed several times with water and allowed
to air dry. Crystal violet dye was solubilized with 10% acetic acid
and absorbance was measured at l=560 nm. Results are
presented as means 6 SD for each sample, and adhesion levels
obtained were compared with the Mock control cell line.
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Phospho-RTK array analysis
Cells were cultured until reached confluence on T75 cm2 flasks
with RPMI medium supplemented with 10% FBS and 100 units/
mL penicillin-streptomycin in the presence of 0.5 mg/mL G418.
Cells were then lysed in NP40 lysis buffer (1% NP40, 20 mM Tris-
HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM
sodium orthovanadate, and protease inhibitor cocktail tablet
(Roche), protein concentration was determined by the bicincho-
ninic acid (BCA) protein assay (Pierce) and 300 mg of total protein
was used for the human Phospho-RTK array kit (R&D Systems).
Phospho-RTK array protocol was performed according to
manufacturer’s instructions. Activated receptors were matched
according to the phospho-RTK array coordinates: a1, a2: EphA6;
a3, a4: EphA7; a5, a6: EphB1; a7, a8: EphB2; a9, a10: EphB4;
a11, a12: EphB6; a13, a14: mouse IgG1 negative control; a15,
a16: mouse IgG2A negative control; a17, a18: mouse IgG2B
negative control; a19, a20: goat IgG negative control; a21, a22:
PBS negative control; b1, b2: Tie-2; b3, b4: TrkA; b5, b6: TrkB;
b7, b8: TrkC; b9, b10: VEGFR1; b11, b12: VEGFR2; b13, b14:
VEGFR3; b15, b16: MuSK; b17, b18: EphA1; b19, b20: EphA2;
b21, b22: EphA3; b23, b24: EphA4; c1, c2: Mer; c3, c4: c-Met; c5,
c6: MSPR; c7, c8: PDGFRa; c9, c10: PDGFRb; c11, c12: SCFR;
c13, c14: Flt-3; c15, c16: M-CSFR; c17, c18: c-Ret; c19, c20:
ROR1; c21, c22: ROR2; c23, c24: Tie-1; d1, d2: EGFR; d3, d4:
ErbB2; d5, d6: ErbB3; d7, d8: ErbB4; d9, d10: FGFR1; d11, d12:
FGFR2a; d13, d14: FGFR3; d15, d16: FGFR4; d17, d18: insulin
R; d19, d20: IGF-IR; d21, d22: Axl; d23, d24: Dtk. Black dots
represent phospho-tyrosine positive controls.
c-Met and Src inhibition assay
c-Met and Src inhibitors were used to evaluate the invasive
capacity of the cells upon inhibition. c-Met inhibition was
performed with 0.1 mM of PHA-665752 (Sigma) and Src
inhibition with 20 mM of PP2 (Sigma) both during 10h. Inhibition
was assessed by Western blot for the phosphorylation status of c-
Met and Src, and invasion capacity of cells was evaluated as
described above, after 10h of inhibitors incubation.
Immunoblotting
Proteins were obtained from total cell lysates of each cell line.
Briefly, confluent T75 cm2 flasks were incubated with NP40 lysis
buffer and cells were scraped. Total cell lysates were centrifuge at
14000 rpm for 10 minutes to remove pellet cell debris. Protein
concentration was determined by the bicinchoninic acid (BCA)
protein assay (Pierce). Proteins from cell lysates were separated
accordingly to protein molecular weight by gel electrophoresis in
7.5% acrylamide/bis acrylamide (Sigma) SDS-PAGE. For c-Met,
phospho-Met, phospho-AKT, phospho-STAT3 and phospho-
ERK detection, 25 mg of total protein extract were used and for
phospho-Src and phospho-FAK detection we used 50 mg of total
protein extract. Gels were then transferred onto a nitrocellulose
membrane (Amersham) in a semi-dry system. Membranes were
then blocked with 5% non-fat milk, washed three times with Tris
buffer saline (TBS), and incubated overnight at 4uC with primary
antibodies. After incubation, membranes were washed three times
with TBS and incubated 1 hour with secondary antibodies.
Analysis was done by chemiluminescence using the ECL Western
blotting detection reagent and films (both from GE Healthcare).
Antibodies: anti-phosphorylated Akt Ser473, anti-phosphory-
lated FAK Tyr397, anti-phosphorylated Src Tyr416, anti-phos-
phorylated ERK Thr202/Tyr204 and anti-phosphorylated MET
Tyr1234/1235, anti- phosphorylated STAT3 Tyr705 (all rabbit
polyclonal antibody from Cell Signaling Technology) were used at
1:1000 dilution. Mouse monoclonal IgG2a antibody directed
against human MET (Invitrogen) was used at 1:2000. Anti-SLex
clone KM93 (Millipore) was used at 1:500 dilution. Goat anti-actin
and rabbit anti-actin (Santa Cruz Biotechnology) were used at
1:8000 dilution. Secondary anti-rabbit and anti-goat antibodies,
conjugated with horseradish peroxidase (DAKO), were used at
1:2000, while anti-mouse IgG2a and IgM antibodies, conjugated
with horseradish peroxidase (Jackson immunoresearch) were used
at 1:25000 and 1:10000, respectively.
Cdc42, Rac1 and RhoA GTPases pull down assay
Cells were cultured in serum free medium for 24 hours, and
proteins were obtained from total cell lysates. Pull-down assays,
using RhoA/Rac1/Cdc42 Activation Assay Combo Biochem Kit
(Cytoskeleton, inc), were performed according to manufacturer’s
instructions, using 600 mg of total protein lysates. Briefly, rhotekin-
RBD effector domain affinity beads were used to bind RhoA
active (GTP-bound) protein and PAK-PBD effector domain
affinity beads for Cdc42 and Rac1 active proteins. Total proteins
were incubated with these beads for 2 hours, and pull down
proteins were eluted with Laemmli buffer and separated on 12%
acrilamide/bis acrilamide gels. Pull down negative and positive
controls were performed according to manufacturer’s instructions;
briefly total cell lysates were incubated with GTPases inhibitors or
activators prior to pull down. To confirm the presence of GTPases
in the cell protein extract, a 5% input control were also runned in
the gels. Gels were transferred to nitrocellulose membranes and
antibodies against Cdc42, RAC1 and RhoA (included in the kit)
were incubated overnight with gentle agitation. Proteins were
analyzed by chemiluminescence using the ECL Western blotting
detection reagent and films (both from GE Healthcare).
Chicken embryo in vivo tumorigenesis and angiogenic
assay
The chicken embryo chorioallantoic membrane (CAM) model
was used to evaluate the angiogenic response and growth
capability of Mock and MST3Gal IV cells (n = 13 for each
group). According to the European Directive 2010/63/EU,
ethical approval is not required for experiments using embryonic
chicken. Correspondingly, the Portuguese law on animal welfare
does not restrict the use of chicken eggs. Briefly, fertilized chick
(Gallus gallus) eggs obtained from commercial sources were
incubated horizontally at 37.8uC in a humidified atmosphere
and referred to embryonic day (E). On E3 a square window was
opened in the shell after removal of 1.5–2 mL of albumin to allow
detachment of the developing CAM. The window was sealed with
a transparent adhesive tape and the eggs returned to the
incubator. The window in the egg shell does not interfere in any
way with the normal development of the chick embryo. Cells, re-
suspended in 10 mL of complete medium (16106 cells per
embryo), were placed on top of E10 growing CAM into a 3 mm
silicon ring under sterile conditions. The eggs were re-sealed and
returned to the incubator for an additional 3 days. At this point the
embryos are at E 13, thus still in the first 2/3 of development. The
embryos were euthanized by adding 2 mL of fixative in the top of
the CAM which is a very efficient and fast method. After removing
the ring, the CAM was excised from the embryos, photographed ex
ovo under a stereoscope, at 20x magnification (Olympus, SZX16
coupled with a DP71 camera). The number of new vessels (less
than 20 mm diameter) growing radial towards the ring area was
counted in a blind fashion manner. The area of CAM tumors was
determined using the Cell A (Olympus) software.
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Immunohistochemistry analysis and tumor invasive
phenotype
Excided CAMs were fixed in 10% neutral-buffered formalin,
paraffin-embedded for slide sections and stained with hematoxilin-
eosin for histological examination. Slides with clear view of the
CAM tumors were also processed for cytokeratin, SLex and p-Met
immunohistochemical detection in order to characterize the
phenotype of CAM tumors. Briefly, sections were dewaxed,
rehydrate and the endogenous peroxidase activity was blocked
with 3% H2O2 in methanol for 30 minutes. Then, sections were
incubated with normal rabbit or swine serum diluted 1:5 in PBS
containing 10% BSA for 30 minutes followed by incubation with
the monoclonal antibodies overnight at 4uC. Incubation with both
biotinylated rabbit anti-mouse and swine anti-rabbit secondary
antibodies (DAKO) was done during 30 minutes at room
temperature followed by avidin/biotin complex detection (Vec-
tastain). Staining was performed with 3,39-diaminobenzidine
tetrahydrochloride (Sigma) containing 0.02% hydrogen peroxide
and counter staining of the nucleus was done with Mayer’s
hematoxylin. Monoclonal antibodies used were KM93 1:60, p-
Met 1:100 and cytokeratins AE1/AE3 1:300, and for both antigen
retrieval was achieved with citrate buffer pH:6.0. Evaluation of
tumour invasion was performed in a blind fashion way by two
independent observers. The semi-quantitative evaluation took into
consideration the quantity of human AE1/AE3 labeled cells
present in the CAM mesenchyme.
Statistical analysis
Statistical analysis was performed using Graph Pad program.
ANOVA tests were used to calculate significance in an interval of
95% confidence level. All statistics were compared with Mock
group and values of p,0.05 were considered to be statistically
significant.
Results
Induction of SLex by overexpression of ST3GAL4 in
gastric carcinoma cells
To evaluate the role of ST3GAL3 and ST3GAL4 sialyltrans-
ferases in the synthesis of SLex structures, the previously
established MKN45 cell line model stably transfected with full
length of either ST3GAL3 (MST3Gal III), ST3GAL4 (MST3Gal
IV) genes, or an empty vector as control (Mock) were used [22].
The evaluation of the expression levels of ST3GAL3 and
ST3GAL4 genes by Real Time-PCR (Figure 1A), showed
approximately 4 fold increase of ST3GAL3 gene in MST3Gal
III cells in comparison with Mock and MST3Gal IV cells, and a
160 fold increase of ST3GAL4 gene expression in MST3Gal IV
cells in comparison with Mock and MST3Gal III cells.
The biosynthesis of SLex antigen was further assessed by
immunofluorescence and by Western blot analysis of total cell
lysates and secreted proteins (secretome). Immunofluorescence
results showed expression of SLex in MST3Gal IV cells when
compared with Mock and MST3Gal III cell lines (Figure 1B).
Consistently, Western blot results demonstrated the expression of
SLex in MST3Gal IV cells, both in total cell lysates as previously
described [22] and secreted proteins (Figure 1C). No expression of
SLex was detected in total protein extracts or secreted proteins
from Mock and MST3Gal III cells.
Since only MST3Gal IV transfected cells were able to produce
SLex antigen, further experiments were performed using the
MST3Gal IV and Mock cells.
In vitro biological behavior of SLex expressing cells -
MST3Gal IV
Cell growth, invasive capacity and adhesion properties of cells
transfected with the ST3Gal IV gene were evaluated in order to
characterize these cellular phenotypes, and also to address the
biological role of SLex expression. MST3Gal IV cells showed no
statistical differences when compared to Mock cells in terms of
BrdU incorporation (Figure 2A), suggesting that the expression of
ST3Gal IV sialyltransferase and of SLex do not affect the
proliferation rate of these cells.
Cell invasion was analyzed by counting the number of invasive
cells on Transwell Matrigel invasion chambers. This analysis
revealed that cells overexpressing ST3Gal IV sialyltransferase
presented 3 fold increased ability to invade in vitro, when compared
with Mock control cells (Figure 2B). This result evidence the
importance of SLex expression for the invasive phenotype of
MST3Gal IV cells.
In addition, the adhesion to extracellular matrix proteins was
also evaluated by seeding cells in plates pre-coated with collagen
type IV, fibronectin or vitronectin. Interestingly, SLex expressing
cells (MST3Gal IV) present an increase capacity to adhere to
collagen IV and to vitronectin when compared with Mock control
cells (Figure 2C). In contrast, no statistical differences were found
in the adhesion capacity of these cells to fibronectin.
In vivo evaluation of angiogenesis, tumor growth and
invasion capacity of MST3Gal IV cell line using chicken
embryo chorioallantoic membrane model
Transfected cells were inoculated into the chicken embryo
chorioallantoic membrane (CAM) and different parameters were
evaluated after 3 days of inoculation, specifically, the angiogenenic
response, tumor size and tumor cell invasive capacity (Table 1).
The angiogenic potential was assessed by counting the number of
vessels with less than 20 mm diameter growing radially towards the
inoculation area. The results show no statistical differences in
vessel number between Mock control cells and MST3Gal IV
indicating that ST3Gal IV and SLex expression do not influence
the angiogenic response. Tumor size was assessed by measuring
the area (mm2) of the tumor in the different groups. The results
show no statistical differences in tumor size arising from the
different cell lines, indicating no influence of ST3Gal IV and SLex
expression in tumor growth potential.
For the evaluation of tumor cell invasive capacity, CAMs were
excised from the embryos, fixed with formalin and paraffin-
embedded. Invasion of inoculated cells was evaluated in sections of
CAM tumors immunostained for human citokeratins. The results
show an increased invasive capacity of MST3Gal IV cells
inoculated in CAM in comparison to Mock cells (Table 1). To
assess if cells invading the CAM expressed SLex antigens, CAM
sections were immunostained for SLex. The results show that
MST3Gal IV invasive cells expressed SLex antigens, contrary to
the observed in Mock control cells (Figure 3).
Increased activation of c-Met receptor in SLex expressing
cells-MST3GalIV
To evaluate the possible effects of SLex expression on the
activation of cell surface receptors and on the induction of the
cancer cell invasive phenotype, a receptor tyrosine kinase array
was performed using total cell lysates from Mock and MST3Gal
IV cells. The results show consistently that MST3Gal IV cells
induce increased activation of hepatocyte growth factor receptor
(HGFR/c-Met) (Figure 4A). The increased level of c-Met receptor
tyrosine phosphorylation (p-Met) was further evaluated by
SLex and c-Met Activation in Cancer Cell Invasion
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Western blot, and the results confirmed that phosphorylation of c-
Met is increased in MST3Gal IV cells, with no differences in total
c-Met protein expression levels (Figure 4B).
To assess if the CAM invading cells are expressing the activated
c-Met, CAM sections were immunostained for phospho c-Met,
demonstrating that MST3Gal IV invasive cells are indeed
expressing activated c-Met (Figure 4C).
Figure 1. Induction of SLex expression by ST3Gal IV transfection in gastric carcinoma cells. A – Relative quantification of ST3GAL3 and
ST3GAL4 mRNA expression in MOCK, MST3Gal III and MST3Gal IV transfected cells showing a significant overexpression of ST3GAL3 gene in MST3Gal
III cells and ST3GAL4 in MST3Gal IV cells when comparing gene expression levels in mock cells; ***p,0.001 Mock versus MST3Gal III for ST3GAL3 gene
and ***p,0.001 MST3Gal IV versus Mock for ST3GAL4 gene. Results are presented as means 6 SD. B – Immunofluorescence detection of SLex
expression in Mock, MST3Gal III and MST3Gal IV cells evidencing the presence of SLex in MST3Gal IV (magnification 200x); C – Western blot detection
of SLeX in proteins from total cell lysate and secreted proteins from Mock, MST3Gal III and MST3Gal IV cells. SLex expression was observed on cell
lysates and secretome from ST3GAL4 transfected cells (MST3Gal IV).
doi:10.1371/journal.pone.0066737.g001
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Evaluation of downstream effectors of c-Met activation
c-Met activation relies on stereotypical signaling modulators
common to many RTKs [28,29]. To evaluate possible down-
stream effectors of c-Met activation, we analyzed the activation of
Src, FAK, STAT3, AKT and ERK, proteins involved in different
c-Met downstream pathways. Our results show that MST3Gal IV
cells present increased activation of Src and FAK proteins which
are known to be involved in cell motility and invasion (Figure 5A,
B). The small GTPases of the Rho family, such as Rac1, Cdc42,
and RhoA were also evaluated as possible downstream modulators
of c-Met activation by pull-down of activated GTPases. Our
results demonstrate that in MST3Gal IV cells, the expression of
sialyltransferase IV and SLex induce activation of Rac1, Cdc42
and RhoA (Figure 5C).
Inhibition of invasion in SLex expressing cells using c-Met
and Src activation inhibitors
In order to confirm the biological role of c-Met and Src
activation in the invasive capacity of SLex expressing cells,
inhibition of phosphorylation of c-Met, Src and both in
combination were performed. The inhibition was tested using
different concentration of each inhibitor, and different time-points
of incubation (data not shown). Longer incubations with 0.1 mM of
PHA-665752 c-Met inhibitor (24h and 48h) led to decrease in cell
proliferation and cell death (data not shown), therefore a 10h
incubation time-point, showing no alteration in cell proliferation,
was used for the evaluation of cell invasion. Src inhibition
occurred after 10h of incubation with 20 mM of PP2 and no
differences in cell death and proliferation was observed after
longer incubation periods (data not shown). The activation status
of c-Met and Src was assessed by Western blot analysis, and results
confirmed the decreased in activation of both proteins after 10 h
incubation with the inhibitors (Figure 6A).
Given the observation that SLex expressing cells present
increased cell invasive capacity resulting from the activation of
c-Met and Src, invasion of cells was evaluated after c-Met and Src
inhibition. The results confirmed the increased invasion of SLex
expressing cells in DMSO control treatment, and demonstrated
the abolishment of this invasion capacity upon inhibition of c-Met,
Src and both proteins in combination (Figure 6B). Moreover, the
results showed that inhibition of Src or both Src and c-Met in
combination were more effective in precluding cell invasion
(Figure 6B).
Discussion
Aberrant glycosylation has been described for many years as a
hallmark of cancer, and many of the resulting altered glycosyl
epitopes are tumor associated antigens [30,31]. These cancer-
related antigens are caused by disease-specific alterations in the
Figure 2. SLex overexpression induces cell invasion and increases matrix-cell adhesion in vitro. A - BrdU proliferation assay in transfected
cells. After 50% confluence, cells were incubated for 30 min with BrdU reagent and fluorescent labeled for proliferative index measurement. No
differences were found between the different cell lines. B - Cell invasion assay on Matrigel chambers. Cells were seeded on Matrigel-coated filters
inserted into two-compartment chambers and invading capacity was measured by counting the number of cells that invade, through the Matrigel-
coated filter, 6 hour after incubation. MST3Gal IV cells demonstrated an invasive phenotype presenting a significant increased number of invasive
cells when compared with MOCK cells (***p , 0.001). C - Cell adhesion to ECM proteins. Adhesion potential of cells was assessed by incubating cells
30 minutes in pre-coated plates with collagen IV, fibronectin and vitronectin. Results demonstrate an increased adhesion of SLex expressing cells to
collagen IV (*p , 0.05 MST3Gal IV versus Mock) and vitronectin (*p , 0.05 MST3Gal IV versus Mock) matrix proteins. No statistical difference was
found in the adhesion capacity of cells to fibronectin. Results are presented as means 6 SD.
doi:10.1371/journal.pone.0066737.g002
Table 1. Parameters evaluated in the CAM model:
angiogenesis, tumor growth and invasion potential of cells.
MOCK MST3Gal IV p-value
Angiogenesis
(vessel number 6 SEM)
20.1564.06 19.3164.05 n.s.
Tumour growth
(total area mm 26 SEM)
4.1361.45 4.2961.24 n.s.
Cell invasion on CAM
(% cases)
1/7
14.3%
5/7
71.43%
*
0.0308
n.s.(non-significant) p$0.05.
*p,0.05.
SEM Standard Error of the Mean.
doi:10.1371/journal.pone.0066737.t001
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glycan synthesis pathway such as changes in the Golgi and
Endoplasmic Reticulum compartments, mutations in enzymes or
chaperons, altered expression of enzymes and biochemical
competition, and even variations in sugar donor availability [for
a review see 1]. A common alteration is the abnormal expression
of sialyltransferases, responsible for adding sialic acids residues to
cell surface molecules and to secreted proteins, and which have
been involved in the oncogenic transformation, as well as in
invasion and metastasis [30,31,32]. Sialic acids are typically
attached to the outermost ends of glycoproteins and glycolipids
that can mediate and modulate a wide variety of physiological and
pathological processes [33].
The SLex antigen is a sialylated glycan structure which
expression has been associated with cancer progression and
aggressiveness as well as poor overall patient survival
[4,5,6,7,8,9,10,11,12]. The expression of SLex in cancer results
from the altered expression of sialyltransferases, that adds the sialic
acid in a a2,3 linkage to Galactose residues on type-II chains [13].
In this study, we have characterized the role ST3Gal IV
sialyltransferase in the synthesis of SLex antigen. Expression
analyzes of SLex in stably transfected gastric carcinoma cells by
immunofluorescence and Western blot confirmed that ST3Gal IV
leads to the biosynthesis of SLex. Moreover, our results indicate
that SLex antigen is expressed on proteins from total cell lysates as
well as on secreted proteins from MST3Gal IV cells. These results
confirm previous observations that described the importance of
ST3Gal IV in the synthesis of SLex, the glycan ligand of selectins
[18,19]. In addition, our results are in agreement with recent
reports showing an increased mRNA level of ST3Gal IV and a2,3
sialic acid residues expression in gastric cancer tissues [23].
The carbohydrate SLex functions as a ligand for cell adhesion
molecules of the selectin family, usually expressed on vascular
endothelial cells. The expression of SLex on cancer cells is known
to facilitate tumor cell spreading by mediating tumor-endothelial
cell interactions [34,35]. The SLex antigen is known to be
important in selectin interactions participating in the adhesion of
cancer cells to vascular endothelium thus contributing to
hematogenous metastasis [36]. These previous observations
further support that SLex antigen plays a functional role in
malignant cancer cell behavior. Noteworthy, the crosstalk between
cancer cells and host mechanisms like cell-cell adhesion and cell-
matrix adhesion interactions, tumor cell growth and motility are
known to be important in modulating the process of cancer cell
invasion. In the present study we performed a comprehensive
evaluation of the biological role of SLex in gastric cancer cells
using in vitro and in vivo models. The in vitro analysis showed that
SLex expressing cells display a similar proliferative rate when
compared with Mock transfected cells. However, SLex expressing
cells demonstrated a higher capacity to invade in vitro in Matrigel
chambers, demonstrating the active role of this sialylated glycan
structure in tumor cell motility and invasion. Concomitant to this
invasive capacity, SLex expressing cells evidenced higher capacity
to adhere to collagen IV and vitronectin extracellular matrix
proteins. These findings highlight the importance of this sialylated
glycan in the malignant invasive phenotype. Furthermore, this
invasive phenotype was also confirmed in vivo where cells
transfected with ST3Gal IV and expressing SLex antigen
presented increased capacity to invade the chorioallantoic
membrane of the chicken embryo. Our results are in keeping
with studies that associate SLex expressing tumors with more
aggressive phenotypes [8,37,38]. In the gastric carcinoma context
it has also been described that SLex antigen expression correlates
with liver metastasis [7]. The modulation of cancer cell biological
behavior by sialylated glycans has been previously described in
Figure 3. SLex expressing cells present an invasive phenotype in vivo chicken embryo chorioallantoic membrane (CAM) model.
Transfected cells were inoculated in CAM and different parameters were evaluated after 3 days of inoculation. Invasive capacity of inoculated cells
was evaluated by immunolabeling CAM tumors with human cytokeratin and SLex to assess the presence of human epithelial cells expressing SLex.
Human cytokeratins immunostaining was used to prove the presence of inoculated human gastric carcinoma cells. SLex expression and the invasive
capacity of cells were match up to cytokeratins expression. Immunostained tissues evidence the presence of SLex structures in CAM tumors from
MST3Gal IV cells that, in constrast with Mock cells, invaded the CAM tissue.
doi:10.1371/journal.pone.0066737.g003
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human pancreatic cells. In this pancreatic model the restoration of
a1,2 fucosyltransferase activity, a enzymatic competitor of ST3Gal
transferases, reduces the expression of Sialyl Lewis antigens and
decreases the adhesive and metastatic properties of these cells [39].
In addition, previous reports have shown that increased cellular
sialylation leads to receptor and signaling pathways activation and
that the hypersialylation contributes to cancer progression and
increased cell motility [40,41]. Moreover, it has been described
that TNF-a can induce SLex and 6-sulfo-SLex expression in
human cancer cells, by increasing the expression of ST3GAL4
[21]. This mechanism has also been shown to be mediated by
neutrophils expressing TNF-a leading to cancer cells invasiveness
and metastasis [42].
In order to clarify the potential implication of ST3Gal IV and of
its product SLex in the biological behavior of gastric cancer cells,
we evaluated the expression of activated tyrosine kinase receptors
and downstream modulators involved in cancer cell invasion. The
tyrosine kinase receptor array allowed the identification of a
constitutive activation of c-Met in SLex expressing cells. The
activation of tyrosine receptors, directly or indirectly by glycan
antigens has previously been observed in other cancer cell models.
Singh and colleagues described that the Thomsen-Friedenreich
antigen (T antigen) present in CD44v6 promotes the activation of
c-Met and MAPK signaling leading to cancer cell proliferation
[43]. Furthermore, activation of c-Met receptor has been
described in a breast cancer cell model that overexpress
Figure 4. Tyrosine kinase receptors activation evaluation in gastric carcinoma cells; increased c-Met in MST3GAL IV cells. A –
phospho-RTK array of transfected Mock and MST3Gal IV cells. Total cell lysates were collected and 300 mg of total protein were incubated into a
phospho-RTK membrane array. The array shows an increased activation of c-Met (HGFR) in MST3Gal IV cells. Activated receptors were matched
according to the phospho-RTK array coordinates indicated in the material and methods section. c3, c4 correspond to c-Met ; B – Analysis of c-Met
activation in MOCK and MST3Gal IV cells by Western blot; Cell lysates were analyzed by Western blot with antibodies directed against human c-Met
and the phosphorylated tyrosine residues 1234/1235 of the kinase domain to confirm the activation of c-Met in MST3GAL IV cells. The results show an
increase expression of phosphorylated c-Met (p-Met) in MST3Gal IV cell line with no differences in c-Met total protein levels in both cell lines. Anti-
tubulin antibody was used to assess loading. C – Expression of phosphorylated c-Met was assessed in CAM tissues. The evaluation of c-Met activation
in CAM tumors show that MST3Gal IV/SLex expressing cells present positive staining for phospho c-Met and that the resulting invading cells are also
positive for the phosphorylated form of this receptor.
doi:10.1371/journal.pone.0066737.g004
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glycosyltransferases and this activation has been implicated in
proliferation and invasion of cancer cells [25,26,27]. The MKN45
cell line model has been reported to have a high level of expression
and dependence on c-Met [44] and therefore modulation of
cellular glycosylation can have implications in this c-Met
dependent cells.
c-Met overexpression has been considered a hallmark of cancer,
playing a role in many tumors and in metastatic progression [45].
In gastric cancer, c-Met expression alterations have been reported,
such as the Tpr/Met rearrangement [46,47] and c-Met copy
number amplification [48], as well as increased c-Met activation
[49,50]. We evaluated the c-Met activation in a series of gastric
carcinoma tissues (data not shown). The variability in tissue sample
processing is known to lead to loss of protein phosphorylation
which precluded the detection of phosphorylated c-Met in these
samples. However, sections analyzed from the chicken chorioal-
lantoic membrane tumors, derived from either Mock or SLex
expressing gastric carcinoma cells, confirmed phosphorylated c-
Met positive staining in SLex cancer invading cells. This result
further supports the hypothesis that SLex expressing cells exhibit
invasive capacity through the activation of c-Met.
The activation of c-Met is well known to induce docking sites for
proteins that mediate downstream signaling leading to the
activation of the mitogen-activated protein kinase (MAPK),
Figure 5. Evaluation of downstream effectors of c-Met activation. A – Increased levels of p-FAK and p-Src proteins in MST3Gal IV cells. The
contribution of other effector proteins, such as AKT, ERK, FAK and Src was evaluated by Western blot for their phosphorylated forms in Mock and
MST3Gal IV cell lines, and expression of b-actin protein was used as protein loading control. Results show increased levels of phophorylated FAK and
Src supporting their involvement as downstream effectors of phosphorylated c-Met (p-Met). B – Analysis of 5 independent Western blot of c-Met,
STAT3, AKT, ERK, FAK and Src phosphorylated forms in MOCK and MST3 Gal IV cells showing statistically significant increased levels of p-FAK and p-
Src, concomitantly with increased phosphorylated c-Met. Results are presented as means 6 SD. C - Evaluation of Cdc42, Rac1 and RhoA GTPases as
potential modulators of c-Met activation by pull-down assay of their activated forms. Western blot analysis of pull-down proteins evidence an
increased activation of Cdc42, Rac1 and RhoA in MST3Gal IV cell line. A-GTPase WB protein positive control (His-Cdc42, His-Rac1 and His-RhoA); B-
Mock total cell protein pull down; C-MST3Gal IV total cell protein pull down; D-Mock total cell protein pull down with previous GTPases activation
(pull down positive control); E-Mock total cell protein pull down with previous GTPases inhibitors (pull down negative control); F-Mock total cell
protein input; G-MST3Gal IV total cell protein input. Highlighted areas represent regions of interest regarding the specific protein migration.
doi:10.1371/journal.pone.0066737.g005
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phosphatidylinositol 3-kinase (PI3K)-AKT, v-src oncogene homo-
log (Src), signal transducer and activator of transcription (STAT),
which are signaling pathways that are involved in increased cell
growth, scattering, motility, invasion, protection from apoptosis,
branching morphogenesis, and angiogenesis [28,29]. Taking that
into consideration, we evaluated the downstream effectors of c-
Met activation and found that FAK and Src proteins showed
increased activation in cells expressing ST3Gal IV. In combina-
Figure 6. Inhibition of invasion in SLex expressing cells by targeting c-Met and Src activation. A - Evaluation by WB of the activation of c-
Met and Src in the MST3Gal IV and Mock cells with or without the presence of inhibitors of c-Met (PHA-665752) and Src (PP2). B - Cell invasion assay
on Matrigel chambers after inhibition of c-Met and Src activation. Cells were seeded on Matrigel-coated filters after incubation with inhibitors for
10 hours. Invading capacity was measured by counting the number of cells that invade, through the Matrigel-coated filter, after 6 hours. MST3Gal IV
cells demonstrated an invasive phenotype presenting a significant increased number of invasive cells when compared with MOCK cells. Inhibition of
c-Met, Src, and both in combination led to abolishment of cell invasion capability of the MST3Gal IV cells (*p,0.05; **p,0.01; ***p , 0.001).
doi:10.1371/journal.pone.0066737.g006
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tion with our invasion assays results (in vitro and in vivo), these
results strongly suggest that c-Met activation mediates tumor cell
motility and invasion, also in gastric cancer cells. These results are
in agreement with previous studies that associate Src-FAK
signaling pathway with the metastization process [51,52,53,54].
Furthermore, our results show that inhibition of c-Met and Src
could preclude the increased invasion observed in SLex expressing
cells supporting the importance of this glycosylation alteration in
the activation of this invasive related pathways.
Oncogenic transformation is often associated with changes in
organization of the cytoskeleton, which can influence cell
migration, adhesion and invasion. The c-Met activation can cause
changes in gene expression of cell-cycle regulators (Cdk6, p27),
extracellular matrix proteinases (such as matrix metalloproteinases
and urokinase plasminogen activator), and in alterations of
cytoskeleton functions that control migration, invasion and
proliferation [55]. The cytoskeleton is composed of a complex
and organized network of various fibrous proteins within the
cytoplasm, playing an essential structural and regulatory role in
the maintenance of cell structure and strength, in cell division,
proliferation, motility, invasion and also in signaling functions
[56,57,58]. The activation of tyrosine kinase receptors can modify
the phosphorylation status of cytoskeleton regulatory and struc-
tural proteins. Signaling pathways initiated by the activation of cell
surface receptors can promote distinct membrane protrusions by
converging onto the Rho family of GTPases [59,60]. Rho proteins
are small (21-25 kDa) molecules that share structural homology
and become activated only when bound to GTP. One of the best
characterized Rho GTPase family members is RhoA regulating
the formation of stress fibers and focal adhesion assembly, while
Rac1 and Cdc 42 are mainly involved in membrane ruffling and
formation of filopodia, respectively [61]. Estimation of GTPases
activation is frequently a molecular marker in the evaluation of
cytoskeleton alterations during cell migration [62,63,64]. Here we
showed the activation of Rho GTPases, specifically RhoA, Rac1
and Cdc42. These results further supports the evidence that SLex
expression leads to cytoskeleton protein alterations in cancer cells,
underlying the observed increased cell motility and invasion of
these cells. Our findings are in keeping with previous reports
showing the importance of RhoA, Rac1 and Cdc42 in cancer
progression [65], and also the crosstalk between these GTPases
and other signaling pathways like Src-FAK in the migratory
phenotype of cancer cells [66]. Our present findings support the
hypothesis that increased expression of SLex on the surface of
malignant cells plays an important role in tumor invasion and
metastasis. Overall, our study showed that tumor cell invasion is
induced by SLex expression on gastric cancer cells through the
activation of c-Met in association with downstream signaling
effectors Src, FAK and RhoA GTPases activation (Figure 7).
These results open new avenues to design intervention strategies
that target ST3Gal IV/SLex in cancer cells as well as the
Figure 7. Schematic representation of the alterations induced by increased expression of SLex and activation of c-Met. Increased
transcription of ST3GAL 4 leads to increased expression of the ST3Gal IV enzyme in the Golgi apparatus of the cells. This enzyme will glycosylate type-
2 terminal oligosaccharide chains leading to the presence of SLex in glycoproteins targeted for the membrane or to be secreted by the cells. The
expression of SLex in membrane-associated and secreted proteins can promote the interactions between these proteins and c-Met leading to its
activation. c-Met activation leads to downstream signaling activation target proteins Src, FAK and Rho GTPAses leading to a modified cell-matrix
adhesion and an increased cell invasion.
doi:10.1371/journal.pone.0066737.g007
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inhibition of c-Met and Src in order to improve gastric cancer
treatment by targeting invasion and metastasis.
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